var title_f36_30_37344="Long axis aortic root dilation";
var content_f36_30_37344=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortic root dilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 259px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEDATQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5h804wcflS+b0PvVUSEfWnLJ68Z74rTnM3BFnzeRwQPc0vnHGCxwOlUpDkjjHFMo57B7NGj5zbjl+OhznNKZ2IyTnI6EZrNoo9oHszRM+Tljk/T2pDKcAAgAnPBwBWfRR7QPZo0DMMHkkUhm6ZyT05NUKKPaB7NF5ZjwTksB60CU9z/8AXqjT0bH19aFMHBFtpWIxjA9PekEr4OD247VXD4PHejfVOQchZ8w+gPqR3oMh7cVX39OBSbs9ODRzhyFzzdx5Y8dM/wCfpVuzd5ZlQAs7MFHPc/8A16zUbLjcxC7uSBnA9QK6bxFZ6Bp99bJ4d1+fVLd4w0ssll5BR/7uNxz9aamr2IcLansnw88A2finS4dEvNItLe+tgWlvoXZLiU9QMsSv1wv/ANfqrX4I+EYRIuo6hdJMh+dFv4U2exytea/D/wAY6XZT2S3V2xuFIXzChUxj1Bzg/SvdtF+IHhfUr7GoJaS3IJVLiGNjkAcZAJ5rScvd93/N/wBehnFXfvb/AHIw5Pgj4DIUJqWoncu4E6jB/LbWNJ8G/CTxFo77UyxYqMXcOSR/dG3mvTdQ+Jnhi2dY0l3vjaAcKQfTkcV5N4k+MmzVl/sy2lnQPwl5CDtI7KUVcj86wpufUuah/TOB+LGmafaXscGgaF9htbRPLkmR3ZpWH8UmSQD9K89tFEtzEjSFAzBQ3ULk9fpXofjX4o3Gu2ktnf6JbwEc7EVgv1POa4/w7baHPpWpXt/4i/svUbYiSzsvsjSi5bqAX6LyB1rSbS2JSbep7/4g+D/w88K6dZS+J9f1S3aZf9YpysjAAnaApIHtWT46+E/gHQfAra/HrmpJFPDvsWkbIlcjKgjGefw71ix/tMa19htotQ8PaNezxRhWml3ZcgAbsdBnrgVj+N/j9qHivwvc6HceHNLt4JlAWSMsTGQc5UHiudVJ31X4I0dONnb82eNy3UoYrnPOKBeS+uST0zVZxxyTSYzwM5/OtE2XyotC4bGM9Pc08Xsmc9D6dqqFfUnOfu5pfcMeuOead2LlRaF0wOcH8zTzek8rke3XNUj25+lC+najmFZF83bbwSAR6UrXbBcALkjPJxkVnqBjg5FKKOYXIaf2sgfc+Yd81V1C7nWdTHLInyg/KxHeoAx/vYAFRXJy4wSQBiiT0CMddTX03xf4k0yAw6b4h1izhLbzHb3ssak+uAw5qGHxJrsF7NeQ61qcd3MpSWdLqQPID1DMDkg+9ZFFZ3ZsTtd3LsWe4lYnqS5NFQUUXYWFpR0POKSlAycCkANjPAxTac3Wm0AFFFFABRRRQAUUUUAFOHSm0tAC5pcjB4plFO4Dga1PDWhaj4k1m30vRLU3V/cEiKEOq7sDJ5YgDgdzWVUkE0kEgkhdkcdCrEEfiKabA0W0e9TU7iwkgxewMVkiLjKkdRnODTLaBizLsG9GwQTz9KqrNJ5hlDPuByWBOfzq1BfyhiSTk8MxGSR/U1omkZTUjpvDvh7UNYkEOm6XcXcityIplBHtzjBr1nwv8PLdbmO4uIdTsrgt5X2J4luAT7uHHNeER39zHIJILmaNgcqwOC31rtrbWPE0+mos91qU0O4Nb/NhCfz4rWDfRf19xhJdz6t8J+CJtCsJriwCDUXU+V58XlMD6Ngtx9K4v4jeGNc15xeeItRsoLWE7Io0vAEjf1+4PyryYeI/EGkWxEDapbxyrsm/0gZJ7gcnisLW9f1O7t4Td6hcHyT+58xvmVff1+tTaopc07P5Dc4OPKkaWsfDwtDJcRaraSXDk70SYOVA7t6D3rzXULCS2kmHmR/um2kKc7vce3vW/FGPOkuLq5eWBzyI5Npb/GtO2jdorgi18lXI2m4l5C/THNW1zdCObl2OS03w7q2rzWsem2j3NxdSeVDEn3nb0Gapa9pGoaDqdxpusWklpfQHbLFIOVPUfpX0D8NbbSLqUzeJL1LS3t13BYUIcj0DeteSfFKzhj8TXlzpy3C6dK58g3MpkkYepY881nOnZ6GtOpfRnEluMZNJ1NBzk5x+FAzkHFZHQO4HDdfagMB0Azng00g8cg5oCkE9PSgNBynng9etKuCe3H6UnPHvxgCjkEHH5cUwHbjnoP6Cne+SCfeo8HdyMn0p2TnPU9eTSYh3r1qKbls+1Sj07YqKY/MPYYpPYS3I6KKKksKKKKAFpR15pKKAA9aSlNJQAUUUUAFFFFABRRRQAUv86SloAKKMV6TpOmeAbqDTxDeayl81v/pTXSoIUn9Exzj61cI80uUmUuVXOa0jxHe6N4e1PRo7LT5INSAMss9sJJowOmx+q1hxRIxyxwuK6LVNLbTbjzYSJ7YkriQ/ernrlDFMfk2DORg5FaOHJuZxnz7F/SUsGlJv2nSIDgIMhj/dJ7Vvwr4Vw0lxbXcYJAURktj61x6XEi5UdP7uOKkSedQ21iB3GeDVKol0JlTbe531hJ4dEhW2Lo0o2pJMCQn19K9y+H9h4WitANV1Cx1OTaDAEnKY4+6RjFfLo1u6VI02W4WMjH7oZP19a6nR9U1W7tZriQwx2TYBt4kCqzeoA6GtFPm0X9fiZODhqz6H1HVPC0EZ3eDtLdJiU3fagGP+6MZBry3V9C0e6e5XS9CurOV2/d3E96Z1SPuAhHNUoPt8PlXctp5WzDeejKGiHY5zyfwqTVPEcNqxlv76W8WYbYWt587f94Y61UYQhq/6/P8AAiU3LQwr/S5dPe0MCPEysPLkdskn1x2Fa2lWfi3xDq8/9mmTU7uQfMqkFgB6Z4FV7i48/DRXw08iP935zgFyewFdL4P8Z6hYxNplhqenWDSjDvDFslc+gbvTa10/O39fcJPuWE0bXbiwlnnS6hjtMibY65Rh13DvXnPi6Obc9yxRreUbVaQ5Oe5xXvei3FjpGlzXPiswxRk/IkalvMJ9UzyT3zXkfxA1dPEN67pBbWdtENkdvnHy+pPanPZxGrKzucNr/iZNT8O6Xov9i6TaGxJP222g23E+R/y0bv61yxyMEMOla0yqsku6ONgflVlOdo961PDmkeH7iHUX8T6pd6Y6Q77NYbcyiaT+6x/hHTmuNxsdUZrY5MDpzjNOCHg54pWTb370mMDqPpUGvoLyGBzS4ycceg9qQZOSTx6mlxwOp46e1UAKpDDkfnSkZz+nNNzn7x6/hTl45JJ96QmKBwajm+/+FSAHAye1RzfeH0pMFuR0UUVJQUUUUALRRRTADSUUUgCilwfQ0uxj0U/lQA2inBSegJ/CjafQ0ANop20+hoKsOqkfhQA2uh8C+EtW8ba+mjaBFFLeujSASyBF2r1OTWBtb0P5V1Xg5LvR7yHWFu57CWJ9qFCySEEdQfTmqjFyehMpqKuy5e+BtW8PapqVtqsNubzTCDPbB9wIIzkEVky3iuzmCMeSRllZeg9DXpFpcWs91LcS6u5u7oHdNcZckejZ61wV9oly2o3HkzItuz8SA/K/4V1uDjFWOPnU5O5StNQYQzWzXIigdflWVC+z2HpWW7nylGVYDI6/rXS22gSGZRL5OwcNIWyD+FZ2saPPYvuZR5RJZSAM4qHGVjSMo3Lfw90S38SeNtF0a9mkgtb+5W3kljA3Lu9M96981j9nfw5Bqmm21lrOpvHNdm0ncqh8tgAcD3wa8b+Daj/hZ/hUhMn+1IME/wC+K+z/ABH5Nt4r0K0jYvJcaibt89UO0DA9sKaxTfM15P8AJm99E/M+VfjB8LtM8DeFNN1XTtRvbiW9uJIilwigAKxGeO5xXmVtrNzFZtaK6xxP1aOMBz+NfR37TrK3w88N89LqcD3+dv8ACvmmaSIyLiEQ7O27du/Orv1/rczdnuRCZorkSIx3g8bxmluZp7iVml5Y9cD+VSTXpdGHkxgNycLjn29KhjmKtuHAznbu4paD13sEWwqQwfzD93v+ddjpuoaimnxRW2m2qg/8t3AL8enORVLStFa9sjJHbMTK3EshwM+g9a7zw1odrp/krr9pKlqx3b1Qgs3pn0963hCRz1JpkkCefpsE17aXcdwnPni4wD9F9ax7rTUuLki0jaQsMFmJfcfc+tejHR4NRS3+y2yXEUT4hUsUJJ6An+IVpPpN5YRXJ1K3jtAcFlDgKQO4Aro5U9DFXPJLfwq39lzFZQs+SSXX5VHfmuH1Sd13QpKfKViMhMZr2Dxxqug3ObW1MqLGuD9nJZXI/vf4V5TLay3lzHBHwZpAkTNxya56ltomtN3epS0DQdT8Q6rBpmi273d/Pny4VIy2Bk9fajxT4c1Xwtqj6Zr1k9nfIocxOQTtPQ5Fery/CLxf4Nu9K1e01iwtL5086GSGRw8WQMg8dcHFcj8RNC8SSLNr/ibVYdSn3JC8nmFpD2HboKw5W1e2h1c1nZs4DjpnH40mOfbFKVwOgpM44IHT16VBoAI68g+tOXBzimggnkA59acoG0jPH8qBMcp685NRzYyMenJ9akU5HNMnILDGeB3pPYS3IqKKKksKKKKAFpKWkpgLQOaSloAATTw3FM6cGloAeCcjOMkdM0e5IzTSP8+lHQcnk01qIeW646Umc8H/APXQozjAyT2rsIdA0GPw3YamniS3udWdsz6QbZ1aNc95D8p+g9atK5EpKIeCNV0jS7TUl1fQdP1V7pRHDJcSujWp5+dcdev6VVvtWdojDGTJGvAfHOBUesxRG6RII3WI9yvT247VGtlcWsiSpl2BwUXkj3xWyTjojnupaseddefTPs88RDjlbiM4b6H2psGr3sNuY45UOSCu5c5rudAvPDV7oc8erIlpqUfy5IGG/Csifwvd3WnzyW80UtrD8wkSAnPoMjpWnI2rp3I5o7NWK9gdTv1eKGJblHA3LF94H2xXO61FeWkyw3LSoCOFaQn8xnj6Vu6RNDp+wPZX9vfE5327FCR2NZGtpLMGuJ5J/N3EES4HHbnuaiSTj5/1/W5UHaXkbnwbntrf4n+G576bybeK/ilZ+uNpz0/IV9XeNfE9neXFnf2EiyXWn3pdFUMvnRgqwJOOATuHHvXw7FcSWsyTQSyRzIdySRsVZT6gjpWi3ibWzk/21qZz63T/AONYQaUrs6JRbVke9ftR6za61aWy6bJGdPgmQRlFIUkqSxwQMHJI6dq+f9PsGubiKFW2F+fmHAqO81jUL6MR3t/d3EQO4JNOzgH1wT1qukz5JVnDN97BPP1quaN1ZC5ZWepqDTZEv3t5HUOpPO35cit/wz4Qu9YvhGiNIo/55xk5/KtfwF4Hu797a8vp7a309hlpJJVbavuiksPxFevwazpvhe0ii0vUliCZLPZTOHl+ucY/WumFNbs53J3tcxfD/hBtKt/LuNH1ESQDzZIYwGV8dDz2q6PFT39ozXljcRyRKY44mzHEi+m09TTpfEmo+KdY+z6dfxx3cdrLd+ddEYCxru2nBOc+pIryv4harr8moy2via5ltr63JQ20inaMEjd1IYZBwRwe1P2yTsuhPLpp1O/g8Uzwva3K3MdmkZ+VbST5cZ/iHaqmv/ERdajmitYla6f5WdI8B8dt/wD9avDlmj4/eMzZxjoKuQztBHvtJZFkLBTwMk+lZ+0b1GqbWjOpvbo/ZZS0gtpJSdu3r+NT/DuFdR+IHhW3upDPC2pW6MAcDG8DAriLu6nnd/PdW2cZxjFdf8HZ1X4leFUY4zqdtyccfOP8/lWVWXutmlOFmj618URTazaSJdr+9TXPscLEbB5b7c59e/NeTftI6Dp2m+CkuNEimS3lvDbyiRyzeZGxBPPQV7HrutGWynuLmVJEsdeREWPAYxrg/ieTzXmP7US/YvAEdqzo8j6jLdgowI2SOSB9RURlLb1NZRW/ofM+o3uhzeGtPtLLRJbbWoXY3OoG8Z1nHYCMjC49RWC43ZxgHuPSnt1J/HFbnhbw/Dr8l4s+t6VpAtofNDahIyCb/ZTAOWqHpuaI58DBHP5etOUY78d/alA2Zz9CM0dxn7uMgZp2C4oHHUEfSo5vvDPpUx+uahm+8PpSYIjoooqSgooooAWiiimAYooo7UAFKB6jgdaB6ZxzUiKpXJHWiwmxvTG7sPSp7K0nvbqG2tIpZriZwkcca5Z2PAAHrXXa34JGmeAdG8R/ab1jqDspgksXjiQDPKzZIfp2H8qzfDejXc10lyomiMZEsZR/Lc47q3t61pGEpaWM5VFFXbFl8MX+lapJZ6/aXGm3caBxBcRFWYdfw4qG7uY5iYgyiRcbTtxj2rtri6juTJNdzXM8zttM9xKXdT6Etya4fXY5o79S6swAwvTkduRW7jyx0OdS55alxLid40W6kKSKTsbaCM1cs9Pa+VRvuBPu+fy+CPQ1z73AERVFbA5KueVPtU1rrl7bywvDK6vHjp3pKSTsx8kuhu3hk8po76AedEdqTYALV0vhbVL7QcSJqMcML48xigKgehU9cVzupeLbnUb9JL23tZGZdjF0IB4xn61lXGmXNzbM8NzCwY7vJWTt/StObXT+vxM+W+jParSXStS0q4t7zTk1eRyXt2s3CuMdWxyRjOea8w8T6xKkT6dqcDnyhtT7RCEdR9ABk+5rA0a6ntklAExk/vxy7SMep9K3L/T7rXGhYWl1JehQI2ikD7/0z+FU6kqnqHKovXY4SVSWwvIqKvQPDngy11a7nsdV1iLQ79ASsV3AQZD9SwArjdVsJLG9lgdkkZGK7kbKtjuDXJOm1qdkZplGrVkokmReRk4JAJ/QVXHysMj8CK3Tq0ECRvptuLZ9uJFHzKT9Tk0oJXu2E27WSNyPxLHoltJb6RJIJnAWUvbIVf1znB/SufvtYmvLjzJViHP/ACziVB+Q4rMu52uZjI5yzcmoASOf6VUqjfoRGkkj0z4e+MNM0rUtQuddtEmtJ9Onsfs9vGEaTzEKjdjse561qfFfVm1k6HqStbxaI9gi2EYYu0CKWDW7ueWZGBIJ/hYV5NAk0v8Aq43fA6qua6/wY/8AatvP4RvWKLfyCaxZgB5V6FKx5Y9EfO1vqD/CKnZ87Bx05Ucy8wUtII0yx6HsKhSR1fepKtjr6U6/guLO7ltbuNobi3dopI34ZGU4YH3BBFQp98EjcOpGabeo0lYk8yRs7nY+uTU1jdSWN3Bcwn97E4kTPIyORn8q6PwJ4G1vxzeS2Xh+zinuY4zKTJMECoCoJ568sPzq/e/CzxVYXcttc6fGssbbXUXCnp1q4xb2JlKK3F/4Wb4gfJf7Co55FsoJrI13xpqmtaa9jd/ZhDIys2yIKcjpg/jV+X4deImAxZqSBnPnL+P1qu3w98RmQKliDk8ZmQc/nVOFV73/ABIUqa1OSYc9enpmgNjGewzmnzRPDPJFICskbFGA7EHHWoz/AExXOdC1HxxPK6xRqzyMdqqoySfQAVLd2tzY3Elte28ttcJ96KVCjD6g8ilsLy50+9gu7Kd7e6gcSRSxNtZGHQg9qs63rOo69qMl/rN7Pe3kmN807lmIAwBk9hS62Az/AKVHOMMPpUueelQy8tQ9NBojoooqSgooooAWiiimAlKDRSigBQp5AxXQ+DtfTw3qjXsui6RrAaIx+RqcBliXJB3BQR83HX3rAjx1OK9T8V+B/B+laTpVzoni9NWu7gKbi1CBfKyoPUe/FUrN2vZkSdle10WZfiToes6NPaa74F0uKJebd9IzbeU/P3s7gV5zgYrDstTIaMFfJh4aIq2dvOPT9Kx7C2SC7PllmV8quf5GlkxbyNazQeSz/dJb5Qfb29q6acORbnLUkps2dUiuWtZ50VbhJDl9vr+FZdpBcXBKTo6lR8rDlD7VXttZutPeVMblPB3nt6iq0N/dyzyi2K78lgrfxVTkn0JUXYg1RlBYqSsm4qysuGFZ4OAu0YI7irl+1zOd9zGwccHNei/APwfoni3xuml+JoLiazltJJYhE5Q70weSOcYzWMnrdm8NFY8saR9pAzipbG6a2lDq8iN1DA819G6X8J/B2oarriLa34trezmntg1wQQVYBc/ga4L9onwPongbxVYWHh6KeO3ltRI4lkMhLE9QT0oqQcHZvUakpLY4XUNSGo+XJPclyqZwyYxjoM9//r1ueFbx0aB5zcXkIOHhjG0qvsa4UbVwQSSOorrtC8RyRHFzAbxEUgB1DbcVVOd37xFSHKvdPR/GGl28VtFrOlRQm1m4NrcjmPtjOevWsvSLbwLqdvJDewy2F8zBZGnYSjOf+WeAMfrXNT+NNWtbNYNP1G5Nq7H/AEeWP5Yz7HNP8O2114iujIbudLxsDcVyG9BitnPmaSRjy8quzf8AE/grwlPYFvDV1JaXEY5F3fRuJT7DAK15PJBciV1WN2Med20Zx+Ir648CfD9JdNZtU07TNXVhjyrhfKeP35DV5R8Zvh5pnhomawc20z5Y2yybx/IYqJwi9Fuv68zWnKS1lszxc87QVCY4JweaRvmbHB/DGaGUDpSDgHjj1rlZ0kkMs0eRFI6buDtYjNOAlU72Yh88HdyCOlQqR6kGpTtIBBJPeiyEztPExXxB4ag8TxNF/aCSLZarEvLu+3KXJzyfM5DH+8v+0K5KLaeWZw2eAAPT/P51s+B9bt9G1ojUozLo9/GbLUYgMsbdiNzJ6OpAZT6qO2ag8T6QfD+tzWbFpYsLNbTYwJ4HAaOQD0ZSDVp6a/1/X9bkNdEfQ/7MGjzTeEPFt9patLqcjw2ceX2ALgO2D2PP44Fa17aTRX8sV4hNwjYk3Nu55zz3qj+yzN9u8F+JNK09z/aKala3mzdt/dbowTu/7ZuMf412HjuaF/Fd68KgKpCkbcfMFwf1Fa4ab5mjOtFWTE8OeFdO1HSI7i/uri3uLmSZLWOLGJRGpJzx7E81Jb+ADdadBfQSXDBrNbpAGUAzFuU6dNoz9a1NGsJNc8IaXHbB1htJbtZ5EbayEBsY9cnAPsa39DuZVj0Sw2ExNpLSkjOSRgY/lU1K01L3X1/UcacWtUfn/rq41m+HpM46f7Rqh/wE4xWl4gH/ABOr4bSAJ36/7xrP79PxrE1i9A3Hrg9O9Gfz7c00DPJp3SkM3r+Pw0vhrT5dOutXPiAsftcM0aC3Vcn/AFbA7vTr71zs5+YD0GKlA6elMuVAdcYGRnA7c03e2oo7kFFFFQaBRRRQAooopKYC+9TWlvNdzx29rFJNPKwVI4lLO5PQADkmoh16/jV7TJ7jT721vbWaa2mikDxTRNtZGB6g9jTSvsJuwt3p19p07w39lc2sqEB4pomjZT6EHkVoaNLaebsusoDwrEfd+opNV1G61O/mudRvrm9mlbc008hZ3PrnvWWysp+YH6g962S5TB++dfdWpSHDFHC8xujcj/62Kzbi6NzCsVyyuVzscnlf8az7PUpbd1VwHj7jHOKsXsUd1Abiz+YE/vFOAU+lacyeplyNPUluLRJoVZbgMhxjdwScdKowI0N1uRQCnHXimOu60PVwCOhxj6iqhbMmcsDjHFS2i4xbTVzc1VlPlyLKRKR8yda9X/ZeLf8ACz7EMQ3+iXJPsdleKxtDACjKzZ54PKn39a9Z/Zx1/S9J8fTXWpLMY0spFi2YGHbAJ5PTFTN3HFcvoe2+F1IvdfLqwY6Zc7cqQW+cfdHf8K8r/bBb/iutMwVOLJV69Oa9avfGWlJ4l0HUtPSWOx06PyG3shbaQQQBnng189ftCakNV8Uw33G2dXdBuBO3ccA46HGKqreTc/IUGlaN76nlR65GPrVzSppYblBBxKTjGOvtVEEDryOtPRgjAozBx/ED0rFOzubyV1Y76003W9VVYbWC2+0AgKkRVHH1zgVYuvCWv+HyZ9V02/ETDezJcJHt9/lY0fD7xXpNvP5Xiy0F7aezlHz/AL45r3zTvh94U8UaWkvh7VLCPPzlJLj7SRn+FlfgGulyptXb/r5nLyS1VjyzwL4x1e2mB0rVL6ZIT8sRmywHvmrXxI+IHjbXdOm01LeaKzlGJQU3s49MgHiuT+Lts/hvW30gRaXI0fK3NjGIif8Avmsbw58TfE3hyLydPvyIh0VwGqZuN9V+n+f5jhGTV0c4uhaq0hT+zbst6eQ/+FVbuwurV/LubaW3cdpVK/zr0MfGzxkbn7QuoBJehAUBSPpXMeMfGOt+K5km16/kuSv3FwAF+lZaPoapzvqc3sOe1KBjjqO1Rkk5608HpuBHcGszV3Hhh3/Wu30nZ4s8HSaXJ82t6Msl3aSO2XuLX5A1svclDudR6bvSuFJx2IHr6Vf0HVbnQtasdU09wt5ZzJPEWXK7lIIBHcHoR6GqTsS1dHReCPGt74TW7SwiRluCpdmYq3y9gR2rpo/i1evLvksLPcw5JyT16muY8eaZaq1nr2jRuNG1RQ656QXAAM0H/AWPHqCDXKdxjk1ak1s397I5U90etL8YdSjXbDawIM8rGzKD9QO9V/8AhcGqI6f6BB8gwoEjjA9Bg9PavL1A7ttOPSnPAysAwbnrkdKTu+r+9i5YrSxZuma9vJpSNryuX2j1JzgUNYeX998kjhV9aZapIFLJkY4z6/St7QtIm1SQguyLnlzznPoKuKvsKUmjn4rYyOPLBI7giphYSKvO1Sep9Aa9Mj8MCGPyoYF3YyBt+ZvXPoKxNS0G5WQ+ayJCo4xwWPoK0dKxn7W5xckPloT2HGfX/wCtTDYSzyDAIwOeOld/4c8H3Oq3JUoq2sZBkmJ+UD69zWxq2m2NrIbLTY1VAOZDyfcml7G6uxe1cdjySSwMed78Dvtpn2VOMzYz6rXdS6muk6hZzaNJDFd2beaJZED4bnqDwR9a5nxRrV94g1m41LVJY5buc7neOJY1b32qMCsZQSNoVHIzDaJ/BOGHrtoplFT7vb8y7vuVwM5opwUk4xzXWXXhzSovCWm6nb6xNPqNw5W4svsLqsC56iX7rfhSjFvYtyS3KfhbWbDSINSTUNBstXa6h8qF7l2U2zc/Ou08nnv6VjB9qsMcH07VtDSVu4/9GbEijCjP3wO9Ys8MsblWQhlOCDVuLirmampCFiCME4A4PpWpY2bzxhoWR+MsjGsYggngir1hO8Uw8sDJwNmeufeiDs9QnG60JL60EbYXepH3kYYx9Pao7Rn3AB1D461b1GSR2/fQ5C8A55FZ0iKAGRsqT09KuWj0IjqrMsXEjxysjL8xxuVehqq21nIIK+oJ6UMV+8hYN/dJ5FDsXHPzds55qdy1GxKE2MElVSOuQeaYpRS7Aupx8pH9ai3YGcZHTNHOCu4f40mxpDjIxTLO5z0w1RszN3J+ppoQs21VLMewqWLMbngHtgjrU2L2ISCTT1QEnt7V2nhTwDrXim3mn0WzN1HEPn2sMr+HU12WjfAjxJqrKsMflBf9aJlMfl/n1/CtFQlbmM3WWx4yuQcA1ctruSCNkRpUc9GWQrj8q94tv2ctUMyx3upwRYG4jy2O4exAxmrOtfs2arHa7tJuUvCRlV+4fxJo9mtm0Jzv0Z87SSNI2+Uu7f3i2TUbY4Arc8V+GtR8L6nLYatC1vcxHBQjr7jsR71gng4J6VDi4uzRpFprQBkn1pScqccY9TQoOeM59qCp4wMk1IxPmHXv+tOU8Yz/APrpueMGpBg9OwxQDEbd6n64o5PJ7e9KV4759aVQM9wO4xTFc7b4d3kWpR3Hg7VCv2LWHX7JLI2Fs73gJL9G+43sQe1ctf6dPp2oXVneq0VzbSGKRCOjA4qKGFtodkfb0P0r2iXSX+K3giyu9Mt45fGukFLS9jUBHv4XOIps92GMMT6fSn8O/X+v68/Uh9bHjCxCMbiwLdME8j8Ks2+9yEbeVJ6L1NXP7HvYNQmtHt2Fzbu0csfUow4I/Cup8OeHLu6nVNkwmcYXyoyzfl2rWEW9jKUktzPsdDlnmUpayqD0hPLN7n2r07wl4WdGSRIGklxtjQL1/wB36eteg/D74Ww6fZfbNflnhkYYQTNtx9F71tSadcQa3EmiLMwUFdyjLOO+B0A961jOEW11X3GbhJ2bOLvvC13pFq02TLdyn94iDO3PbNcRe6LPqGrLbzzIsUXMxAJVB6Z9a+hLnRJp2Emp7N3Gy3ik3Nn/AGj61XTwrpehW8uo64TKAS8dqOFHf5u5qHiIW1/Av2LvoedW+mQp4fjXT7WSDTUfMTMCnnN3bHevLPF+r28KTw2LP8h2yORwfbPevS/iZrmpaqjXF8GsbHZttrSFhlgfp/OvB9WLFWBUp83EZOcf4mqlUk1roZ8q5jEmlWbMSIxJ5JPeo4LMyEjuRx7Vp2GnFyyJHukY8uew+lT30dtb7YIgCUH7xkOST3zWVtLs05rOyN7T5/hnb6daxaroXia41BYwJ5oLqNY3fuVB6CiuMubtPN+ZR9M9KKh+v4L/ACN1J2LuheH3l1DZq8F1bW6Abw8ZRiew56fWvqf4Y+H9J1/wtJol9brNZBDsTIDx/T1NeRaH4rv/ABmZY/EFz9rvMcPPjL+3A4rt/h9rd54Z1m3aWVDprtsLAcofQ+ldtKLjSvDd/wBfd/VjllLmqWlscv41+Fc3hHUnls3d7Mt+5mI4XvsPvXm/iW2gui7ErDcIcMMH5vf6198yRad4g0zEkcN1byL8y5DAD2rxr4i/BiKaKW/8NfLKiszQSHOR/snH6Vzxqwn7r0ZpKlKPvRd0fIMqOnyPtOD1pixMY2fqB27ium8S6HLp87ZVlI42svIrCtDL52AVz0y3T8azcbOzLU7q6L1oY57cRPKA6jIDnr9KoXVqIsMGwrdcn9afNZXC5dYyFPPFQxSqsitISxHDK3QinfoxJW1TKzptbAIJJ4waYpx0wPrV68SMkvChjj6hT2/GqMmMn1qJKxrF8yEDYI74qZZY0YFVJXHIaq9PMZVdxGV6ZHSpi30KaRsafraWrjdaRMFO5GXh09ga6O98Zwa1bTLq2m27lVws0QEbgduOlcDR0q41px6kSoxZ3fgbx5rfg/U3n8M3gtgww0cwDLIPQ57161e/tJapeWEaJpNtZakvIuY5Nyj3weDn3r5uRzuzgE447YpxbMmHH1x3rNqMnzNalJNKyPpuz/aV1CC2jj1LRLe6cjBdHIZj64xivNfEfxb8R6nfPNaaxqVuNxYR+bsVR6YB5rzZZGR1O/efRT0+lSteJDKHtEdePmMoVufoRVKEF/VyHKbOmPi7xHqtxJPLeR3s0gwftaLJgexbNZl1FdarLG19HHA5+UMsO1W/IYrEMrecXUsjk5+X5f5VoWd+zTKt7LNLEv3V8w4z+daxktv1/QiUWtUa6+Ata8nz0gjkj5ORKoJ/rXPT2NzDIVkhdWHUY6V9P/Bbx7otvYQ6brcFpYliBHKVEwfPqWzivZtR8NeG/E1mFRbCRfvLJbRxZHvkD9KVR0otLVFQ5pK97n56vazAZeJwrdDtoEB58zKkcAGvt/VPgvoc9rKBNeSykZQFY1BP4AAV5qn7PWpSTuZHgQ5LCN33DH1HepXs5axl94N1FvE+bEtZmXKRuwUZJAyKfDZSyuUCkN6Yr65svgM0ckAl1mGK2H+sihhJOO+Ca6qz+EPhey2hrP7cRkl7k4I9htpOdJfaGlUfQ+O9O8M6ve4WDT7qZlwQVRmGPw4Fe3fCG31fwW01vrOizy6fezQyTTW6fv4VUgleOSh4yo9M17xD4ctILAWVgrafbKRvUNyV9AeuKralptnYW4/s6JZ71OQ09w64B7kij21J6JNi9nJa3PDo/Ay6r42vXunuLDTrq6kmWSCJy7AsSCTjjPvXsujaZonhOwcaVHJvIw753u7fU9PwrktZ8aHw3A0OoapHcTu2RBZAszL6Fj/U1w194yuNbukXzLi3tzwLe0c789s4rZpz02RlzKG256cdTvHuXEFsXuT96W8uSyw57Lxn8q6zw/aXT2XlNdbXJ3SvGMHPpxXIeC/DrLAlxdpcfaJB0uJTIxX6E8fhXd2umXSKqfaPs9oB/qo/vN9SK58RKEVyqyN6Sbd2F4ZNPt5E0SzWW5APzFsDJ9x3rzjXEvoN11r12JLz78dtuwg9Cw9RXol1utLOU2cIjTP35ZNqt68jJ/MV5v4n1NZYhGllFLvfoJNyu3r0+b8cUsNq72+fUK2iPMvFEtxqMUk1zdCNGBLt/Ew9F9B71xkelWUQN407S84G4D9PWvUNS0+S/V444PLdBly2P1bPI9hmudvI9N05wyKk3lKSGHCg+tdzijjuzhbvTr1E3QZt1m5CnqB7+lYV1LFbxbUBVVyGZRksa6a61yK7aTfuKucYK/NWRqelKsO+QYP3lA6Y96zdug07fEcq8Ek7GQwnnoQOtFXvILEkwuc9w3BoqVFdjo5/M6e0vrS0uV2dFGY5lTp7Gu+0HVbHUolJlcTsQGjYYVx3IPr9a8OSafcxjDAjgjP8q7jwZM/kid0XAPIJGT+Fb0qr5rHPOCSufRvw01ywtbw26XUkYY7YldiwHt717IrZUMOvY9jXzF4SuYjKn2eKOYFstZzdMeqHnmvoLwjcRXWmxG1mZ0X78UnDIfQZrLGU7++jfDz05Tk/i14BsfE+nzXLKsV1tO6TbkNjpu/x/Svjrxd4bvvD1/JDcHayHhsnOM471+hj8A4UsCOnr7V4T8bvhfe6rE+reHkS4REy9rITvQ55KZ4A9s/hWFKoprklv0/yKqQ5fej8z5WTVWKKkzY2jhlGc49RmlexE8X2i1mWZBjzEAAI+lQ3di1pdyR3kLxN0xjABqJLeBQrJPgn2qk31Islqjo7S3T7KCYXaHoVbDcd/pWLqthDLMz6bmQAZZAclahiuLi2kaSCaUY7qep/Gti3uhqsyk2gEyKAZYRg49SO9ac3MrMlXhqmcoYiDhuD6GnpHKoYx9Mc4r1Kz+Hc+u2JutPu0eYjlGI3t7Y7VhDwwNJmlt9ejns5yCqF/lQf7WehoeHcdXsX7dNHEoFZiszFBjg7c0yWPZj50bP9013Op/DvVRbm80V4NXs1Te80Dj5PqDjJ+lca0BR2jnVon6YZSKznTcXZo1jNPVFWnKQGyy5U9qsrbDeV8yPI9Tx/KoGBDbWCccVnytFXTG7gOg/Okznjt6UHGeKVVB5PTvS1GPR+gJ4HapopmyAfmHQLkColVc8jPpivb/2f/AHhjxjpXiebxJDdTTaekcsP2aYoApDE9OpyBVRZErHkVtdxJJskhZlJ5+evQfDnjm50mzS30y9FtErbnTOwN7bh3r1Hwb8GPCOrzagLq0vggCR2w+1YJlIJ5+XpgDmvBfiBpdt4f8V3VjYpJHDCF2h33nPfnA71s7xurmHKpWaR9F+AvioJiY5p711UBvJt8Sbj3+ZzmvYNB8Uwa2u+3tZYEzhjcELj6etfBem+ILqymSS3ldRnkFQAT+FdVp/i+7kvFe61M7FGVyzYH0VSP8aiUKdTfccak4aPY+6ZkXy28wgR9znA/Oqs99b2/lqrBt3A2/MPxIr5d8OeLtQvFBj1K1YhgBBJdlAffDHrXfzX7ahYomoyXczofmt7SUIQPYjqKzjg+bW5p9Y8j1Wa7tr2UqdTijjHDJGVOT9T0rgPig+l2OmXTpPqL3QXYfs4bI9+OKvaZv0q3DQ6HKLaRcrMsYZwf9oZ5qvpdgmsXJvdYsZAqny8bSCc/wCzninCj7N3b0+QTnzK3U+fbO2tprjF093In3l+0Esyn3CcmqGr3et+FmbVbbSJHsTIFF4xJVT2BGBtP1zntX1/ZaBYWxUWeiwqg48xyoYg+2K0xpdrNZzWt5ZWz28imNoigKOp4wyng0p4mMVaP6ChQe8j55/Z0+I2qeKfG8+n6obVLZLJphvdizSB0UBcnnhjxjtX0jdStDG0gA2KMsTXD+HPhJ4N0D+1VtNHt7iLUJFkaK8UTLFtHCpuBIAJJ9eevAxDq3hS60lA/h7VdRsEHKwef58AP91Y5t2B7IVrjcvazOlJRRoeIbu1vokGpkra5+WJFYeYewwOT9Olc9N4d1PUJElsdNWK2I+SElFcZ7tzjn0qott4oe4Fzf2sWqBR92xmW3aP3EcgYH8ZVroPDWvW2oS332a31CG5t7V2kF9GQSfYqSjY/wBknHrXZGTpxtAwcVN+8N8MwfYbHW01CztZ5baaH91OFkCbuCO49+KS38OafbzataXVlaMNSvJLa2ZrdCU2ox+XjAycDtU+ia3JLYeJNU+zW/nRpB+5PKEgNyfr/SrPh57W7stFnv55Y7mS/lkgVQSHkx91jzgflUNzTcnp/na44qLSSPlHxpa3Nr4jv1ggVAkuwbECqmMZwP61z9xFKXaS4dkXnOWII967rx9f2tn4m1Utumc3DjaByvPr2rzzVtShvjsKuFU5OD970rrdvmci3sZk9yBIREs3ljgH1op0kgLkvcGM5+6euPwoqeZl/IzoJGLAxlgVHBPatm3S4QrKgJ/3DnB/CsZY9oQgAHOVkB+U+xr0DwlZW+rRPb+ctlqIX93vYbJB75qqceZ2YVJW1Q3QtXmiuo2a4mjmj6EHr7Cvevhj4kvZLyIvIs0DHBkQhSp9COn6V4LdaTcaReRrqEHkXKnkOcB/oeK7Xw/rK2LC8s0McykF1HTjvg963jFK8ZGalZpo+uUcSpuVs56k8ZplxG0sJVX2Me5GQRXAeEfH8N75Ed3IAr/Kem5D7gdfwr0OGWKaPfE4dSM5U5/P/Iry505U3qj0IyUloeAfEb4UzGS4vLZPNhmYlkVc7fZcc5968F1/wdJYSEEFBvwpYYA9ia++9pBI644rgfiH4E0vW7OW9LPZ3CLktGheN8D+JAD+gzXVDEKelRa9zmnRcdYM+Nm0WSK284IMbc7OCW+n/wBes5I3WY/Zwqc/MQcgfhXpfiTQW06drVporeXlwDkbh6juPxrznUrC8064bzY8ZO5pA2VIPqRW01ymUXfcv2V9q9hKjWdwq7+SV+Y/5+ldtFqo1Wy+yeIJ4bhSMGXJwme3PQ15e0d5CQ72sirncpQHA9wfWtzTPFuoWckSQRLNHH/z3twzAn1HelCpyO9huLex1CRaj4YnEujz2eo2LfctJ8O2D/dPb8aqywxeLmkEOlxpdbuVM2xgfQZOMVu6D4o8J6jZpF4g8PJ5jvhhFMVMrfT+H6VH4t8DaHLvu/C17Ppsg+cW08qlV9FUjnP1rRST0h93T9SbP7RyuufDHVNKtBLMjxN38wqU59CCa8/vLV7edo3I3D0BwfpxXb2njLXtG/0LUH+1W4wPKm+cY9j2rsE8U+BfE0UUWveHHgmCFRPZyvkHHXaSB1z61hP2culn9/8AX3G0ZTjq9UeIkcnjA7UqgggjmvS9Y8D6DJEs+ha60a9fLv1+c/QIK4e/0yeylZHMbqCQHRhg1nOm4mkaqkUa+j/2UcHRvHbNgH7JFy3To/WvnHDbsYOfTqa+if2YNa0rS9N8TQavBcu90YF/dlRhF3cHLDnJ7VG2oNo9u8HafLf+FrBIwi/Z9VW4cyErlVHbjrXyj+0O3/F2PEB6BpBj8q+nr7xvpkz27iO4Hlakl2RhM+WBjH3utfLXxuuI9U+J2t3cAm8mdldQVyQpHfsKpuUm2+pN42SRwMTIHXcpIxyc1v6XaW9zMoluktxnK7hkVFp/h7ULz5orYmI4zh1Bx9Ca6fT/AAwLktaW7XT3iHAXyk4P13VpGLbMpyT6npvgDQtAZYZNTuIJEyNq29r88mP9oE4r3bSxpltAfsGkixjIH7y4Q5YfrXkfwy8D65a2u0LaCUDI8xGytez6PpF7aWardzRm5HPmQOQCfcGjETSSTeva5dCL7D10wXNwLq6mlRV6Rh8Rn/gIrXjt4InLRRIhPoKZHbgSeY4HmYAO0/K2O5FTivLnNy0OtKwUUjOqn5s/hWTPrLrO0cFoXAAwzOBuPtUqLlsHqa/865PxzqFza2rnTbOF5Yxlrq4yY4h9BjJ/EVtFrueMtLOlrGByoGT+dc34j8OWmrW3zNdXEq5K3Erk478ZPIrWhGKn7zFO/LoeT3es3t4komvJp7ckkNHE0IJ/76Ofzq3oPiL+zjdNDbiJ5YDbyPKCV2n054PfnNUdcsbOxZhc6sZIV4ZIIyBx269fb9a5ho7S8u4f7PtZ50Bz+/j2j8snA/OvYUY2sjz22jtLXxvb2el39hblJbe9YB2WFnOQMcMOMUR+PDpkNjFGkQXT5zcx74mO5mHQkHkfSvPtQvPLlkVJllmA24t+QnsSelcZrmuAyNEhZl/2D1PtUSUOoKUtkL43u01TxJqF3ucRXEpcttKA9Pu1z/m2ojb928S7iBzlmq6tvLMBc3ysiZCqucF+P8DWjb6ZM/mS/Z1jYAkKxzt46salQbHey1OaayllYtDE+ztkUVbupo0mKu/mEDG5Rx+FFLQq7OchlaJsr+VbOnawIJU3KPLHVT29xWFRWCk47HTKClueoWviWx1S3S01tfOhBxHdNy8Y9AKsPZ3ulxefpV6t7ZsAxwfmHoCOf515bHMVI9umK6fRr5bcGaCeaCU/eUNnOfQV0U6vNpL/AIPy/wAjmqUuXY7Xw74suIr1optkfqrg7gfavdvAHja9eFi6yTwg4BwPl9m9RXzdbyw38sStcKznO1GHC13ng2XUNMuUlsLwxkH5oi3+sHcEenFbQgpKz1REZuDPqnR9btdQTAO1uhxyB9fStQgH7pUt1PpzzXk2geKrV7sCWBrC4bnBbcD79q9F03Up5drSLCYTzvjOevrXFXoOD0OunPmMjxV8P/D3iQTfb7JVuH+YzoxDMe1eH638KZRNdWlkyxOAW8i5UhAg6bSfvH8a+nYpEmjLwlWHPPr7e1R3FvHdRKlzErDqBj7pxwc1FPFSjpLVCnRUtdj4b1DS73QJDBcLPbkZIgkU4b3BPQVzN7dW1w5WdjaTfe8zGcn8K+5vEfg7TNcdRqVlFcsFKiVuCg9PevK9b+DfheFmKjU7d3P/AC0O+Mt+XSuiM41NIu3kZeycdWfMcelmVg6X0LSMcAjqPc11GjPPZWr+bd2l9CzDKFTu7c5rqdZ+H2mwXD2lu4jnByZhEwR/YN2rJu/BOtwma2trKW6G3O+0AkVFPYnI5rXkcHdGblzaFO/j0HULZkh0+yS4I+adJT5n5E4/Sqvh/wAP2T3RERvBeoQVJKlfbkirX/CPavopX/Q7jBGW8y1xt9e/PerujTatZTefFvt+eP3BBdfXkmqV73kvwJv0T0PQbW91bSrKManpGk3lpxiXcjSKPVlQDipdX8AyeMLGS40Wx00My5HlBhn25PFWvC2rXd1HDJdXFtAVPzvdREfoK9Y0jUtBulXD2DTfxeU5Uk464/KirW9mrb38/wBLl06fOfKer/BnxLpkyrcW4i3cgorOB+Iqr/wrjUolWSZxgKcnI4P419mQqqXHmadDazow5AkO78ySBWgoMoBls0jPuVb+lcjxEFvH8Tb2MntI+G9H8HXd9JIiW2qTyo2C1vD5kf5gGt+88KG0dISpFw3AiljaNz+BwPzr7LjCRg+UiRn1RQv8qbJFFK26aKJ2/vOgY/rURxkV9nQbw7e7Pnrwp8PNXuDD/a1npGn2uBiedY5WcewGa9e0nwTpFsbeZY7aZoxw6W6Ln6YFdKYICADBFgdAVFSIFRdqKFHXA4FRPGTkrJ2LhQjEcSSoBOVHGKjE0DMUjliZh8pUMCQfp2pWOPmJIC84HesZ9S0+C4LJaxibd8xBCsvuf0rkgmzbQ2uuCPwqOeUQQySSFUCjdls4x+HNZt1qsUA3wSLIGw371toA9AelYWpzvM7FdQuJW4ItYApUfU/nVQouT1BySNEeIrErG0haaWXCgWsLEH8WFUry6WNz9qtns42bIR1ySPUkf0rM0rWNTx5NrYQ26BiCrbi+fXB4ArRvHkRPPmufKTvIF3bG/wBkV1Klysz5+YUanbp8r3L2axHmW4TehH+ySDj8azL3xHolz+6srh9YllBbaWLQoR/eHRPwqLUJNHvoWfUpZZCoKsGbazAdyi9Pyrh/E3iHT9OTFmI7O0ddoSGHbv8Aqzc1pCknq76f1uZzm0aXifVdH06SJp3tJtRlBEan5lTHpjJH1rz7UkguY5Hlt5WiZs77qfZHnqNqA8j6gUrxWdyEubiQwgDMartLk+39a5jWbUTzhpnYsMkeY2di+pJ4/OutprzOaTuZN/dRurxPBM8auQViUKjfQDt70tho0t/LG628dpDnCyPwSPRR2/GobjUrKyPyzs7qeiYOfp6VRuPE7DIEu1D/AMsQck/U1HMr6k8r6HTTwaZpjtJcTNIRxhWO4/U+9ch4h1Ke9yufJtE4WKM7R9TWfea6szKZUdsduw9Mf57Vn3Fx9pOWXap/hzmlKakrFxptasrOxJ5Y8cDBoqOR8NgEYFFc7djpsQ0UUlSaC0+KRoz8p+tMooA1dNuoPNH2suoJ6rxgfWvSdJszd2qNa37yngqWbAHp83415GDzwQDirthql1YuTbTPErEFkB+VvqO4ranW5d1cwqUebY9xtNf1PT8QajcLfqMYa7h+YgdArDqBXY+HPifJpZjj1DTZljxgMBzz+gHtXimg/EKSB44tWtxcWwG1lPPfnaf4a9L0HWPD+riNLG+EZZsixuwCOPR+p/GuuM6dRcvNb+v67HO4zpu59F+GtZsdato5bGbypH7FO3uK6pVJUfMDkcY4zXjHhK+XSpFgurdIYnOVuYx989hx/KvRrXWpElit76LzZXHBj+8F9SO1cWJw8oy906qdRSWpvOitzyfXH86jZSSQcMOvI/pUkU8My5ikH/AuKlA+p7nFcWxsU57eGZPJnijkjcYKMox/k1zl74K0K5aFxbS2XlnI+ySGPcf9oDrXW7cHLck8U0jDHggE/p6mnGpOOzE0nujjP+EEsgd0l3dSleQrPx7Zq3p2gw2wQXunWU8rc+YkQGB710+0bcFTtHUZ6U0Y8wYx+PHb/wDVVvETas2SoRWyKSWdmgIitIowRzhB/Wo57CDzlnW2tVkjHBMS5PoAe3UCtMr67iSOM9fesPxCLGeye21K1vPIYjmFSCcehFZxcm7XL07DNT1eHRo2m1CB44CfvRurY+gFYkPxH8Oy3gjF8VU/LteFkwf948V4p4x1EaXrxh0mS+nXHMckRjKD6nrWhoep6ZeeW/iK6uxg5UFwyA++BxXYsJFrV/1/XmYOu72R9CWF7b30Ye1niljP8Ub7hT2urcSbGnjDehNcBoeqh7gDQpTd2/8ADFDcrGff5SK7XTXuZV8y7spbc9MSOrfjxXLOjyddDeM1JF1JBICVBGO5GM0rssYy7AD3qVUJOPuj+VYWsjUHR4Uv7a1GMiVcbx+BrKMeYpuxR8T+KLHTR5cl7JalT88n2ZnUj6j2rze8+Iun6leyQG1cEZKXKpndz97HX04qx4mspor1Wm8XSX9wwysYtsp9CRwK5HVdJRbgS4aa5GD5vksoX05HGOa9LD4dWunr/XkclWrK9i/qmorqKq01+0Kwtks6lFB7ZU/hWrp9z4tvlCaO89/bzDbvaAIn4PTvC8lhGUm1W3j1a/ZxEQ0wKDJ6hfbA616qur7baeFLNkWKP7ikJ17AVdWXKklG4qcebVs88k0nxLYLA+v+IorSFePIjIZ2P90kda14tGvtVnZC8VvZsB/rNxLD+8D0FU9avLi/P+ga5GrKTtxtlZfYnHFYMmq6l4ehAuNcMzk8Woj8wv8Al0zRFTcbq1wcop6nQ+K9Emgsmi0y5KXSjYJ1XJUfXvXmd5ob2ANyBBdXbZIuZ3yY29kNaOoeMtYMTSXEDjkhRPMp8r8BXknivxR4iup3SeT7PGwPzIAocZ6j0q1zRXvK7Jk1J6F6/f7NPvvL0T3ZJOIV+/7Y/hqhql7ZNan7TIEC9YixOfr61y8V7tibNwN38RY/M2f51kak0Ym2xzM6jkMT2rPnYlC7sW7y4sN0hVCzHoemBVG4uLfASzQxx4+ZnwWJ61RkYZOOv0qPtisnNnQqaJC4GcZPck0jSM3U9OlMpKi5dgopaKBhSUtJQAtFHbrRSABSg4oAzRigByketTwTvBKGRijdeO1VscAmnL6E496aJaue+/DX4+TaIkVl4i0m2vbbIVriJdsqIBjhe5z3r6G8G/E3wL4nWCLTr+CG+n62tz8kox/eJ/xr8/wc+mKmSZwAN4wOetOSctbsV7aWP0yzGU+0QxrdRYyrRkN+C1Sn1q2iMMFzHLDLNwkYBya+DfCPxN8VeF5rc6VrVysEAIS3mO+EA9tpr0bR/wBozX1kzr1lZakxGBIieU0YPXAHWojHW019zG5dj62s5EKN5V2suOqOeAfTNW9w2ZfA9T2Br5r0D4z+F7q5nVrcaZBGN4ku5HBkb2AzzXdab8Q7DVWtW043NzHcZEe+dAHx7EjH49ap0IyfuyJ9pbc9UnklCbrVI7hs5GWwAMe1Vn1Bo5cJZXUp5LOuAqn0ySK821rxPqlu0htdImuRH1WBmjKn3K8GuWHjDxNIgivxcWVvPwDOpdVH904yfzFaRwM+qJlXj0PZNVurpLZjE0dtu/5aBjIU9wo4Jrl21UNvj/4S6T7QQdiSWoiB9uTXnsdrrM7iW18VWlrIeQqSypkewVSM806/03xFLBJDfrLrluF4mS6V9p4zxIVrSOFUXra39dLP8yHWb2L/AIx0vUL+KN72TT7ox/vN3nlHYflXI28nkujaWlq1yuS8VzErpj65Ga5jxQdAiJiktr22uVBwlxJ8h/75JxXDgu2rKILVZ4Dgfu2ZvyOBzW7ny+6/1/yuY7u6PqfwXftqaLDdx+HY5ABtj8kRNn1HzV6Vp8NwU2iW0RR0EI38evWvCvhr4J/tGGKe48O3YsscT3FwYTz1woB4r2vw34f0/Ro/K06COB8fNiVnY/ia4sVFJ/1+rOujJtamlPZecMXU7vGB91Rt/GqMg0y0yiCIH/byTz7mtoZVtpDYx1I4rH1aC+SUvZXaQptIKSuCCe2ARXJT10bsby01OX8Q6osTL9mhECd3+yh8++RXmninxBYybpb7W7oxDgW0QEef09c10vjnVNYtbr/TdX0yGAD5Q4G415VrUlwzLNHdaU/B2zCMH8a9SjTXL/wzOCrUbdi1Hr+m6lvksVuVtyQGBcKyfhjrVifxLYxtJjXHuHK+UROCGXsBXFNpl49w8+ozJI27fHMsojH4YrnNWuo3lmRpocj52eOLexGf4jnmtHJrV7mSd9ju59bs7K6iFpdPFO4wUgAzJn1rJm1x7SObyIpZZ85cSt0+o6muQj1PR4raL/SXhEvyv5Y3FcfxFev61UuPFkdvbzw2UXmSZxFcEbQV9155/GplVS1v9xSpyeyNe61TxHqELS28NxDbE8vjEY/A8iuTur1mMhnk3yKdp/eZ/Kq2oa9qWoJ5dzdO0YOQg4ANZZJPU1zSqLodEKTW5YmljZflViwJG5umPpUBOaSkrNts2SsLRSUtAxKKXHFB60AJRRRSAdg+1dr8HfDFp4v+IujaNqKyNZTyEziNsMVCknB7Vt/8LiuyBu8H+CT7nR0/xrpPBHx7h0PVnvr7wP4dLrGVik0y2W0lRjwcvhsgjjFJVLP4X+H+YrSfb7/+AcJ8X/C1t4Z+JGr6Ho0UrW0DjyY95lbaQD1xkmuIdGUlSCGHUHg19Fax+0Ppxvzq/h/wLplp4hLc6jc7ZWKkYYZVVbJHGc02X41+AbmV5rz4V6dLdSHfLJujy7H7zf6v69afPB66/cCUlorfefPSqNpxg8cn0r2X4k/DLSPDvwl8KeI7L7aup6lGjXCTyDYNybjgbQR1qvbfFnRTrKm5+HPhH+yTId0UdmRMY89N+7bu6c7ce1ew/wDC7Phh4n8LQ2fifTZLZLV8wadLC8yfKuEwyLjB6Yp88Y7p/d/w5LUj4+dCp6g0BT/eH519Dn4s/DBnYv8ADGEqD8uDHms3X/il4Be1j/4R74b6WlwGy/8AaA3IV9tjZzUqUXtf7indb2Mb9n34b6b8Q9V1u31c3QjtLUSRG2kVcSEkAHP0rzLV7NtO1O6tHOWgkZDyD0OOte+fDj49+HfDcd+ZvBcFhPclQW0c7Q6AfxeY3X6VQ1b4p/DWXULWSy+G0EkMkhN61zjzCp7x4bG761XP0sTy63ueDZ9xVm2gkkZNisSzKq49ScV7lqfxO+FIsJjpPw0iN6B+5+1BRHnP8WGzVXQfj2PD1rJBovgPw3ZwyN5jpGH5b1OaFK/RjcTL+OPw6sPAEPh1dPnu5Jb+082489gcSdwuAMDrXkqyPG+4MQw6fNjFfS2rfHPwL4uttKl8aeE7q8vLRDuhTa0G49cZOSOMisq2+I3wdMcn2v4bqmJCE8tQcp2J560pVIvdP7mJRa0PHbTxx4os1WO28Q6pHGvRBctt/LNbVt8WfF0MrP8A2mJd4wwljVuPxHFXNf8AiD4bvra/tNP+HWgWvnBkhuFMnmxjs2M43CvMv6U4u22n4Dcb7nuuhftCavp21brRNJuolGNphVG+uQtdXafHzwlq1o0fi3wq8Uik7Bp6oePXduUivmAc9+aCT159ad3e9394OKPo+b4nfCnzCyeFNTnwCF89snH180kVHD8Xvh7HIGTwZcxADC7Lg8e/XrXzoGbB54NLuPUHFV7ST6sj2UT640n9oTwhBHEwsNeQocBGumfj2BbpWpdftJeE7hHQ2GsqvUtGMEH25r40DMCMEZPNKHPTJBz9KycFe/8AkVqup9Ral+0bbQsy6T9uZCMg3MWSD+fNc/q3x5XURG2o2p1GMH5rYxGEH33A1897iPT2pw5HarT5dV+gnFvdnreq/FHRrxy8fhYxk/wteF0x9CK881bxBPeXbyQRRWsRbIiiHy49DzWKS3XP0NMNU5ya1YKnFO9i1NdTSszNIw3HOAxwPwquWPOM4NN5oqTS1hQTnPeg8cHIpKO2KQCUtHWgUAFFFFACUtFFAAKMUUUwCikoqQP0q/4Vx4H/AOhN8N/+CuD/AOJo/wCFceCP+hN8N/8Agrg/+JoooAP+FceB/wDoTfDf/grg/wDiaP8AhXHgj/oTfDf/AIK4P/iaKKAAfDnwQOng7w2P+4XB/wDE0f8ACuvBBHPg7w3/AOCuD/4miigA/wCFc+CP+hO8N/8Agrg/+JoHw58EA8eDfDf/AIK4P/iaKKAD/hXPgj/oTfDf/grg/wDiaP8AhXPgj/oTfDf/AIK4P/iaKKAD/hXPgj/oTfDf/grg/wDiaP8AhXPgj/oTfDf/AIK4P/iaKKAD/hXPgj/oTfDf/grg/wDiaP8AhXPgj/oTfDf/AIK4P/iaKKAD/hXPgj/oTfDf/grg/wDiaP8AhXHgj/oTfDf/AIK4P/iaKKAD/hXHgj/oTfDf/grg/wDiaP8AhXHgj/oTfDf/AIK4P/iaKKAD/hXHgj/oTfDf/grg/wDiaP8AhXPgj/oTfDf/AIK4P/iaKKAD/hXPgj/oTfDf/grg/wDiaP8AhXPgjP8AyJ3hv/wVwf8AxNFFAB/wrnwR/wBCb4b/APBXB/8AE0f8K58Ef9Cb4b/8FcH/AMTRRQAf8K58EZ/5E3w3/wCCuD/4mj/hXHgj/oTfDf8A4K4P/iaKKAD/AIVx4I/6E3w3/wCCuD/4mj/hXHgj/oTfDf8A4K4P/iaKKAD/AIVx4I/6E3w3/wCCuD/4mj/hXHgj/oTfDf8A4K4P/iaKKAD/AIVx4I/6E3w3/wCCuD/4mj/hXHgj/oTfDf8A4K4P/iaKKAD/AIVx4H/6E3w3/wCCuD/4mj/hXHgf/oTfDf8A4K4P/iaKKAD/AIVx4H/6E3w3/wCCuD/4mj/hXPgj/oTfDf8A4K4P/iaKKAD/AIVx4I/6E3w3/wCCuD/4mj/hXHgj/oTfDf8A4K4P/iaKKAD/AIVx4I/6E3w3/wCCuD/4miiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The parasternal long axis view shows a greatly dilated aortic root (Ao), with a diameter of 6 cm; the etiology is aortoannular ectasia. In the Marfan syndrome this degree of dilation is considered an indication for prophylactic surgery.",
"    <div class=\"footnotes\">",
"     RV: right ventricle; LV: left ventricle; LA: left atrium; rPA: right pulmonary artery.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_30_37344=[""].join("\n");
var outline_f36_30_37344=null;
var title_f36_30_37345="Hamilton Rating Scale - page 2";
var content_f36_30_37345=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F60363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F60363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Hamilton Rating Scale for Depression, page 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 685px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Hamilton, M. A rating scale for depression. J Neurosurg Psychiatry 1960; 23:56.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_30_37345=[""].join("\n");
var outline_f36_30_37345=null;
var title_f36_30_37346="VF bilateral HH";
var content_f36_30_37346=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F77953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F77953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bilateral homonymous hemianopias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 426px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Humphrey visual field (24-2) showing bilateral homonymous hemianopias; there is a complete right homonymous hemianopia and an incomplete congruous left homonymous hemianopia. This patient had bilateral occipital infarctions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_30_37346=[""].join("\n");
var outline_f36_30_37346=null;
var title_f36_30_37347="Saphenous vein cutdown cannula in place";
var content_f36_30_37347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Saphenous vein cutdown cannula in place",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Secure the cannula in place and apply a protective dressing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_30_37347=[""].join("\n");
var outline_f36_30_37347=null;
var title_f36_30_37348="Amphotericin B (conventional): Patient drug information";
var content_f36_30_37348=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amphotericin B (conventional): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     see \"Amphotericin B (conventional): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"     see \"Amphotericin B (conventional): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F134687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fungizone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat yeast infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amphotericin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697798",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may need extra potassium or magnesium. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. You may be given drugs before this shot to avoid these signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3796282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney damage. Sometimes this can be long-lasting.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698630",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cloudy or pink-red urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11286 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_30_37348=[""].join("\n");
var outline_f36_30_37348=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134687\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026669\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026671\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026670\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026675\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026676\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026678\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026673\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026674\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026679\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026680\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=related_link\">",
"      Amphotericin B (conventional): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=related_link\">",
"      Amphotericin B (conventional): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_30_37349="Diagnostic evaluation of vulvar lesions";
var content_f36_30_37349=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic evaluation of vulvar lesions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/30/37349/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37349/contributors\">",
"     T Minsue Chen, MD, FAAD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37349/contributors\">",
"     Aileen Langston, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/30/37349/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37349/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/30/37349/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37349/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/30/37349/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide spectrum of benign, premalignant, and malignant lesions may involve the vulva. The challenge to the clinician is to differentiate between normal variants, benign findings, and potentially serious disease.",
"   </p>",
"   <p>",
"    The differential diagnosis of vulvar lesions is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20618?source=see_link\">",
"     \"Differential diagnosis of vulvar lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed history should be taken prior to having the patient undress for examination (",
"    <a class=\"graphic graphic_table graphicRef59050 \" href=\"mobipreview.htm?40/54/41836\">",
"     table 1",
"    </a>",
"    ). Important features in the history are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How long has the lesion been present?",
"     </li>",
"     <li>",
"      How did it look when it first appeared? Is it different now?",
"     </li>",
"     <li>",
"      What treatments (home remedies, prescription and over the counter drugs) have been used, and what was the response?",
"     </li>",
"     <li>",
"      What symptoms, such as itching, burning, or pain, are associated with the lesion? Are there systemic symptoms?",
"     </li>",
"     <li>",
"      Are any other family members affected or have a similar history?",
"     </li>",
"     <li>",
"      Are there any lesions elsewhere on the skin or",
"      <span class=\"nowrap\">",
"       oral/vaginal",
"      </span>",
"      mucosa?",
"     </li>",
"     <li>",
"      Is anything new or different, such as medications, personal care products (eg, detergent, fabric softener, soap, feminine hygiene spray, sanitary napkins), occupational or recreational exposures, sexual partner?",
"     </li>",
"     <li>",
"      Are there factors that ameliorate or exacerbate the condition?",
"     </li>",
"     <li>",
"      Is there a vaginal discharge or history of sexually transmitted infection?",
"     </li>",
"     <li>",
"      What is the woman's skin care and hygiene regimen, including douching and hair removal? Irritants in these products may exacerbate the underlying process or alter the appearance of the skin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hormonal status should be determined, as hypoestrogenism may alter the cutaneous appearance of the vulva. The presence of extra-genital rashes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    comorbid disease may provide additional clues to the diagnosis.",
"   </p>",
"   <p>",
"    Intimate partner violence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sexual assault should always be considered, especially if there are other signs of violence (ie, bruising, laceration). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20601?source=see_link\">",
"     \"Evaluation and management of adult sexual assault victims\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steps that can be taken to improve patient comfort during physical examination include having a female assistant, talking to the patient as the examination is performed, and warming instruments to body temperature. It is useful to have a mirror available to allow the patient to assist in identifying the concerning lesion.",
"   </p>",
"   <p>",
"    The entire area of the vulva and external genitalia should be examined under a good light. Care should be taken to spread and inspect the labia, as well as the hair bearing areas, to avoid missing lesions hidden in redundant skin. A speculum examination to view the vagina and cervix should also be performed, especially if vaginal discharge or complaints are present.",
"   </p>",
"   <p>",
"    The following characteristics of the vulvar lesion should be evaluated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lesion morphology (eg, macule, papule, patch, nodule, ulcer, tumor, plaque, vesicle, bulla, pustule, cyst) (",
"      <a class=\"graphic graphic_table graphicRef82154 \" href=\"mobipreview.htm?33/29/34267\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Size and shape of individual lesions",
"     </li>",
"     <li>",
"      Arrangement of multiple lesions (eg, scattered, grouped, linear, etc)",
"     </li>",
"     <li>",
"      Number and distribution of lesions",
"     </li>",
"     <li>",
"      Color",
"     </li>",
"     <li>",
"      Consistency and feel (texture, tenderness)",
"     </li>",
"     <li>",
"      Presence of secondary changes (excoriation, lichenification, scale, crust, fissure, erosion, bleeding).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Non-vulvar surfaces, such as the skin, mucous membranes (vaginal, cervical, ocular, oral, nasal, anal) and intertriginous regions (axilla, inframammary, infrapannus) should also be examined. Regional nodes should be palpated for lymphadenopathy if the differential diagnosis includes either infection or malignancy.",
"   </p>",
"   <p>",
"    After the examination, patients should be allowed to dress before discussing the findings and management plan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar lesions may not demonstrate classic clinical features due to moisture and friction in this area; therefore, additional studies may be necessary to establish a diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37349/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Diagnostic procedures can be categorized into three general approaches: macroscopic, microscopic, and biopsy (",
"    <a class=\"graphic graphic_table graphicRef63309 \" href=\"mobipreview.htm?3/40/3724\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Macroscopic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macroscopic examination refers to the characterization of lesional tissue without a microscope. Procedures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of a speculum to visualize vaginal discharge, the vagina, and cervix.",
"     </li>",
"     <li>",
"      Use of a lighted magnifying lens to observe small details of lesional skin. Colposcopy provides even better magnification and is particularly indicated for patients suspected of having vulvar intraepithelial neoplasia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24808?source=see_link&amp;anchor=H17#H17\">",
"       \"Colposcopy\", section on 'Vulvar colposcopy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32952?source=see_link\">",
"       \"Vulvar intraepithelial neoplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Application of 5 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19011?source=see_link\">",
"       acetic acid",
"      </a>",
"      to the vulva and saturation for several minutes to highlight areas of acetowhitening, or hyperkeratosis in areas clinically worrisome for vulvar intraepithelial neoplasia, carcinoma, or genital warts. Alternatively, toluidine blue (1 percent) can be painted on the vulva and washed off with 1 percent acetic acid after two minutes. Hyperkeratotic areas will retain the blue dye and should be biopsied.",
"     </li>",
"     <li>",
"      Photography to objectively document the location, size, and morphologic features of the lesion. The photographs should also document adjacent anatomic landmarks",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      include a ruler to facilitate accurate lesion localization and clinical comparison. A copy may be sent to other health care providers if consultation for diagnosis or treatment is indicated. In addition, photographs may be sent home with the patient as a baseline to facilitate periodic self-examination. Alternatively, a diagram of the lesion may be constructed for the medical record.",
"     </li>",
"     <li>",
"      Use of Wood's lamp, an ultraviolet light source with a nickel oxide filter, to differentiate areas of depigmentation (ie, vitiligo) from hypopigmentation (ie, post-inflammatory hypopigmentation). Depigmented skin will appear fluorescent white. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31543?source=see_link&amp;anchor=H4044225#H4044225\">",
"       \"Dermatologic procedures\", section on 'Wood's lamp examination (black light)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Microscopic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopic evaluations are performed if indicated by the findings on history and macroscopic evaluation. The use of these procedures depends upon the differential diagnosis. Tests might include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Saline wet preparation, vaginal pH, and amine odor (whiff) test are rapid and inexpensive methods to evaluate vaginal discharge for infection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36633?source=see_link&amp;anchor=H3#H3\">",
"       \"Approach to women with symptoms of vaginitis\", section on 'Diagnostic evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Potassium hydroxide (KOH) preparation is used to detect the presence of fungal elements in vaginal discharge or vulvar skin scrapings. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31543?source=see_link&amp;anchor=H4044416#H4044416\">",
"       \"Dermatologic procedures\", section on 'Potassium hydroxide (KOH) prep'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vulvar cytology is a rapid and noninvasive technique to sample large areas. Either a scalpel blade or curette is used to firmly scrape lesional skin. The specimen is then smeared onto a pre-labeled glass slide and immediately fixed with 95 percent ethyl alcohol or spray fixative. Alternatively, the instrument used for scraping can be rinsed in a small aliquot of saline and the liquid submitted for cytospin preparation or a liquid based cytology screening kit can be used (eg, Thin Prep). Cytological examination may demonstrate the presence of dysplasia, neoplasia, and infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37349/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tzanck preparation evaluates cells from the base of a vesicle for viral cytopathic changes, including multinucleated giant cell and steel gray nuclei. These findings are seen in herpes simplex, herpes zoster, and varicella (chickenpox). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31543?source=see_link&amp;anchor=H12#H12\">",
"       \"Dermatologic procedures\", section on 'Tzanck smear'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;One or more vulvar biopsies should be performed if the lesion is clinically suspicious for malignancy (asymmetry, border irregularity, color variation, rapid change, bleeding, non-healing). Biopsy should also be performed if a diagnosis cannot be made confidently by visual inspection and other noninvasive methods, if the lesion does not resolve after standard therapy, or to address patient concerns. As an example, a biopsy should be recommended for a woman who has been treated for candidiasis in an appropriate manner, but continues to have itching, erythema, and surface exudates. She may have contact dermatitis, vulvar intraepithelial neoplasia, carcinoma, or extramammary Paget disease; thus, a biopsy is indicated for diagnosis to direct further therapy.",
"   </p>",
"   <p>",
"    Vulvar biopsies can usually be performed in the office. The indications and procedure for the biopsy should be discussed with the patient, and informed consent obtained. After proper positioning on the examination table, the selected site is prepped with a cleansing solution. After the procedure, the patient should be instructed to keep the site clean and dry, and other special wound care instructions, if needed, should be reviewed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40264?source=see_link\">",
"     \"Skin biopsy techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Shave versus punch biopsy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shave biopsy &mdash; Shave biopsy may be performed if the suspected lesion is confined to the epidermis. A shave biopsy removes the top layer of skin and is used when the lesion is small. A shave biopsy should not be used when melanoma is suspected.",
"     </li>",
"     <li>",
"      Punch biopsy &mdash; Punch biopsy is indicated when the pathologic process is dermal or in the subcutaneous fat. A punch biopsy removes a small (2 to 6 mm), circular piece of skin tissue and is used when all skin layers need to be examined (",
"      <a class=\"graphic graphic_figure graphicRef67259 \" href=\"mobipreview.htm?13/6/13411\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local anesthesia (infiltration or topical) should be used for vulvar biopsies. The topical anesthetics",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/12/36032?source=see_link\">",
"     tetracaine",
"    </a>",
"    , liposome-encapsulated tetracaine, liposome-encapsulated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , and the eutectic mixture of local anesthetics (EMLA), are all effective, but only if placed 30 to 60 minutes (depending on the agent) before biopsy, which may not be convenient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37349/abstract/5\">",
"     5",
"    </a>",
"    ]. Effectiveness is enhanced when applied under occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37349/abstract/6\">",
"     6",
"    </a>",
"    ]. It should be applied sparingly in order to avoid potential side effects. Alternatively, the site can be infiltrated with 1 percent lidocaine with or without epinephrine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hemostasis and closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemostasis is usually achieved with pressure or electrocautery. Alternatively, chemical hemostatic agents can be used; we prefer aluminum chloride because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    sticks may produce scars, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/18/19747?source=see_link\">",
"     ferric subsulfate",
"    </a>",
"    (Monsel's solution) carries the risk of iron tattooing. If bleeding is not controlled or the defect is large, then the biopsy site is closed with an absorbable suture (eg, 4-0 Vicryl, 5-0 fast absorbing gut). A small wound that is hemostatic can be allowed to heal by secondary intention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pigmented lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, atypical-appearing pigmented lesions are completely excised to ensure accurate depth assessment. More than one punch biopsy may be necessary to adequately sample a large, heterogeneous lesion and repeat biopsies may be necessary if the clinical and pathologic impressions do not correlate. The biopsies are obtained from the thickest region of the lesion and from any ulcerated areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37349/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Ulcerated lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A non-herpetic ulceration of the vulva should prompt a biopsy. An incisional biopsy is used to establish the diagnosis when the ulceration is large and only a portion of the lesion is sampled; the sample should include the edge of the ulcer. An excisional biopsy to remove the entire lesion is appropriate when the lesion is less than 1 cm in size. The number of biopsies that need to be taken depends upon the size and location of the lesions, their appearance, and the age of the patient. The etiology may be neoplastic, infectious, or due to systemic disease. The evaluation of women with genital ulcers is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12538?source=see_link\">",
"     \"Approach to the patient with genital ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Unifocal and multifocal lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar malignancy commonly presents with multifocal lesions, so multiple biopsies are indicated if the concern for invasive cancer is high. Biopsy under colposcopic guidance is useful for diagnosis of intraepithelial neoplasia, carcinoma, or flat warts and is performed after applying a gauze saturated with 3 to 5 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    to the vulvar skin for 5 to 10 minutes.",
"   </p>",
"   <p>",
"    There is an increased incidence of microinvasive carcinoma in unifocal lesions in women over age 50, thus a biopsy should be performed in all lesions that have no known diagnosis to exclude invasive disease. The risk of invasive disease is highest when a slight ulceration accompanies the lesion; excision is mandatory in these patients. Lesions that are ulcerated, bleeding, nonhealing, rapidly changing,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    asymmetric should also raise concern for malignancy, and biopsy is indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9303?source=see_link\">",
"     \"Vulvar cancer: Clinical manifestations, diagnosis, and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, two to three random incisional biopsies are sufficient to establish a diagnosis of vulvar intraepithelial neoplasia (VIN) among women under age 50 with multifocal lesions and no ulceration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32952?source=see_link\">",
"     \"Vulvar intraepithelial neoplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Lichen sclerosus and lichen planus",
"    </span>",
"    &nbsp;&mdash;&nbsp;An incisional biopsy is indicated in women suspected to have lichen sclerosis or lichen planus that is unresponsive to standard therapy or has undergone morphologic change. The biopsy is indicated to exclude atypia since women with atypia are at high risk of developing invasive cancer and should be closely monitored. Those without atypia can be treated medically. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/45/6874?source=see_link\">",
"     \"Vulvar lichen sclerosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/5/36952?source=see_link\">",
"     \"Vulvar lichen planus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other studies may be necessary when indicated by the differential diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Gram stain, fungal stain, or culture (as appropriate) for bacteria, virus, fungus, or mycobacteria may be prepared from lesional tissue if infection is suspected. Contact the microbiology laboratory for accurate specimen collection technique and media, as well as, test availability. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36633?source=see_link&amp;anchor=H6#H6\">",
"       \"Approach to women with symptoms of vaginitis\", section on 'Diagnostic studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Epicutaneous testing (patch testing) is used to diagnose allergic contact dermatitis. Potential allergens are placed on the patient's back and evaluated for development of type IV delayed type hypersensitivity. Genital skin, however, is more permeable than exposed skin due to differences in structure, occlusion, hydration, and friction. Therefore, patch test results should be interpreted for relevance. Topical pharmaceutical products and cosmetics are the most common source of allergic contact dermatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37349/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=see_link\">",
"       \"Overview of dermatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ultrasound imaging may be used to evaluate large, cystic,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      subcutaneous lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37349/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinician's challenge is to differentiate among normal variants, benign findings, and potentially serious disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A focused, but thorough, history and physical examination should be performed. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Procedures which can provide additional diagnostic information include magnification (lens, colposcopy), application of 5 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19011?source=see_link\">",
"       acetic acid",
"      </a>",
"      and toluidine blue, Wood's light, cytology, Tzanck preparation, and wet",
"      <span class=\"nowrap\">",
"       prep/gram",
"      </span>",
"      <span class=\"nowrap\">",
"       stain/culture.",
"      </span>",
"      The use of these procedures depends upon the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any lesion on the vulva that is clinically suspicious for malignancy (asymmetry, border irregularity, color variation, rapid change, bleeding, non-healing) warrants biopsy. One or more vulvar biopsies should be performed if a diagnosis cannot be made confidently by visual inspection and noninvasive methods, or if the lesion does not resolve after standard therapy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the patient is concerned. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37349/abstract/1\">",
"      Foster DC. Vulvar disease. Obstet Gynecol 2002; 100:145.",
"     </a>",
"    </li>",
"    <li>",
"     Lynch, P, Edwards L. Genital dermatology. Churchill Livingstone, New York 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37349/abstract/3\">",
"      Turner ML, Marinoff SC. General principles in the diagnosis and treatment of vulvar diseases. Dermatol Clin 1992; 10:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37349/abstract/4\">",
"      Jim&eacute;nez-Ayala M, Jim&eacute;nez-Ayala B. Terminology for vulvar cytology based on the Bethesda System. Acta Cytol 2002; 46:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37349/abstract/5\">",
"      Eidelman A, Weiss JM, Lau J, Carr DB. Topical anesthetics for dermal instrumentation: a systematic review of randomized, controlled trials. Ann Emerg Med 2005; 46:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37349/abstract/6\">",
"      Juhlin L, Evers H. EMLA: a new topical anesthetic. Adv Dermatol 1990; 5:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37349/abstract/7\">",
"      ACOG Practice Bulletin No. 93: diagnosis and management of vulvar skin disorders. Obstet Gynecol 2008; 111:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37349/abstract/8\">",
"      Bauer A, Rodiger C, Greif C, et al. Vulvar dermatoses--irritant and allergic contact dermatitis of the vulva. Dermatology 2005; 210:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37349/abstract/9\">",
"      Farage M, Maibach HI. The vulvar epithelium differs from the skin: implications for cutaneous testing to address topical vulvar exposures. Contact Dermatitis 2004; 51:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37349/abstract/10\">",
"      Nardelli A, Degreef H, Goossens A. Contact allergic reactions of the vulva: a 14-year review. Dermatitis 2004; 15:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37349/abstract/11\">",
"      Chang SD. Imaging of the vagina and vulva. Radiol Clin North Am 2002; 40:637.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5450 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-89ED0DCEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_30_37349=[""].join("\n");
var outline_f36_30_37349=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Macroscopic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Microscopic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Shave versus punch biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hemostasis and closure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pigmented lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Ulcerated lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Unifocal and multifocal lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Lichen sclerosus and lichen planus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5450\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5450|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/6/13411\" title=\"figure 1\">",
"      Punch biopsy vulva",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5450|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/54/41836\" title=\"table 1\">",
"      Patient history vulvar lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/29/34267\" title=\"table 2\">",
"      Morphologic terms vulvar lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/40/3724\" title=\"table 3\">",
"      Examination vulvar lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12538?source=related_link\">",
"      Approach to the patient with genital ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24808?source=related_link\">",
"      Colposcopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20618?source=related_link\">",
"      Differential diagnosis of vulvar lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20601?source=related_link\">",
"      Evaluation and management of adult sexual assault victims",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9303?source=related_link\">",
"      Vulvar cancer: Clinical manifestations, diagnosis, and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32952?source=related_link\">",
"      Vulvar intraepithelial neoplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/5/36952?source=related_link\">",
"      Vulvar lichen planus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/45/6874?source=related_link\">",
"      Vulvar lichen sclerosus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_30_37350="Acute lobular hepatitis high ALT - low power";
var content_f36_30_37350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute lobular hepatitis in a patient with an unusually high ALT level, 7500 (low power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 249px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD5AbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6mzhSSaB70uBSikAmecU6iigApoB3E549KdRQAUA5o7UgFMBaKCaKAA0UUUAFFFFABRRRQAUUUUAFFYfi7xBb+FfD91q17Fc3EMBGY4FDSHcwAwCQOM/kKm8L63b+I9CtdUtEljhuFJEcy7XQg4II9eKrlly81tC/Zy5PaW0va/ma1FITgEnoKWpICiiigAooopAFFFFMAooooAKKKKACiimSyJEheV1RR1LHAFAD6CQASegrnJvE9vEb+bKzWsCRmMxclyw9s5HI7cViazftfaffSTayttYSQLLG9tKAyjICyI/ucjbgg/WtFTb3HbXU7hrmFIPOaRBF/fJ4pkl9bRzxwvMiyyHCAnG49cD1rzWLW43tp9FmlEtwtmLmJZQdktu7bOSeS/rkdWA71X0+e607VNVLQStaQL5iSTShBEo2+XGuBnuQT6ZzzV+xtuy/Z73PUjdxi7S3XLMVLkrghQPX0z2+hqcyKELFhtHfNeSDVg93eXiPZpHE8ltJMkLr5UjkAjeWAIOUGPUHHNXri6XTdJkgknE0So1pNbPOXkuZwgICtnO7jHJ7nNJ0XsDptHo012kTxL97eeo6AY61Wt9YtLh50jZvMgcRypt5RiAQD7kEVwNzrNxb3Wk/vSb1kWB7WdQizllycHsyqGPHXFRXclubOxSW4+w3iwi+khkm3r8jgsGYd1Az7gU/YdxKPc9NtLuG7h823fcmSuSCOQcHrUySI5IRlYjg4OcV5Tda5BbpZaldpL+9mdIQhdULsG2qd2OCM5bGOeAKv+GdVVba3nS1eS8nnYTggRtGw+XLAH0AHuADSlRaVx+zdrnpNFcBNq9/d28E8V41p9nnaKWZ4sbyDyBGfvKR0bNQ6Z4nu9SZLqymmktJ4P3UrhUQMGwUZfvCUc57YxS9jK1xcjtc9ForgtG8S3FzG8K3aecP3qSFfMjkRQpYK3G4c4JHQ5HaorXxFLeXFtC16CDH9teUKTC1vvO0qQO4/TrS9lK4uR3segMucc4H86XjgVwWua5qhvUj0q9tJrORwhZDhkU/McYBywXp0BFU4fFOpQ6J5EEPnX8cJkhElyCX9NzY556nmn7GTSGqbauekNnHFNBwMtxXCjUtSjmLRSMt7d2plcyNvhhkXGBtJGOCRwOTyaZdTXGoN9puo5mNsd+ACm35uCATkdCOnQ5FT7LzFynfRtvG5WDIeQRT65bTtUgi8PzxaezRzWsRINwGIByectyRnOM9sVzt5qga+juJ769tI4iTJ5oyMfKeBjBUk4z+VKNNsFFt2PSAwfpmnimRpsUAnJHen1BIYooopgFFFFABRRRQAUUUUAFFFFABRTZHWNGeRgqKMkk4AFRXt1FZ2slxMW8tBk7VLH8hQBPRWdJq1vDaR3E25UYKTgZ2hjgE/mKxrzxfbo8KW8b5aURnzI2B6nPHbocE1Sg5bDUW9jqqK53S/EovLm1t57OS1mnV32yuo+VepAzkjkfTIzVi41tv7QnsbW0leeOMSb2GIzntnsaHBrQLM0dQs7fULSS2vIllgkGGRuhrM0ySz02e30bS7dI4kQv5YbBVcnL8/eGcA45ywrDn8SLJqV3aX1xC8UYWBraBH3tIQrNhsc8N90dMZ+m9pk2j3d+L+ymgkup4fKUhwSEU5Kgdhk5puDitR3la3Q2qKZLIkUZeRgqDqSage+gEskMciSTxjc0SsNwHqfaosSWqKxbDW7e58yZi0KKBuDkcdcY9+OlXH1S0SNJXk2xSJ5iORgMMZ4/Cm007MPIvUVzOo+I57W5gRbI+XMjMsjH5OCo5boM7uB1P4VpaTrun6sJfsU/mGKVoX+RgN69QCR82PbNNxaVx2drmpRWbeava280lu0oS4VQ2HU4APQ59OD+RrE17xctjCTbQO86NhoihZnOMhVUckkEH2FONOUtkJK7sjraK4vW/Fk8Qs4NNhW4vJlYtGnK5C7sbu3HAODzVaz12RRLBqq6g8c7B0d4xlMlQFHlnIG7jJGODzgU/ZStcpxaVzpNQ8SaZp+pCxu5ik5XcBtJB4J7eyk1WTxLb3sEcmmyRvC0rxtcnmOMqcc8jJJ6YrkbhrWfTNY1m9h85IJZg0ClZdhX5VZW45x2OfvEZqq95qNnaT37SRx2bLDFNcxllbyyGGY48EAoxA6ZIzzgVp7JW0HyX2Ouk1bVNOa/lvIZLmBMtEIFViQBnpkYBxgdTk1V1fX7W/m0/Trm3jkNwyyzQNIQ8QBJ/h7gjp0POKzJ9VMEgvdRuBYxQnYJVjaSLLkAZHuvJbotU9Vi+3LZtcRPdySSIJZLSJEW9iIcGPcck7R83B+lOMFe7QRV3qY+m62f7Hmhh0KMTWy+e0UqvCzuWyirkk5Kg/MT26c1ZhWS/RrKy0iW0bULMSEzqy28n3cqCuGjkUDC5x69qu6igOpWsVrBGII9salcMqAhj0A+VsnBJ6jFZl7ruueH9b8+8trya2a2i/dMBh2JIVYyzA72+7txkFhWyfN8Nr+puveVkvxNC/wBJgv5Wt5vsdvFJZyedDISJEJwBKvIDL1Gcddrdqi1a91BXiurKYXGmbRA4iKgvOJAhQl+5PAPscVVv9Qjv3kTWbD7HZzRbZIbnmR1c4kQuuTwTDhRjk963rKWa8tkQ6rJNMbhpIkt/LJMSPgIc9RlCCTjBPGKl3juZvmilzIzLXT72Wy+z3MemNavfLLa28UjFthBE7FhwWDEndzjHrRPc2lvrJ0y9gnkb7P5zyXpBjtUAZVbzNpAZ8t7kA5qW4vZrHUre/aymSzhkd7mZXBMKBWXaVyTksRhQBuBBzkVcjs7iJrqWKJr69nkzK0zKrx2xc4QOBg7AWIBGTz3NPzYc7erOO1BNQ0DRNKtdNtFvbxrwPZiNU8hWYsSGDDMaEMxAB6gAE5p1yTFLBPbQBlubWVmDyShdmFjiHzDKlWdlIzg7m74FdHqUMEk0d7qdraGzvQkHmlDE9xgt5cRUgZ5xjJHIzWTHpllpj/YYLXU7ryHiuGWa43eYRkhJWYhYyd21V43bQwyRW0ZprbX+vyBNbyRvaG6aJCbeCDUL2YvEr5RmREJ2fKzk7VXhipOep70aU+na39uaTQrqyvIJcgSjyB5hwQ6/3T6Z5wR61R8MadJHbxrNDNHf30wWWMY2XKKDkuWJy4BwzHDHHQ4zW3FLbwR6jeXM0lrZQxE7Z3zCQrLtdOehOeevI6VzyWrtuZylZvuZ+p2l7bzWi31zb/2ksb4nii/1cbHPKZPTGA2MEr2zU9rOba3dptPLyQy5MCQ/vHZmx5ny8An7x/XFZ9rY6hJIl1KYYI3tWVxErLLBcAhl2yEjdHj+EjB60ujXsz2kUs8ly2qLCS7INtpcFiu5kBY7ly3DdMBsU3G6KctLM0dB1CEWs1veJHGkLzCR4YmWG3VZCCBgdeQfxJyapa7DFJp01lcXJi0+yYNJPdKXR4hltoCkMP4eT1GRWddR6rrdjaaTf6XHp88lzHHcXEFypV0UvvZApyqcJtbOTk5AxTJ2uJory4077ZqBgjZrZWuXSO5LyK+9pG4KrjAGM4B7EU+RJ3uaRTvcnEtkl/m23iawZzKttEyGJfKxtAGFZj8uAcnHSqehQW0+p3CRWklvBJAklvIGZ4zCP9ZCVYbUO7ORnPf2psmt6hqWu3N5puix3K6dGYPM+0EiYAJ5iQg4DYY4Dk/w8egkm1d2vNNkstGk0y1mVg63UIV4mEhCx7VPtu3cDHOT0q+VpW/U0UZ282X9Vi+y6zo7WMrWbEGyB86I28WdrBWH3ixAYKM9WJ5qtpmuiw1zXLfW5TtlMaQ3oAaWTOQEVUHRWVgMnPzVXfTZv+Eoiukih05bm5W5u0uFWZtSKoCGQH/VlSeq855qW8nY+JZLC2XXYs2dxEm9s27MSSnz53BwWwDnpmhJNW30Istt9DYXUbiS2sInvd1pcwPFGxXzXnYqSST90gqp696ydGvEjgks7p7uVJLkQpGbYqYcgMqKOmwADPoal0nT9Jtn021uIreHxPNpYZ4LcFUTa5JdNw+VgzEZJGcmoodSuNUn0+SfUoSI5itutg4LzCN8OzA8lRuUMvqD2xU8qs0loOKWx7VRXF2utz6cupSX9y1ysMu0IIdhd2wQEY4BGOB796zr+91e48Rw3sOnwNaW7yCK4kuNoERiDcqG4YsSMkZAB9a5FSbe5z8up6LRXm0mtSfbp5by6hjhgMYXynIMyO4wuByGOPlPRs4rq11+FtJW9AkgTIDLdRlGUbtuSp5H4/WiVNxE1Y3WYKpY8ADJpkM0cyho2DAgHj0IyK5y/wBbkYBdNubWW8D7TCZNqqBhiWJBwdpH51nWt496NPv0vVIuGR4XZWiVxg5DY6n2OBS5Ha7EdxTJZEiQtIwVeBk+5xXJW9+bKytoJbgfM7sG3McDltuGySeG49AKo69fRysLmZ2gLIyx3CwO2I2TIQ4IZWzzwO4HU01TbBHX32rWtkG8xyzhS2xBknBxj0zms/UfE1pZ6fJeE5hjR5HJzkKvX5Rz2OPU8Vzf9rTNbJJKgFxPaCWOwjxKzuOSOBgcd88+nFZOqSwXFrFc2sS/2tLYSWtu7SiWLcTxEWxgnfjGRzVxpK+pcY33O11rxD9jsorkMsVu9u9w0roSY1VQ3K9c47darR+JnnQS24chtsaRmFmLO+SrNj7qYA+btnmsHWdWttJtNO0mWyur3Uo4fOEVsctgbVLckfL8xPoMU5Fnk0e4/wCEfuruFkt0it7mW3E0so+8xQkjfkfLycZFNU1ZXDlslc3dUmfVIxBM06RMm2SOCQYLkYKM3UYPPaqOn6tLLo9k/wBpt/sX+qLgtwUJUAEjLEkDrj8aorcxXun2ZsreS1W4lkedXjNvMzD5ixTqGLAbs9c1i3uqahf6Qtli3muJ7km3+yKV8iVVLou0Dn5lYZYAdzVRp30BRbR1SMJdDAsLs2+GfmMHegL5GC3vxz61i3kjXFzfIJG0y5uIJEE7QmRBKF3h0yRuKgHIHoeaSwfS4dEdbyS4uLBnkL/aZ96rGuA6vJnaApcg5OTt74qnfW0V3cyCRj/Zxnigumk+SPyyhAaF8gkYZFB5zt75qoxs2OK1ZJb3KaPaXeo/Z2u1vGWWCOGUyi5UxjL7Mfut7KRxhehNbeqyW9rdw39xKttJGpuJ45JB5QXq7nP3tpIBIxgYrOM8djfTJo1na3eoTxz3Mk5by/3qoBGrMRtVmBU88cMcVjC1W7s7Sy1W1XUlWCKK6t7hUeaQM67CWXjKsQSFxuK56Yp8qerHbm1NGS0mu9TMFjdxzJBLBfOH3l3lkkZj5qfKCgVeB1HHHy8tsPsg8SM9hNKbBniCWdvbgRocEtIXGNgww68kjjrVWwtPEP8AbbPeX+mmSOFQLSFpFt8mQje0jchyAVxyVOOxNYcelzaprmrHSbvyreyxEbppmkAEUke1hEWP74KrjJUDcAe9WorW76GqitU5HX+NEvr+GaQxXUsayiCGKJ1QoxYAHeSBtbjk8jPGap3V9d2fiLc76g11FJLFcYtDKHjVFlBU9BtDFQeeSRz2kGosmj6pq0tsJp7Vo3ntn2MBhdxXzH4bbuz2wwAHSrdhYRazb3dmszz/AGm4S5kkQMvlOUXKurHChsDKD1PeoTcVaWxmnZWa0Q23uNO1OW++yanNLBa6lFmUyAeXOo5gIAAEYDKO+Mk9aueIJjC6zGdbbTmJmvEGZjcYKgoqYLegyvT0qrp32Z9Q1HyLmwme3CtJ5JHkl1LZHAJDDHIPdeKnj0uxsNWkvJ7yVoIW/c72YbGfqgyOVb5SefvAmlomZ6JlDW9Vv1ljuZYIRpknk3MVvLIvm7csA21gAB/q2K5yAD3qOS/1O5jtZ5PIs7cXcnmta5dmhEZAlKvho8OEBK9PfOaNW06TUJza36S6qpt/9KAnQRNnG19jD+8GChTjAySao3F81tDDca/p7CwkMiXM0UkjSIFTC7gmS6lhyeBhuR1q4pNKy1NYRUo6bmv4olk1OK3sWjS5by0jmnUFftLs21gAvO0ZJByRk/jWbZ2z6jql6LbUL+3vreFIt7xjDREkDMbrztAK+Zk8u3riq12lrb3Qe5W5Go3kcaQz6ahjlEDPuZMgYiTcdpccgHtXQCxDxT31rKbKFowsheeRmijAO4qxOUJ65x785o+CKQP3I2/q5lWd1ImnDUdO1KwFiWaxh+0MPKnl5URgoemTjkcEUrXV1Zrc6hapJqFrEiGXRLUJ+7kzhtr4y2MHg9SpOeaq39haQapNfyS3Zimt0knFipcJhxsRAvozOWYDJGCcVBFBZaf4jh1Uaquozy2UcVzm7ADwuSnmsCSX64BPAAPfmrsmr/oW4p6mnNHNaK+pNcRxRWgkls7ecspKnC4cKdpyQNvB2rjvmnQQ29lqEaahHKsayLdbHfy7S2bDITFgYLMzMdp5JO7jArL8PahLpWlGw0qa2RLINFY2jyCcvsXfIrucfMC4AA6jHrW7HptrrVnasdbmhjLF3hlRQHbhuCQQMEjlfcc1Ely6PYTVnrsYGp31v/a523LTajGsNu1pFcMkMjPuWMMSNpUbuTyeQcdK3LeGKZUXTVgvbzT7oNO91O0xsmlAMqxt6BWIXIwAccVjyXWm+EfGl3qL3F0NOYLLkAzAzMXLZjUZVQpjAx0wKW8vNK8OandahNK1nHMu+QOjsHVvkBPG0nbHnnLYyD2q3G/wp+Rc4Xty32/pG5YJNpFvBDYT2SIiCCK0sYyqPKep24ztBIJYEgZOcVneJ9evbm2lMVoZ50dS+ZVUKd+x1BDBl2ZyW/h3KeoxWDp93Kmu2d5FiSx0uPbbSSKkhulkTPmBgf3MO1kJOBnZz6VpXV/Jqc8dvdWkltc3Fqsxso5oplcykL8+BkIpCncCAwfFHs+WV9xKjaSb1LI1BfDmjLLqM8MN8jJJNFZndEXMh+6CAWfDAt3ypNVUNsIHkTR9MsrRJ5DJdTARExhy6yuCNykFmbGQMnng1VsbTVJNH1SW10qwsbrS54bv7dd24WCeVkHmyxZBKNjjcc4JOfa9BdSa3q9wl5bXem3TQRFJ2cTWqSLkOsYwNxG4g+oFPlSu1/X9X8xqK1JX1C01lLTTtRthdNOkEl3sTA3IGbzJXA2lDhSoH8RxxUWvnehIeRvsO66WWNVlurjZuC7FQj7iuRyDwfUZp0UN/FcwJah9RE/7+G6hkEVtEu/5YwDkqGVwSMnJT6VJZKn2uNbGK9na1Mubidl2qGxtw5UHnB+Vce/BpJW1Qlyxenr/AF+RBa3un64Le7i1W4aGCbyZojbGSJ5AA4ds8jG3hugPvWvp8kGrahe6M2m2d3LJBFc3M7Ou6UZPlhgMk4ULgkcZ44qvqOjWogGn2scZf7Mto9o8zSQpG2WBdF+6zYbknGM0yGefw5qVwuqNHa21xNbrp7Nnb91R5WF5wApwemDz0paST5fl/SJnyTXu/I2rLwzdXjGObVdRsmjOZNPDiSEqzMIwccqNgAwrY7nNZ914Z8SweMb2WE2bWF9G0cLI522gG3agQjK7juLEZBIU44xXOajrWoahqmoT3CNa6fcL5un3UNxIBMcMArgFfmOTtB9j2qTRdW1jQ4bGCTUL25WbT454XviIwhX5pDK7ks27PygDjBzgc1ap1Ff3lftYy9lOEb6Mqahe6rpdnp+jalqV291CXuJjb3MdxcOo3KgDkDe/mkAKFAGVX3q5oB1G8nZnub6/ntzDZz2c9rDCGh8osSyNjYCzAMwzyuBwaxvEviXRL3xtZ2PirT59LvbyBTa3oWOWOPIDBknPMYBLISB/ECSMDHe6mdHu7KaaC1s30q3hRozcugjdyw+XeTkjCjluDxgmtKjcUk46v9SW7Rs1+Bx8s+of23HZySR2+3VAtn9ptd9opKuTHGzFS0m0Fvl+Vd+0ZrXN9Br3jTRCdamupoBKGtI4fLPmL8ro6EjHyuPl6/Jkc07T9cvLqz05tPtNO1MtcSy3ksEnk29pIUXb87ZMgXJDMnHYgdK8/wBBnvXa0sdZ0vWbNb3Vru5kuLWPzRbBlZQyyoCVYSKSMcFOehpqHOm3o16efz6G1OLbduiPaPEMUdpZxzRpHC1u8jqxTYqEKecD5e55boeawJ7Oe50rU7tbq40+d5HlW4aVWM5JTYd2CVQgBcDsWOOhrjdSi1qW60l5poP7W1CWG0a+t9TElrFGitvDI3yyyON2ARjJA69eo1WSS1t7C6kglhgtI3OyO52Eps2oFX7rZZgBkgD14rn9koWSdwjTatZ3ZVijn0mCyj8QQOljDaoodSztZvIMTMbgnI27W5Q/dzntU86w6rq8FydPe2gSOOVL6K7aMXRU4jjUbgSoJLd9wHvzW0+41SLRJbybT7NYbYMDCZdxnBw80hABwxIf5QP1Na7atb3tvoEls7m4fabSAhhu+XdzGCCeBnHYqT2o1vcqbcXe2pm6XLFbaJaz6T4inGk20k0vnuwkBhBIZXaQblUNye4xirQttTju2luLC1vr2FQsU/l+VFLG5U/K3JXJG4le+BTkvNO1Se6msEkvriGSexl4ypmXh4mQr93gHceM881BqN/rGnw2zXtoboQR2/2a2gYvOhfCyyFyNuFJGDj+E8UO7fn5jjJvZGrpGtxLa67NHqFldCN8SJG0jGNUkZGyrA7SAD0GGYHtVXW76zjv9A0a3mmvb25SS5jE+AThCVdsj5cH8cDoRUmrw3mnatcX0Rh02x2b7mbyQ7tjIHA5YD5RtIGAcg5qOy1OxVvtF1YX73ex5o0htAC2BwoPJ3AN0JHL9+0JL4kr/wDDEcuvMlci1fUl0u+s9VR5Z7uRYbSJkg8ppJQTmNmYhNpbO3PTdjPNUdU8SXD2+oW9hK91em3jP2q5iSFhNI7FYm3AKmxSCNw5Hqa2dVg0vU9N+wbWifTYvKihuZNps5cHEgk5/ebWQg84x61hnQY49R1FdZbUJreOAWixzHct7IyqpYnBDjoM4GDk+9XBwteS1RUOSS941fEdrqGtW8+maqY49OuVWARSMX86VtjD54yrApsPcZz6VoXsbagtxbCa5tI4Y4vO8yU+dHIHUrsY9V2lvm5z09cZia5d22vWOgiHT01GS2knvBbN90hcBo93LMMqMMBnnHSsrw5HfTaux1DUob1oYd6wXkgJkkMmGeUJkhVYEKo4BJ6UuWVrt2tr/X3C5LLmeljfs7m+s57xdQ02Y3F5c/uYsMSzHGXd1OxV4wAvP4mqtrquowag8cUU90s8wghWaMpwq7mbzsHOQRgYwGUjtUGuapJNYyNBppvdYsWZRDCDvgdjtEkZOQ4LBgCcYxg45qbW7S4TTLGGDUntzcypOs7Rs7RS5UvGSG5diSAAeBu7ChR/m6kwSavLqba6jZy6lay36XMLNZsftC3KywxtuCskhU4J6ENjGDjg8VzsWoaNpWkpJBb2tjZWt95ItYirt5xXKugHBdlLDZ1+YHiui8P2cVnM0trE3lsvymQGOOMZO/eCoIyoDA5wT6VhWGlXks97fasbPS7aS+8y3uBeiaBodzcoi4UMPlOTk5bnpUx5db7Chy3avojO1CPd4Vmura51C/vlZ53ggjUTxxb/AJrdUOSOvJySD+VdJBHNClumki6lSZkg8v7gAlAYyTKAu0jG3K9Ae1N1HTNOTTryC71W4k+1scPZxFDIGjJwJBwTgZyO+KT7PdapFpt1b295FHFcBrm0UqryRPFjy5OeGXIyM84Jock195btJeRBDeXs9ot9i3lkjZhFLMvSAjY6YODkOp5YjIGaztUe5kstRvIYZEkNyLaze2PkG7dQRGrjAI+fknOCBkHnFa11o0JtHsdBNskEMBa2lkzLbqAxHl4PJ43A8ilg33V7Mt3cMbS9jxa2rR4+xtGoyCRyrHJbk9MEUJrdArboy/E2tJollHomnrFZfaPnuLYbpZcyl3chQDhw5BycjBPtW9aS6Zrmm6YLq58h71N2yF/L+17U+bYDzt5DA9sA1X1DTJtLZ9Qmu4J0t5xPZ3FwpAtkkURvDheZAVyQzdMj0zVaHR1eWMgtLLZxfao8JtkELOzIoGcgjCqdpXIGCMcU3yuK/P8Ar5A+Rx90v3c1/HqqJ9m87TRIRNNHDuaMopJVhwS2cBSM56HAwawNTtbqfxJcQW0GoW0lzIssH2eMwbCwXBeRThiSpJBPyqD7V0WnR3VtPorak900EVvcT3bTS7nDkYXeFXEhCgjIx06E81kaL4mkvL9rhoY5Zri6ltzMryJCYo1LIzZGIiybRk87uvpShdXaXQIKSbstiSe1trY6JHc2nnQw77eJ5IzEHlOPNLEnJ5QNl+pwQTWjJp+k+HIvtX2keZDctdyI6hyNy/vApA3MTgHkk9e1Y0VsNVvL3/hJtDv9PtJo4oZDNcNcxh0fCAFSc54bdjHr0qpaW9xPbrcxXLLP9sWNhBL5kQgZhvV0zgPjcMg8ZGDjiq5ejZTp82jZcvJ7MatPFqavJJLcF5cJ8sO/IXaoxvzuHIBAI5PQ1fhXULQxT2BM0yvtZXnkXO1iGkdNv3m5xnjgYOKzX0KOTT9EMBurR47nE6xx5mG6QfOsx+6AAu4DKHke9Uo3uLSC5j0b7Hc3LWktw2oo7tJhldoJBIQeuWyOQCTt44ospbDaUo3R1T6c91++0zU4Y5mYQ3qJueON0QnYu1hsw7ByOp6Zwa0/7Jmt7VLewYNbwoGjWWXetwzHLb92SMHIGSfvD0rkbX7FDeR3WmXVolxqkMEd157vG8wcERyY+6HJDnoMkdK29Mjs9Q09oNHME93DeLDfLHdEmJ05Zy2OXwAcdDyOgrOSa66ehz1INdTGu5LbStSktbEy21ndywRyvNMCrxKdpMXzFgxaSNc8fw8YFRzWezWNRXULue2cmPUGmWdY2+RgGj2qeVXaisSMHzK53RbS9i0W0g0uaOS4iVY1ure9YQshc5YAoVdiI8NjBGSOOtXdIvZ9K+zi51bSLCfTFMLo00srBZCxJYuDz5qAiQZBUYx0rocLXUWdfsnBaM3ZLOK+1MaldQfZYEs0+0iaUiJAGVmUQg53BVXkNg571BpHluJDbGee4vRFdR3fktBDIfuJ3POwgEd8VFfzajrthaW0mt2F1YtcCeS6si7O0bSfu1GOQSM5bgcYwc5qe0vtR0/Sp9Wmha5uJ5/NmW5EgbDSbFWJEMm1ccqBn3xziLNK1zKXuR8yfW4dUsPDzJHCo1pwQlxbSRxq7FwGch/l3BCeOenrxXHvqWpafqMesWtvFrc0sMkUv2a5EOyKKZg0a7kxL/F8oCsdp9jXe65qelabdW/243dzdXNwPLVrcSREIfusWwqjGDkkdM5qDVDb7/tE+oWLx288jxzrGsj207fddNuVUYY/K3zZI55pwm0rOO/4hRk0tVuc7qw0+9XSvK1IX8izy3ECywruTIAWOM4IM44Kpkd2PArXNna6hYwWS2N2fKxcX9nKWMqnO9UVzxgyKMgcY4HFYKyWl1ZTWeqpBJpup3TnS7Keyl866mj6zO/B5XlQMcHGTirVlpivqGoabcaneaVqdwWg+2WkbRl0aMSgAtkHG1xkY2jgYNVJWXoau7Vr7GuNZmt9PSfUdJHk6jD5NzHcSLHFauxURRuVG7J3EAgYz+FYa3dxquoaXPYrcMlxCfNuPJRY4sFwbctyww64JxhgOvNXNHnudM1Ge1milvjbNbjzbe2XzLwqjEB2YgEoSDkDA6HrV69iJ1e+W6eW6srl5m8xJTFFAvlcRlc7mZt+QF5yeBxSVk3oS7QkYNnaS218txcGPXLizujZwypIowjQ7nt7gbR+7RlBUDuVHFbK6l4fv9esNRlntI5hEIATuRdjAgQ7TlWG+KQEnG0DH1503EV5oel6LdxMgvSXaeD9y06mAMG2EfMB8qBZPmIXPWpm3zhLvULy80zT5LFUkuIYkRo0fhBJJ82ZASeAAB5uOeTVyhfVlOF3ro/6/M7HXvEi6xpd3bW1tDeafNbMZ7aKdVa5QqwwmDlTlep4I6c1Qa9SfQraORL+5t7iFtm2NmCo2eHbk7l6KMjPTNZ1tPqElhdrLFoMV9DMsdh9muHGzdh5A2AGBxuZeP4s1gaLfnUZIdJu7/V3vNMmNsZDbzo5Y5Cs3UEHb1bIOM8VMaaS06EKkmrLobeiaXqc2jCK41W5ggjVNRivLYLJcyzBvmUqxYKBsPy4I5x/Dzt211D4h8NbbK3mu7eZjDH9pcLPMUOGMmcHcCDz6YrnLLTIFuLvR9MhgsbyeGSWW38x5o9pPlqQrKFw27c4Ugg7evNQ2ngm7g1Cezt9PSWIWu/57tktQ8iuJUwo8zLbVJC4zkc1b5ZXcnrv/X/DkTVO7bfXQs6LqWu3MkcB1CwN1a3BS7iEWbl1CMDE4HB2FkwV46ktWzayz21oLOC2mhd5fIlnTllAXJ8t2JwgctyRySRTrLSdEWS2u7zbp2s3rCMTRKFeXaFOzeTlc7B8uc449ab4luhq9rcRtHPY6IQtzf3DoTuQZ3wdQyHGDwKzlJSlZLT+vv8AIcnGUlp/X6mRfa1f6ZHpo1SOaEavcv5ekTwwyZhA2naQRhcsHJO5ucVc0rUG8TXzXOttpz2thE32WaOEgTgbg4jWQZaMxvFuYcEjA61Vv/sfjFdE0r7PdzeRay3drfGUK9ogRRHMS2MswOQW6FenerGg6pZalqiWmppbSwRWkhR9QiFvdARuMSEKAnlMUB3eoHFVJLl0WvX/AIAOLUW2tf0M650XRdM0/wDtLxDFHJdzyMl/fC0Ro2XazbXiAymEIXcgDdCc1p6XoGlTabNZnT7qawuFRZReTlpbgRnMbks5YLgkAHBBOTiuZPizSte8StpK2bqgZoIpYZ900kiHczEDlEOOGJ6jHTIrX1y6t9SC293fahp15qUKqhNlmeJiwdkEijbt2rtKk5G7JPIFXKM1ZSun/XYpwldbq5Bew3WsaCsum2VvZ6tbEWNvDEyz/YhKoUoxTjbsKknnqOtQ61JeNay2K3JstJj1k2uNDcvcTwBMNnn5SrKAQoI7dOa0dZ0HRpLu3u9FSw01dPR5C8UrI8MC7T5oRTtfDgD5sYGc1Vv9BuGuL19C0+MWFw8b2t8l3FOI5WVN00YPO9sknLYyme9KM46fr/XzLi4u2tjRvL601ew0y3stNhe38pLtL2PbHbmbLB3aNx1RgCAect7VQ1SO2v8AWprnUdNkmtx/xLRCIlt53BjZmljw+WGQNgwCNzYzinaf4dv7vZDPplvaeTZyQixmZf8ASXkKk71XKg79251Bzu44pRp9n4V1qG2uprIz3KxtBZlzJLKyEhAXc7shS6knjAAUHpUJxTtF6j5YJ2T1/r9DR8rWdJm063s9auGseWULH5rw5O8BmbLEYyoPJOetUrS+1qxjtWUTzW+nWbCeSxjVPOYShhiMf6s4L7j1OSOCKbZXkFm9npkGj3DRw6Uyu2moWUR5LB4J85YElkAPIJrQVo9CsDbxx3M0bXc83kJH/pE+9DLH8yBfL+bOQw57nJo1W6T+4yntytblbJvjbyQ3AttVNubhHjkmgRwQpZnUcgA4xvJ7571M8cWpa7p0WpW9/FrSxRtNLBcFEV4zvMe0/KyfMPmAPUc1Wsb7VLeW8hm0qyufEKpseZ1xbSqVBMaqGZ1whycjBOeg5p02uWPh7XpLW91JRpcaTbdNfaZr6WQBtm8njAdcIMY4Hehpt2X9f1/VhLR6LppqbXiQJezHTLu2YT3N4PKEE5GyFDu8x2wNh3H7o+8APes+00mc6LbvrsE99frdI7TM4VlKMfLJWM4xg5xz710Qf7ITLL5S2aApvfaxfLcOW9ccfhWVfveC3XSnFharNM810cM0U0TmRYSGB++SI8qSOelZQk2lFApWXKjK07W5b22T7Da3UtzaOyXJub2IzusLgBsLzu5IOR0GO4NbemQM0qyXkR+wXEoktpo5AJ7py5I3rhcAqeQfp1rJtrNY9Blv7B7+zhl2mztioE0IKBUVickkMGDBsjJyelVxe6YuvT6fc6rcXes3eY7eCaYTJHJtCttMY+VCQSQcY/Crcea/KO0ZP3S9pp0+LS55or9dVuGRzH9jtAHULJGpeDdkkKAm4knJWp2aKUXkOg3630kifaXx8yhhtbHy4bDblyQSDk1BBpOo+HoEEOizXEctnJJdXNvceYEkcMGiXf8AMULYbavpRdRapc6SttPcJ9n8lUhaygMT71I5ypBQAqOvByAaWjd0/wCvkDSlqnoRajabhcSXM4GyS3F1cWW7aiqx80blO5UZW4Vidu0t61X8Pa/pFlp66de6zN5mlXKFp7kBE2kNIrJnJOY8hn/EYBrrvENhqklzPDYXKWzTWvky3nm7VhdjkHZj7wJ4OeRkcVlQ6TZXOtm3tvJVIbB7fMMI86OSTlo0fIAHCtgZPzkcU4zjKHvepz3utS5p8D6lo17qWpTWvl6ir+VbCdxF9ndF2CQn7r4J3EDGGrPtdEt9N8V20897qotbtpnWBhm0mIChhhRtAwMjgA4JOa0YDqIt1SS2028Kb0M9s3lsX+VWLDnGdpDDcfugc9oI7SS6ubZ5ftlrf+SsLMRvWaAJukXajbY2O4qD14wMgioV1fXQmnNttJ6FLTpIpRc/ZBcxaY9pJ5/2EM1uzI+FEZUH5+MfKOmeDRLrmnxw2tlZyR3F27eZPax27rceYCyRzh8DJHl5IPO0dMdWaJr9zDpU2pQqk+j6aixFNuzdNvG8qy54QHbsxnI61Y8RXy7buS9uZIJ5JxbLPak3EFtIpZlkCtjJycNkZPTHSny+9Zo6mnz2aHaebiG7mnvLiG0T7S8s0f2gFZFVTH5wwSEjJBYDtj3xW2sSXenxrPdzXNwTiWJ1VGm2IyM5JHzAgDpjj2rg7A6vo955WoWcEdm80tr5+mKyLPNt+UlVyUQru44+Zc55xWp/aulaGllDp93fX91YyQwzS3CM0whkJT7RuIzKcvjH3Rk56CnOm29NfQKkddNzrPCtpdvpv2O/jnBiljjEl4Ek81No+dCvGDkgHtg8Us9tFbeJri5vJEiNrCIYCjcFWGWZ16A/LxnsDisKXUY9O1C4vZnuLi1igt7CDyWw0koncKNrMCxbP3s7cLx1qXxxqdxaW0uoQWd1dklMvBtVpGUNiMrgkAMME9g+RnpUKDlL1/4BzLmcr9zI8MPO+kyajrtzN9muYWjXEoKupmYxeW24ncFIB9M9eK6CK8s7y016x1e3hk+yPIXRlLqI9ithlxhjt5wM4wa5G6u7W7gg17R7S1jt2EhEVxaHy4xESDtXqshO7kA7gB6VoaLa3/224uLC4EqytH9oDkPBFLkea6Y5G4fKw459M4rapBayen6eR0ySkr7FWxvfFT69Kl5DCdOFoZbO3iD+Yzrn5skLuG7ACEjKkntV+4t7mDT4JbeOyuNDvgss8bOIZ0LqemeMcIFHBGDknFVNdvLLR9Rs72Sa9hsLiJ7V7Fw7vLJGzeVHGh+6G5G4nn5eRmt6xkuLlL5byxaNrZyYrhYPKD7gpVdpJ3BVKqTnG7OMVMukraA5NWkkYlzaXGnyLOPJexuIpUWP7W2/92xkQRgqQxYHB9icZxmsf+27W38TXmh3NlJp+yNLqwtLlTOyvLGNqxRqAojXLllJOCOOOj4NUW5vWlh0cQX+nyAT2+oOTBFufdII2JwkojfOQMYbAJ4rpb2C01qS8g1DVZJZbbY1xax/uyvO3lASdkmCQCej596b9x2kjRO2s+pieLreaTTJYriO6vbvypJNtgghim6bldc4yOepHGcc1nSeI9UvbTU4buy05Rp0qTzAyG2kQGAY2lM4Ysc+ZyMZGKqWy2+p6AIp7hoYb2VXutMs7do5jcLcMHmLbi4xxuGSFC56Yro/D32u/E91a28N7b2pmjeeeHZ5TAARxFfvyrgkZ69zwQa0aUI2avYppR+LoZscB1fxHJYWlxcKsUkE8xgby2aIKCJ9pGJE3jYNuOpJzW1q9hmK1jsFs7e7WRVkuNQjM2ZGl5WNUAEjEqTtJHXPSqOmC90nX4GltNTuWgmks5GjuxNDMHI8w7T8wSNjheflx71lzW4sPHEITV5oIbiNriC1aZniSWPDOkgB6MACMjJ/vDoVytvR7L1CSlJ2T6HR6dolrKhivLzfdRxzW8d0VjeON5NzExqDuC5yoRicbR9al8G3t1o/inUm1GBEa8WNsrH8hiTKKd4HDkkHa3QHArj7bVo7vUrc6xDtgNlJNK0MjLbvEY1OGijOSSxO1jzj1xXomi69Y6qi30IuDDBa7pJkJS3EhJGxg/JYBc89jmoqRlFNNXuY1ozhF8yvcq3Wh3ZnuNHvWsLrTbuOUxiWSSd9zOGCFjjMYH4547Ck1HRvL8OXek+H7HRobCVYzHJPEvkH5iWzGBuLgL945zkU5bm5E2o3M5uNHt9Nm86OYKJIp4RgkKCCcHBB5B7jtWDaWPmapNLLe3+oSXkss8E8LxrDYqA0fkpkF0YCRjnAJwOeuZjfdvb8yYqSt5DYSl1praldXtyL+5+eKaKPy4pJXXy1by2BK4AwCccHmr0NzbX2vN/bNukN6NPYuq3AaHyiNu8x9Mn5l3f7JHQ1YaOeHw/dQeH0kltNLcxyxNAQxjUcwqXIyfu/P0O4/Ws+bTrXUIJredobO0VWtJAEMCRWzYJTIIBK8gdhuNVdO9zRWd3/AEipFdXHiDwwbOfRb17j5YzLJGI41SdGIKSIRuTCqWZecMBir2lxfa9YvbTW7VIEso0OnWX2ZWgkWPakdwJMnDhicDI4OcVnqLu4tV0SO3ura1tSqp5F6pkxGVMDRkjZ5ZRNxz0yRj1u6Ve2p1qQtfSv4e+zpdTXF5MyTRyqzHPlnASPamcgBW61UtnZDa0stiDxFFd32l2tvqml2k+s3LLI4iv/ACmR41O3DY3OBkZUfdBPXFL9k1HZfx3FlbQ2ZvkVEMruGjGN0qhMYJbLLu9gelO1e0t10qxTTrD7Tqa3ZntZYZQFLGQM8pbPK/MTsz8w4HHSjqmp3FtrN1pV1L5Fh5bfabsw7PO8tC0mxAdwAUrg9QwI9KcbtWj/AF6DinLSKHaJYXNn4ieSL7J5McSN9tupf9LuIujSu+za2cKNpO7IznBxXQzXFtqFl9tG2G6tbh9KvDLJKDsVj0IK4ckqQ+PbmuJupkvNH0m0mU3tvNdmHZOxgQQFsxnySw37hjax7g8VtavpHifRtEsY7vUrgG53FmkfzjEQ+VZ5SvQJwFI5ZgM05wUmruzHVilZydmY2k+N9St/EH9kXVjLfQad5vlz2UczMzIWALggEpv2A4+uSKv+FNd+w+Ilgvbyw/4Sm8DQs8MrvH5bruWVnY7XCBSNvGO3vm6D9q8W+KDFEkljCFsoIGuQcPsdy7+W33zmNurZH8ux+Kml6PoMKyQ2dl50pUC3a3Qm9cyCSVV6EEhSSc4HUAkVvP2an7Ll1a6f195hV5FJJrX9bDdN0+VNfGpNptzNdmMzkLKy2sTkf6zac/vj2wOATyK0rq4mm1CFHuTaeTYKXs7m42W/znly5HzsCCDzkYpi3NlfRJfDVZrdbXbc3N1JCIDJBtbahjflAvAJIGcA55qp4texn0e7s0tIL+5YkRafdOQpLBQsgIGdmHIJGMHvmuNtykrkxadtCGOzsEm1ZdWto57O6JivL11MKvEjbFQgHLoBg7hxyM1k+LvtbadbWmhJEmjy2ex1jdEEKo3LSSEE+X5YIVcY3ZJ7Va8L63cX0VzZRWNncXFpuiinjaSOKPBQNA7P8ysQMjggjHOaXTNQ0nVfss9uzPelpLK73x77mRNp3I3bH8YwMAEkZ5q0pQldrY6VzQlzNbf0it8PtUjgt9U0mPT1uI5ds0l6l0JWMbnA81wSwkGBgDhgMiuhm8mZzBdSWa2ltdSAWzSqimQAMGLnGG28lef0rmov7M0L+z9D1K0a3uzcllktZWeYxRq0UdzOQVwpBbk5wOMdxU1jVNF8TW2n2Mdteta294mXaPyw7SxsVYjkuSqA7TgkMM+lN03KfNbTv+oTXPPnivn+po2Ojwxazc3+pahY21tbrI8OnyKqiaDbt3uOSU3gMGxyD+FM0zRjBop/4Saz06K1cQb4pI3eFAxbeyquNshJ+8MgL19K0dPtrnR9PstQ1BEnvLaANK6qExAR9xR0AH3sHPI9qt6xejxUqX9rq1i9tDG9lIzxFo/OJwfMj3YkXn7vHODnFRzyb8u/oTOcl5rv6DLK9g03VRcy6yZbBGi+ySyINkEbv8qgj5mDHB3HtgcVk3Nz4i1UajqBv9Le9SNQ1stqssltMsitFtJXdgZB2t6ZqujNp0cthJL9k0yWJo7OLSC0jysykyTqACIlQqzKoJOc+1RaZZaZq9gtnb22v20qM80l5LdATOqZGbiT7yrIpIBIPA6jFUoqPvfohxjvJffYvahPrnhS1d9J1LS7iW7Bhjt2/dStctjzCrZCkKCzcAZOBiptH13VYNIdNTuL7UdSspg5u47Lku24lWUOu5CBsVuME5xjBrn4tPivrCFtStrMNEixy20s7SwrAFcxETKGKvtG4suC20dM4q14NvIY9S8+yubq/tbhvsV7K6zFmjjJZJg21QjbHOVIPQ7fe3Fcr0u/T9fQc6UeRvrubXxBubGzg03z7m5sbKwjguNgJJlQNtCo4ILPyc7SeBnkZzmf2jY+J9R0u7n0y+lutNvIZRJCyR3dsfMYRrNCRu2qCcnuCCCetZlrqVtoFjrFre6Vp1+8WnSXdupdmMlq+VijYOAflBCsRg4PFHg221axvbB9AureTTdSuFMc5BMtogUlnxIoyoJkUbj/AHMDPUUFGHmtmEaPLC76bP1Om1aNRBr9019JBYxG4t5Dc2zuqjyisjDn5k5jYFRnIYDrU+nW8um2mnrvF9HZWsFssNvISAGH+t2HkHavfJwtP1m71FdMlivJbia4s545ZZrKDzYZm3cRqzf+PDPBHYVn629vFbahp9ndarc3wg+0zSKm/wC1B1IjxsIYgHhSvpyc1lFNpJiWqsT6zrt5ZWs7zzobeV/KfUEWQSRZl2eUNv3W24w3UM2SOKveHrq8l0Kz1OWJVuNM3ZtXUPOXB2lXc7dpY56j+IHrVvwxdajc+YtzFanSYbdYzd+aUkeZVBJ2DIBB3ZJOeMdqdpWn3GozR6Oy6fZWpjZrhlBZ7h5EId4ieoVypDODz9BUykkuVrYxk425bWfc6ERXGpaCIr6aOwvrkbriGNgGXK5ZBg843Y3DHIzgVkz+D4bctc7bKYnyVjM0RkcKjqx5PJZtq8k4BUHmuXu9Nh0qK58L+H72bUNbhikkE1zO0dxAGJ2mKXB/iXlf8a0hqGrXuqX9tp85SPT7hRdR71mW5hdCyBSOUYZbIwM/LyRU+zlH4Xp+hjaUU1F6Ekt/cRaxPBdPBZ6Ubx2BZyzTkr84kLfdUtvPbG0YNPjsbHTfF73oit5izLJPulbMZjXCOo6BVBIJHXuKIv7G1STaLgTanNbiSe2ukaGS5jGUVnBAO0Hd8vpmuL1q2u/+Ejvm1OOC/wBIsRHfQ20M8caPBkq28kZZCeQMnOwAnmtIQ5rrbQ2pKMtNtD0G1sbS/wBPunup4BBNJOstmSFkJZvmjDAjaOecZJJ61zehaxBFpeq6dp0txZszSXNzKIkaWBDtxAw3Elyhwrc/dz7VW1C51XUdEtoI4Hd59PLNBrMCRtJLFJx5isOpI6/7IIx1qtpNzomp2F/c6Rp01lq8xJv4LyM/aFbeT9oXIPmYc/c74x1GC4w9131/QdOkoxfNt+XqOsYrqTTdMfw9NaatBfTNJLbpmRQVaQ+c0pbcuPlGMH5kA6GukjvYobCGK3tvtd/BcJEFmZUea4XJkZeMMyjk4PVSOxrmbLRtdmsNQnGuX0flTeZDbxItm4mWRVO1if8AVkKSFwRhh1NaepRJe2FwNXFs2o6PM17aRwP5jLEX+VgT0f8AdnGDxu+YY4pzSk97/wBfI1qWvo76li/uNd0m8iez8q/iuLCR2mkkhXEiygo5JwRhW2t24HfrPrGq2Xh1NXvrqaRLSxuzc3JUtNcmSZI/L2MGyqjO0qQBhOBjmuFi1XVfEv8AaWk20IvbG8mieCSQq37uQEBS8eBsEoTepBxuzjFVdR1fVrfxJZLoGj6h9s121GnSf2rcKUeeKV2kLOuQzAb04IKg8DpWkcPd8srX69P60v0FUpOKW1zSvrlbqbRYobu4tlfVBPHbM7TrMdz/ADEKAqKY33luikjpjmx4pZtd1d9SWT7Ms8VtbuFuSkkUv3vKkXrEQ6A56bWbJHFZVnq2qaLb3Vxqeo2E97p1kiafFfWQMlzmTYSkilt6eUuCy9Q6s3SptOgSDUJItJju9f0+S3lti9+JPIIkdTIIy3DZT5d6ZxgZHPO/Lb3l0/4f/L8SZSXPY9CW80gaZJHY6mLXUrieePEzsIUnJbdGGCjaAzOVzjk96ytUtP7Nit9Os7y9S31CJZBqFuoP2h1OViJ6sSAxcYGQSc9q5u0lvx4hnbSmnexkjdpIY9QSRo1jCqspDLmSM8hc8jGe+K1fCHiu/s/EEvhjW9Pt4VWDFjcQklTGEXaqqq4LDlmOe5BxjBwdCUU3HW2tv67GUbq7Wq/r8i5qNnc2XhafUlljj1HULq3zbz7TF5j7FeENyVhIGeORnII7aGmwrDHAltFcpp1uiWcVpbyb4gGYhzvY/PsOc9wB3qa5gs7y7W81BrD7JCHEQuWMsiMHJmUqRxhQoHp06AVzuuXFu/iS7gs7e+S7tJIrhlt3KiWERuwCgHDc5Gw7SfesknJWNIy9psaHiS2nlkuX8P2aT3ltAkiBromO/iQZYGNT95RlVJ7tWdbFjJqWoWDX4t7iAxCWK4KCGRVjTDA4+cY4K5BIYA81p6DHcPqlxdWJmtrxfMggjncxg8AtlMcKxw/Bz/Kp7/RtSmvree9tLO72Ptvpo23FJosvF5YB4w5PBx1oUlH3WWpcvula5jeCLSb2K5F1LZziWP7TbvFE9yWC7y2NyjaZMKMgjBJ71i+I79n1G7v7m9urPSXvJvt+nNCm1xs2gEk5ZXVeAvLZ7GtvXdGfUdOW9iWUXtkrSpYCIuJ5wgZUk+b5NpUYzx83vVODXF1LS7V21R7WK4WOwEQhx9nnx84QEfJIBlQDkA+1XB/a36MUXdXSu/Qx9NvJNLudPW0We50aJXKWL6aGeeNYlkE6SAZdt6IOcEkAZJHMOg32i6l4zvrvUWiuLOC0S9nto7QoXfaChILAhlYqFVxyehOaj8X2/ipdGOpwRXNzPawy2ZMkK213bxvu8tmXBQjcBuKYP3cY5rk9IlnitLOG0hvrHV1QSX186xBVeWQOxc5JO1FbA4yyjjJIrshRhUptp6vTT9f6uKM2m0nZ7f0z2fW7fTxqrXsepWMV9fQyWiNNKIGSCLBk2bBg7cd+QTjOOKqNpdxf6lHqOi3sV34ektpI5bMMJBcNvbcjRYK5APzHO75SOlXPAdlba/4T0uW7OnXdrcK9wzxRKscjNIS4II67j8wOPmXOKzb6W50q4W3Wzhlv5lIhhsHZFZGkYtJk7QX2upbHfvXnxupOCeq0JhOT92Lu9tSvL5Dx68mk3WrPPoUcUaGI+ZC/7k42Q5w4GRlCecDBpuqtc2NzDqKxRx3plcXmoCIyJHYglyV6Eeq8MQTjkc1s2N1e21zFBd3kcgiswgVbYIssxO3cuCcr2IxxxzVLT9Gjv9OjSOSOOe8kkljazdkG9UwF3jkD5QMj+HIFNSs9dv8Agf0zVSSd3t/X/DlGSGc6hJpFjNpt9EtvBFcyX0nmy3W7aX85ecZjUbe3vXldjq2uTfFKXQ5L1r3Tp5JTbI6GRbcruKMi5ARhgrz905zXs89vqE1tZ3zXNnputXDRpKpiW4jRk3Fkx1w/Y5zyKydVsrCx8R2erbrhJ7WKVo7aKA4ZWOZpsRgtvIJGG4OPXmk25K0Xr/V7mlOrHWLW/wCZo3dtLpr6fqmsXVvaWcNiVu7pinm3UjjBQBeA42qwC85HQ03Vdbex1Ke/1FLWe0lQeRp0aLNdXkeQqsAcfIS+dhzj5vWtCa4vZrhLSGylWyW4MRvcII4uAd4BJzg4BPHWsXWNGvZ/P8rRxbaq87SLNbupE2TtEcncqVCs+3HbHNELP4zOKTfvB4fsdZt5nsbm6BNlGC1zJGxMjyPvmhUuMNGFUJkcqQasIlsujzTX0sRkvwthJHNGIw0hLK8iOvzDcu0Dn+EEUPpd/aSaetpPdWZsLiQywsTKtx5gyxY9Tzkg81eHiJmtZpNRa3axiU3Nvc7MoIGPckDDg7sjsMU23J3X9f1uEpXd0Z9lZWRurlFuLmWxj037uDMF2s2WE33mYYxg9KwtYa4tfEOg6hpx1C50hLN7aETXJSNJDtZluH52IVHByeUA75rtT/Y9t4defRoZLOeXGy5skMis7FiN6rnC/ezjrn6Vxus6N4t1zwxbItnPrNo1uqsba6WBxJsYtuxtDAHC4C/N3rag05Xk7LbX+v1MJ1byTfTudX8K9Ba0h0zULHV7q4sLIzxywnhZ5nZg79SNgbO3GOmec1S+J1xPqWm6qLu7S4soQ8Qt0iDvvAjO5egBAJ4J75zwBWP4U0uRtLv7Ge6msrxA9m6WM7eXMxiUqRGxysqhclQAB1qTW7bUH1f7Hr+hwL4bSLFo894nmwhVEfnAjnD7lUqTngelOMUqzm3e3p/TMr/vOe97a/iQ6beyWvhCSx1O7l/0geVZSTtmeR5MkW7SE8nPsFAQj6dBoiWWueHLcf21u1C+nkg+0LKYbtMAO8Knb8m1gPl/u9zXG/aNV0zT2s/Ej2Qu9NiS6DvBvWKJJdmFI/1jOrOOSCNoPGa19OlJs9IvryxxdXd4s1wtum8rJMdil9zHGEVdy9AT61Ven1XfodNKLcLt9ehtWtpdvZ248Sz26ahfSB1i8weXGDkRxp2kyVznOTu9qyLS0sfBuuaFqcVtZ2UF3bvZXNm5/wBWwUuPLkY5K8YwScVRaJ9S8P6yJLXS57AeVKjXTr5wkUOr+UFJEZMaDYAQBnd3NU/EkV5rWjy3N9bPPCkiXFtb3xDsUEShWGxcyAuSrKQSecHpWUYa2b0e/wDX9bGsYtt3ejO7086fqt/qcE9xbxOsUwa98xEuLZRITGFcE/IfmOTxx0ri7PUYNLl1N7KzubU6dF5IuJ5gq6gowVO/u7FiFyGGOOOlSeK5/tN3dW+qWkNzpVkyed5EK+Y80kXyFFIBCIA2Bls7jStZa/o0VpL4vtEuLWLZNFbyWKTpbM2FUGRcbSACMk4ywJ6UoxSWr36f1/SKhTSXM3v0JU8UeHdP0Zl0u01uS7upLeKW5aHKyNgOIm3HaBmQjHGcEdq0Hlgl8TT6jcgNb20iwW8EMJ2SPKUQSK24LuDFwVI/gyM1B4oENnctqHiG3u49FuoljuYopt7xXBwoVUwABwW3+uMYzzZkSLV9Gnt4bKbTvDxurjZfRFUSLaQUnbks0hbeQ/A6ZFKytzLr1FJRS51fXd/oWrJNM1eCW+0jTUmWMvbv9nmKIkcasE3LGRgFjllAP3vauW8Om905NVv9K02LVdKmsvtMjM523AWPaIEO0sVQ5+U4PA5PQ9L4qlbRILJYfK/saHEiARyOTNGzO5KxgYzwck/e/hqvq2mXssd8upRRSxQzxyRCO9ZJ7lmUNKrAfedSwCodowRRGyWuz7kRkoxeujOZN5fT6hqsMGkzJf3xgd7PT9yzqZIRs34ADRqyEHkAbvc12Xgq7nktNQIe+ttTlthPPYx4njswpMbtGVU5cnd8uSeCMcVH9iu9S0SaTUZL7SbdYBb+U0uJfPUhULyJy4IzkdDvPeqfi3WY3ubPT45YtPvbeNJZ9NtFRczJJEw8suyKwwsnOcgHdik37VcqX9L+v+CKtUU17O33Ek2hRywazqV/5EESyTeRFp9x5hkB+Zi7FQ4lZgVbBA4UYyAaW6awkh0y+sY4bR7OWEytChcywSBVfLrl1kAABbHJXacc4zILXVEvhpWqw3VxbtevLcSQzN53ktukRgFxsXKj+Lnaeua6jUtMs38S6da6e2nJqFq0WpW9wrgTCMuQwf5SWR2OeDzkntypO0tXf/IJr2aSvcw9Ks71dZv47O1ttHaVWQzhiTIxO5gYyNnVSQ45IIHfjooD5+oXGr6UI2snshBjzMcxFlCqhUEgljgk4yowO9ZwAmvf+JZq8V7Y2O4TGKVHkmmEm/YoI+VSvy5z3FMk8Q6HYyalpeq6lemAFb/zbiD5EVnwIuAcorbRlcj3zRJSk9v6/qxM5KWqK/w7uvEdr4hu31rTZf7LluTIJxKqiAsq8mHP3SAzFhkbs45NaNxp2u6zcpcTvNpUiyvERp8qtJcxuAqzGRsHAA3FcZ49cVrRXd7ZT6oZ5Ek01pFZZZ1+YeZwQAOcKCFGBjuTya42SS7u7ie/0NbySRJUt2sjd4BjXpuVs+VlcEgc9COTy1ecnPRbAlKpNzikvyLelawms6Xf2cmoyrKs88jao9uCGbHzMF6psPAVuu3NQeC44bjWLG38ya+g1VBLJcCTy4rllVgseUAxgI7bTkYOD0FWpLa5xLa6dGd4txEbi+umeR50+TDoy8RHG75T82c8ZNbOg3enadbafYateWVvdxRMjW1vKsSh1Acso3ZBCkZGeM+9Epe6+XqOTioe6tzfls2K3ct7ieSKT7MCFEcixOMna6nIwSOTjoeleXXN9pOtW+oWsWoJYahd3RjK3Bmjy8eEiA3LlWDKvK5AYc55r0TXdR0SDSb1tRSYS6nbNJP9kgLggrsB3kFQ23BAP68Vg/2Ndywac2tl478NJbRJblVdP3gkC85Qllj5Y9m7Gooy5VeWhGGairspSeHI9QYWdnqV+dSecTW9xqaLIqbYlAVypDAMp4OFbrniqd39s8EW+k6Z9qQwwyDz7p4MRkNL88LhdwiAGzZwMls5HNddrf2DS5YJry7+wXl+DPBAyo0cEgQmVieCfvcknAOMVz1wWtPDNymoXyX2k6hPFbWjX0ZZThPuzTIP3kZIX5zwehNXTk5W5tV2No1G0k9V2/4Jb0+5gsWn1CO7MVop+xmx1BzJLbuFJJiYFsnBUMmfmxnPar9g1rctfxeHrOPT5rBfs6vd2/lZkdSC6DnCsMEMQQffpVC4tFS/sGN5PaGzjV/scM0ZhRiwJVsgsWcHGRghQQDzVHQfGGm6dos0FnpDJcG0mupY5IXEZ2BWVEV1+ZE3YHK5I6ck0nByV4q7M5wla9NNk3h/TvDmi+GNR0+zhtlU3Uhnkn2qsBYr5khJOFRdiFimQpC8Dth6hDHYXi/ZW8uOG1b/AEhtSIVFDLELhUGdpwWAYAA7ye1dA+oaZZ6PJqlxC0FvaTShrq5gH7ti43YT5SA5OBwd3HWvA7z4g6VqXxAluLtNTi0iZJlnEBjR4GcFQU2gb1VduQ3J+YfW4SjSvOo7I0jG979fzPWLCLTr/UrePQdRv57XQrhLvzN6Ss7eWsaNExIkMeeDnI/d45rV8A6nHpl/KitfR3EcuG06Nd0cizTMVkRsMigL85CkY+YemOd8JJper2tp/YOqy32piaNIbyZmW4WFNwnDu5bZGxIITAxuBxySPQfEEV1omgw6bJrVlHqFvCjDUHtUYXOSRJ/o4PZGHIz9Oa0nKMlyLVP+r+f9WOKs2pKLex0Fxf6Xb+N9Cij8m1a5320KgKonwhYgDGTjb7D5h14Fc2nh8f2qi31+iSQ3dw9vGmyB40kkZN0L4JEmFAZScPnPBpPhlo8suuQyssc9lZPPN9qlhdZN74EG0kAZ8pstgHBwO1a3xE8ItqTub2/MukzmL/R5Pk2TK2VfzFIY85wBjk81zrlhU9mpdP8AP9DFq2qepyur39hpeta5f62Z2GsRJC7Ryeb9lMYlw42ZOwmM8AE5BBwK021G5mOl3Vij3elsvkvLLc/PICdobaq4fPJDZGBVKPUvDPh+01az1Swn1fVJJJU+zpCTJDBIoPlyyDhDsYnJI44zxVfw54dutIvbjTtPiimhS3aaxikvGIt/NwwjlUYwOpUY9TnJraaja7X37NWt/kddLlcdd/wK2uaXq+raPZTzWVxc6pdzwyTKrqklpg8uoyQ+0j+LJIatbUtPt4pr7UdFiighvoZ4rm4F0RGs/JBZVPzMWypI+bJxVzfeaPFFGGub+aCJ2a5T5pUZwAMJjDHJIGAMAc1DHYWsOiC61QQtNBbie8tJJjHCjh9wlJA279x5cDIx9Kz9o9O39f8AANueyV9v6/pD9Ok02HR01kbre9u4luLuOJyI2baBlmPBXb3GO+aQ2Ump6romoQTqb2K3YTPaIghZC+eEGQXYDgk/wtyDWYupNBr13ookinhurmW8ha1kLtEMqqJN829SM4PBUg9RWbFpdvY6ta+G9Lvo5LNLlpxDHL5VzCiruaNX6EHe+Ocgcj5qahvrr+g+Tr1/T/gHUazdpBay6VcaNcz6TYqFmjdSyzbh91lYl3VflO4EnrxxXGWdpLqWnPLrLzX2h2ypHp0cdx5CXM5BZApB+cncilmYLuHAroPGdhcWdrpN9pkyeKb+1Yss812qCGMAgyHBy5GNvrxk81RvNaY63aaf9guft91axRS26N5tvG+/PnyLggAgjkMeo7g1dK6j7n9fqvUzjDmS5d/61JorSFbmwsmCQwWl3Iyad9o/eyXLoSok4IVcsR6AkcmrXhDyL+5l1fydSXVbaDyZPtI3NHGV+YIMbWOOQV4JFY/iDxZrWmw32qatpcGmyRhpDeW6mVWYsIgGXG9VZcH1yR2BrW0m7mkv4LuNP7UuwLfzLcH97AdmBIwXjIRyWQDGDnOVqZKXLq/x+/7zRxfK33/r8TYtJnjmKpphvZYgjgPhEEj4LPuwCD3wKxr82t5pY0qLTYBaK6w3tlLcPBMkHmfK8aoCxwwYgDGR1rYkbV3SE61q7Q2F5cySxHT4lZY7VEc/PIQAoKgcjnJGO9UdFg1G7064n1G+uXs7uCSG3iurZUnVI2J35XJYFCAWzk5BA5NRGy96/wCZDStdvt3Oj0+x0PUbPT/sL3EX9l3KmFJI2jSaSJTGC3BLqR+eAaqarcWy3t/bLZyWF7IiSWmoywM8QdQ5UMRjBALcZwc4PPFcxFJPLeRTapr7wrFcC60eC2uD5MtntG0yYVd2CSCpI+bjpWn4iim1SKwu/tlzPpCXM0ryLZKyumCUjG0cFHj256kk+opKCUld6f0/mYOLjJa3RQ0q8tdUmTTvE1pLYajqca3N3G7AB2iC7ZQgYgAFVJHGcc5rTvtUm1TVTaaHc3l1cQRB47cwrGt0GKlnDNhgQAQcYxnBqh5M85ZbiKBNOuX+z21nJYLK01sqjcpbduVceoySO9aXiHX4dI1CyMcDaaJo5yJJNsTrGsgy5HGUx8xCtuxj5euLcbytFX/IqdRJ6LXt0Gappniey0eC5t4bWG6lMibLl/L52nywCrnbjGa47QtIuPFWsm8XUD/alzbxrJJd2yNHcoZHV2jQN8oYIM5wDnPU8dib/UrTwtf3ep6rqGtWtyQYoIYI5XgibJBwD+8wDn1K44zmsrVLS0ukvbu80u6tHhmiZ2Eh3RquFjmVVb5YyScqB68VUJOMWtO11/wTXDzlq/xJtW0qx8OWWrTNGbuUsZLuSLeEt4I2EiRIFGDhUxgYyQMmvSbd7YWKSWXlG3OS7omzcRxzx14H5V5pqF7dy6FPD/bEsk9olz9phYxRSyYcIJc5bEYIYY2gt9a6D4ceIYHsY9C1OOKzvLSNYo/Lh8u2uBgbnhfPzc5JGBjkYODWVaEpQ5t7M4q6lJczL/iDSYtWivXhle01KSIxre2xAmTjAIPfGT7jJx1rzKzvNbubS6s9TfUtVmdJ7a7NmsMTyog4dYnIzJxzg7cHjJIruPFXjLTdN1Gx0vT7u0m1a7ulgk5Z1hB9dgIDHgAMQPmBrkdcW4PhjTvEkEs8VzBLNc+ddpGJUs0kXchZOEYtkAHcCVFb4dSikprR7XM6CdyG1uobjXlWxVbrTL6eN3uJrfMRuWXMjhvuq0qDa0YA2sucHJrLGkzabc6no0c8264kkfTdN0+6xKkLShiXkKjbs25GTzkjmpfBltruk+HmtZ9Vkh11pTttrpkkt4JfMVlUIVALsHPRvmLE5rsba+hsm1+yubG61YpZjUllmk/eq8jMVgB5KDK8Z4HTPHOlSfJJqOv9bno0m4Ju2nY5iysYL5ZbPULcXuoXxdI9aHlojMina67TiM4JVSfmODU+gaNYWn2XyLIXDRCWZop7wvdWbnGFQY6MVDL+dAsrOO6v71tEtbC2kjgljWRsIXjxJyhwDKWaRVGDkpkZzUkAazgkutO1i1uklnGptcyBlZIFlG+FjjChEwMcHJIwM1m23on/AF8jolK+x02iXv2DwVYabptpPdNLbOY76+Vd0DnlfN3nljuC7R6GjUol8S6Mlha3qy3SsIr1YrkAQLghzsOMKOSCB1K9qjePRLuxiureyZLWbUmlsrva00RmJYl8AllUNnJOAB06VzWn6Vf6VdTkTCyivEmuuTui3yP8ynjgFOM7sAkZ5rGMYu7WjOaMVJuWzXcS7v8AWbbUreG2sjf2+n3Yiu7eW6Roo4JEURFerqpVN25jncWHOQRvaZaJpekazq+j2Rto4opbTT7OGQbYieWfJbaQSQTu6YIBwa5q4uG0TQLm4ms9M1e6jtZZbkQzKp+yklngj2jLCNgFyfQ+wrTu/G2iW/haGO1vXt7aONQUijJmWeYZA4++4UncpXGcGrlGUrKKNp6rlijB0zVPskttocui2l1ez3UkM8kNy3SVS7tuUlVk2jOwNkADpnFdfZ6DBNZ6TdWcUmmX678TRYJWUpyWRSQykKDhj+NcNfKun3kF9qmmx3d/OZdstrdiIw36oCC2SPvJEhyRjPUHNa3h2BZkvLnSFzFdxw2dwWlkgbKxgyJKmFVGI2hCudwzgDOauqr+9HT+tepVRW1vr+Y6S61PTnbTLja1jeNI/wBq1gmJbnbD5m1lQdGOVx2Cgcnms7R9Thi1C1Mmn28emJBPqdwkbRLEglhUoGVtzAhNoCjBY89KnuoII7KS3vrK4ttQt44xNay3gY29puK+bE3O4IN+GOXBZgKhttTfVreyjXWrjWIvtBsrry7RopDbyZQGSXAy+WjwTj7ueeRRa6/r9NDSEVJaejO30NG1XSbe8SKFLu+uNkthqu1Xgs2URmCIx/dj4BU9DnBxmpNPTSvDupxW9k7XF5cgrcyiVI2jVSxjjVDgsfk2ALxhcnHfM8NSaYf7PFuL944JJYme9dHlmQDaybnIcIHjTBAGW47GuMjivbn4kXGt6X4ah1CKzuGt5V08GLyTyH3jJznknjgmsow5uZN6f1Y54UXJtbRS/wCGO71HSI7u4utU06HzJ7a1KmC3VVlcI6kRmQHOWMZyTzxjtUi3KXuhTW0WiXYvUQJ9gugAdzOrEqWODGARlQcdhVTWILz+2QLPUbTSntphI3lMBNLalgSMADO6TPOeg781QX7VJYwT3VsNS1G5uVH9oLKXigVN2HXJGMDGdvGSCc4qlG6V3/X9fMjlfKm9Ttgkd9LfS3lu9tfTp5Pl3AV1miUHhNpZRu/DIPOMVzc2g6a1vqwW7t9OuvMhWUQsUKou0QB2Y9flA+UgHA4PIqWDX7i4sdbs722uruS1kFqLqXbALgOu1HPO3yzgqT23D8K0mqLqXhvTbi1d4T8iiSEiZ4XYEL52B8yqwPzcDgYxUqnOLttsTRjON/kXbuGW8NrZapci5ntL8yPGijZcfK2wRv8AKFb7o5JHGD1rmfC+i2914neXXLTURPC7+Y15axrDJcSlVkG5PvNtfAwNvy5ycc79sqXNhoq+FZ4brR47lvtDCZGE6naTubk7t5J4wT0rN0ebULq2ur7TZ11S+aSQac90roj26sNwkQYKHJZRn1HNXHmUWk7foawk0nZ9P69CW81jWtSuLOSwttLudPe4KRSQxylVQTeWmQuRwgO4n+Wa2vE2tanMbP8AsuWygkiu1cwXkoWSURqweJV2nG5TksDkfpXCaEuojVW1RtY07TNLj3pH4ea9MiRvHH5IVSuBkM2eDgcZOena6SIbySK7sNUgu4NLh23ywxCaQxbcMCxJbcp3EY5w2CDgGipFQlfSy/qwVI042utBX1vRl0DV9btVjlkFlHLJKx3ogYBVUBgGIPXOP4ecVFeeHNVeE+dOdTM8aRxCdfMtk+dWJZAQBgISAOmQM1t6VaQWc0dpdwRyxLAxhuYkEaLwAN8YY78g5HGBtPtWPYXsYtf7Lsnv31FGSC5lefzJ1YyBtxZOHblXxgALwwFYxb+z/SFGfI7UzDvvDUOjaVcrc2nmxWkfnmOWdRBcTuWJMZf7pRQcAcAH15rRmlg1eMy3OnfZ4zGsdopuTDMNjKXYkDKqyOGCNydp7c1s3zWviizktL7Tp5AyrP8AZ7mL5VdDnK7cbic+oBx6ViaZe/YrSPXn1rRpUnjiUMLkJHPKRjEobJ3DnGP4cjHFaXlJXfxFqq3H39Gc/rjXsbW3k6VYeIo7i5S3tZY7xFjvliVmjWYHG51c5JGMgkc9Kb8QvCkmqaNd3GqaaX1eJZpXmlii2yh0WTYnJKqpXYAuCS5YEZIOp4UvtAbxBNYeKr+DVJbSAH7PDblYXaKSX98sQUKMKyruH3hzXWSafNfalqH9mzXkkOpTreWl95D7UVSrCElsqF3BuwO04wcZrWb5JKMlt3Wj/peRy1K6jK3Y88/4RttA8Ky2nhWOCG8utOE/lqQ0q+YXLqerkqxjAwCwEeCTuJrqtD8E/wBoXFjbXt1dvrdisUwuJbYPHIQIyS8jD5trj5duCAozkk1teDPDdta3dnr1zqltfadDBOkdxHOdqO7qTg9wCpUZIx75r0y0igtVWKCBYsAA7VA4rnq4l01yUzmnO7CwthZ26wBpJAo5eVizOepJJ9ayfFAjTwfey6wYWEKedIeNiENuBBb04wT6VvPjBJwPUmuM+KF20OhpYWyWtxdXkqf6PMpPmRowd+B1OBxwfoa46MXKol5mSep5/aWOnReFoNWFn9s1ia2u4Gns3Ki/b7rO7L1VyowT0J9an8QWM9h/Zlumm27QzLHG0/nlJreVlCoGYY8yMFsfeyBk1zeoalHbNqNpvEHiayjm8+zhuGAJBDKkTkbTGI1yyAA5PGKbpuu/2TptmWfTbuwnaIW1q9z5hjgcISrjq0n3m3t2z06V60qU2+b+vl+h61GlNrQ6PVn8O67BDp+qyyWSWsLs1xFOArfJ5TqpzksNwbByenrVGz02CDRoriwuriPTNUhktbmwdCziB1wJypBbeQEAPIGR71Tt9BvJdal868s5ZLS6Elq1ncbD5uwlUYH7u4HDY3FgB0wDXQ65ZWclxfbVvVmRlumhaR1aWSMKQFVckJ0yAO9Z6RtFPQ0aUZKMWU7DS7DVNBl1Q2GrzXwRLOC5ZRBeBMDLEKQWGSScjnkdKyPEL3j6Y8GsQ301xZTnTlkjlWJp5nUP5jthQqxgEjcpHTmrllNexW1lc6Vp000jJHqNrax25aRUJ2zWz5bKkHEgcjoGUZNdDZeI55r62nlUWV3LLHbzafeMrgpgnYozw5Vg2Ou3tSvKLvv89gc5Rba1X9f12MTwZHDp0msto1ha3U88duY4p5cRmJ/maYNjgMCzbOf9WD/FWf42meG01XUIN0GrRSw/Z57aRwi7DtUSkffCtJkDAOcAgjms+c2X9p310sklu1zBJCU8w3cDP5mxJBhz+7OVVQV2gIw4ra1GfTPEFnaXepWtrd2hyq3U9k4itduwmQgN88bH5gx4AHetEuWam9RzhrzrqctJcX8+sXMmt635iiVGPlXKw2sRj2qXnCtlWLbh3BbnHSustr3T7Sa705rl7PU4J4r9LcSJEZ0UAlWlG4Zc7mwcZXPABrz3UoLy4+26Lql9eXE0ZXbPEscE7K7EASqxyyhijrjPyEdO0nhdNXu4orIWt9eyxyGK/S9t4o5Lkyq43+ZJlypi7ngDmtZ001dv9PQ6fZc8dXZHp+mpqN3Y+I9MjS3tktkt4Hh0+QnEG3zJEQOdoYq/lqwAOV5HSugsxb6rFYx2kEax2MhWxmhuBKLaMxlFnk5G7JJXaM469q4WOxku9Pe0KS21nDNFNcxvbxm4lcnG5liJDoRGgBHoDW94l1oaRZ313qAu9MjmsZIxmMNDA5YhMouMyNnIAPAznGM1yTjd2jv/AF+Z58qV7KPU6K4GkXGlxW+syB7VXjEu1SEHJOGPZSUyfYgng1meLU1CLTIogI7PRCkkUjR3KxukLhjlFPy71AQq5I5JrgfiNqWo3lhJYwWkkTWktq0NtGjqdRkkBVt3G0xbRgqf7pHHAroLPQ9W82GLWNNOqiexFqVkvAtpGy4aLdCEG0E5TK9FXoaFTUEpN/L/ACBUXBJt/L/I1/DPiB1s0s4tNaO+jsbedZ8K6W6OvyxmUkeYflycd274p3iLUY7ZdOa0tlS6uJPLheSJZFijTJLbSfl3lyoPUg89Kw1sYbC7soNetiLiCSG5SZbkSJbSAti1dBjIUSALwMjk9K1NWtrGbTdSubFWgfVIZIJ9RZCsNmIshXZSccDgYpcsVLTqDpw51LozM1XVwNElu9StksEDTWNxbln8pWwD5gdEOMYZR6ZJ9KxtJ1y11XULnSdcRHEdiIYNsckcd1bIyfIQGJMhYBVl6NjjrWlp13cnw7LJa2s1/fQwR2U4hnMMEqoP9bAWGGJVs4/iPtTtD0Pw7eXI0tpJbLSJ7GOe382cxxtIrMpiCYUnIJLKWOSAcYFdCcIxfMn/AJf1+IezcFLsU/D/AIQutAS4jtbC01G0vrr7X9ovozNLaFF3LCxP3sHaVJwCS3HSt2LR5dWTxGJIUuL+wlV4EnvldYg580HZHymASuAeenTNdPFeWp8P2v8Awj1i+rrAsdur7gZp4nADOxwMYwTx3ANcR4i0zSJ/F2lajo1pbNqzXjW5s7p/L3jAVmZgMb1ypVSeecAkVlSm5N30/q+upkpSkmnucn8PPH48J6paJdx3I0hopHmub1UdmcZbdEsYyVPyfN82OAKwPEms6n4u8W6+LXUiLeSZIraxS3VXKO/m75YT1VdoLnk5K+4HaTxahePZT6qsv2rSzPbqbuVCk1rKcEtiPljgAKMN271g2PiOzg0ODWNS0nSF1GZI7fz7K4MTzgpsAHH7tl2gHd8uE4Ir1abi5ucI+89O/XzFKnNT5ztPhJqdy9/f6VeLcX8dpK8EuqvGViLg8AZyxYZUYzwMY4FbdzrejPd3Gt6dq017bxiK2uLa0XzDGAxUOAuGKkluTkcZFeb/AAsutbj8GXtnaWWpC7vLqWRriZysckYVWLNKwIVmLjBxlsdeBXQaabo6RfR6Y11pd7Yxwww+fZFpApBbYWU4Y5BywGDuPc15+IpR9rJ+djWNO7bb7f8ABNjwkZfEBn1A6baC1ubdZEnmZTJH5bERqQRzxuff1UnHWsnX5NM8LmG5BtbmxtzL9p0vyy3mBgTuyScMrF25xkADNWZIbq0mgv2aOEK4neYzY861b5ZGcsDgrIwOB2wCeprSvdbsl0O81C1iSK48uTaLtfLUEqcRlWzkZGMHht4PpWWvPdK6fQ0d1LTbsc7NrmsW8uhXUskFvI+nC2cPNmOSaXIjkKADIBHTIPPHQ1v65r9tJ4ftLbUJBo1wyyxwy3sR/cFAdzlVyuwnBUE85AzXI+I71dXFjexyaZa2K2UlwoklZI3ZkHmYVNxVowcqezZAroILqR/D2jG6VbK0lhTTLWAwxyNKw2nepOS0R8tcKcE5Oexq5wXutrU0nTWll/Wv3kWo6Jpmg6RJLfx2d1c3tu0EFwYyLdIwyOrOuRt3OU4Hr7UzXNBt9MbStbtp9KN6WSfVLn7XIsBlQhWAflSgYkYI5OMnjma5e5aGG21bRpZtLvEkju1nVT9idyJAzlQA0X8JPbaOtQvHrLeGtUs7KyjXT5pIobGwlihKQLv2zFoWII5JcHJBG04HNKLlpr/wSFObd+bUZpEiHxPqcOq2l2vh68uS95O9mrN9qeU/JvIH7kq2CSuNo4NYtqraV4g03Tp47k6I6SWrXsJYQxySSv5EiqCEP3QTJyRx04B0/Dtze3+lafBeHVbW+E0kl5JqMyNEZdny5G8eZHuOFjA5K47VZjlNxLq+nWMTXc1vatLBaTuEtZIpATJM0K4KFiSuCSRgH3oel/68rlu92v67Ed7c2EOgSfZtQaOOz1S5Z11GDzJJrrI2unPEWWLAKckntzU4s9TuG1PVdLm0mW3z5J1W2kLMUVcSOYgCd46BWU/lzVORdJuvBmrrqE1xcLbXCzWcsl+Z5IysYJkDwryFIkIB6lByK3PDkN3e+K9CExurSwntXe2WO4KKspiJZbhVOH3ZLBuORg5qXom+19/vITlBOz27/eNWzt5bdr+xBuNDns40e9uLgp5ckTSll9cNv6R5BKkDjkusNU1KPSpLSzuJoddS9SK7ATbF5g2GUAhd2JFUMC4z8xq/rGrGwM9nrNpANHtPMS2aKYN+7jVNuIiPmYMshDcbdo+tZdrpyaB4niaw1S4tYZi11DFc3Z3XDxyZmB3ZBVllLYHzErWdrr3vkRS96HveqLkkljpH9mT6V/Zp0q0luZJVSDzERQGJUyuf3Y3F+RxlsdKqWN3H4U8NyzrDYJ4dspYo3a7R/Njh3ndkj/WPlscDng1c16z1XWtKsory0uTcG5dbmOwvkjjWFmdC3q6j5SAecnBqvL9s1PRNLivpJtPVs7gy4JRW2iF4m52sM5z61pGzirvrqJK8VdhdW8154Rni0uC2vJNSthcRssRKzREkrCfn3EqCWGMdxgYrQu9Nu7/adscWvDy5YrFbghZEUsqvleo5bIPHHrWPGX820s3v9M0PTtPud1rGVWGWYhjlVRiMHdkqwJBUk85rE8N3t5c38dxoOuLpNw99PEBdKZXkklLbItzfKSCp+QEkBs96vlk03fb+tfuKVOSvKLNjRtL1VdQ07TrbSbcMs7pdy28kcdvNMNhWcovKsOeCPmCjpmrt/NdzXt/PplhqZ1FrXyhDEqZ2+aVP73oDghtp7c9aTUbvR4rN7nTU1NYp7hZb2505SkTySRsu+N85+Ur8zDgcdKs6FJLqWj3kesveaHCLZbaC9N8Cz7QAJV28Kxzgt/ERmpk38bRLnf3rFTxTo1vd+EYhZxlrYzI900BK7yGAlT+6pLncwIwRnjIBp+p2Fpp/imw83Ugpkdb61s7G28p0cL5bylgAJVzgnPI9xxU2s6XcaXdzyJJbxW1zaPY24uVDyPLv3sThgrNIqADHzd6q6hHEbPSbPS4bvSL63sjK0U3yrZ2oYB18w5BYsqrjkjcSaUW2kr6O46bdkr6ak/hq7ubeO4a+mMSR25jE0P72K3ly0jqxwGGNwAGCBtxz3g0y9gudb8O6vptldQ6qYWljluIAMxMqrITgAM5UAjJ6HA9ue0HxlBLqd1q2mR3EMeoR/wClwWqhX+0bGKsqOdol/dnJGQQVJ5rubL+1n1Ke7e3imtXPmt9o3hf9XuRgN20YyA4HcUVIezburX/qw5e7dtGGJBrmrXj3d+bW/lnilitLN/LMSk7ljkQn7x2nOP4fpWPf6kLjwbqcvh2xbT9UjvIhJYSQBvLcOFYLkEMpZiue4yR0NO8Xas2qalpb+HwkcNxKy3GEKT4RtjGKTAY8biPLOcnkYJr1zwP4VubJVuNauZblI5BNZwyAL5RK4Zn243k5ON2ccnqeLnNUIxnL7vToZVKtoq23YreEPCEN1qR1nVLa1Xy42tbWGOHYViJDMHJ5+/uwBgYOcc12OoeciwQW9sfLy2ZFcIIyoyox79OKsNH5V80zXJCyqsawMVC7hk5HGSxHueFrkfHPxB0jw/E0H9pWtvePL9nWadGaKJ9pbJxgNgLyARg4BxmvMXtMRNKKucUnzbklvf2mkadaQWtlGu8Gaa2x5TRK2WZyp4X5jkhiM5OMkYrk7j4tW80bT6NHHLp4Zo/tKnzHyMAHyzglS2VBGeQT0rmfEOvLqvhiTUrP7Hp0WrFSZdVt2Q3L+ZtWSPOFIZCxCyED7uOATWHq3hXSz8QLK+1i4OiS2JWeOGX91EVMjHaQOCSW3MysMAcrySPSp4anFN1Vd/1cmEOfVux69onjue70GC/uLO1mEu3ZJZXAn8zIGSFAB4JxgZPtXIORrHjCDWtMvg9x+5i1C1MzI3lNGzIGGduOVOAAQep4xTbfS7vSNIt1vZ9Ns7GeOWaQLhLeHzHMj7ZFKlAEYBT/AHu5rzrWDqN1r01naX9zLp8s7SXcqQGRyqOqFpWXHmIoC4KkkDOcYrShQg3J09P8jqwtBVJaysdB4usfsOo2T63qMUuqS+Vd3sFtArG8eN5DbxhcYXA3IHJ+YcHJxV6+8MaXceJZ7pI5hNdK1s9iVQI/7nKw4wC7DHTcMbDiurto4btbJYIXXTZmCSfawYVkUAeWY1YZIBXhTjqT3rF1KW68Spcn7BZXWix3Egu4TclJ9sOdxLqQNzcAcjAOGqI1ZNdvuOuMrrTSxNpqWzNPBrRli+xzvvt5nieSXaB5cxIHJWM5GMHGc5rR1s3un3cOpu2li9MTxTT+RJMImkX5NjZAKM6ovPPPaqXiS20a2uDfaRpF5Pp0xtpGWwlz5Plg/OFH+rTYpBbOGHFZOr6zqEGsqvh6e4lhuI3Edq8nkqVMatICvJkZRtZdnHJBIPXNRc3ddv6/piacvfRvWE9no0sM0l1O97O4S2jkQMybPmaDf15O5iG7Nx0Arl/Gep3V744NxpltNJBayRXULQ3CxLHP/q2Mw27ipKhDz9zaR1Nd1rs+m+bbPd31vHLDfeZDLFbBlQIAvlyNghXJJ69QQO1Yd3Zw3ph1+536ckbqgRZyY2fzSAzBcbW2xg7iSB6HFFKST52t0RCSTVRrfQueDF0ZF1O2uIlt2ubiWGziu1CPdRLlnQwgABBkkBeCrBjyTUfhy10++srtba1T7P8AaVjQQ3Jlgtz8xPlpxt+Vl+U4GMDoK43VvEd5p/igTeIzLZR2Vs0LRwSGd5onKgSuRwFYY+6AefbFdP4Rt7PWPD97byfYbTVtxmhltiytHEnMZywyww7qTj1XAqqlNwXM3vbzNZwlCPO3vYw/EmkTKLWx07Sf7T1TDX1ybyFWF05lXCvMG+QLzgE4wuKr+GIE1HxNf+Irg3elz2ymL7LcSjzlk+ZGV2IJaJmOAMEDaOwqS1m07RYGS2urv/WCzso7G4LPMrS7/uNj5AMAKRk4YA85q5eaObjVbWe2vYWuYJj9vXTD5NzCZoxsdlJ/eKkibgDjAPQ8506NP7/6+4J1JppLr5feabWw+3QXmlXdxJqM8zohdVlkW68td4VgPLBUDbtVlT6mr13qUtxJDcS6dq81skxaa1khSUKC2A7Yy24HG1Fz1yakmurODRkhhvYrMIPs9oAotUQoACVyRuLO/PXBOcZArK8TSlb3VZra41JJhEGvWsSgVCNojh8zO6PmTcWwcg5yAKxinO1zOM3KXLbbYvNEdZFzql9fTxJa3+UdEZRmByAoXAbqCxGep9KyYFni8QNHFKEup/8ARpr7zd9+wjEjK+0fu2BXGOA3C5HGaoaVHbXG/Tm8R362i3LTNIrM5JdOV89Ad3Kls/LgmuttHisfDq6TdXcd7qr/ACpOZxDKzfNtYMoO3KgnIwccnmhrk0WppV/dvl/Toc5HNc3r6D/bNwdIknD5ubMlZbyUlRGHBXBIVATzkZwB3pmuLHfmHUdVjhtYJFR57Ga4ELbojhYnXJEqyOqnJAI6ZqC+t7vxNper6RYWNhJD9pa5tZ1JEEzgcEyMQXkZVZSyZ28Hpmo9OsF1E3Wnavpunzf2fdieW5hI2WRKmYeV3lA2qrDuW9s1o9NdmjTSOvVfkzSu9L1G7TWVh1m3SfTUgvbq1kiM8TBlz5LxAAw42EgKc8+9U7bRbewtTHrjapPBKwMM89s/ksSqsvUtIrhVKgqQuAVPIrqJZ4tV0a2ub2WSf7RIWm+yW5gLGVfle5GcjapC5z129Krz6bqGhR276dqkBiQCeRXIYS2qocfeJyzSORuG0nJz0zURqu3K3b+u5gptaN/0jL0zU9cFzoUljbwraTSqt7bwbt4jcNsYK43RjaAVII5zmsf4hm00PU72eOYNJbwraxWMsbFoJ1ZZElDnlyxCZPJBPXBq1qk/iC8tILqS1NldJcfarawtS5a9RcFFlYjKBSe3BBOO1cvouptr11p8V5Fqmo6jYpa3UAmujcRRgSdNuFYsQMZJIHOeK6qSs+d2t5Fxi+bn6dTufC+kPp9sJANQS0DxTTLqkqlAQVYkE8hiWPJ5ygx2rC8eaHYXyRzeGrHyZ4NSisvtAtGd0mYh984ZA+0RhSTkgluQTg1eXWr7xqZtO1S1ntGhhDTaXI+3zUDrsfzTj96qE8Dg7h/dqte6Fe3l7c3On3mgTjVnSLXLCWSVgrJLlZFcNgOF75G0rx6VNPnpz55Oz/r+vwMJTldN7/p/Whv+HrzW9BjXVdbmsL06kJGt1gR0gimx8iyk87MKAowT2yeK6P7eHghW71OK2iaCPzTbkNFaNjLkZ+baxOFz/drkZNGgsJpTb6gYLSe6NrHZSX6zYtDlmRdpAVw25oyMsvTPPHVado1vZ6Ajz3E8sL2MkRnwu4Mucq2zksoGzI5G3jk1zVlF2l38iOeDV3ucgfDuuww2sF1c219am/Eiw+YQYgoIGSBnbuCNtHq2eMGtXXLFf7DsLbU7OKSC4mS2lg8j5FhZx5kxwx2qAueTkHFUPB9nENQJiQW8csUMixwXuwPMoCzOVfksoKL8xxzyMk1f1eO7sJoLzR7BIrJblreW1VnYy27sFZhEAPn56EkYzTlJuaV/0N5S99IgvJYbTV4Vu5ltbGNZoVtYrOQrPaIqAHau7c6sBtJxkMcZxWV4f1SwuPCqzXFxbyeZciO30+Of/VsH4kJOWiV2ZeHPf0rd1Ke90m0zp+oWT6sJjI1u4dkEaoAI0UHKHaAehGSQKxJPD2i3NtLqmhaYojuLpri7aCd4S8qg8wdVYDe6bcAZ+lOLi1qVdW1/r/h+4viHVdP0+bVptL/tvUbl1UzT383lWlkFTehRiDuIyPlAOeOPWDQ7Fr/R4ZLjWooLXU0SOyk1OEXd3I5kYyBhgdcAKASAF9qv2vh+3eGfU9Bea6uTF5b2t7ePJFDIUEbeZtGPMHyoQewBHXIzDNZeGSYGvNalGm2032C3uIBHaySbNoWMKAzPt39BkZLA9atOLXLDf8RPWL5XsdRD4Zm1mxcXWkSwajM7yxt+6LWhQl0dccEF/nC84LkE4zXNeJdSvNMv4jbTLqGsEG2ubq+QLGm1FLNGoZcs28lgTgFMd62NN12607QdJ1SO0a9nlsbeK8geeYLCsgBzGeQzBWwcnOQpqjp/g/SdRudLGpahqNrfGG6S0WJVYKCTumkcD/WMHDBSTyPqKzi+VuVTb+vmKE93Pb+vmO8FXdzrcN3oTxWgsBbm3zaApFbDaCQJA+XyFGeTg7uRXRWmjxx21wdL1P7TeypGw+YhYUX5gwY8kEDJGSGxgmr3hOztodEtrdbjTrpoXmaP7KgXyYnc/MT0OB9/HJPXNRQadHZ+HtSOkm21LUZkZ1e6QKL3cQ7KMHhDlgOwJNZSneT5dNTKpVTk1HRdv8ynZXMkpS2FxbXmr6fZhU1C9jkiR9+Smwfc2n5QzKSTjHFY2reIPsVrp8l3DY3OiS3aR2U5tlkMUz/eOGw20MrEbecdc9K0tfujZRJcT2cemNiC2vX+0KIoI/LOGiBOAA52jbgk1kxQanqjzmzmlkWDUHEqz3BhYyFQVCZXayjfkAjHORWkUt2jSnT+03p/X+Zo/wBr6todjrVw4utb/fRWtsLaBVbIYkvG4+8Duw3oQfery6hrk11fLqWjhrRoIo7ONbxV86RlBlGSDghiRnjJqje6x4i0iK4vz8+ni3nYLczRqluR8yDCrlgR8oI54561R8G6s3izTyniC1F1p9zE0pkmR4o/tZABjU4zHsIIHXLcinyWjz2X9fd2HKOnNZWLEUV9q+o3to3h0T6eXk8jzbaOYt5LBVKsSMHjgHrg1mzk6dqg1v8AtOCe2+xzTGz+zKkbTh2LFSoCCXaCC/3hjuOKe9vDpl9pnkQtBLMIY5RCspEbYKxw56f89D5nouCOaf4ltLlNTiu4JdYOilo7d4LCFZXuQcscPn5VBADZHIwO9aL4rdGaRSez0f8AXmanhuKTTtLkEi2l5pt3HLcILOffM7bdrxpnjcwBJVQACT9a51Z9IsNE+0f2Pc3bapapHHpcLGdXRACmFBwFXaATnrn1rptcig1LTrCz0JrfTb2DUMRT2zbiuN3mKwAxknrnAGcH0OTaajbwWd5cpqMjz2kn2c2s0JaSS4MoR2IXHyKckbSAAT6Uou65urf/AAxMJN3fUz/FHjC40/VHNr9tOjLbbZjJGGaG7DMI1Qt/qlPUEjGM+9X9O1l/Ets81pb6q2qCAPHa3mBbOrBFlmU42uMcgHq2SBya2b3SYl8R3zveSJLdwLdX1z9phMgjjbakJTH3HXI3EZ4wTUtgbjVbO3mtnfR9JhMd5PIZQXSIFSEQj5FUDcGU8AYOOaTlDlXKte/9f8OQ6sIQVkcr4u0Q654el0rUdZgaPRI1XfGmxBuXeDgYUDYAgUHaN3OOK0YNPvJvh7af8I3JcW8V/c27w3K7hcupVQ4ijbgHAc4Pylc+1aeh6NZXcuo6Vd/2nbLAwa4Ms6yfaLmRXYKAhwdqGMgcL7V1kV3p/wAOPB2mx3PnS3ap5NtbSSmWaQsw3c855YFiOAOBgAVM6rXLCOrvorfM5quIly8i2MDQlm8L6pa6bquox3SrOsttFcfu5I1J+dTxghA4YufXGOK9Jk8UaR/aAsYLtLq6AYtHbnfs2jJ3EcDqOteI+D7298SXrz+I7621LS7i7u57ZpZgMllCLbCMglQqb2YdOQcnrV+y03TIfFUMekaQim1iEEt5BNukhDNsaJlPLL8xYucnDAL2wsRh05Pnetum1zKEb6NWsdRq/iHUvGdle2mgWlzYBN8UdxcxGMyN86bonzxgDO7B+8MeteY6roOo6nqP2LUxpd0uiw29yR5bzRyTSMEaGRUJdlJ2newUjnqK9J03UNQ0mwWyv9MitbaF4LSC4tv34aFk2sUHJVV4GGHTr3qo0Ul5BDc2MU1lcOyW15bvL9nlmgV2G0gHAYKSRgdhzTo1fY3UUkv66+n5lQptTckedQ6CYbi4ttdsbrVLa1ghgsbiJRND54UJvZSQWEZWUBSMEKOp67/g/T00iW/l1+9t7p/s1vMurPE0sylsKw3kHcxK7QgJIC5Oc4rpvA9t4cm1O8hiF4Lqe3YS/alZXSMOyxhl6DaF4A7bSfvVzl74eumtNUTSdSaRbKzU6daCJFi2l8hOTk5EbLuYD7/U1tOu6l4SdtjeLjNuM9C08urWmiyQ654bsUOmQzXlzJsBgck7lkAGQSxGSP4PxxWJeF7yxS00+zjiv5Ld7aK9jlZobJJH3AeYhDB2Ox+OmfStvUtT0qbStGsraJtPvi8y2dvcEqEaSNw5mQ/fi3BuTwcDHBrF0FdVWO1ksL6xEcVnGqKxMlvI0cbCWRAoAzllz3GCKUW1Hmat950wiuVtqxoaJdeINV0t31W+jumFqtvbG0xKxlDbUuQ7HLA4bqOcVg3uiXujT6XaaShtN2+ytXju3RZ8qS8gGCqyFzwpOSR0PbrtEsY1e1hsruI3LR7Z45IVQRIwyG2A7kXKPsAP8ZPaoPEOnXGm21zrsXiO4g1JYlFvChLCaRUI2GN/lYE/MSOV5JNRGquflVrPpYFNRnpZfIzotN1GGCKFmi0LVhF5M86MC9woB8lCGPoAz8YPI4xVO40XTtB8X2MFtd3MS6nOZbW5vpRHHb+au2SPaVOW+TBUn7rL3rXvtN01I9LkvpZ7i/mllluUu/30MzNEfOx8rYjVWbbyAR0pL7VY7O5udHsrCC0GlPD9kmtxnMsybtxVgShO11GDnJx9KjOT+H+un5/gONRylyrzOg1XVLXwu6LqcRvJ2hSH7NKsUCDduxlsAfeUnknGMisfxdO2naHeajo5ku9OikeVrdykqxu5BE+6TIGw5AHT588Yo0wpceG44dXFpq13eAoRbuHYojDzSqyAEKrbWbBY5Y8AYFUbXUYo5p9T0tZNY0qzhaHTpRE6RRyPHgQ7OtwWKrk4O04x3rOEUnft9zMIwik7rb7n/kL4rtZYRaXweRruUm6slhnErLM+xRsUhRtVTlCTgbz8uavXmqyvcWIdLA3MzJFMs0jG5hZNpkjyuAXVWBPY5z0qRrSW5kvLvUrqe+murJTJBYOR5LNlMQbiuVIGQGO7OcZxXP6DjSLa2ESagLjbJMsN/H5xgNuCJblsHIcqypgduapJSj3aNKck/d3sOsGXxrcpPo0SW2rx3k00z3SMkcZ5XaJEA44jbp2IIq14i8PxpA9jpsdprL27rHfxx3ZaaVGbdsErkYJb06Hp0xUCP4v1XSNR1V9KjW3vIzC+nwRrbxXZeTyzKNylwwChySNu3HfNaWsXRu7PUrPSbG1LQyFLXy4jE4ZQrES5Gch2LhlOOF7mr96MtNl5/qKpUm5xjB2s9r7HQ61piXUTmKO3u7O2dI7fTrxVjj+XZj96wPzKQ3bknHvXBeO9N1CzvZZ30i2mLpJCTGqeZqgRtzkgEqkQGwlz8w29OeOzttfvrmyu47p7CHbbNFMiqHuUkVgAzDO0x7WjY5GfmHSsbWBa6t5OjWckVpbQ3J/tSXS7ZjtmZNhRh1VXJAPUfIoOc5rOi5Ql72xlRnUpy0MvS0Sxe2NxZ6paJPZMzjTrl45ZNp52Lja5VZWYk8kRlgKbfGw0/wANBopUvb67uDcb3ZRI0OFLqkxYeWu0jB3E/NjHNXvD0MSaBfWWlwSwaN56WkjxyhWSRXYsw5wVC7fuYyDjsagluxp+kWT6G6XlnFdS3d/YyzpJKisChbymGfLLkEgc8sOOtaJ3lbz/AK9DqdSTlzPvt/mXvCupJFe2Wo3kr6bi4isrnTZbcrGs+H2MVx8hOcEgYPrxmu2+x6NeJqPh3w8umlZrljcwLMGkT5BvYI3RlcocfSuM8KaDfaZrH27V7m+ctCnkTMhmBiVR8ivySTuYbG5AxgYzWtda34fg1DZHaHTZZ4JXWYxKku1gjPKJcgoBu+YPgk8jNc0480/c1/L+kYVvekuT8DH1+5/4R3xFNaYudl2qeZNGomlRyNheQkkOrOMZAwp4NM8Ua9aSRtpMWlp5m4xROsAnRAih2aQfL1bcDjvV7QjCfClzpXig3Vrc3FotnFexZeERyEqVBDN846szYGSMmuWuvFx8NapcXOi6dA4QbNt7IxuXhQBGLQjjA2MckjIAatoQ53ortfj5msI88rWu1+Joa3fX9zZXFw2qXiwTyfZ4xZP50cMePLCsw6AZDHBHcZwKj0bS10pNKhcw6ZJuki2jVdpuFYgOrKeApVt+N2VcgcZoLJYeIrJL27hMV7Fc6hE025AiPksiKuVKMhYZPIyCADTdP/sTVraRNUuLSCx1GGcQq0pWKNPMHluvmDIkxsBOM52nvVvRWWxenLa2n/DmjqMukaTcfadK0sWR0m4FlLIF5+0PDsAYkMzYJTPPVgckZrmb+0t/CPhueHT77VbfS579Ql1tWdL4qhD70JAUMS3UnhBkZ661rHqb3WnwQa5BNcrcCB7a8nw6hQ4/iGWYgZBYElk7jBro102+3aXa6q632jTGG0mMshjAbO5pWQDac/KuDjn61SnGFru//A9TC6ov+tv+HM/R7tJYdLlttIgtbV7qZY4UlULGArKUcIMclcKwDEF/Wtiz1DSLSzsLWC+P2e5c2tuAvkl2chnUKwzkcNk5zu7GsLWEluPD8WkLb2WlWIWaaaWynWEbI5mR448BnBOVfcAe444rX1OWOXwxD4Z0/ULgzzE2wv5IBIY9gAwWGAsjYX5evJNZSSla/f8Ap9TD4mvUtXVxE11p8dy2l39jfT7Ykddso3MrRcHlhtXe7Duveqiw3N1a3UcktzBBLcr5UTSs29UddkqyJkiNxtyOnWub8c2Vpa6LCBb7Ev4RGJJVMrWtva7gSseSVUhmw4zgsAeDW34e1VLaJI0mtIBbQQ2YvDIESULt3xouAH2kqu7CgE9Khw5YqUf6/r9C1spLcr2n2g2sIHiGXTLxl+zSwxWau0C3DAxw7ckKRtIVnJIznisG3TUtF1GOdryO2lsZXtoru9kklllicjZsjTIJYjB4JBBJrptb1FImuY57bULWScK++ziLyNKjgKAowGBUcnJx+FReLrbxAl26HT9K8mZ1exvZUEi2sylSfPyPkGC20qOMVpCVtHaz9P66msZ/c/60I/Czxnwumtat4otY9NtNTluo2jXyzcHGCjDO5gGYnLDPcjGKo3FlcWM+p6xZG9ur7TJboIL7dO1tEyxrJMmehyBJuG0BSwVTxV/UNO8JRadqF8qCWAxSw3c1rmVpzIVbA2n5QeDjHAqXRtNt78veaZeNYWUlqLWHyJWV42Qk5kGSA/T5jzwKXOlefT0/AlxTTl+hcEc/igRCx1CwljfypLa/iVjK5/5b+WxYFSQCOh6c1R0nQYzdeI9MhvL3T4RNA0kdnOVa3upDuKhydpLAKSqjjkd81DrMR0iDTb7TNPm1ZrK3EMMsc28SysPKYkDhiSg3Mem48Vn+P9U0fxBJp3n2dwMOiKsbs0K3UQbejJw3ADAyLnj1xSipPRbP9PIIRbsobP8AA6HXZdKs/D9z9iigtBGW+zwTuiCaTcpyQq5Q7iPm5HzVUuL6zisYbvTLWeQQahNHeoyEJBPtbkyMVURJwN+CPlFS+H766g0LSUs7dJ9OZ1gF1MnKRID+9kOed/ABB2kBTjsNCInWre9RtPn/ALDutrgSytncsjB0CsA2CqA7cYbdjvWafLuZ/C9V17mDeNcXelRWd3c6brBuZR9qvjEohlt4XPyOob53UktlQAAw9Kx9N/0SaCRZ7zTrlbiG5n0hIgYbsLOvmXKSOeYym0DHoRxV6yj0+9vtDmv7mNra1MksVteweSYInkWNBtJ3RnIQE8A5DGrGswad4y0q9uNOk2atp0yxusisj28fmfMMAEMpVSR1DZzWnNyvle3XT+v62OlPl93ZdfvL72c95qPiH7TI0BEySrLdTiSJ4X+UwJCfuElQOnJ5qt4+1CLRBpcUNtLqoCo72V0wWG6RGCqAR8qOCY2BwfzpL1vCI1fR4vs2o2N3dzSNamfzdw/e9JDuwVkkzhORxxjPPQ6VpuhancKb63mvheI08cMCmQJvVsqpACgbYs4P3WIHUip5lBqU07drfIzbV02nbt+Bgtq6+I9Sj1CbTbyCGMqI4rlw5A3neVUA4YbCAeBhsd6f52nahdwDVYRJpyXksVvDIdsCSx5L7hkHkZxwRx64pi6RfR6ZDpZ1K2EAuXFlJc3kscoA2tEj8Ft4ZDleBjNWtXvvtd21zqN9a2SxCOGaO6dTACj5eePgljncnBGecc1TSvaJXLHaJn+L76SS5A8P6a+malbpcyR3v2Ib7j7kjFApIxJlwWPJK44NNPl2jPfy6a817aBkS61ZgVO6RZWgRFYn7pwoGcHjPrd/4SrTLTxDYNG08Wi6XbtItsynDFlVV2lvmdWPJOOCV9TUWpvqst3ZRWcU1payi5icW0iytBtl3rLuPHzAYC4zg9eKqCdlFqy8/wCv6uDbhFK2hzKxajpeoxRsi2sUFxcC5vH+dobZVEksTgszEbnQ4I6gYHNdNeiALbW1ppy/a7m1BllS3jiePLbPOlYHayuGJUHnjpmsnw/4cm1LQdT+xS2cuqxTJ9suDKVVLlU5WVcnzGZiwJHDcZxik8PX+p6hqED6cJ/7Pwr6haWpUSW9wgwBIHOXQ7WwowAGHoK1kuZtp7fIuSVTtoL4dS3EEkt+JYtQW4cG21CQCTUmVCI33D+JYsHeoySCDnNVLPxDPdRi7u9TW9nd0gLzWkpGn/u2kkeUqFBIKsrpwNgBPStOOYaVDoMmp6dONb1NBFFbmLK2bISuNoxtDsUGD93IJ4qvINF8T2lu17fsb3y57u5RVEEAmhG6V/LbLlgCUJBO4Ke3FNSV25LR9f66f1sZOnFtytp/X4G74asrdbU2nhme4nsreQsN4Rvtsfl7QN5HAB2jPUCNaL6+8SLpN4s9kdLuJ76C00/7E6zSBi2cSMRyuRjp36cVR8J3V9d6Ra3vhi8vV0Z7aNJ1IhdxKqfdgCgbZScE7wFIc9MCt6SJL/WoRBPJa3tiYL25+0J81uzEnaCTtGVXG4biAW6Vzzdpvm1/P5g7KT6lSynh8SR29ndaPOkV2UiubV92yGWJlJULkbiJM/OMAgc5Apy2AupYY7yCbTxb2jR2wW8Et0ZC7KXOcg4wrbzyPmBrK1R7keHnmvL2e3u4tUiaYW+QsT5JMLyJw6fMAX6ZxmrsrXMVvFcX1lEdWWOSOddPLRSzpE4ZYlZlw2dwJO4Z6DIJqXHsDi0vdI/FWh2+ka0+rpFrN3PeW7y3EstwkSSqDGjIZABnCqzhRwe/bGTd3N1qOlW9l4fF2kWu2jLDqZlV1TLlmjckgIpXcOuRxjOK67xBqGp3t5pmnadZaktvJiG6md41NvvKs7gnPzckYHHBFc/f6ddeFtZ8MRWlpN/YN1dXMQgVd+wAAIygDjjOCc5BaqpybSUvi6fJaF03olLf/I6+5sxpvim0srf7HHZ2tqJVkMyrdSIp27eRzGMk7s9evWsHUNP0XRkgiupzDoV7bXfnCS4BFyJAJDKqEZ3EBh8pGAO+aq2mr22u69FNo1w16sUq21432VJIvKwWaH5+V3HALDuvtUMXiEabfaXo+vRwQaakS2UYj+dZpnJ3jJzhQCvK9C3pUxpzTt5a9/8AhyVCeiv/AFqWNL0N9PvrC/s0W+kispbmG2upTG8YKKscSOOCsYwvzZPzkg1reIVj1a40nVZLGc3FoJYLq3jIeHzHjUuJFwN6BQVUgckiqemaMl7qd7Nq7Q/YLa5mMUdyrswlZdrKC4ChV+XaR8vFW5JpNI0GG3Kx6rqF/byu2oIBBBeSKjHDMoO0mM4467MA1MpXkmtXsEparqzNstAuYYHuND1C+tra68ye5mtIlne0lDRlImRuc+X8gVRx19Kbr9lHZapqCafc6fZvZrK7m4Z4pYpZgCHbccONpY7jn5unek0O+8nTNHNla3ofTr6MyJO5imMb4Lzy4+WVj8xB6FT61uarLbS3kq2s1hqus3Mf2q2ivkU7kXLbMDk4AT5iehHFU5SUtf69fkTKUoT94oCO2SOzGl6wfL0ucwXPlGPzbgKEYvyOd7EbgnUnnOOH+EtOTUrI6feTWA8uMXUJtUMbrE0oZZMDAUu6Hcq91681TurbT4JryHTLW3gvnfy7gy/KI2fkiJwPldchxkZ+7W0dFlh1G1nTV9QcrGdrXl4Y/Jj2vuk2Y+br0bI6EdKiTVrXCcna21zJuLzVo1u5NXgt7izgljUxSWgjiu4pG5Ji5YzLgqoDDJINN0rUNU1O3tDpFmmyW8uLad4LbyJLQtgl3+ZgWRSvByGY9AKh1rUFhXVNR08XcsnlRLbXkxQ29yxUSB4ZcHYBg4LfKG9zUU/iS1uNQvTb6hpEmm7pJnmhkeGRY0hAYjaQ7NuwxcAjbxmtVFuN1EzVO60R00+vy3uiW6JMb7WbFDGIbcrudwcAyhCwQLhd+Mgcn2rjr6C0OhXl5o8Ml3qOq38dq9zp8skQtcscSRk5zHuYHIwrbRV3Tryz0az32mmW1zbNctaLbiUQGSULy0kjE5LMh29M5DNXOzTazFo50u2js5ZxBHPNbC523VhIsbbJTKpAmYkMSq9AMY5zVUoJPTa5Ps3qo7M6PSjdDxRdJd3dxMscJLXrwpJMkmV3eYqAApKgXbjJBQjqK0LbWJo9Fu2lvHh1Ez7Jo2hZ1g37ZUV0IyDt2gHtn1BFcpo0UiaBqGg2Wp28b3X2o2z72kLQxlU+VASx37XYENgFsgdhsXkl4vhq30uwurhpLy5Zkv41LP5Ualws7Fgd+5fLJyOOuKU6a5v62Ras3ysta5K82lz/AG6S10ixmWOSeGIGZormb5THKEAOzDIQy4IOexxWhqA0yx06SLTNNe5ulh+zhWtDKZiJVSSMYbcHHlk9h0YnArn28JXmpzWp8VCHVGliS5Eih0AUqqur4baWHIVt33m6Y5q7pkOs22hTxA3JeKZX08x5huWVWCyB1kO44LZxuOVGAeRUPlaST/yKskkoy1/AzJNSvLLRb690PVNRu9IVR5kkblPKjjkKSB/N5QEbeR8wIYg4Aqv48uJ7m5s7iRVmthMywraxgM2X8tA6ucy7gAx6rxx1FUYb/wARX+nppUGntaXd4JdOu9SS1JQwncSrK/K4IwSw/iPetC1uvECvYam+mwaeuk6akg02WELFOvnH5FLA7OEB3A5BC8YatlFxlfS+v+X9fidkYOnPmdtCtr2ian4W1WwubrUbW9u7uRIprKGRxullLYcoudqlVI6EEp0pLm7skvho2ra/5M0ckUQvRYkLeYyPJmYAgHaccDoeac1lcHVZ/Elzeqlq5a/tPNuAXQyqAiEYyDFINoG04LEjnNS2Ph5dYt/L0/8Asq6kkvftzGFWBaNiuZOW+SSPdgEgZGCO9HOkryfz/rsKUrpc7179vL5DisdjLYwaomoS29tPDLBPBcFonlaV2EQQruSMbsE+mOK2rGSxuYEuEexFn9qlLxiALFZ5+Z0YY+dcjOR1P5jOtI9B8P3OnLrMusXVylwtuGafYHMUjJ5qquc5ZsMM56EgVJqkekX9lqeuW4mNpKD5Vmy4E7RyZD5I3BwOASQMGs3rbexi5c1t/UWwtfDeiI7XN1cahb5F8s11B58qodsaIGxv3hnOB2DV1NmdKbRr7zHOwzTNcXSW5CrMuFckcdM7emePasPTbLRpGu5TvXXlk+zTWpVJZTGWV4iWXlcEgAnGMDI4Fek6VoVhr/h6NNVtJAxeTz4ZF2fOc53AAbuuc9zXPWqpWu2c9bXVtnk9xNdabrOnap4R0ebU7OZTamCMyNPGokwztGTgZOBuIBXPJr2bS/CNhaeTJceZc3EU/wBoSSRiSJNu0MR0LAEjNU/A/gOz8KXd1epe3t9fXEaxPNcvn5VxwFHAJIyT9K7GscRX53yw2XXuZSavoea/FHwje3eh311odxeG5jsfKjhjkw2UlEwZTgksSu36MeOa4Ix3DTRW+sadamO9Mf2ZjbkAorb23KzbYnDv2GWVenAr6GIyK4lvCNl4et9bvtGheS61G4N3cCeVmUMxG9kH8J4zx39uKdHE2jyS+QQm4nnR0KW4kgudIvLm5a6kdBfi5Dx2pZ2L7V77WwAPfrVbVtBlvr218Pvf3N7c+e6pK4WbEgVi7MrHjC4XDDGGAHY1pxeE9Y0+W2tYXup7j7WZFuY7QRIyCNt4lVGC7WzhScncfyg1mxk0q2sk0u4udP8A9DmDz3Q3zZUEKQ//AD0GACTnKhR2zXUp6+7I6VLVJMzLTw5KviK5j1myj097u3mRYbG72LM/BEm3aCrrHkZyQB0xms5bm/0m3snk1Ozs9Bu3YBLi2eKR28xnJWLby2zALMfvH35660kljtdP1G7u5Jb2S2RppZo2hygBLybMtsfB6ZAbjpWdrt/PqGhWK6S7XEUjvBaXkU26VY8DLbXXlmkDLu/hU9acaspSs9v+H7lwbcrP+tyTXdTuNWs5bWyY2dxJCsT2l5FIrqVkVTI6x9V+XI2n+Idqy/FXhz7DoscU2p2/9naU8JW4wyGKTCKrRMd27c4ZWBPyg+1d9o7alFqTbLe51KMFpIwVRWwpUGIngcZ+8x5xVeT4YWOo6bd3gsUtb6W7e7hQRCJ4zuOUYhiGD4GTx24rKNeMGk3ZGcKkabS6fecdpmmibUTr+ry21lo86JG+nGErDuj4EUa9wJBuDEHKk4wAKfPFp0ltcWq2oOm3Url2ZhmTC4VHV8EfMdgxgDaBg8132l+FPE8jW02oX2l27RH5IY7bzViB67N3Q44rq7jwlo91qNrf3Vqst7brsWVjyy7t21h0Ybuee9RLEpPV/d+H/DidRKV3r6HD6FpNjonhtJzZxXo1O4dzbRRLsUMgHlyMAclSDlupx3xWXoVkdPvZ4dHsFGoBxulSYeW5DKyK4IBbCO2B2HpmvZLO0t7KAQ2kMcEIJISNQoyTknA9zT1hjRiyRorM24kKMk4xk++AK53iG736mXtN/M8etb+3mvvMh1OVp5rdoYhJsgZE81yZlhkI4T1wM7KqaHqr+EZbi7ujYz24inurNbGQD7XFsDbvLxxwGIKnHbnrVXxFq2iW13qSSpA95e3b2x8y3MgMjKG8rA5AYfMR33ZrC1Hwzq9ppFvq2kQW8Gt2ip50VmjZaMZGxVUgSL8y/LhcY6nnPoQhGWkuvc3p09LN6M3rPXZ/EXiJtQ+zw2zHT5LpLKYIZ5X2b1MQz8pAOCx74rDv9Ja48aWEBsTNJFZwTyXV7dK5AwQ0hQ4UqAWztOSeaiu7+PxPqOlX1xDe6Wt759rDPCGWaYo375VyCoQ/L19xVnWtSiay0eTXUaKI745YW08PNNC4bCbcfIMhATxkLmtUnF+6raW/rubR5oS9xdP8/vIp7lda0q0t767trDULN3Ml2mA8UOZCMK2cj93GWTPRh1qf7ENQ06OK/wBXtl0+R0Wz1PTpFRhPyrb8nG58sCo4Cg9yKxLXWbPQdRtor3TtDl8QqqeYYt8qW9uXXZCi8eZKQRgdgO9TJpyv4Z/sltR0aO+Tz7RNPiQOk1ywDO29mw6kkcgbl5A5FaKLVunb/P8ArQU3ZJPZk1hrcMt9o0cEa/bdIu0S+heWNhcpKjI53pw7RAc5BJ65NdVZX9lqGrtqGl3M9zbsI4zcSWislxNyFuFkXBJCrsI6A4rlrOzttObSbbwnpOg3E8jJe3EkczTPBEPuks2dqE4AYdCDxzzD4fXVrO8ubTSL648+P97LJZRI9q6vuDRwFflTG7JbHVM0qkIzTcXb19f8wcItcy7f8P8A8A9IvtDj1C9sZy011eLKJJZBdCJYZduAXTP3mAXGcj5fXrz2tDStavkvLaLS21eCeU74pkP23ZHjyzj7qfOWIA5xnHetBrO9ns18mWxe+sFWKwiuJyFN0qhCsjdJMCQkHHJzXOPotzHod3BHZ26xRL5CS+conywZmZxjDHdsjUqQdhPSuelpq5GVJK+siTRdQ1jWfFJ0e00mZLG2vEnkv4h5EbxlDsJZlJYgjhR1K4zit261y30WeGTWLiSBVUQXOz99ErO+EY8dDtYFjjaeCOuOQvNPn8MahDo5vnimuNLaKaK3vnKPMMRr5akMUC5Vg/Xlj0FdJYbf+Eg1u0soY7S5td9xd24iac3MRBlWMznhZi0hbHPXOTmrqQTd+lv6fUqpGN79BYtOn+xy2N5Y2sej3xmhE1vwkErMcSrbuMyhgfm5xwTgCm2Os3stlqKanbtc3Gj26vNp1vtluJGBIUkgbOgDDZyAcEVlXvivTr2fRZXM9pqrwpKwWHzTaNOhVYRIUwoJ28cdc+orovDgnm0uC71ZoLSZHL3EbeWUlKvz8q/xBVDE9Mt2xUTTiryRMotQbf8ATI4Yrm0vdMurt9LtWvnNrcQGdmEsI3MpizyJMHnjnHsKlZbS/mjkXUb65t5JYrYJDIZbd48Eq6tjnKuFYjoU9q0vEviLRdR0qG802O0n1JZGitQdjzb2k8k4XqOSA3fFcjp2lG1lFzp13AZbyCK08nTSVt45IiwmRWYbQck4OOoxnnNTFcy5paMF7+stGZ2m2F7p3ia8vD/pEqX8kctvDGruTEjL5rvldoaOUZ29Djjg1o2up6Dr0FolhJCljE8dxFaTEEyMSXaIKRnhog3X5ivHetLxJaKl7ollo99dQNpxZZ5jmZljA+YOWz+92FsEc43Vp6T4csbDw3a6LDqxaCwkMjSYC+ZHtbcpJ+6MNnIORntW1SpFxU3v/wAP/wAAlVUmmzB8Mw3d614LxBFoc8j36wTP5jzQzRjEBiJLLtY8kEjJwBzmqK+LpNH0+1sNJjN7aXUs0Flb6hZBbaKLGF2yIclABgJje3cjpXT2GlW+kyWl1qcJlm0uxO67QMwMYVT8gyWIG3POSTzXEeM7rQZtSvI9Cne8sdQijlWxiUrFcOJEZtpXmNwWZnG3JWlT5as2mrr8P669Pkbw5Ks7NaHVWPiXVdE8RyaRqlpZnToBHbKLSDy/s0rDkqWY7olJBBGCMgEcGtzXIYbvULq0tkijms2it53ltkbzI3CF1LHldy7Ru75ry26a5vrG6nnsYIJfPimu4p7dGt4rhp9hCSFmw23b8xIGMZUZr0HU7phrheXVX0WRbVg1jN5U5kUnAlBJI4O0e/TvUVKaUk1v/wAMZVaKjZx07/gYfh99C1uS7W81S6IKNJcWsjvDJmR90ZO4b8hF2EBtpAHTiporw6r4pNleRte211Ask3DiCOGKT5J1cgluQqgA7T15FEWnTeIdMl1K9ubXWI4LsPsvbURosW1ZD5ci45OBg5KnkVv+FLtrvwnY/b1gntpYlEVxHbbIZYgclTGB8igEDb3AzSqSSu1r09PwHOXKm9/09CnLJaNDf2ltq8b6FFa/ZSl/ta3MYUtIxYYfIUkZzjgVylqUTxHc6fb3dheC5WNVisohHIIljj27BJkEeUrF9pIK8DBrTupLyeS7kgu4nup1MtistsPLW337ZVZwpAfggAg9AT1rD1nUNbKx32rpFNdaclvPGlpKArou1piSf4iu7hTjBx1rWnGyauOELvRnUPcXF3pWnvFqUNyHhEUtta20dx5pdxG0oH3gFPB59znFUtWvLTS7+y1S5sxeraxIWEmIzLAcb3ZcfK3LEDGODWbBa6r/AKU+lra20CB5YzaRBZAnn5RApHyqynOTnkHPHNa3hvSllmuL+8ure6gt4Y4UtkIuLSN1L70eM5+bBXByBzxxUWhHroNr2e+x0V01lOyPaPbNpUjxW9pNGWDS/wAagOuMqw24x7kk1GNNl1fRfO16y04KZ3jhXTJmiCpIu1nfdgb8788enGa1NDlu54rSDU9Njtd7/Z4I42BU4QjcpwNnG4Y7Y713Nloscdv5d44uds5miygXy/7uMdSP73U1yTq8mhwJcrPPtZsYxZ+TFaC600yCcLCGRvMZtyOhPysc5z6ccVyXivWpr3UtSuPCn2/7QLSIB5CRtyTuRvMBCnK5ZvwI4zXpvxKtVbR7KJGAlglNzGXk8tcoCSd2CMgEkA9SOoryS7uBHrF9Pc+ZJeQ7UjnCvGIEwN/mfwuxLMT1AzW2Gaa5uv8Awx1YeClq9bf8A0vDGlX9r4b07So4G/skyG5+3rf5eR5T/AFALRneeW6HjPQ1rwaRDF4O1bSL7TTMJI0UGwmEhmZI1G6JXOIwrKAFJOSuT1rG1CSaG2t5pLW4h1jT0mFvEshcTREFUYRjhhuCsBjAPTBqPSLLULXSbm4stGvLeCSJYFWNTu8rBYsUP3W3ZyMZw3Uda0ld636/r6lunKSbTS1J1hhNhLqU66XDqUIUXW8GeFQrJJIuMZ3sDvwRy+e3NReHr6S61A3QuJYtGvrTY+LRDPdyGRym3A+55YKYOMYHGTmun8BeF9RnhhubnTrSw0+KGMW9jJHxKGTJZiGPzA4GT2BHNdnpXhHThDY3Nzp0dnfwrylvKwRSTkgYPKk+tYVK8I3juTOpFXiziLXR01jVoNWudJS0EMqyyGUFw0bKScJn5JMnBJHPPWq1ppjjVtQ/sfT0uoHlWKW1nJWcLH8wO85DDDEANg8jnAr2K1sre1QrBCi5ADEDlgOmT361MsSK+9UUMRjIHNc/1hmKqs5jQfC9tBdtqc0AhubjbI8agbgwHG9hyxAwPTiuqoorBtyd2Ztt7hRRRSEFFIDRQAYHHA46Vn3mj2V7fwXd3CJpYM+UHOVUkYJx0zitDpS0J22DY53UvC1veNZhJ5LeG0I8uOMAhh0KuWzuBHFUx4F06XUrq7vnmuFkZDDEW2rAFO75doB5br24Fdbn1FKKpTktmUpyWzK9nZ29msgtYUiEjb32jG5vU1YooqSQooooAKKKKAPm7T5bO78avFLplre6xFe3MIZECzb0aPa8isMswXDB1PQleea3tbsL3UDPd3+q38d3LELZoLT5ViLrt3BQN3BAY5OVAOM1VvIL218Yz32ll3tL4Nazyw2zBZLllLCdupxwF+UDGSK5XxdbvpmvJe/aZrm6/s6O1vQsjW8Tz4b5gz8OrMCu0A43ete5GKqTXK7af0vI9BR9pJcrtdf16G1rF7qk15f3NvbpbaTZoIiHvXt1lZVVxMrHgbnwrN025zzmuhuNZufGclhqFmFttP8AJdZ2QY80AFWi3NgABjuUjO4Zrire70y8aPQdMi+2ajpEEovLYqRFN5igmNCCF4YIhJ49Bir+q6vpUml2s813cJci6gmVN58q2AVhkhvuxECSMsARk+1J002rLXYOW6XLvsap0zwfNqtna3S2epXMEC+ckUrMy3MiNgIW/iOxio6rtHTiuN1Dw/Y6ABJb29/ecxHzbiyG0RsxcAxjBaQLuUkAcscitqfXLTWbWeHUdMS9uNKmaOOSzg2G4LMwcoQeqR4GT6E10mmavI1leW+oXUdxcxbZo9UMTJFcWpbG5mXnzFClTyMYFaRdSkr6vur/ANdyPaVIStK/9djlbG6Oj6/LPFqVjb3S2NtaWtrqG+3ixLID+9jHyx/KMgA9ue9aXh/V4LlNVur/AEeXTZbGNreLTYUMYjaRArkMCFkEhIKjquCc8jObftZX2kfYdFA1CKa7htkRICY4Ru8xrhSRmRsOq8nH6ipn8GW1o0Nhp2qW0FxcQ3LxQSM1wZ1Xb5nmJjBTJY4wGU4wSBRPkt72jf6GlRR+3pc6pdNv5rG209/OXz13yTo+TbAHKhGXGcHPJ7DnNcrptnpenaO2jx6vf2Qhtmlj+2QPDGzeaf8ASAncbkK7QR8rdOc0Ge0tZ1s5/EEbpJG1rfTW8BDwrFIzOksZbaAFYIWX5uQeRUetahbeF9fsI9ClkiiEC29rbkl4pyQ6JEjnOGwwc46nGaUIS+G/n2FGMl7seupenazi8Zx2mmrdQ6hI6z3DlQFnIUKibnOMnAPy/e2n61veHbCy8TTX9yz3SvqN4ruFYiFZLUgBQSAQGYK2DnoR2rz7RNI8Q+KrC8S20a71bT7pluLqeQpAFvAmT5auV77RxwO2RXR6PoHjbRrxbm90Ccuo3pdxXCzNbqwUPCFLNuDBVBZVAU85IzUVeS1ozV1pv/X9IqpTfLv72251PiyaXVtc1HRdV0C4uNMRI7hn89o45JCAV2Ff4xIuMnjBPrzl+Fopzqer295ZfYI45QkbvAHaWYIQZQ+MOWXAZeny8E1l2PijXLXR4bvW0u0aQGLzvsJbEjOy7WXdtJ4Q4HGFJ61bh8dLrSfbftUs0dg0iDyIHEMkKxB0kfI/dnc3zbc/KMDiodKSi0lp3/ruc8YzjFpLQvjSnuZlkubZW05J0k+yOixbJl4SSJ0GW3PycnHGKrWlrHHBdRx3cGnj7Smo3ttEv+jMdx3gO3zD5lQlQRgj0NXjqtnql3d6a15ObKVXgks5bbywiOpMbCUYG0lHxjnkDriuf8fwWtt4aa4so7QanOi29xbWisGnlO3bKhyCjAA/O4I6ZFKCcpKMtLji5N8r6mhosMNzpNxLq0D2MF9czxalmQ5u2LOPMWPaCwZWI4xgDqay7jxNBpN3/ZyhXXyyllJE4itfJQqEdpDkjIBUsQRng0yFb9tIsrm4tLZLaxtA102obvtcMacqUlHGSAT7E8mnPBYWnhOOZdKgv9KlVWO3LMsbSNJJGWCkttfO5AeNvXmtUo311uy7JP3tTe8MSzy6Vq1lEt7DbwF/s7Xsys0aMT8vBzjcr4cn7rKRWN4Zhtphqr3L2sk1nPJc3FrYzSbbctGFkfJXlyV9z19a1IfDkTeHbO2sNNh0yyvYmnuLq0vtyxISX3xuwyVPA6dHPTFUrOzutO1PUJk1bUobUtPHcW8dz5xlwm5DC7AGPBc9Aeig1nzRalZ7/wBeYlyvmaf9f8EuR2lnHbW2l7obmyTVGn8uBHiZt20LJKc4bYSGZjxx7UzVvEOkWmm6ldeGXmknO+6k82MurvEVRyBJ8oQFgTjHCkikstH0rUrG4up52tm1KyjmuZBMJSAXVhE0gJ6jaCOBjOK5vW7DxD/wjWjhdSg/suXy4p4rWKQy3HlFg6w5AIBCr0wcj0HKioyer+8SipPfU63RtL8jVLCbVdRS50q2scLZQxEQbQoEmCuFZSWUqSN3HHesawkvL65ni0G/gmtY7lotk00s6cq2wKW+UnAw+49Rjg4qfRtC8RSSXOlxXdxdLHdR/vharslVfLIeQsfmCsG4zu59hXcaV4Bvbe7eRBpenxPIjPHaRHbImcyo6nht2Thjyp5rOdWML3d2KTSu2zyvT9ES00Cz/s6WG1We98i6+9icozsiKoAAUPwSRyOpro9L8F3GuWlyLe5iIntIzJp5VoliuMZLowY+XyWyB3xmvT9S8EWF4sduxmFrJL5l0qvt83C4Ge/YdMdK6i0tILSIR20SRoOyisp4x2vHcUsRfVbnkul/Da7imlluJzIblQjSQl0kEojaMyEtwBgsOBzkGu78L+DNM8PWltDbRsxt3Mke5ydhK7cD2A4A7CumormnXnPRsxnVlPdlO+tFltdsaKZIzviz2b1z26nn3q2M4GRg+lLRWRmMkjjlXEqK4IIwwzwetRi1gClfJTBO4jb1J61PkZxmigCtFY2sUCwR28SxKnlhFQABfT6VNDEkMSxxIqRqAoVRgACng0UAIAAMDpS0UUAFBNFIaAFozSdaDQAA80ppO9HakAAcUGgUZpgBXIpQMUi0tABQKTqaU0AFGaSkFIB2aM00UopgFLSUnO72oA8L8QeIYodun37hMxu7XMEzLCLMS7SAyjf5iqwK8cHvwKzfEWr+H7zS7O1u4b24hmgmliiUrskVApjnPmMNpLcA553HIq5pdpBf6ze6nbHTItQ+0zwFraZmbygwUh0bBV9yLnGAARjOahuNSg1jVrA2cFkGUvbXySWahEdSqmKN+x53E8ghT6V7MFGLVr6fmd0VFdPPc4a1sr+wUaY109ld39nOS8kZaWaNgDEAwHMitlWAOFU8H00VsdM8QaNaR3cN7FcTeVp9zcXq+XczNxtijOcA5Lsd3DLkduNwWlhp01xcadqEmn6Pt+xRzm2WfcSWkEkYGf3bMwYEnsOBWfqthp3iW1sNRj067jkunVjLK5Ep+ZlV3ZTncyZK4Hyqxz1FdXtOZ823n5ms6ylZtbljxBpZtL+0tbeW/sbiyaFLGZFVormTGXjkTPI2hRuJAz+NdN4c+wwR6prF1C8F9HJHDslywkWQKXSMKdgB28YyQwJzzUStaQ+Gxq+ka3bTRX0arAtxhIoJwxVUAIzzyMHqUBrHOoT3flveaTaMLiRdOGIWiuUy5zIUB2rGV3Nu6ksKx96pG3b+mczj7Q5/R/F0lzfxaP4SU2jzTmRg9qAZf4i5VSVVSVAP8QzxiuittbuNKtdL/eadE1yshkSK3d1jldwm0uTk4dWyGOScj3Hl81xbeE/EtvqWiTTyX8F6bXzJbTba3XzHPy5+Vh6Dg4UjnNey+DfB3ii81JWjt4ND8MIixrBeoJLu42gfvGxyCWyfmII3dDWmJlSg+y/F/wBaHVXjHSVtO7ND4V+DdFv7PUotW0+xmuLC/ZYgkvmtBwrAF8AlgeeckDAJPFekweE9AhuY7hdHsTcRP5qStCrMj92BI4PuKv6TplrpVoLeyiCJnLN/E7d2Y9yfWrteLWryqybucM6snJtNgAAOKKKKwMRvlptK7RtPUY4Nc3ceDrCXVIbqF5LSGNShtbVUiilUqFw4C5IxkdehrpqKqMnHYabWxxdz8NvDlxDYRzWjTCxEiwCaRnVVYg7SM8hSFx6YrkNL+FepBXbVtUeWQzo5WBwvmoOWWViuZFP3QpxheMnGa9joraOKqxVrlxqzjsz591TUNH0v4ip9uuZv7ckVrWMwwlYRGFCi3kBPzEMdwYDvjOOKbYaJqEdvq1tazWqW5tpo1t1m2rJdODvCq3yoAv8ACRzk969r17wvoviC4sbjWNNt7uexlE1u7g5jcd8jqOnB44FWb3RNMvolju7C1mjRt4V4wQG9a2eLjypJevy7F+1SSstTzHRfCdrrUuk2xllls9LjaAKzbVjiKbGi2hdkikr0PIHOa65fCDXNw8t/dGJBJ+7gtDtRYwTheR3U84xyK69ECLtUAL2AGAKdXLKvOTIdWTOVi8B6ChlBskMLujLCo2ImzBUALjgEZxW/a6faWtpDbQQIsEIxGhGdo9s1boqHKUt2S5N7sjjijjz5caLk5O0AcnrT8cjk8UtBpEhRSUUALRQKM89KACikz6UtABRRRQAgpaTvS5pAFAozQKYAaSg9aDQAYpaaTxmlHIoACPekPenYpDQA1c45oGccdKQnnpSg8UALk06mE04UAFIM59qXvQTjFACEnPTilGaX6Uc0rAN70opCDkUvSmAUZoo285oA8H1Tw3purWmoxXNi9lepBIiXJkRWRlHBIXBcEhSAeDkdOazvDFtPYyjRdWS6tUbSEIE0MQj3F2zKUbIDpuyRkj5sV2tx4FnhFpqBtGudYR5HdoJPLRi4CjKlscKAM8+vWuhsfBFhd6Da2WuWUL+XGYym4uduQdpc5LDI6GvSeJjGHLe6/I6fae7Zu6PJtH8OtbaleXPh26gl08Nm5kaJYx5iEKY/KGByvRh0PT0rP0y6uDd6u2mrqy6lqa2s7WsqoAuVwNh4GVVvXkDBwRXuc/g+zYLHCzR2+xY2hVQqlVYMigjBAUjjB+uaoz/D6yuLa2trmZ5YI2Zm8z5mOWJ2qRjauSeOeOKr69F35tblKrBv3jyyz0+XUJPEcWn29rrOuxmFwEciCLy3ZY92SPmI3E4PUdqv+C/hn4iu/EMl/rYfRtLY+a1o1ytzM8pOT5ZAxHHzwCWPHfqPYtA8M6N4fEw0bTbWz84gyeTGE3kdCcdeprZrGpjZO8YbP7/8geKaTUV/X5HN2fgbwzaywzDRbKa5hZXjuLmMTSoy/dId8sMdsHjtiukooribb1ZzSnKbvJ3CiiikSFFFI2ccdaAFopfrRgUAJRS0lACijNNXPenYHpQAUUd6KACijNITxQAtBqMvxRGSevWgCSkFLnpSZ5oAFGOtLRSGgBe9NB5Ip3Qc0YoAQjPej8aWjrQACkFBNKDQAh60hJ3dKU0ooAKD9aCOaQc0AKDmikGBmjNAC55prexpaQ8nPpQAzPFOXpS7eaaSV4AzQAEYp6jgUinIpen0oAD+NBAP0o5IpR0oAKKDSDrQAUUveg0ANJwM04cj0o4NFABSUtJQAUUp6Go3+8PrQA+ilooAT8KOtLRQAUYoPUUUAJwKAc0N0oWgBaTPNLSDrQAtJmlPUU0daAHUE4opGoACcDJphfinSfcNIaAG7s8U7HtxSL1/GnUgG7eKdjBwBR2px7UAJiloopgJnnFA60fxUf40ALiiikXpQAHk4pR0pj96cv3aADqaMdcUg606gBMUooFFAAaQUHqKD0oATI5o4zik7mlPQUgAcd85oxQOtLTEIaKKKQAfWkGe5Bp3akoAaOSakA9qaKcKAEIFJTj0ptAxN6jvSggjrSN0po6fjQBIMDvRmkoouB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There are numerous mononuclear inflammatory cells scattered throughout the parenchyma and many areas of focal liver cell necrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_30_37350=[""].join("\n");
var outline_f36_30_37350=null;
var title_f36_30_37351="Diagnosis and management of central airway obstruction";
var content_f36_30_37351=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and management of central airway obstruction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/30/37351/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37351/contributors\">",
"     Armin Ernst, MD, FCCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37351/contributors\">",
"     Felix JF Herth, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/30/37351/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37351/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/30/37351/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37351/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/30/37351/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central airway obstruction can occur secondary to a number of malignant and benign processes (",
"    <a class=\"graphic graphic_table graphicRef55320 \" href=\"mobipreview.htm?35/31/36349\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients may develop symptoms suddenly (eg, obstructing foreign body) or more gradually (eg, most malignant obstructions). In many cases, patients are incorrectly diagnosed as having asthma or chronic obstructive pulmonary disease, which contributes to delayed recognition and therapy.",
"   </p>",
"   <p>",
"    Interventional options for central airway obstruction are subject to the availability of experienced personnel and equipment. In addition, the stability of the patient, the nature of the underlying problem, and the patient's overall prognosis and quality of life impact the choice of intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The broadest range of management options are available at centers where a multidisciplinary team specializes in the evaluation and management of the impaired airway.",
"   </p>",
"   <p>",
"    The diagnosis and general approach to central airway obstruction will be reviewed here. Specific management modalities are discussed in detail separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark of the severely compromised airway is impairment of oxygenation and ventilation. Patients with minor obstruction are often asymptomatic, since airflow limitation is mild. However, rapid deterioration may occur if swelling or secretions increase the degree of luminal impingement during a respiratory tract infection. It is not uncommon for patients with subcritical lesions to be misdiagnosed as suffering from an exacerbation of asthma or chronic obstructive pulmonary disease (COPD) while the true etiology is anatomic airway obstruction. Patients with airway obstruction also frequently present with pneumonia; if symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic infiltrates do not resolve within four to six weeks, bronchoscopy should be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23945?source=see_link\">",
"     \"Nonresolving pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms and signs develop when airflow impairment reaches a critical threshold. Patients complain of shortness of breath, which is often constant and unresponsive to bronchodilators. Monophonic wheezing may be present, and can be unilateral if the lesion is distal to the carina. Stridor is a sign of severe subglottic or tracheal obstruction. Breathing becomes labored in advanced phases and heralds impending respiratory failure.",
"   </p>",
"   <p>",
"    The onset and progression of symptoms depend upon the nature of the problem (acute with foreign bodies, slowly progressive with an expansile goiter) and the location of the lesion (tracheal versus bronchial). Patients with long-term artificial airways are at increased risk for subglottic or tracheal stenosis and tracheomalacia. Removal of the airway or capping of a tracheostomy tube can result in shortness of breath or stridor, which should prompt a thorough airway evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15545?source=see_link\">",
"     \"Endotracheal tube management and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/42/11945?source=see_link\">",
"     \"Overview of tracheostomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of studies are employed to confirm the presence of central airway obstruction and estimate its magnitude:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain chest radiographs are rarely diagnostic.",
"     </li>",
"     <li>",
"      Chest computed tomography (CT) may detect airway compromise, but the test as generally performed is not sensitive. If an airway lesion is suspected and time permits, a high resolution CT with three-dimensional airway reconstruction can prove helpful [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/6\">",
"       6",
"      </a>",
"      ]. These new imaging protocols may assist in both the initial assessment of the lesion and in objective grading of therapeutic success and follow-up (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64358 \" href=\"mobipreview.htm?23/44/24259\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25256?source=see_link\">",
"       \"Radiology of the trachea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Flow volume loops can show the characteristic changes of airway obstruction, frequently before abnormalities in the spirometric volumes are noted (",
"      <a class=\"graphic graphic_figure graphicRef73686 graphicRef76811 graphicRef76796 graphicRef80922 graphicRef74178 \" href=\"mobipreview.htm?25/53/26450\">",
"       figure 1A-E",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25878?source=see_link\">",
"       \"Flow-volume loops\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Direct bronchoscopic visualization is the gold standard for confirming the presence of airway obstruction and also aids in discerning its underlying etiology. Often the differentiation of endobronchial or extrinsic lesions can be accomplished only at bronchoscopy (",
"      <a class=\"graphic graphic_figure graphicRef57329 \" href=\"mobipreview.htm?41/18/42287\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38135?source=see_link\">",
"       \"Flexible bronchoscopy: Indications and contraindications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of central airway obstruction is divided into two phases: initial stabilization and airway interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Initial stabilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a stable patient, imaging studies and pulmonary function tests should be obtained as outlined above. A patient with severe tracheal or mainstem obstruction and marginal lung function requires initial stabilization to secure ventilation and oxygenation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endotracheal intubation is preferred. In the presence of a compromised trachea, this is most safely performed with an awake or mildly sedated patient who is still actively breathing. The use of paralytic agents may be hazardous, since intubation may be difficult or impossible. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15545?source=see_link\">",
"       \"Endotracheal tube management and complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In cases of severe tracheal obstruction, use of the open ventilating rigid bronchoscope is the preferred method of airway control. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7412?source=see_link\">",
"       \"Rigid bronchoscopy: Intubation techniques\"",
"      </a>",
"      .) The rigid bronchoscope not only provides a secure airway during visualization, but is also a therapeutic tool [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/7\">",
"       7",
"      </a>",
"      ]. In emergent cases, the airway can be dilated with the barrel of the scope (",
"      <a class=\"graphic graphic_picture graphicRef53603 graphicRef68017 \" href=\"mobipreview.htm?15/27/15800\">",
"       picture 1A-B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bronchoscopy should be performed after the airway has been secured and appropriate gas exchange documented. During the bronchoscopic examination, the airway is inspected, lesions are assessed, distal secretions are suctioned, and diagnostic tissue is obtained if needed. This information is used to plan further interventions aimed at opening an airway and maintaining patency. If no dedicated airway team is available, patient transfer to a specialized center should be considered after the patient has been stabilized.",
"   </p>",
"   <p>",
"    An appropriate course of antibiotics should be administered after a patent airway has been reestablished in individuals with postobstructive infections. The usefulness of empiric antibiotic therapy after interventions in the absence of evidence of infection is unproven. Similarly, there is no evidence that corticosteroids are effective in reducing complications in this setting. It is advisable for all patients with a history of airway obstruction to carry a card or bracelet identifying them as patients with complicated airways or indwelling airway stents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Airway interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further interventions are planned following the initial assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/1\">",
"     1",
"    </a>",
"    ]. The number and scope of therapeutic options has increased dramatically, and a given intervention must be chosen carefully in the context of an individual patient's situation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/8\">",
"     8",
"    </a>",
"    ]. Multimodality approaches featuring a combination of several interventions are preferred for their mucosal sparing effects and long term success over dilation alone (",
"    <a class=\"graphic graphic_algorithm graphicRef54361 \" href=\"mobipreview.htm?21/46/22255\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64246 \" href=\"mobipreview.htm?42/49/43803\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rigid bronchoscope is the preferred instrument for unstable patients and when significant bleeding is expected. Its nonflammable nature also makes it the preferred tool for many laser bronchoscopies. For most other interventions, the flexible bronchoscope with use of conscious sedation provides a therapeutic alternative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/33/37394?source=see_link\">",
"     \"Rigid bronchoscopy: Instrumentation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43816?source=see_link\">",
"     \"Flexible bronchoscopy: Equipment, procedure, and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Foreign body extraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foreign body aspiration is more common in children than adults, and can lead to sudden, catastrophic, central airway obstruction. Both flexible and rigid bronchoscopy can be used for foreign body extraction; the selection of procedure and technique of removal are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/36/35399?source=see_link\">",
"     \"Airway foreign bodies in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Rigid or balloon dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In emergent cases, the airway may be dilated with the rigid bronchoscope. During this procedure (called bronchoplasty), the patient is intubated with the instrument under general anesthesia. The optical telescope is advanced through the stenotic airway opening and the barrel then pushed through the obstruction in a rotating motion. Bleeding is usually minimal due to compression of the lesion by the rigid instrument (",
"    <a class=\"graphic graphic_picture graphicRef53603 graphicRef68017 \" href=\"mobipreview.htm?15/27/15800\">",
"     picture 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In less urgent cases, sequential balloon or rigid dilators may be used, particularly when the stenosis occurs after transplantation or long term intubation. For sequential rigid dilation, the patient must be preoxygenated carefully, which may not be feasible in severe airway stenosis. Balloon dilation can safely be performed with the flexible bronchoscope (",
"    <a class=\"graphic graphic_picture graphicRef70533 \" href=\"mobipreview.htm?15/2/15407\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/9\">",
"     9",
"    </a>",
"    ]. The major advantage of sequential rigid versus balloon dilation is that there generally is less mucosal trauma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27126?source=see_link\">",
"     \"Flexible bronchoscopy balloon dilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dilation is immediately effective for intrinsic and extrinsic lesions, but the results are usually not sustained. Mucosal disruption from these techniques may in fact produce granulation tissue and accelerate recurrent stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/10\">",
"     10",
"    </a>",
"    ]. For this reason, dilation is frequently followed by laser",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stenting procedures, as described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Laser therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nd:YAG laser therapy is frequently performed utilizing the rigid bronchoscope, but can be safely performed with the flexible bronchoscope by experienced endoscopists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/12\">",
"     12",
"    </a>",
"    ]. The tissue-light interaction leads to thermal tissue damage and destruction of obstructing lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32151?source=see_link\">",
"     \"Basic principles of medical lasers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38645?source=see_link\">",
"     \"Bronchoscopic laser resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laser therapy is indicated for short endobronchial central airway lesions with a visible distal lumen. The technique is most commonly applied in cases of malignant intrinsic airway obstruction or in postintubation tracheal stenosis. The effects upon airway lumen size are usually immediate and accompanied by excellent control of bleeding, but as is true with dilation, they are not long-lasting.",
"   </p>",
"   <p>",
"    Large series have demonstrated the safety of laser therapy in experienced hands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/14\">",
"     14",
"    </a>",
"    ]. Complications include combustion of the endotracheal tube or fiberoptic bronchoscope, hypoxemia, respiratory failure, and destruction of bronchial wall components.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Electrocautery and argon plasma coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;These therapies also rely on thermal tissue destruction. With electrocautery, a high-frequency current is applied to the lesion with bipolar probes. When the current is directly applied to the tissue, heat develops and leads to tissue necrosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11447?source=see_link\">",
"     \"Endobronchial electrocautery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Argon plasma coagulation is a related therapeutic intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/15\">",
"     15",
"    </a>",
"    ]. Argon gas is emitted through a Teflon tube that can be passed through a flexible bronchoscope. This gas is ionized because of exposure to high-frequency current and an electrical arc is formed which allows for desiccation and tissue destruction without direct contact. The penetration depth is reliably 2 to 3 mm, which makes the argon plasma coagulator a valuable tool in treating superficial bleeding and debulking granulation tissue and tumors such as papillomas (",
"    <a class=\"graphic graphic_picture graphicRef68710 \" href=\"mobipreview.htm?33/10/33953\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Photodynamic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photodynamic therapy is approved for malignant intrinsic airway obstruction due to lung cancer that is unresponsive or unsuitable for laser therapy. After injection of a photosensitizing agent and a suitable time interval, tumor tissue that has retained the photosensitizing agent is exposed to a laser light of 630 nm wavelength. The laser is delivered through a fiber introduced through the flexible bronchoscope. A nonthermal phototoxic reaction leads to delayed cell death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/1,16,17\">",
"     1,16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37749?source=see_link\">",
"     \"Photodynamic therapy of lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This therapeutic approach is also suitable for completely obstructed airways due to the predictable penetration depth of 5 to 10 mm. Follow-up bronchoscopy is necessary to remove debris and secretions. The main adverse effect of this approach is associated skin photosensitivity, which can last up to six weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cryotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As opposed to the thermal effects of laser therapy, cryotherapy relies on repeated",
"    <span class=\"nowrap\">",
"     freeze/thaw",
"    </span>",
"    cycles for tissue destruction. Cryotherapy may be performed through the flexible bronchoscope and spares cartilaginous structures due to their poor vascularity. The intervention is more time-consuming than laser therapy because of the need for repeat cycles, and a repeat bronchoscopy for clearance of debris and secretions is usually necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10453?source=see_link\">",
"     \"Bronchoscopic cryosurgery: Principles and technique\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38292?source=see_link\">",
"     \"Bronchoscopic cryosurgery: Indications, contraindications, and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cryotherapy can be performed safely in complete mainstem obstruction, but its delayed effects do not make it a first choice in acute situations or severe tracheal stenosis. As with any tissue-destroying interventions, long-term stabilization of the airway is often necessary. Stenting or radiation in the case of malignant lesions may achieve this.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     External beam radiation and brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy is a variably effective treatment for malignant airway obstruction, and therapeutic effects may be quite delayed. External beam radiation also may produce unwanted effects on thoracic structures outside the airway, further compromising gas exchange. Endobronchial brachytherapy is a treatment modality that has fewer of these drawbacks and is particularly useful in patients who have received previous maximal doses of external beam radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32038?source=see_link\">",
"     \"Endobronchial brachytherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After a patent airway has been established by laser resection, dilation, or other methods, a hollow catheter is introduced through the flexible bronchoscope and positioned under direct vision. After the catheter is secured, it is loaded with a radioactive source [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Depending upon the results, airway stenting should be considered. Adverse effects of brachytherapy are usually minimal (tracheobronchitis, cough), but severe hemoptysis and fistula formation have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Airway stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stenting should be considered to prevent reocclusion after patency has been restored to occluded or severely stenotic airways. Stents are the intervention of choice for external obstruction and are also highly effective for persistent proximal bronchopleural fistulas and tracheoesophageal fistulas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The first dedicated tracheobronchial stent was introduced in 1990; numerous designs with various advantages and disadvantages are now available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34823?source=see_link\">",
"     \"Airway stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Silicone stents generally require introduction with a rigid bronchoscope, but are comparatively inexpensive. Most metal stents can be introduced with the flexible bronchoscope; their greater expense is partially offset by the fact that neither an operating room nor general anesthesia is needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. New stent designs combining different materials are currently being evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stents are generally well tolerated, but patients require periodic follow-up. Patients should carry a card detailing type and size of the indwelling stent. Stents do not contraindicate subsequent intubation, but intubation should preferably be performed under fiberoptic guidance if the stent is in the tracheal position.",
"   </p>",
"   <p>",
"    Meticulous follow-up is indicated to identify potential problems at an early stage. These include recurrence of obstruction, growth of granulation tissue, as well as stent occlusion and migration. If identified early, these complications can be addressed in an elective manner. At our institution, a first follow-up bronchoscopy after stent placement is performed after six to eight weeks, which allows for repositioning of migrated metallic stents. Thereafter, we perform interval bronchoscopies every three to six months and as problems arise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Surgical resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical intervention for airway obstruction is usually reserved for severe, benign, relatively short tracheal lesions. Patient selection is crucial, as the operative morbidity and mortality may be unacceptable in patients with limited cardiopulmonary reserve.",
"   </p>",
"   <p>",
"    Patients should be referred to a center with a large cumulative experience if surgical resection is a consideration. Techniques that are commonly employed are primary end-to-end anastomosis and tracheal sleeve resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Anastomotic complications that result in recurrent stenosis may necessitate multiple dilations, reoperation, or permanent tracheostomy. These complications were noted in 9 percent of patients in one large single center series of over 900 procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/36\">",
"     36",
"    </a>",
"    ]. Risk factors for complications following tracheal resection in this study included diabetes, prior tracheal resection, and stenotic lesions longer than 4 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients undergoing laryngotracheal resection were also at increased risk of anastomotic complications in this report.",
"   </p>",
"   <p>",
"    In the future, biological tissue engineering techniques may be used to create tracheal bioprostheses covered with mucosal tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/37-44\">",
"     37-44",
"    </a>",
"    ]. Tracheal transplantation, which has been difficult to achieve because of the limited blood supply to the airway, may also be possible as muscle flap reconstruction techniques continue to improve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37351/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central airway obstruction may be extrinsic or intrinsic and may cause a variety of symptoms, from shortness of breath to respiratory failure and death. In the decompensated patient, immediate restoration of ventilation and oxygenation is of vital importance.",
"   </p>",
"   <p>",
"    Subsequent interventions are based upon the nature of the obstruction and refined according to issues involving quality of life and the duration of expected survival. Frequently, the best therapeutic approach employs a combination of several treatment modalities, and should be chosen at any given time in such a way that leaves open options for further therapy (",
"    <a class=\"graphic graphic_algorithm graphicRef54361 \" href=\"mobipreview.htm?21/46/22255\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Close follow-up is necessary in order to recognize complications early and intervene accordingly. The most comprehensive assessment and therapy can be provided by centers with a multidisciplinary airway team specializing in compromised airways.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14194828\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Heinrich Becker, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/1\">",
"      Ernst A, Feller-Kopman D, Becker HD, Mehta AC. Central airway obstruction. Am J Respir Crit Care Med 2004; 169:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/2\">",
"      Ernst A, Silvestri GA, Johnstone D, American College of Chest Physicians. Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. Chest 2003; 123:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/3\">",
"      Bolliger CT, Mathur PN, Beamis JF, et al. ERS/ATS statement on interventional pulmonology. European Respiratory Society/American Thoracic Society. Eur Respir J 2002; 19:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/4\">",
"      Stephens KE Jr, Wood DE. Bronchoscopic management of central airway obstruction. J Thorac Cardiovasc Surg 2000; 119:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/5\">",
"      Seijo LM, Sterman DH. Interventional pulmonology. N Engl J Med 2001; 344:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/6\">",
"      LoCicero J 3rd, Costello P, Campos CT, et al. Spiral CT with multiplanar and three-dimensional reconstructions accurately predicts tracheobronchial pathology. Ann Thorac Surg 1996; 62:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/7\">",
"      Colt HG, Harrell JH. Therapeutic rigid bronchoscopy allows level of care changes in patients with acute respiratory failure from central airways obstruction. Chest 1997; 112:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/8\">",
"      Beamis JF Jr. Interventional pulmonology techniques for treating malignant large airway obstruction: an update. Curr Opin Pulm Med 2005; 11:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/9\">",
"      Hautmann H, Gamarra F, Pfeifer KJ, Huber RM. Fiberoptic bronchoscopic balloon dilatation in malignant tracheobronchial disease: indications and results. Chest 2001; 120:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/10\">",
"      Mehta AC, Lee FY, Cordasco EM, et al. Concentric tracheal and subglottic stenosis. Management using the Nd-YAG laser for mucosal sparing followed by gentle dilatation. Chest 1993; 104:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/11\">",
"      Noppen M, Schlesser M, Meysman M, et al. Bronchoscopic balloon dilatation in the combined management of postintubation stenosis of the trachea in adults. Chest 1997; 112:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/12\">",
"      Duhamel DR, Harrell JH 2nd. Laser bronchoscopy. Chest Surg Clin N Am 2001; 11:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/13\">",
"      Ramser ER, Beamis JF Jr. Laser bronchoscopy. Clin Chest Med 1995; 16:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/14\">",
"      Cavaliere S, Venuta F, Foccoli P, et al. Endoscopic treatment of malignant airway obstructions in 2,008 patients. Chest 1996; 110:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/15\">",
"      Morice RC, Ece T, Ece F, Keus L. Endobronchial argon plasma coagulation for treatment of hemoptysis and neoplastic airway obstruction. Chest 2001; 119:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/16\">",
"      Edell ES, Cortese DA. Photodynamic therapy. Its use in the management of bronchogenic carcinoma. Clin Chest Med 1995; 16:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/17\">",
"      Cortese DA, Edell ES, Kinsey JH. Photodynamic therapy for early stage squamous cell carcinoma of the lung. Mayo Clin Proc 1997; 72:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/18\">",
"      Hetzel M, Hetzel J, Schumann C, et al. Cryorecanalization: a new approach for the immediate management of acute airway obstruction. J Thorac Cardiovasc Surg 2004; 127:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/19\">",
"      Mathur PN, Wolf KM, Busk MF, et al. Fiberoptic bronchoscopic cryotherapy in the management of tracheobronchial obstruction. Chest 1996; 110:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/20\">",
"      Chella A, Ambrogi MC, Ribechini A, et al. Combined Nd-YAG laser/HDR brachytherapy versus Nd-YAG laser only in malignant central airway involvement: a prospective randomized study. Lung Cancer 2000; 27:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/21\">",
"      Nori D, Allison R, Kaplan B, et al. High dose-rate intraluminal irradiation in bronchogenic carcinoma. Technique and results. Chest 1993; 104:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/22\">",
"      Suh JH, Dass KK, Pagliaccio L, et al. Endobronchial radiation therapy with or without neodymium yttrium aluminum garnet laser resection for managing malignant airway obstruction. Cancer 1994; 73:2583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/23\">",
"      Freitag L, Tekolf E, Steveling H, et al. Management of malignant esophagotracheal fistulas with airway stenting and double stenting. Chest 1996; 110:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/24\">",
"      Wood D. Airway stenting. Chest Surg Clin N Am 2003; 13:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/25\">",
"      Dumon JF. A dedicated tracheobronchial stent. Chest 1990; 97:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/26\">",
"      Becker, HD. Stenting of the central airways. J Bronchol 1995; 2:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/27\">",
"      Wood DE, Liu YH, Valli&egrave;res E, et al. Airway stenting for malignant and benign tracheobronchial stenosis. Ann Thorac Surg 2003; 76:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/28\">",
"      Dasgupta A, Dolmatch BL, Abi-Saleh WJ, et al. Self-expandable metallic airway stent insertion employing flexible bronchoscopy: preliminary results. Chest 1998; 114:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/29\">",
"      Saad CP, Murthy S, Krizmanich G, Mehta AC. Self-expandable metallic airway stents and flexible bronchoscopy: long-term outcomes analysis. Chest 2003; 124:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/30\">",
"      Bolliger CT, Breitenbuecher A, Brutsche M, et al. Use of studded Polyflex stents in patients with neoplastic obstructions of the central airways. Respiration 2004; 71:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/31\">",
"      Noppen M, Meysman M, Claes I, et al. Screw-thread vs Dumon endoprosthesis in the management of tracheal stenosis. Chest 1999; 115:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/32\">",
"      Bolliger CT, Wyser C, Wu X, et al. Evaluation of a new self-expandable silicone stent in an experimental tracheal stenosis. Chest 1999; 115:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/33\">",
"      Grillo HC. Development of tracheal surgery: a historical review. Part 1: Techniques of tracheal surgery. Ann Thorac Surg 2003; 75:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/34\">",
"      Grillo HC. Development of tracheal surgery: a historical review. Part 2: Treatment of tracheal diseases. Ann Thorac Surg 2003; 75:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/35\">",
"      Bisson A, Bonnette P, el Kadi NB, et al. Tracheal sleeve resection for iatrogenic stenoses (subglottic laryngeal and tracheal). J Thorac Cardiovasc Surg 1992; 104:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/36\">",
"      Wright CD, Grillo HC, Wain JC, et al. Anastomotic complications after tracheal resection: prognostic factors and management. J Thorac Cardiovasc Surg 2004; 128:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/37\">",
"      Saito Y, Minami K, Kaneda H, et al. New tubular bioabsorbable knitted airway stent: feasibility assessment for delivery and deployment in a dog model. Ann Thorac Surg 2004; 78:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/38\">",
"      Kim J, Suh SW, Shin JY, et al. Replacement of a tracheal defect with a tissue-engineered prosthesis: early results from animal experiments. J Thorac Cardiovasc Surg 2004; 128:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/39\">",
"      Kojima K, Ignotz RA, Kushibiki T, et al. Tissue-engineered trachea from sheep marrow stromal cells with transforming growth factor beta2 released from biodegradable microspheres in a nude rat recipient. J Thorac Cardiovasc Surg 2004; 128:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/40\">",
"      Bugmann P, Rimensberger PC, Kalangos A, et al. Extratracheal biodegradable splint to treat life-threatening tracheomalacia. Ann Thorac Surg 2004; 78:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/41\">",
"      Jaquet Y, Pilloud R, Lang FJ, Monnier P. Prefabrication of composite grafts for long-segment tracheal reconstruction. Arch Otolaryngol Head Neck Surg 2004; 130:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/42\">",
"      Grimmer JF, Gunnlaugsson CB, Alsberg E, et al. Tracheal reconstruction using tissue-engineered cartilage. Arch Otolaryngol Head Neck Surg 2004; 130:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/43\">",
"      Kamil SH, Eavey RD, Vacanti MP, et al. Tissue-engineered cartilage as a graft source for laryngotracheal reconstruction: a pig model. Arch Otolaryngol Head Neck Surg 2004; 130:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/44\">",
"      Martinod E, Seguin A, Holder-Espinasse M, et al. Tracheal regeneration following tracheal replacement with an allogenic aorta. Ann Thorac Surg 2005; 79:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/45\">",
"      Cibantos Filho JS, de Mello Filho FV, Campos AD, Ellinguer F. Viability of a 12-ring complete tracheal segment transferred in the form of a compound flap: an experimental study in dogs. Laryngoscope 2004; 114:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37351/abstract/46\">",
"      Olias J, Mill&aacute;n G, da Costa D. Circumferential tracheal reconstruction for the functional treatment of airway compromise. Laryngoscope 2005; 115:159.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4384 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-C2273CD5CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_30_37351=[""].join("\n");
var outline_f36_30_37351=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Initial stabilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Airway interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Foreign body extraction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Rigid or balloon dilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Laser therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Electrocautery and argon plasma coagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Photodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cryotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - External beam radiation and brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Airway stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Surgical resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14194828\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4384\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4384|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?21/46/22255\" title=\"algorithm 1\">",
"      Management central obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4384|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/44/24259\" title=\"diagnostic image 1\">",
"      CT reconstruction of trachea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4384|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/40/28302\" title=\"figure 1A\">",
"      Upper airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/31/35325\" title=\"figure 1B\">",
"      Flow volume loops in airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/0/16397\" title=\"figure 1C\">",
"      Mainstem bronchial obstr",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/63/36860\" title=\"figure 1D\">",
"      Partial mainstem bronchial obs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/0/12300\" title=\"figure 1E\">",
"      End inspiratory tail",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/18/42287\" title=\"figure 2\">",
"      Central obstruction types",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4384|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/58/29603\" title=\"picture 1A\">",
"      Rigid bronchoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/16/37122\" title=\"picture 1B\">",
"      Dilation with rigid scope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/2/15407\" title=\"picture 2\">",
"      Balloon dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/10/33953\" title=\"picture 3\">",
"      Juvenile papillomatosis bronch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4384|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/31/36349\" title=\"table 1\">",
"      Causes central airway obstruct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/49/43803\" title=\"table 2\">",
"      Interventions cent obstruction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/36/35399?source=related_link\">",
"      Airway foreign bodies in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34823?source=related_link\">",
"      Airway stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32151?source=related_link\">",
"      Basic principles of medical lasers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38292?source=related_link\">",
"      Bronchoscopic cryosurgery: Indications, contraindications, and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10453?source=related_link\">",
"      Bronchoscopic cryosurgery: Principles and technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38645?source=related_link\">",
"      Bronchoscopic laser resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32038?source=related_link\">",
"      Endobronchial brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11447?source=related_link\">",
"      Endobronchial electrocautery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15545?source=related_link\">",
"      Endotracheal tube management and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27126?source=related_link\">",
"      Flexible bronchoscopy balloon dilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43816?source=related_link\">",
"      Flexible bronchoscopy: Equipment, procedure, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38135?source=related_link\">",
"      Flexible bronchoscopy: Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25878?source=related_link\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23945?source=related_link\">",
"      Nonresolving pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/42/11945?source=related_link\">",
"      Overview of tracheostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37749?source=related_link\">",
"      Photodynamic therapy of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25256?source=related_link\">",
"      Radiology of the trachea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/33/37394?source=related_link\">",
"      Rigid bronchoscopy: Instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7412?source=related_link\">",
"      Rigid bronchoscopy: Intubation techniques",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_30_37352="Vernal keratoconjunctivitis";
var content_f36_30_37352=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vernal keratoconjunctivitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/30/37352/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37352/contributors\">",
"     Pedram Hamrah, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37352/contributors\">",
"     Reza Dana, MD, MPH, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/30/37352/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37352/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37352/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/30/37352/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37352/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/30/37352/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are five main types of ocular allergy: seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and giant papillary conjunctivitis (GPC). VKC and AKC are chronic, bilateral, and severe forms of allergic inflammation affecting the ocular surface. These two relatively uncommon types of allergic eye disease can cause severe damage to the ocular surface, leading to corneal scarring and vision loss if not treated properly (this occurs more commonly with AKC than VKC). Type I hypersensitivity reactions are important in these diseases, although they are not the only pathophysiologic mechanism. VKC is reviewed in this topic. AKC is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37910?source=see_link\">",
"     \"Atopic keratoconjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GPC is an inflammatory disorder that represents a reaction to lid movement over a foreign substance, such as contact lenses. Toxic conjunctivitis is not allergic in nature, but it is frequently confused with allergic ocular disease. It develops with protracted use of topical medications, mostly due to preservatives. GPC is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/60/5062?source=see_link\">",
"     \"Giant papillary conjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/19/6452?source=see_link\">",
"     \"Toxic conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Seasonal and perennial allergic conjunctivitis, the most common forms of ocular allergy, are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/2/34856?source=see_link\">",
"     \"Allergic conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;VKC most commonly occurs in boys living in warm, dry subtropical climates, such as the Mediterranean, the Middle East, central and west Africa, South America, and Asian countries, such as Japan, Thailand, and India [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/1\">",
"     1",
"    </a>",
"    ]. The limbal form of VKC is seen most often in dark-skinned individuals from Africa and India. VKC is generally rare in cooler climates, such as Northern Europe and the temperate areas of North America. However, the prevalence in these regions has increased, probably due to immigration of individuals from susceptible populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exacerbations are common in the spring (hence the name \"vernal\"), although reactivation often occurs in the winter. Initially the exacerbations are seasonal, but perennial attacks increase after a few years.",
"   </p>",
"   <p>",
"    Males are more commonly affected than females. In one series, the male to female ratio was 3.2:1 in patients &lt;20 years of age, but was nearly equal in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/3\">",
"     3",
"    </a>",
"    ]. Age at onset is generally before 10 years, with the earliest reported onset at five months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/4\">",
"     4",
"    </a>",
"    ], although VKC can infrequently occur in adults. Patients usually \"outgrow\" the disease with the onset of puberty.",
"   </p>",
"   <p>",
"    VKC is associated with other atopic manifestations in approximately one-half of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. The most common concomitant atopic diseases are asthma and allergic rhinitis. Aeroallergen sensitization, by skin prick testing or allergen-specific immunoassay, was reported in over 50 percent of patients in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/3\">",
"     3",
"    </a>",
"    ]. A family history of atopy was also reported in about one-half of patients in two studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. In another study, atopy was more common in patients with the palpebral, or tarsal form of the disease, compared with the limbal form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/7\">",
"     7",
"    </a>",
"    ]. VKC was associated with a family history of other inflammatory diseases, such as psoriasis and thyroiditis, in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact pathogenic mechanisms of VKC are not fully elucidated. Classic IgE-mediated hypersensitivity and T helper cell type 2 (Th2)-mediated responses are thought to play a major role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/5,8-10\">",
"     5,8-10",
"    </a>",
"    ], but other mechanisms may be involved, including IgG-mediated responses, basophil hypersensitivity, and cellular delayed-typed hypersensitivity.",
"   </p>",
"   <p>",
"    Evidence supporting an atopic origin for VKC includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Seasonal incidence",
"     </li>",
"     <li>",
"      Increased number of eosinophils and mast cells in conjunctival specimens",
"     </li>",
"     <li>",
"      High levels of IgE in serum and tears",
"     </li>",
"     <li>",
"      Increased levels of mediators derived from mast cells and eosinophils, including histamine and tryptase, in tears",
"     </li>",
"     <li>",
"      Therapeutic response to mast cell stabilizers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conjunctival accumulation of T helper type 2 (Th2) CD4+ cells may give rise to hyperreactivity against substances that commonly contact the conjunctiva. Offending allergens include pollens, dust mites, molds, and animal epithelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/7,11,12\">",
"     7,11,12",
"    </a>",
"    ]. Nonspecific stimuli, such as wind, sunlight, and heat also probably play a role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mast cells play a key role in the development of IgE-mediated reactions. In addition, they release mediators that stimulate fibroblast activity and production of collagens I and III, resulting in the typical formation of giant papillae in VKC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/15\">",
"     15",
"    </a>",
"    ]. Histamine, interleukins, and other inflammatory mediators are found in elevated levels in the tears of VKC patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. In addition, there is increased expression of histamine receptors (H",
"    <sub>",
"     1",
"    </sub>",
"    , H",
"    <sub>",
"     2",
"    </sub>",
"    , and H",
"    <sub>",
"     4",
"    </sub>",
"    receptors) in conjunctival tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/19\">",
"     19",
"    </a>",
"    ]. The necessary vascular supply of the forming giant papillae is provided by capillary proliferation. Chronic conjunctival inflammation in VKC is associated with increased staining of mediators that may stimulate vascular proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all patients with VKC note ocular pruritus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other symptoms of VKC include (in approximate order of frequency):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Photophobia",
"     </li>",
"     <li>",
"      Thick mucus discharge",
"     </li>",
"     <li>",
"      Tearing",
"     </li>",
"     <li>",
"      Burning",
"     </li>",
"     <li>",
"      Foreign body sensation",
"     </li>",
"     <li>",
"      Pain",
"     </li>",
"     <li>",
"      Blurred vision",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    VKC is named as such because severe symptoms most commonly occur in the spring (hence \"vernal\"), at least in the first few years of the disease. In one series of 195 patients, symptoms began in",
"    <span class=\"nowrap\">",
"     March/April",
"    </span>",
"    in over three-quarters of patients and resolved in September in one-third [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/3\">",
"     3",
"    </a>",
"    ]. However, approximately two-thirds of patients noted the occurrence of severe episodes year-round and over one-fifth had chronic symptoms since disease onset. An additional 12 percent of patients went on to have chronic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHYSICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral eye involvement and presence of giant cobblestone-like papillae on the upper tarsal conjunctiva (conjunctiva lining the upper eyelid) are nearly universal findings in patients with VKC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other signs of VKC include (in approximate order of frequency):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Conjunctival and episcleral hyperemia",
"     </li>",
"     <li>",
"      Superficial keratopathy",
"     </li>",
"     <li>",
"      Sticky, nonpurulent mucus discharge",
"     </li>",
"     <li>",
"      Horner-Trantas dots",
"     </li>",
"     <li>",
"      Corneal shield ulcers",
"     </li>",
"     <li>",
"      Ptosis",
"     </li>",
"     <li>",
"      Blepharospasm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examination of VKC patients may reveal a predominance of upper tarsal signs (palpebral VKC), limbal signs (limbal VKC), or a combination thereof:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The tarsal or palpebral form involves the part of the conjunctiva that covers the inside of the eyelid (tarsus). Upper tarsal papillae are discrete, enlarged (&gt;1 mm), and give rise to a classic \"cobblestone\" appearance with flattened tops (",
"      <a class=\"graphic graphic_picture graphicRef76654 \" href=\"mobipreview.htm?12/31/12785\">",
"       picture 1",
"      </a>",
"      ). Subepithelial fibrosis resulting from papillae hypertrophy can cause increased eyelid thickening and ptosis. Thick, ropy, mucus secretions are usually present and associated with tarsal papillae. Cytologic examination of mucus secretions reveals a predominance of eosinophils. Physical findings are generally confined to the cornea and conjunctiva, and rarely involve the skin or lid margins.",
"     </li>",
"     <li>",
"      The limbal form involves the limbus of the eye, the thin border between the cornea and the sclera. Gelatinous, confluent, yellow-gray infiltrates (Horner-Trantas dots) are pathognomonic of the limbal form of the disease (",
"      <a class=\"graphic graphic_picture graphicRef53133 \" href=\"mobipreview.htm?40/30/41440\">",
"       picture 2",
"      </a>",
"      ). Punctate collections of epithelial cells, eosinophils, and calcified corneal concretions may also be observed. Other corneal signs, which may also be sight-threatening, include superficial peripheral neovascularization, punctate corneal epitheliopathy, shield ulcers, subepithelial scarring, and plaque formation secondary to accumulation of inflammatory debris. Shield ulcers are usually found in the upper half of the visual axis (",
"      <a class=\"graphic graphic_picture graphicRef64926 \" href=\"mobipreview.htm?10/2/10272\">",
"       picture 3",
"      </a>",
"      ). After resolution, the ulcerated area leaves a ring like scar. Vision loss in VKC is uncommon, but can occur due to corneal scarring, neovascularization, and amblyopia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic analysis of ocular tissue reveals proliferative changes in the epithelium, cellular infiltration of the substantia propria, and hyperplasia of connective tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/3,15\">",
"     3,15",
"    </a>",
"    ]. The inflammatory infiltrate includes eosinophils, neutrophils, basophils, lymphocytes, plasma cells, mast cells, and fibroblasts. Conjunctival scrapings of VKC patients show a predominance of eosinophils, while basophils, neutrophils, and lymphocytes are rare. Increased numbers of mast cells, eosinophils, and lymphocytes are seen in conjunctival biopsies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no established diagnostic criteria or laboratory tests for VKC. The diagnosis of VKC is based upon the typical epidemiology and clinical features of VKC (eg, young boys living in warm climates who present with ocular pruritus and giant papillae on the conjunctival lining of the upper eyelid). A clinical grading system was proposed to aid in the diagnosis and management of VKC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical manifestations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Physical findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main disease to consider in the differential diagnosis is atopic keratoconjunctivitis (AKC). However, in contrast to VKC, AKC is perennial from the outset, affects predominantly the lower tarsus (eyelid), and commonly presents with vision-threatening corneal scars and neovascularization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy for VKC is long-term and requires frequent follow-up. The management approach includes both pharmacologic and nonpharmacologic therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical antihistamines and mast cell stabilizers are first line pharmacologic therapies. Treatment with topical corticosteroids is best undertaken by an ophthalmologist. Patients who do not respond to these therapies may benefit from an allergy evaluation and possibly allergen immunotherapy. Additional medications that may be effective in some patients include calcineurin inhibitors, nonsteroidal antiinflammatory drugs, and oral antihistamines.",
"   </p>",
"   <p>",
"    A proposed grading system may aid in choice of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/22\">",
"     22",
"    </a>",
"    ]. A more severe baseline grade, a younger age of onset, and a higher rate of recurrences of ocular inflammation were all associated with a worse visual outcome in a series of 110 patients, suggesting more aggressive treatment may be appropriate in these higher-risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of underlying conditions, such as blepharitis, is also necessary for successful management of VKC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/38/19048?source=see_link\">",
"     \"Blepharitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nonpharmacologic measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several nonpharmacologic measures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of nonspecific triggers, such as wind, heat, salt water, and sunlight whenever possible",
"     </li>",
"     <li>",
"      Avoidance of eye rubbing, as it leads to a mechanical mast-cell degranulation, as well as exacerbation of the allergic process",
"     </li>",
"     <li>",
"      Avoidance of known allergens in patients with IgE-mediated disease (this can be challenging, as patients with VKC can react to multiple allergens)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"       Artificial tears",
"      </a>",
"      , especially in patients who develop tear film insufficiency due to the anti-cholinergic effect of systemic antihistamines",
"     </li>",
"     <li>",
"      Cold compresses",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Topical antihistamines and mast cell stabilizers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical dual acting mast cell stabilizers and antihistamines are typically chosen as first line therapy and should be used on a daily basis throughout the affected season. Alternatives are a combination of a separate topical mast cell stabilizer and a topical antihistamine or a mast cell stabilizer alone. However, the dual agents were more effective than mast cell stabilizers alone in studies using a conjunctival allergen challenge model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/24-29\">",
"     24-29",
"    </a>",
"    ]. Topical antihistamines alone are minimally effective for VKC and are not used as monotherapy.",
"   </p>",
"   <p>",
"    These agents have two main actions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As mast cell stabilizers, they inhibit mast cell degranulation, which is the first step is the allergic cascade. They also inhibit leukocyte activity and dampen mediator release from mast cells, basophils, eosinophils, and neutrophils.",
"     </li>",
"     <li>",
"      As antihistamines, they competitively and reversibly block histamine receptors in the conjunctiva and eyelids, thus blocking the actions of the primary mast cell-derived mediator [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/30\">",
"       30",
"      </a>",
"      ]. This also helps reduce the late phase of the allergic response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dual acting agents include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/25/33168?source=see_link\">",
"     olopatadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    HCl,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/60/16323?source=see_link\">",
"     epinastine",
"    </a>",
"    , pemirolast potassium, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33024?source=see_link\">",
"     ketotifen",
"    </a>",
"    fumarate. These drugs have been studied extensively in seasonal and perennial allergic conjunctivitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. However, there are only a few nonrandomized studies on use of these drugs, specifically olopatadine and ketotifen, in patients with VKC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/29,34\">",
"     29,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one observational study, topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/25/33168?source=see_link\">",
"     olopatadine",
"    </a>",
"    hydrochloride 0.1 percent significantly decreased most signs and symptoms of VKC, including itching, tearing, burning, mucus discharge, conjunctival hyperemia, and corneal involvement after two months of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/29\">",
"     29",
"    </a>",
"    ]. However, photophobia and limbal papillae did not improve significantly. In another observational study, patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33024?source=see_link\">",
"     ketotifen",
"    </a>",
"    had greater improvement in itching, tearing, conjunctival hyperemia, mucus discharge, and photophobia after three weeks of therapy than patients treated with olopatadine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33024?source=see_link\">",
"     Ketotifen",
"    </a>",
"    fumarate is available in a generic formulation and is over-the-counter in the United States. Common side effects of these medications include stinging upon instillation and headache. The dual acting agents alone may be sufficient to treat mild acute symptoms. However, addition of a topical corticosteroid is generally required to gain control in patients with moderate to severe acute symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/2/34856?source=see_link&amp;anchor=H17#H17\">",
"     \"Allergic conjunctivitis\", section on 'Stepwise approach to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Topical mast cell stabilizers include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37712?source=see_link\">",
"     cromolyn sodium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/35\">",
"     35",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    sodium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5555?source=see_link\">",
"     lodoxamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Mast cell stabilizers have repeatedly been shown to be effective in patients with VKC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. In particular, efficacy of topical cromolyn was demonstrated in several small randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/40\">",
"     40",
"    </a>",
"    ]. In one of these trials, 4 percent cromolyn sodium demonstrated significant improvement in conjunctival and limbal injection, limbal edema, tearing, and symptoms summary score compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/35\">",
"     35",
"    </a>",
"    ]. In this study, cromolyn was more effective in patients with evidence of IgE-mediated disease. Subsequent studies demonstrated that lodoxamide was more efficacious than cromolyn sodium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The onset of action of these drugs is 5 to 14 days after initiation of therapy. Thus, these drugs are NOT useful for acute symptoms. In addition, dosing of mast cell stabilizers is four times daily, compared to twice daily for most agents with combined actions. These features may limit patient compliance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to an ophthalmologist is highly recommended for patients who do not respond to two or three weeks of consistent therapy with an",
"    <span class=\"nowrap\">",
"     antihistamine/mast",
"    </span>",
"    cell stabilizer agent, since topical corticosteroids are typically the next line of therapy.",
"   </p>",
"   <p>",
"    Observational studies and one randomized trial have shown that topical corticosteroids are effective in treating VKC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/3,36,41\">",
"     3,36,41",
"    </a>",
"    ]. In the randomized trial, a two week course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/49/41748?source=see_link\">",
"     fluorometholone",
"    </a>",
"    0.1 percent was more effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    2 percent in decreasing signs and symptoms of VKC, including papillary hypertrophy, Horner-Trantas dots, mucus discharge, conjunctival hyperemia, and tearing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Corticosteroids suppress the late phase reaction in both experimental and clinical settings. These drugs, in part, limit the inflammatory cascade by inhibiting phospholipase A2. Consequently, they reduce the formation of lipid-derived mediators from arachidonic acid, which prevents leukocyte migration, hydrolytic enzyme release, fibroblast growth, and changes in vascular permeability.",
"   </p>",
"   <p>",
"    Close follow-up with an ophthalmologist is required, due to vision threatening side effects of topical glucocorticoids, such as glaucoma, cataracts, and secondary infections. Patients should know that blindness is a risk of unsupervised topical corticosteroid therapy.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     Prednisolone",
"    </a>",
"    acetate 1 percent and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    0.1 percent have the greatest risk of raising intraocular pressure (IOP) among all topical corticosteroids. By comparison, \"soft\" steroids are a group of topical corticosteroids that have a greatly reduced risk of causing increased IOP, because they undergo rapid inactivation upon penetration of the cornea. Topical \"soft\" corticosteroids include prednisolone acetate 0.12 percent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/49/41748?source=see_link\">",
"     fluorometholone",
"    </a>",
"    , medrysone,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/48/39684?source=see_link\">",
"     loteprednol",
"    </a>",
"    etabonate 0.5 or 0.2 percent, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/13/20691?source=see_link\">",
"     rimexolone",
"    </a>",
"    1 percent.",
"   </p>",
"   <p>",
"    A short-term, high-dose pulse regimen of topical corticosteroids is often necessary in patients with VKC who fail to respond to two to three weeks of a dual acting",
"    <span class=\"nowrap\">",
"     antihistamine/mast",
"    </span>",
"    cell stabilizer, particularly those with significant seasonal exacerbations. In severe cases,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    acetate 1 percent eight times daily for one week leads to significant symptom relief, and thereafter should be tapered rapidly once control is gained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/42\">",
"     42",
"    </a>",
"    ]. In less severe cases, pulse therapy with topical \"soft\" steroids on a two to four times per day basis for approximately two weeks is effective in gaining control of the allergic response so that mast cell stabilizers, antihistamines, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    have a greater chance to work [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/36,41\">",
"     36,41",
"    </a>",
"    ]. Use of topical \"soft\" corticosteroids for greater than six weeks is associated with a significantly increased risk of complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Allergy referral for immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be referred to an allergy specialist for consideration of allergen immunotherapy if control is not obtained with topical corticosteroids after two to three weeks of therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39049?source=see_link\">",
"     \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcineurin inhibitors that are most commonly used in ocular allergy include topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and systemic cyclosporine. An important advantage of the calcineurin inhibitors is that they do not cause the same side effects typically seen with corticosteroids, such as an increase in intraocular pressure. Thus, these agents may be used long-term.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    diminishes the effect of interleukin (IL)-2 on T cells, and leads to decreased expansion of clonal T helper cells. It may also inhibit mast cell proliferation and survival. Cyclosporine reduces collagen production and induces apoptosis of conjunctival fibroblasts from VKC patients.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    has similar mechanisms of action [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    2 percent emulsion improved signs and symptoms of VKC in several randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/45,46\">",
"     45,46",
"    </a>",
"    ] and observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. Both randomized trials demonstrated a significant improvement in symptoms (eg, itching, tearing, mucus discharge) and signs (papillary hypertrophy, conjunctival hyperemia, Horner-Trantas dots) compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. However, several patients in one of the trials required a brief course of topical corticosteroids during the four month study period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a small randomized trial, topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    0.05 percent was more effective than topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33024?source=see_link\">",
"     ketotifen",
"    </a>",
"    fumarate 0.025 percent in preventing seasonal flare ups in patients with inactive disease at the start of therapy (seasonal recurrences occurred in 10 of 31 on cyclosporine versus 18 of 33 on ketotifen eye drops) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/51\">",
"     51",
"    </a>",
"    ]. However, previous observational studies of cyclosporine 0.05 percent have demonstrated variable results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. A 1 percent solution was effective in one observational study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some investigators have advocated for more concentrated use of topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Specifically, topical cyclosporine 2 percent may provide excellent therapy in severe cases of VKC, and can be used as a corticosteroid-sparing agent. However, topical cyclosporine is generally not chosen over topical corticosteroids for acute exacerbations because of its much slower onset of action. In one study, topical cyclosporine 0.1 percent was less effective than topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    0.15 percent for acute flare ups, with less improvement in symptoms and signs and a greater number of patients requiring rescue therapy with dexamethasone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is recommended rather than topical corticosteroids if the corneal epithelium is compromised, particularly in the presence of shield ulcers. Dosing is four times per day initially, followed by gradual tapering when the disease is quiet. The authors prefer the 2 percent concentration. Long-term use of topical cyclosporine is considered safe, unlike chronic use of topical corticosteroids, and only minimal amounts can be traced systemically. Efficacy of topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    in patients with VKC was demonstrated in small observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the authors' clinical experience, systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    can be helpful in controlling severe cases of allergic ocular disease and thereby reducing the need for long-term corticosteroid use. However, no randomized trial has been performed evaluating the utility of systemic cyclosporine in the treatment of ocular allergy. If administered, dosing is 2.5 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. The patient must be closely monitored for any adverse effect including kidney dysfunction, bone marrow suppression, hypertension, tremor, hirsutism, and gingival hyperplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Additional agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs block the action of cyclooxygenase and thus inhibit the conversion of arachidonic acid to prostaglandins and thromboxanes. Topical NSAID preparations include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/55,56\">",
"     55,56",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/5/25683?source=see_link\">",
"     bromfenac",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/57\">",
"     57",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/58\">",
"     58",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/42/33440?source=see_link\">",
"     flurbiprofen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/59\">",
"     59",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/60\">",
"     60",
"    </a>",
"    ]. Ketorolac was shown to be more effective in treating symptoms of VKC than placebo in one small randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/55\">",
"     55",
"    </a>",
"    ], and had greater efficacy in treating symptoms, but not signs of VKC, than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    0.5 percent by day seven in another randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/56\">",
"     56",
"    </a>",
"    ]. Flurbiprofen demonstrated lower efficacy compared with topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/59\">",
"     59",
"    </a>",
"    ]. Indomethacin treatment showed mixed results for VKC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/60\">",
"     60",
"    </a>",
"    ]. Overall, these agents have minimal to no role in treatment of VKC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Oral antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral nonsedating antihistamines, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"     fexofenadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12934?source=see_link\">",
"     desloratadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/45/44757?source=see_link\">",
"     levocetirizine",
"    </a>",
"    have demonstrated efficacy in the treatment of allergic conjunctivitis, although no extensive studies have been performed in patients with VKC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/61\">",
"     61",
"    </a>",
"    ]. These agents have a slower onset of action compared to topical agents, although this is not relevant if they are taken prophylactically. Oral antihistamines may be useful as add-on therapy in patients with moderate to severe disease. Maximizing the dose of nonsedating antihistamine will often improve efficacy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/2/34856?source=see_link\">",
"     \"Allergic conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral antihistamine use may be associated with drying of mucosal membranes and decreased tear production in some patients, especially those with concomitant dry eye. This side effect can usually be countered with the liberal application of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"     Cetirizine",
"    </a>",
"    causes sedation in a subset of patients, despite its categorization as nonsedating.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment of corneal shield ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corneal shield ulcers are a vision-threatening complication of VKC. Sterile corneal ulcers are treated by debridement of inflammatory debris and the use of wide-spectrum antibiotics, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/46/4836?source=see_link\">",
"     gatifloxacin",
"    </a>",
"    four times per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37352/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. Patching, bandage contact lenses, and temporary tarsorrhaphy (upper and lower eyelids are partially sewn together) may be required to help the epithelial defects heal. Infectious ulcers should be referred promptly to the appropriate specialist due to the high likelihood of vision loss and the complexity of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vernal keratoconjunctivitis (VKC) is a chronic, bilateral, and severe form of allergic inflammation affecting the ocular surface. This relatively uncommon type of allergic eye disease can cause severe damage to the ocular surface, leading to corneal scarring and vision loss if not treated properly. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VKC most commonly occurs in boys living in warm, dry subtropical climates. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common manifestations of VKC are ocular pruritus and giant cobblestone-like papillae on the upper tarsal conjunctiva. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of VKC is based upon the typical clinical features. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management approach includes both pharmacologic and nonpharmacologic therapies. Medications include mast cell stabilizers, dual acting topical antihistamines and mast cell stabilizers, topical corticosteroids, calcineurin inhibitors, nonsteroidal antiinflammatory drugs, and oral antihistamines. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Efficacy of some of the topical mast cell stabilizers, dual acting mast cell stabilizers and antihistamines, and calcineurin inhibitors for treatment of VKC has been demonstrated in randomized trials. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a topical dual acting mast cell stabilizer and antihistamine as first line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternatives are a combination of a separate topical mast cell stabilizer and a topical antihistamine or a mast cell stabilizer alone. (See\" Topical antihistamines and mast cell stabilizers\" above).",
"     </li>",
"     <li>",
"      We recommend a short-term, high-dose pulse regimen of topical corticosteroids in patients with VKC who fail to respond to two to three weeks of a dual acting",
"      <span class=\"nowrap\">",
"       antihistamine/mast",
"      </span>",
"      cell stabilizer (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Topical corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend using topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      2 percent as a corticosteroid-sparing agent in patients with moderate to severe disease who require frequent or prolonged courses of topical corticosteroids (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Calcineurin inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest adding an oral antihistamine in patients with moderate to severe disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/1\">",
"      Kumar S. Vernal keratoconjunctivitis: a major review. Acta Ophthalmol 2009; 87:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/2\">",
"      Montan PG, Ekstr&ouml;m K, Hedlin G, et al. Vernal keratoconjunctivitis in a Stockholm ophthalmic centre--epidemiological, functional, and immunologic investigations. Acta Ophthalmol Scand 1999; 77:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/3\">",
"      Bonini S, Bonini S, Lambiase A, et al. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmology 2000; 107:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/4\">",
"      Ukponmwan CU. Vernal keratoconjunctivitis in Nigerians: 109 consecutive cases. Trop Doct 2003; 33:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/5\">",
"      Lambiase A, Minchiotti S, Leonardi A, et al. Prospective, multicenter demographic and epidemiological study on vernal keratoconjunctivitis: a glimpse of ocular surface in Italian population. Ophthalmic Epidemiol 2009; 16:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/6\">",
"      Tesse R, Spadavecchia L, Fanelli P, et al. New insights into childhood Vernal keratoconjunctivitis-associated factors. Pediatr Allergy Immunol 2012; 23:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/7\">",
"      Tuft SJ, Dart JK, Kemeny M. Limbal vernal keratoconjunctivitis: clinical characteristics and immunoglobulin E expression compared with palpebral vernal. Eye (Lond) 1989; 3 ( Pt 4):420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/8\">",
"      Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res 2002; 21:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/9\">",
"      Mantelli F, Lambiase A, Bonini S. A simple and rapid diagnostic algorithm for the detection of ocular allergic diseases. Curr Opin Allergy Clin Immunol 2009; 9:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/10\">",
"      Offiah I, Calder VL. Immune mechanisms in allergic eye diseases: what is new? Curr Opin Allergy Clin Immunol 2009; 9:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/11\">",
"      Mumcuoglu YK, Zavaro A, Samra Z, Lazarowitz Z. House dust mites and vernal keratoconjunctivitis. Ophthalmologica 1988; 196:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/12\">",
"      Fujishima H, Saito I, Takeuchi T, Tsubota K. Immunological characteristics of patients with vernal keratoconjunctivitis. Jpn J Ophthalmol 2002; 46:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/13\">",
"      Bonini S, Bonini S, Schiavone M, et al. Conjunctival hyperresponsiveness to ocular histamine challenge in patients with vernal conjunctivitis. J Allergy Clin Immunol 1992; 89:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/14\">",
"      Pucci N, Novembre E, Lombardi E, et al. Long eyelashes in a case series of 93 children with vernal keratoconjunctivitis. Pediatrics 2005; 115:e86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/15\">",
"      Leonardi A, Abatangelo G, Cortivo R, Secchi AG. Collagen types I and III in giant papillae of vernal keratoconjunctivitis. Br J Ophthalmol 1995; 79:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/16\">",
"      Abelson MB, Baird RS, Allansmith MR. Tear histamine levels in vernal conjunctivitis and other ocular inflammations. Ophthalmology 1980; 87:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/17\">",
"      Leonardi A, Fregona IA, Plebani M, et al. Th1- and Th2-type cytokines in chronic ocular allergy. Graefes Arch Clin Exp Ophthalmol 2006; 244:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/18\">",
"      Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin Exp Allergy 2006; 36:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/19\">",
"      Leonardi A, Di Stefano A, Vicari C, et al. Histamine H4 receptors in normal conjunctiva and in vernal keratoconjunctivitis. Allergy 2011; 66:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/20\">",
"      Abu El-Asrar AM, Al-Mansouri S, Tabbara KF, et al. Immunopathogenesis of conjunctival remodelling in vernal keratoconjunctivitis. Eye (Lond) 2006; 20:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/21\">",
"      Bonini S, Sacchetti M, Mantelli F, Lambiase A. Clinical grading of vernal keratoconjunctivitis. Curr Opin Allergy Clin Immunol 2007; 7:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/22\">",
"      Sacchetti M, Lambiase A, Mantelli F, et al. Tailored approach to the treatment of vernal keratoconjunctivitis. Ophthalmology 2010; 117:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/23\">",
"      Kumar S, Gupta N, Vivian AJ. Modern approach to managing vernal keratoconjunctivitis. Curr Allergy Asthma Rep 2010; 10:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/24\">",
"      Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol 1998; 81:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/25\">",
"      Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol 1998; 125:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/26\">",
"      Berdy GJ, Stoppel JO, Epstein AB. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. Clin Ther 2002; 24:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/27\">",
"      Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther 2001; 23:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/28\">",
"      Uchio E. Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops. Clin Ophthalmol 2008; 2:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/29\">",
"      Corum I, Yeniad B, Bilgin LK, Ilhan R. Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density. J Ocul Pharmacol Ther 2005; 21:400.",
"     </a>",
"    </li>",
"    <li>",
"     Abelson MB, Weston JH. Antihistamines. In: Clinical ophthalmic pharmacology, Lamberts DW, Potter DE (Eds), Little Brown, Boston 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/31\">",
"      Abelson MB, Gomes P, Crampton HJ, et al. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther 2004; 26:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/32\">",
"      Gous P, Ropo A. A comparative trial of the safety and efficacy of 0.1 percent pemirolast potassium ophthalmic solution dosed twice or four times a day in patients with seasonal allergic conjunctivitis. J Ocul Pharmacol Ther 2004; 20:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/33\">",
"      Crampton HJ. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial. Clin Ther 2003; 25:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/34\">",
"      Hida WT, Nogueira DC, Schaefer A, et al. [Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis]. Arq Bras Oftalmol 2006; 69:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/35\">",
"      Foster CS. Evaluation of topical cromolyn sodium in the treatment of vernal keratoconjunctivitis. Ophthalmology 1988; 95:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/36\">",
"      Tabbara KF, al-Kharashi SA. Efficacy of nedocromil 2% versus fluorometholone 0.1%: a randomised, double masked trial comparing the effects on severe vernal keratoconjunctivitis. Br J Ophthalmol 1999; 83:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/37\">",
"      Bonini S, Lambiase A, Matricardi P, et al. Atopic and vernal keratoconjunctivitis: a model for studying atopic disease. Curr Probl Dermatol 1999; 28:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/38\">",
"      Avunduk AM, Avunduk MC, Kapicioglu Z, et al. Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis. Ophthalmology 2000; 107:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/39\">",
"      Leonardi A, Borghesan F, Avarello A, et al. Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis. Br J Ophthalmol 1997; 81:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/40\">",
"      Mantelli F, Santos MS, Petitti T, et al. Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis. Br J Ophthalmol 2007; 91:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/41\">",
"      Bonini S, Coassin M, Aronni S, Lambiase A. Vernal keratoconjunctivitis. Eye (Lond) 2004; 18:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/42\">",
"      Kosrirukvongs P, Vichyanond P, Wongsawad W. Vernal keratoconjunctivitis in Thailand. Asian Pac J Allergy Immunol 2003; 21:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/43\">",
"      Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, et al. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology 2008; 115:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/44\">",
"      Vichyanond P, Tantimongkolsuk C, Dumrongkigchaiporn P, et al. Vernal keratoconjunctivitis: Result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment. J Allergy Clin Immunol 2004; 113:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/45\">",
"      Bleik JH, Tabbara KF. Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology 1991; 98:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/46\">",
"      Pucci N, Novembre E, Cianferoni A, et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 2002; 89:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/47\">",
"      Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol 1990; 110:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/48\">",
"      Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea 1993; 12:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/49\">",
"      Tomida I, Schlote T, Br&auml;uning J, et al. [Cyclosporin A 2% eyedrops in therapy of atopic and vernal keratoconjunctivitis]. Ophthalmologe 2002; 99:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/50\">",
"      Avunduk AM, Avunduk MC, Erd&ouml;l H, et al. Cyclosporine effects on clinical findings and impression cytology specimens in severe vernal keratoconjunctivitis. Ophthalmologica 2001; 215:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/51\">",
"      Lambiase A, Leonardi A, Sacchetti M, et al. Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study. J Allergy Clin Immunol 2011; 128:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/52\">",
"      Keklikci U, Soker SI, Sakalar YB, et al. Efficacy of topical cyclosporin A 0.05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children. Jpn J Ophthalmol 2008; 52:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/53\">",
"      Daniell M, Constantinou M, Vu HT, Taylor HR. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol 2006; 90:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/54\">",
"      Tesse R, Spadavecchia L, Fanelli P, et al. Treatment of severe vernal keratoconjunctivitis with 1% topical cyclosporine in an Italian cohort of 197 children. Pediatr Allergy Immunol 2010; 21:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/55\">",
"      Sharma A, Gupta R, Ram J, Gupta A. Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis. Indian J Ophthalmol 1997; 45:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/56\">",
"      Kosrirukvongs P, Luengchaichawange C. Topical cyclosporine 0.5 per cent and preservative-free ketorolac tromethamine 0.5 per cent in vernal keratoconjunctivitis. J Med Assoc Thai 2004; 87:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/57\">",
"      Uchio E, Itoh Y, Kadonosono K. Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis. Ophthalmologica 2007; 221:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/58\">",
"      D'Angelo G, Lambiase A, Cortes M, et al. Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol 2003; 241:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/59\">",
"      Sud RN, Greval RS, Bajwa RS. Topical flurbiprofen therapy in vernal keratoconjunctivitis. Indian J Med Sci 1995; 49:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/60\">",
"      Gupta S, Khurana AK, Ahluwalia BK, Gupta NC. Topical indomethacin for vernal keratoconjunctivitis. Acta Ophthalmol (Copenh) 1991; 69:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/61\">",
"      Alexander M. Comparative therapeutic studies with Tilavist. Allergy 1995; 50:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/62\">",
"      Gedik S, Akova YA, G&uuml;r S. Secondary bacterial keratitis associated with shield ulcer caused by vernal conjunctivitis. Cornea 2006; 25:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/63\">",
"      Ozbek Z, Burakgazi AZ, Rapuano CJ. Rapid healing of vernal shield ulcer after surgical debridement: A case report. Cornea 2006; 25:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/64\">",
"      Solomon A, Zamir E, Levartovsky S, Frucht-Pery J. Surgical management of corneal plaques in vernal keratoconjunctivitis: a clinicopathologic study. Cornea 2004; 23:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37352/abstract/65\">",
"      Cetinkaya A, Akova YA, Dursun D, Pelit A. Topical cyclosporine in the management of shield ulcers. Cornea 2004; 23:194.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5549 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-0039180376-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_30_37352=[""].join("\n");
var outline_f36_30_37352=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHYSICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nonpharmacologic measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Topical antihistamines and mast cell stabilizers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Allergy referral for immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Additional agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Oral antihistamines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment of corneal shield ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5549\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5549|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/31/12785\" title=\"picture 1\">",
"      Upper papillae in VKC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/30/41440\" title=\"picture 2\">",
"      Limbal form of VKC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/2/10272\" title=\"picture 3\">",
"      VKC shield ulcer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/2/34856?source=related_link\">",
"      Allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37910?source=related_link\">",
"      Atopic keratoconjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/38/19048?source=related_link\">",
"      Blepharitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/60/5062?source=related_link\">",
"      Giant papillary conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39049?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/19/6452?source=related_link\">",
"      Toxic conjunctivitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_30_37353="Renal disease associated with hepatitis C virus infection";
var content_f36_30_37353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal disease associated with hepatitis C virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/30/37353/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37353/contributors\">",
"     Nassim Kamar, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37353/contributors\">",
"     Lionel Rostaing, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/30/37353/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37353/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37353/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/30/37353/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37353/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/30/37353/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a strong and likely causal association between chronic hepatitis C virus (HCV) infection and glomerular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Several types of renal disease have been recognized including mixed cryoglobulinemia, membranoproliferative glomerulonephritis (MPGN), membranous nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/3-9\">",
"     3-9",
"    </a>",
"    ], and polyarteritis nodosa. Crescentic glomerulonephritis may be superimposed on any of these glomerular lesions.",
"   </p>",
"   <p>",
"    Less commonly, other glomerular lesions have been reported in HCV-infected patients, including focal segmental glomerular sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/10-12\">",
"     10-12",
"    </a>",
"    ], proliferative glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/13-15\">",
"     13-15",
"    </a>",
"    ], and fibrillary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/16-18\">",
"     16-18",
"    </a>",
"    ] and immunotactoid glomerulopathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/17\">",
"     17",
"    </a>",
"    ]. In some patients, glomerular disease may be clinically silent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Clinically silent glomerular disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Glomerular diseases can occur both in native kidneys and renal allografts. A renal thrombotic microangiopathy and an atypical variant of acute cellular rejection have been associated with HCV infection in renal transplant recipients. Acute and chronic transplant glomerulopathy also have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/10,21\">",
"     10,21",
"    </a>",
"    ]. It remains unclear, however, why only some patients with HCV infection develop these complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic provides an overview of the renal diseases associated with chronic HCV infection and the approach and response to therapy. The diagnosis and management of HCV infection and of HCV-associated renal disease following renal transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus after renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MIXED (IgG/IgM) CRYOGLOBULINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed cryoglobulinemia is a systemic vasculitis. Affected patients typically present with nonspecific systemic symptoms, palpable purpura, arthralgias, fever, renal disease, neuropathy, hypocomplementemia (C4&lt;C3), and other manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/22\">",
"     22",
"    </a>",
"    ]. The clinical manifestations of the renal disease may include hematuria, nephritic range proteinuria, and renal insufficiency. Fifty percent of patients have moderate renal insufficiency, and hypertension is present in 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In general, the renal prognosis is good [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/24\">",
"     24",
"    </a>",
"    ]. However, renal disease is the primary cause of morbidity and mortality in patients with mixed cryoglobulinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/24\">",
"     24",
"    </a>",
"    ]. Laboratory studies indicate the presence of circulating cryoglobulins, which are most commonly type II cryoglobulins in which the rheumatoid factor (or antibody that is directed against the Fc portion of IgG) is a monoclonal IgM kappa. The complement components, C3, C4, and C1q, are usually low. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Type II or essential mixed",
"    <span class=\"nowrap\">",
"     (IgG/IgM)",
"    </span>",
"    cryoglobulinemia is associated with HCV infection in up to 95 percent, including circulating anti-HCV antibodies, polyclonal IgG anti-HCV antibodies within the cryoprecipitate, and HCV RNA in the plasma and the cryoprecipitate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/4,5,9\">",
"     4,5,9",
"    </a>",
"    ]. HCV RNA concentrates in cryoprecipitate are ~1000-fold higher than in the serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/5,25\">",
"     5,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HCV may also be responsible for some cases of type III mixed cryoglobulinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/5\">",
"     5",
"    </a>",
"    ]. Type III cryoglobulinemia is characterized by circulating cryoglobulins comprising polyclonal immunoglobulins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=see_link\">",
"     \"Overview of cryoglobulins and cryoglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is strong evidence that HCV-containing immune complexes are directly involved in the pathogenesis of the renal disease. HCV antigens have been detected along the glomerular capillary walls and in the mesangium of patients with HCV-related glomerulonephritis, mainly in those with MPGN and positive HCV RNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/6,26\">",
"     6,26",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Histological examination of kidney biopsies demonstrates glomerular infiltration by activated macrophages. The glomerular basement membrane shows double contours caused by the interposition of monocytes between the basement membrane and the endothelium. Subendothelial deposits of IgM, IgG, and complement components are observed by immunofluorescence and electron microscopy. Vasculitis of small renal arteries is present in 30 percent of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association of HCV infection and idiopathic MPGN (ie, in the",
"    <strong>",
"     absence",
"    </strong>",
"    of cryoglobulinemia) is controversial. Although some patients did not have circulating cryoglobulins in the initial reports of HCV-associated MPGN, the majority subsequently developed measurable cryoglobulinemia, but not necessarily the extrarenal manifestations of cryoglobulinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/3,7,15\">",
"     3,7,15",
"    </a>",
"    ]. Although case reports exist, most subsequent studies failed to show a conclusive association between chronic HCV infection and idiopathic MPGN type I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/10,27-29\">",
"     10,27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, circulating cryoglobulins are often difficult to detect and cryoglobulinemia may be unrecognized in many patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .) For this reason, HCV-infected patients who have MPGN without cryoglobulinemia should be managed with anti-viral therapy, unless contraindicated. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Indications for antiviral therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MEMBRANOUS NEPHROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small studies have suggested that membranous nephropathy may be induced by chronic HCV infection, although the data are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/3,7,10,28,30,31\">",
"     3,7,10,28,30,31",
"    </a>",
"    ]. In one study, the prevalence of membranous nephropathy was significantly higher in HCV-positive compared to HCV-negative renal-transplant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/32\">",
"     32",
"    </a>",
"    ]. However, in a study of 19 patients with membranous nephropathy, only one (5 percent) had anti-HCV antibodies, which was not different from that observed in control patients with diabetic nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, these findings suggest but do not prove a possible role of HCV in the development of membranous nephropathy. In addition, in contrast to the findings in mixed cryoglobulinemia or MPGN, complement levels tend to be normal and neither cryoglobulins nor rheumatoid factor is present in HCV-associated membranous nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore, it is not clear that there is an association between membranous nephropathy and HCV infection. Some clinicians would consider the administration of anti-viral therapy in HCV-infected patients who present with membranous nephropathy. Others, however, would not treat with therapy directed at HCV given the conflicting data related to the association. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Indications for antiviral therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     POLYARTERITIS NODOSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyarteritis nodosa (PAN) is well described in patients with hepatitis B virus infection, but also occurs in association with HCV in the absence of cryoglobulins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. In one series, among 161 patients with HCV-related vasculitis 31 (19 percent) were diagnosed with PAN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/36\">",
"     36",
"    </a>",
"    ]. This disorder is called secondary PAN.",
"   </p>",
"   <p>",
"    In a review of 78 cases, the onset of PAN occurred at a mean of two years after the diagnosis of HCV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/34\">",
"     34",
"    </a>",
"    ]. The patients had typical symptoms of PAN and necrotizing inflammation of medium or small arteries in biopsy specimens. Twenty-six percent of tested patients were also positive for hepatitis B surface antigen. Antiviral therapy with interferon alfa usually leads to improvement in the vasculitic manifestations, but the vasculitis may be exacerbated and new cases of PAN have occurred during interferon alfa therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44488?source=see_link&amp;anchor=H5#H5\">",
"     \"Renal disease associated with hepatitis B virus infection\", section on 'Polyarteritis nodosa'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Interferon alfa alone'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients infected with HCV who develop PAN may have more severe systemic manifestations of vasculitis compared to those HCV patients who develop mixed cryoglobulinemia vasculitis. In the study cited above, compared with patients with HCV-related cryoglobulinemic vasculitis, patients with HCV-related PAN more commonly had fever, weight loss, hypertension, gastrointestinal tract involvement, severe mononeuropathy, and elevated C-reactive protein levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICALLY SILENT GLOMERULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to symptomatic renal disease, clinically silent glomerular disease has been described in patients with HCV infection, primarily in those who under liver transplantation for cirrhosis due to chronic HCV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In a series of 48 such patients, 30 had a kidney biopsy during surgery; the remaining patients either did not consent or were considered at risk for complications from renal biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/19\">",
"     19",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immune complex glomerulonephritis was present in 25, which was classified as MPGN in 12, IgA nephropathy in seven, and mesangial glomerulonephritis in six.",
"     </li>",
"     <li>",
"      A clinical renal abnormality (elevated serum creatinine, hematuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      proteinuria) was noted in only 10 patients, most of whom had MPGN.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Post-transplant follow-up was not reported. Thus, the impact of clinically silent glomerular disease at the time of transplant upon renal and other outcomes following liver transplantation is unknown. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above observations suggest that all patients with mixed",
"    <span class=\"nowrap\">",
"     (IgG/IgM)",
"    </span>",
"    cryoglobulinemia, MPGN type I, and perhaps membranous nephropathy should be evaluated serologically for possible underlying HCV infection. HCV RNA should also be looked for in the serum and in the cryoprecipitate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most HCV-infected patients have evidence of liver disease as reflected by elevated plasma aminotransferase concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/3-5,7,15,27\">",
"     3-5,7,15,27",
"    </a>",
"    ]. However, serum aminotransferases are normal in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/3,4,15\">",
"     3,4,15",
"    </a>",
"    ] and a history of acute hepatitis is often absent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, seemingly normal hepatic function and enzymes do not exclude the presence of HCV infection.",
"   </p>",
"   <p>",
"    In addition, HCV-infected patients should be screened for proteinuria, hematuria, hypertension, and renal function, as well as for cryoglobulinemia, complement and rheumatoid factors. A kidney biopsy should be considered in the setting of significant proteinuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impaired renal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Indications for antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association among MPGN type I, mixed cryoglobulinemia, and HCV is well established. If it is determined that the degree of liver injury",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other extrarenal manifestations are not an indication for antiviral therapy, then the decision to treat is based solely upon the potential benefit for the renal disease versus potential toxicity. The main indications for therapy are moderate to severe disease (eg, nephrotic syndrome, elevated plasma creatinine concentration, new hypertension, fibrosis or tubulointerstitial disease on biopsy) or progressive disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Interferon alfa alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of reports demonstrate a beneficial response to chronic antiviral therapy with interferon alfa in patients with HCV-induced renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/3,5,7,15,30\">",
"     3,5,7,15,30",
"    </a>",
"    ]. In one, 14 patients with HCV infection and MPGN with or without cryoglobulinemia were treated for 6 to 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/15\">",
"     15",
"    </a>",
"    ]. Approximately one-half responded with disappearance of HCV RNA from the plasma. Protein excretion fell in the responders from 6.1 to 1.3",
"    <span class=\"nowrap\">",
"     g/day;",
"    </span>",
"    in comparison, there was a lesser, not statistically significant reduction in protein excretion in the nonresponders (6.1 versus 4.2",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"    There was no significant improvement in the plasma creatinine concentration in these patients, possibly due to irreversible renal injury.",
"   </p>",
"   <p>",
"    More compelling evidence that interferon alfa is effective in HCV-induced mixed cryoglobulinemia comes from a large prospective trial in which 53 patients were randomized to conventional therapy alone or in combination with interferon alfa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/37\">",
"     37",
"    </a>",
"    ]. There was no clinical or serologic improvement in the patients receiving conventional therapy or in those who were given interferon alfa but did not respond with a decrease in plasma HCV RNA. In comparison, HCV RNA fell to undetectable levels in 60 percent of patients in the interferon alfa group. These patients showed improvement in the cutaneous vasculitis, in cryoglobulin titers, and in the plasma creatinine concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/52/36682?source=see_link\">",
"     \"Treatment of the mixed cryoglobulinemia syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cessation of interferon therapy has led to recurrence of viremia and cryoglobulinemia in almost all patients in these studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/3,5,7,15,28\">",
"     3,5,7,15,28",
"    </a>",
"    ]. This observation suggests that the efficacy of interferon alfa is directly related to its antiviral activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=see_link\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal dose and duration of interferon alfa therapy are not established. Relatively high doses are required for elimination of viremia. The regimen used in the mixed cryoglobulinemia trial was to administer, if tolerated, 3,000,000 units three times weekly for six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/37\">",
"     37",
"    </a>",
"    ]. This regimen was tolerated by most patients with the major side effects being flu-like symptoms, malaise, and insomnia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/3\">",
"     3",
"    </a>",
"    ]. Viral RNA titers should be monitored every six months to predict disease relapse.",
"   </p>",
"   <p>",
"    Whether or not higher doses or longer courses of interferon alfa are beneficial in patients with cryoglobulinemia is uncertain. One study compared three different regimens in 303 patients with HCV infection; no mention was made about possible cryoglobulins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/38\">",
"     38",
"    </a>",
"    ]. A regimen of 3,000,000 units of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    three times per week for 18 months resulted in a greater improvement in liver histology activity scores and a greater likelihood of sustained normalization of ALT levels than regimens using a lower dose or shorter duration. In addition, a meta-analysis suggested that treatment with interferon alfa for 12 months or longer increased the sustained response rate from 14 to 35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The improvement in viral response to prolonged courses and higher doses of interferon alfa therapy may also be true for mixed cryoglobulinemia. In one review, a cumulative dose of 621 million units (equivalent to 3,000,000 units three times weekly for 69 weeks) appeared to be an important cutoff; doses above this level resulted in cure in 15 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/40\">",
"     40",
"    </a>",
"    ]. In this study, the only pretherapy parameter that was associated with a complete response of cryoglobulinemia to interferon alpha therapy was the solitary anti-C22 (HCV core) antibody pattern on RIBA-2 testing. This pattern of HCV antibody positivity was present in about one-third of the patients reported in this study.",
"   </p>",
"   <p>",
"    A short course of a much higher dose of interferon alfa may be effective in patients in whom lower dose therapy fails. One case report described a patient with HCV-induced MPGN who did not respond to a regimen of 3,000,000 units of interferon-alpha three times a week for six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/41\">",
"     41",
"    </a>",
"    ]. However, the administration of 10,000,000 units daily for two weeks followed by the same dose thrice weekly for six weeks resulted in the disappearance of serum HCV RNA and cryoglobulins and remission of nephrosis. The utility of this approach needs to be assessed in a larger number of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite these substantial benefits, interferon alfa therapy can induce",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exacerbate glomerulonephritis or vasculitis in some patients with chronic hepatitis C virus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/35,42\">",
"     35,42",
"    </a>",
"    ]. The clinical and pathologic features of this phenomenon were evaluated in a series of 23 patients with chronic HCV infection and the appearance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    worsening of proteinuria soon after the administration of interferon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/42\">",
"     42",
"    </a>",
"    ]. Proteinuria (mean 2.1",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    began approximately 12 days after the onset of therapy. Among the 11 who underwent renal biopsies, nine had mild mesangial proliferative glomerulonephritis, one had membranoproliferative glomerulonephropathy, and one had glomerulosclerosis. All nine patients in whom immunofluorescence was performed had IgG, IgA, and complement deposition in the glomeruli, with only trace HCV core antigen deposition in three. Proteinuria cleared in almost all patients one month after drug discontinuation.",
"   </p>",
"   <p>",
"    The possible induction of glomerular disease has also been observed in some patients treated with high-dose interferon for malignancy and other non-HCV related disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/43\">",
"     43",
"    </a>",
"    ]; by comparison, others have reported benefits with interferon in a small number of patients with non-HCV related glomerulonephropathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, in some patients with or without HCV infection, interferon therapy may cause, exacerbate,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ameliorate glomerular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/45\">",
"     45",
"    </a>",
"    ]. These observations highlight that interferon therapy, despite being generally beneficial, may be associated with renal risks in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pegylated interferon and renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pegylated interferon has largely replaced standard interferon in the treatment of chronic hepatitis C. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=see_link\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .) There are concerns about the safety of pegylated interferon in patients with renal insufficiency. Concerns are based upon studies that showed reduced clearance of interferon in patients on hemodialysis. Limited data exist on the clearance of pegylated interferon in patients with estimated glomerular filtration rates (GFRs) of 15 to 59",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2. However, one study, published as an abstract only, showed no difference in the clearance of pegylated interferon in patients with creatinine clearance greater than 100",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    versus those with creatinine clearances of 20 to 40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two small published studies have evaluated the frequency of side effects of pegylated interferon alfa in patients on hemodialysis (ie, the group deemed most likely to have reduced clearance of the drug) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 12 patients who received pegylated interferon alfa for 48 weeks and 13 non-treatment controls, side effects due to pegylated interferon included anemia (75 percent), fatigue (58 percent), thrombocytopenia (33 percent), and leukopenia (33 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/47\">",
"       47",
"      </a>",
"      ]. No side effect was severe enough to warrant either discontinuation or dosage adjustment of the drug.",
"     </li>",
"     <li>",
"      In another study, 35 hemodialysis patients were administered pegylated interferon alfa (135",
"      <span class=\"nowrap\">",
"       microg/week)",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      (200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for 24 or 48 weeks and compared with 35 untreated controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/48\">",
"       48",
"      </a>",
"      ]. Although the ribavirin dose was reduced in 11 patients, no patient required an adjustment of the dose of interferon. Side effects attributable to interferon developed in most patients and included flu-like syndrome, myalgias, and fatigue. Seventy-four percent of patients developed severe anemia that required adjustment of erythropoietin dose and one patient was withdrawn from the study due to anemia at 12 weeks. Anemia, however, was presumed due to ribavirin, not interferon.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Though small, these studies suggest that pegylated interferon may be used in patients with reduced clearance of the drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Interferon alfa plus ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     Ribavirin",
"    </a>",
"    improves the rate of sustained virologic clearance when given in combination with standard or pegylated interferon alfa (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28184?source=see_link\">",
"     \"Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=see_link\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    ). A few uncontrolled studies have evaluated the effectiveness of this regimen in patients with HCV-induced renal diseases, and a small number of patients with HCV-associated mixed cryoglobulinemia have been successfully treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/49-54\">",
"     49-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is limited by renal insufficiency. Most patients in the published reports either had normal or near-normal renal function or, if renal insufficiency were present, ribavirin was not given until renal function improved after other therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with renal insufficiency, the accumulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    induces a severe hemolytic anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/55\">",
"     55",
"    </a>",
"    ]. In addition to a marked anemia, chronic hemolysis may contribute to iron overload, liver iron deposition, and an acceleration in liver fibrosis progression, all of which may exacerbate HCV-associated liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/55\">",
"     55",
"    </a>",
"    ]. Ribavirin plasma concentration predicts ribavirin-induced anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     Ribavirin",
"    </a>",
"    dosage should be adapted to creatinine clearance rather than to body weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Ribavirin should be used with caution in patients with mild renal insufficiency. It is NOT recommended for patients with estimated glomerular filtration rate less than 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2.",
"   </p>",
"   <p>",
"    In addition, the side effects of the combined",
"    <span class=\"nowrap\">",
"     interferon-alfa/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    therapy are substantial and many patients with renal insufficiency cannot tolerate the regimen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the following approach is not recommended, there are anecdotal reports of patients with moderate renal insufficiency doing well with a proportionate reduction in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    dose and other measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/50,53,54\">",
"     50,53,54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One series reported benefits with the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      and interferon alfa in seven patients with varying degrees of renal insufficiency (eGFR between 10 and 65",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      and hepatitis C associated renal disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/53\">",
"       53",
"      </a>",
"      ]. However, such therapy was reasonably safe only because of close plasma hemoglobin monitoring, high-dose erythropoietin treatment, adequate iron stores, reduced ribavirin doses, and (most importantly) close monitoring of plasma ribavirin levels, which is only available via a high-performance liquid chromatography method developed by the authors of this study.",
"     </li>",
"     <li>",
"      In another study of 25 patients with HCV-related mixed cryoglobulinemia with glomerulonephritis, 18 were treated with interferon alfa and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/54\">",
"       54",
"      </a>",
"      ]. Six patients in the active treatment group had plasma creatinine concentrations &gt;1.7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;150",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      Anemia necessitated a reduction of the ribavirin dose in eight patients. Over 50 percent of patients in each group also received plasmapheresis with or without steroids, before or overlapping with antiviral treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After the end of treatment, 67 percent of treated patients had a sustained virologic response (defined as negative HCV RNA for at least six months) after follow-up of 17 months. Five of the responders cleared cryoglobulin completely, compared to none in the non-responders or controls. Among responders, purpura and proteinuria improved, but kidney function, polyarthralgia, and polyneuropathy did not.",
"   </p>",
"   <p>",
"    It was not reported whether anemia was more likely among those with decreased kidney function nor whether reduction in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    dose was related to non-response. It is also not clear whether resolution of proteinuria and other manifestations was associated with plasmapheresis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antiviral treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose disease manifestations are not controlled by, or are not appropriate for, interferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    may be candidates for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . Use of the anti-CD20 chimeric monoclonal antibody (rituximab) that depletes B cells was promising in two preliminary observational studies in 10 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More recently, five HCV-positive renal transplant patients, who developed renal function impairment, de novo nephrotic syndrome and severe hypertension related to type III cryoglobulinemic MPGN, were successfully treated by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Unlike",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , rituximab therapy was not associated with a flare of chronic HCV infection in seven kidney-transplant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/64\">",
"     64",
"    </a>",
"    ]. However, this resulted in severe infectious complications in one patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hence, if administered,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    should be given with caution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Acute severe disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral therapy should be delayed for two to four months in patients with severe acute disease (renal failure due to rapidly progressive crescentic glomerulonephritis, neurologic involvement), particularly those with mixed cryoglobulinemia, while they undergo more aggressive therapy.",
"   </p>",
"   <p>",
"    In this setting, patients are initially treated with plasmapheresis (to remove the circulating cryoglobulins), corticosteroids (1000 mg of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    daily times three, followed by oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ), and either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to prevent new antibody formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/52/36682?source=see_link\">",
"     \"Treatment of the mixed cryoglobulinemia syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At present,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is frequently used in this setting because it is better tolerated and, unlike",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , does not seem to enhance HCV replication.",
"   </p>",
"   <p>",
"    Although there are no controlled studies, observational data suggest that this regimen leads to a reduction in the plasma creatinine concentration in 55 to 87 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/23,67\">",
"     23,67",
"    </a>",
"    ]. Renal function can usually be stabilized, although death from active vasculitis remains a major problem in patients with mixed cryoglobulinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     KDIGO recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for hepatitis C in chronic kidney disease were published in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. The guidelines suggest that patients with HCV-associated glomerular disease be considered for treatment with antiviral therapy. The suggested regimen depends upon the estimated glomerular filtration rate (eGFR).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For eGFR &gt;50",
"      <span class=\"nowrap\">",
"       mL/min/1.73",
"      </span>",
"      m2, pegylated interferon and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"     </li>",
"     <li>",
"      For eGFR 15 to &lt;50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2, monotherapy with pegylated interferon",
"     </li>",
"     <li>",
"      For eGFR less than 15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 (including patients on hemodialysis); monotherapy with standard interferon that is dose adjusted for a glomerular filtration rate less than 15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antiviral treatment is recommended for at least 12 months. Patients who relapse following monotherapy should be considered for treatment with pegylated interferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , providing creatinine clearance is greater than 50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p>",
"    Additional KDIGO recommendations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among MPGN patients with nephrotic-range proteinuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rapid loss of kidney function and an acute flare of cryoglobulinemia, one of the following therapies should be considered: plasma exchange (3 liters of plasma thrice weekly for two to three weeks);",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (375",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per week for four weeks); or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for two to four months) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      pulses (0.5 to 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      for three days).",
"     </li>",
"     <li>",
"      Relapses of systemic cryoglobulinemia and membranoproliferative glomerulonephropathy may be treated with additional doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Those with HCV-associated glomerular disease should be treated with angiotensin converting enzyme inhibitors or angiotensin receptor blockers to reduce proteinuria and achieve target blood pressure goals. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     COMORBID CONDITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Human immunodeficiency virus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are coinfected with human immunodeficiency virus (HIV) and HCV may be at increased risk for HIV and HCV disease progression, including renal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A paucity of data exists concerning the renal manifestations of coinfection with these two viruses. One study assessed the clinical-pathologic features of HCV-associated glomerular disease in 14 patients infected with HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/70\">",
"     70",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A wide range of renal manifestations were observed, including hematuria with an active urinary sediment, nephrotic range proteinuria (with or without hypercholesterolemia), renal insufficiency, and hypertension.",
"     </li>",
"     <li>",
"      46 and 33 percent of patients were hypocomplementemic and positive for cryoglobulins, respectively.",
"     </li>",
"     <li>",
"      On renal biopsy, MPGN and membranous glomerulopathy with atypical features (including collapsing focal segmental glomerulosclerosis; diffuse mesangial proliferation and mesangial deposits; and segmental endocapillary proliferative and exudative glomerulonephritis) were observed in 79 and 21 percent, respectively. One patient had pathologic features of both viral processes.",
"     </li>",
"     <li>",
"      The outcome was dismal, with a median time to dialysis or death of approximately six months. The administration of interferon alfa to three patients was not beneficial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that the ability to distinguish HIV-associated nephropathy from HCV-related disease is extremely difficult without a renal biopsy.",
"   </p>",
"   <p>",
"    The optimal treatment of these patients is unknown. As previously mentioned, interferon alfa in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is the current treatment of choice for chronic HCV infection. The experience with these drugs in patients coinfected with HIV is relatively limited. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diabetic nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis C virus infection may adversely affect the renal prognosis of patients with renal disease not due to HCV infection. As an example, among those with diabetic nephropathy (as determined by renal biopsy), individuals infected with HCV have a faster decline in renal function compared to those not infected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37353/abstract/71\">",
"     71",
"    </a>",
"    ]. The mechanism underlying this observation and whether this adverse effect extends to renal diseases other than diabetic nephropathy are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic hepatitis C virus (HCV) infection has been causally linked to mixed cryoglobulinemia. HCV infection may also be associated with idiopathic membranoproliferative glomerulonephritis (MPGN), membranous nephropathy and other glomerular lesions, though these associations remain unproven. We suggest that all patients with mixed cryoglobulinemia, MPGN type I, and membranous nephropathy be evaluated serologically for underlying HCV infection. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Mixed (IgG/IgM) cryoglobulinemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many HCV patients have clinically inapparent glomerular disease by biopsy (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinically silent glomerular disease'",
"      </a>",
"      above). HCV-infected patients should be screened for proteinuria, hematuria, hypertension, and renal function, as well as for cryoglobulinemia, complement, and rheumatoid factors. A kidney biopsy should be considered in the setting of significant proteinuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      impaired renal function.",
"     </li>",
"     <li>",
"      Patients with HCV-associated glomerular disease should be treated with angiotensin converting enzyme inhibitors or angiotensin receptor blockers to reduce proteinuria and achieve target blood pressure goals. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'KDIGO recommendations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that patients with HCV and MPGN with or without cryoglobulinemia be considered for anti-HCV therapy. The specific antiviral therapy varies based upon the estimated glomerular filtration rate (GFR):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among patients with normal or near-normal renal function (estimated GFR &gt;50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2), we suggest interferon alfa, preferably pegylated interferon, plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with an estimated GFR between 15 and &lt;50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.72 m2, we suggest monotherapy with pegylated interferon.",
"     </li>",
"     <li>",
"      Among patients with an estimated GFR &lt;15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 (including patients on hemodialysis), we suggest monotherapy with standard interferon that is dose adjusted for a glomerular filtration rate less than 15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pegylated interferon should NOT be used in patients with an estimated GFR less than 15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=see_link\">",
"       \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       Ribavirin",
"      </a>",
"      should NOT be used in patients with an estimated GFR less than 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Interferon alfa plus ribavirin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that treatment with pegylated interferon for at least 12 months be considered for patients who respond to interferon within the first 12 weeks of therapy.",
"     </li>",
"     <li>",
"      Antiviral therapy should be delayed for two to four months in patients with severe acute disease, while they undergo more aggressive therapy. In this setting, patients are initially treated with plasmapheresis, corticosteroids, and either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      to prevent new antibody formation. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Acute severe disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/1\">",
"      Sabry AA, Sobh MA, Irving WL, et al. A comprehensive study of the association between hepatitis C virus and glomerulopathy. Nephrol Dial Transplant 2002; 17:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/2\">",
"      Sumida K, Ubara Y, Hoshino J, et al. Hepatitis C virus-related kidney disease: various histological patterns. Clin Nephrol 2010; 74:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/3\">",
"      Johnson RJ, Willson R, Yamabe H, et al. Renal manifestations of hepatitis C virus infection. Kidney Int 1994; 46:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/4\">",
"      Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/5\">",
"      Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/6\">",
"      Sansonno D, Gesualdo L, Manno C, et al. Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology 1997; 25:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/7\">",
"      Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/8\">",
"      Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med 1999; 106:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/9\">",
"      Beddhu S, Bastacky S, Johnson JP. The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore) 2002; 81:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/10\">",
"      Cosio FG, Roche Z, Agarwal A, et al. Prevalence of hepatitis C in patients with idiopathic glomerulopathies in native and transplant kidneys. Am J Kidney Dis 1996; 28:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/11\">",
"      Altraif IH, Abdulla AS, al Sebayel MI, et al. Hepatitis C associated glomerulonephritis. Am J Nephrol 1995; 15:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/12\">",
"      Stehman-Breen C, Alpers CE, Fleet WP, Johnson RJ. Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. Nephron 1999; 81:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/13\">",
"      Morales, J, Morales, E, Andr&egrave;s, A, Praga, M. Glomerulonephritis associated with hepatitis C virus infection. Curr Opin Nephrol Hypertens 1999; 8:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/14\">",
"      Horikoshi S, Okada T, Shirato I, et al. Diffuse proliferative glomerulonephritis with hepatitis C virus-like particles in paramesangial dense deposits in a patient with chronic hepatitis C virus hepatitis. Nephron 1993; 64:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/15\">",
"      Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994; 46:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/16\">",
"      Coroneos E, Truong L, Olivero J. Fibrillary glomerulonephritis associated with hepatitis C viral infection. Am J Kidney Dis 1997; 29:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/17\">",
"      Markowitz GS, Cheng JT, Colvin RB, et al. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol 1998; 9:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/18\">",
"      Radhakrishnan J, Uppot RN, Colvin RB. Case records of the Massachusetts General Hospital. Case 5-2010. A 51-year-old man with HIV infection, proteinuria, and edema. N Engl J Med 2010; 362:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/19\">",
"      McGuire BM, Julian BA, Bynon JS Jr, et al. Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 2006; 144:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/20\">",
"      Arase Y, Ikeda K, Murashima N, et al. Glomerulonephritis in autopsy cases with hepatitis C virus infection. Intern Med 1998; 37:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/21\">",
"      Gallay BJ, Alpers CE, Davis CL, et al. Glomerulonephritis in renal allografts associated with hepatitis C infection: a possible relationship with transplant glomerulopathy in two cases. Am J Kidney Dis 1995; 26:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/22\">",
"      Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol 2009; 4:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/23\">",
"      D'Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998; 54:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/24\">",
"      Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/25\">",
"      Kamar N, Izopet J, Alric L, et al. Hepatitis C virus-related kidney disease: an overview. Clin Nephrol 2008; 69:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/26\">",
"      Cao Y, Zhang Y, Wang S, Zou W. Detection of the hepatitis C virus antigen in kidney tissue from infected patients with various glomerulonephritis. Nephrol Dial Transplant 2009; 24:2745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/27\">",
"      Rostoker G, Deforges L, Ben Maadi A, et al. Low prevalence of antibodies to hepatitis C virus among adult patients with idiopathic membranoproliferative type I glomerulonephritis in France. Nephron 1995; 69:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/28\">",
"      Yamabe H, Johnson RJ, Gretch DR, et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol 1995; 6:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/29\">",
"      Madala ND, Naicker S, Singh B, et al. The pathogenesis of membranoproliferative glomerulonephritis in KwaZulu-Natal, South Africa is unrelated to hepatitis C virus infection. Clin Nephrol 2003; 60:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/30\">",
"      Stehman-Breen C, Alpers CE, Couser WG, et al. Hepatitis C virus associated membranous glomerulonephritis. Clin Nephrol 1995; 44:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/31\">",
"      Uchiyama-Tanaka Y, Mori Y, Kishimoto N, et al. Membranous glomerulonephritis associated with hepatitis C virus infection: case report and literature review. Clin Nephrol 2004; 61:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/32\">",
"      Morales JM, Pascual-Capdevila J, Campistol JM, et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation 1997; 63:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/33\">",
"      Cacoub P, Lunel-Fabiani F, Du LT. Polyarteritis nodosa and hepatitis C virus infection. Ann Intern Med 1992; 116:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/34\">",
"      Ramos-Casals M, Mu&ntilde;oz S, Medina F, et al. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 2009; 36:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/35\">",
"      Beuthien W, Mellinghoff HU, Kempis Jv. Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature. Clin Rheumatol 2005; 24:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/36\">",
"      Saadoun D, Terrier B, Semoun O, et al. Hepatitis C virus-associated polyarteritis nodosa. Arthritis Care Res (Hoboken) 2011; 63:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/37\">",
"      Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/38\">",
"      Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995; 332:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/39\">",
"      Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/40\">",
"      Casato M, Agnello V, Pucillo LP, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997; 90:3865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/41\">",
"      Sarac E, Bastacky S, Johnson JP. Response to high-dose interferon-alpha after failure of standard therapy in MPGN associated with hepatitis C virus infection. Am J Kidney Dis 1997; 30:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/42\">",
"      Ohta S, Yokoyama H, Wada T, et al. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis 1999; 33:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/43\">",
"      Traynor A, Kuzel T, Samuelson E, Kanwar Y. Minimal-change glomerulopathy and glomerular visceral epithelial hyperplasia associated with alpha-interferon therapy for cutaneous T-cell lymphoma. Nephron 1994; 67:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/44\">",
"      Al-Wakeel J, Mitwalli A, Tarif N, et al. Role of interferon-alpha in the treatment of primary glomerulonephritis. Am J Kidney Dis 1999; 33:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/45\">",
"      Cattran DC. Interferon therapy: a double-edged sword? Am J Kidney Dis 1999; 33:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/46\">",
"      Martin, P, Mitra, S, Farrington, K, et al. Pegylated (40 KD) interferon alpha-2a (Pegasys) is unaffected by renal impairment (abstract). Hepatology 2000; 32:370A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/47\">",
"      Kokoglu OF, U&ccedil;mak H, Hosoglu S, et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 2006; 21:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/48\">",
"      Rendina M, Schena A, Castellaneta NM, et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007; 46:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/49\">",
"      Misiani R, Bellavita P, Baio P, et al. Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin. Nephrol Dial Transplant 1999; 14:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/50\">",
"      Zuckerman E, Keren D, Slobodin G, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000; 27:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/51\">",
"      Jefferson JA, Johnson RJ. Treatment of hepatitis C-associated glomerular disease. Semin Nephrol 2000; 20:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/52\">",
"      Loustaud-Ratti V, Liozon E, Karaaslan H, et al. Interferon alpha and ribavirin for membranoproliferative glomerulonephritis and hepatitis C infection. Am J Med 2002; 113:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/53\">",
"      Bruchfeld A, Lindahl K, St&aring;hle L, et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/54\">",
"      Alric L, Plaisier E, Th&eacute;bault S, et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004; 43:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/55\">",
"      Kamar N, Boulestin A, Selves J, et al. Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C. J Med Virol 2005; 76:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/56\">",
"      Lindahl K, Schvarcz R, Bruchfeld A, St&aring;hle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 2004; 11:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/57\">",
"      Kamar N, Chatelut E, Manolis E, et al. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis 2004; 43:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/58\">",
"      Bruchfeld A, Lindahl K, Schvarcz R, St&aring;hle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002; 24:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/59\">",
"      Lin CC, Philips L, Xu C, Yeh LT. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J Clin Pharmacol 2004; 44:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/60\">",
"      Zaja F, De Vita S, Russo D, et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum 2002; 46:2252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/61\">",
"      Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004; 19:3054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/62\">",
"      Basse G, Ribes D, Kamar N, et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005; 80:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/63\">",
"      Basse G, Ribes D, Kamar N, et al. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 2006; 38:2308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/64\">",
"      Kamar N, Sandres-Saun&eacute; K, Rostaing L. Influence of rituximab therapy on hepatitis C virus RNA concentration in kidney-transplant patients. Am J Transplant 2007; 7:2440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/65\">",
"      Basse G, Ribes D, Kamar N, et al. Life-threatening infections following rituximab therapy in renal transplant patients with mixed cryoglobulinemia. Clin Nephrol 2006; 66:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/66\">",
"      Kamar N, Rostaing L, Alric L. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int 2006; 69:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/67\">",
"      Madore F, Lazarus JM, Brady HR. Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol 1996; 7:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/68\">",
"      Kidney Disease Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitits C in chronic kidney disease. Kidney Int 2008; 73(Suppl 109):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/69\">",
"      Covic A, Abramowicz D, Bruchfeld A, et al. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. Nephrol Dial Transplant 2009; 24:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/70\">",
"      Cheng JT, Anderson HL Jr, Markowitz GS, et al. Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection. J Am Soc Nephrol 1999; 10:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37353/abstract/71\">",
"      Soma J, Saito T, Taguma Y, et al. High prevalence and adverse effect of hepatitis C virus infection in type II diabetic-related nephropathy. J Am Soc Nephrol 2000; 11:690.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3065 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-094BD8D684-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_30_37353=[""].join("\n");
var outline_f36_30_37353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MIXED (IgG/IgM) CRYOGLOBULINEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MEMBRANOUS NEPHROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      POLYARTERITIS NODOSA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICALLY SILENT GLOMERULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Indications for antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Interferon alfa alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pegylated interferon and renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Interferon alfa plus ribavirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Acute severe disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      KDIGO recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      COMORBID CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Human immunodeficiency virus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=related_link\">",
"      Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28184?source=related_link\">",
"      Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44488?source=related_link\">",
"      Renal disease associated with hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=related_link\">",
"      Renal disease associated with hepatitis C virus after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/52/36682?source=related_link\">",
"      Treatment of the mixed cryoglobulinemia syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_30_37354="Chronic asthma in children younger than 12 years: Controller medications";
var content_f36_30_37354=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic asthma in children younger than 12 years: Controller medications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/30/37354/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37354/contributors\">",
"     Gregory Sawicki, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37354/contributors\">",
"     Kenan Haver, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/30/37354/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37354/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37354/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/30/37354/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/30/37354/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/30/37354/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of long-term controller medications in the treatment of chronic asthma in children younger than 12 years of age will be reviewed here. The recommendations that follow are based upon National Asthma Education and Prevention Program (NAEPP) Expert panel guidelines published in 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of children with asthma, an overview of asthma management, trigger control, quick-relief medications in children younger than 12 years, the management of acute asthma exacerbations in children, and the management of asthma in adolescents and adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26010?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/9/44184?source=see_link\">",
"     \"Trigger control to enhance asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39670?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Quick-relief agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33034?source=see_link\">",
"     \"Acute asthma exacerbations in children: Outpatient management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/23/11642?source=see_link\">",
"     \"Acute asthma exacerbations in children: Inpatient management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18154?source=see_link\">",
"     \"Treatment of intermittent and mild persistent asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26745?source=see_link\">",
"     \"Treatment of moderate persistent asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR CONTROLLER MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Asthma Education and Prevention Program (NAEPP) Expert panel guidelines provide recommendations for the management of chronic childhood asthma in children aged 0 to 4 years and 5 to 11 years (",
"    <a class=\"graphic graphic_table graphicRef80908 graphicRef71181 \" href=\"mobipreview.htm?28/58/29614\">",
"     table 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"     figure 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78322 graphicRef64986 \" href=\"mobipreview.htm?29/50/30510\">",
"     table 2A-B",
"    </a>",
"    ). Their recommendations for the management of asthma in adolescents and adults are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18154?source=see_link\">",
"     \"Treatment of intermittent and mild persistent asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26745?source=see_link\">",
"     \"Treatment of moderate persistent asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Controller medications for children younger than 12 years of age include inhaled glucocorticoids (also called inhaled corticosteroids or ICS) (",
"    <a class=\"graphic graphic_table graphicRef68517 \" href=\"mobipreview.htm?26/18/26925\">",
"     table 3",
"    </a>",
"    ), leukotriene receptor antagonists (LTRA), chromones, sustained release",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/49/24344?source=see_link\">",
"     theophylline",
"    </a>",
"    , long-acting beta agonists (LABA) in combination with inhaled glucocorticoids, and systemic glucocorticoids (",
"    <a class=\"graphic graphic_table graphicRef57761 \" href=\"mobipreview.htm?2/45/2782\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the NAEPP recommendations for the initiation of controller medications for all children ages 5 to 11 years who have persistent asthma defined by symptom frequency, short-acting beta agonist use, impairment of normal activity, and risk for development of future exacerbations (",
"    <a class=\"graphic graphic_table graphicRef71181 \" href=\"mobipreview.htm?26/62/27629\">",
"     table 1B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initiation of controller medication for children ages zero to four years is based upon the severity of symptoms and exacerbations, the frequency of exacerbations, and the risk of development of subsequent asthma (",
"    <a class=\"graphic graphic_table graphicRef80908 \" href=\"mobipreview.htm?9/40/9869\">",
"     table 1A",
"    </a>",
"    ). We recommend the initiation of controller therapy for children at high risk of developing persistent asthma. This group includes those who have had &ge;4 episodes of wheezing in the past year that lasted more than one day and either [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the following &mdash; Parental history of asthma, clinician diagnosis of atopic dermatitis, evidence of sensitization to aeroallergens",
"      <br/>",
"      <br/>",
"      or",
"     </li>",
"     <li>",
"      Two of the following &mdash; Evidence of sensitization to foods, &ge;4 percent peripheral blood eosinophilia, wheezing apart from colds",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We also suggest the initiation of controller medications for the following children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those aged zero to four years who consistently require quick-relief medications more than two days per week for a period of more than four weeks",
"     </li>",
"     <li>",
"      Infants and young children experiencing severe exacerbations less than six weeks apart or those who have two or more exacerbations requiring systemic glucocorticoids within six months",
"     </li>",
"     <li>",
"      Children with intermittent disease who experience severe exacerbations, especially during periods when they are likely to be exposed to known triggers, such as seasonal pollens or respiratory viruses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dosing adjustment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with controller medications may be escalated at any time, although two- to six-week intervals are usually necessary to adequately assess the response to a given intervention (",
"    <a class=\"graphic graphic_table graphicRef78322 graphicRef64986 \" href=\"mobipreview.htm?29/50/30510\">",
"     table 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"     figure 1A-B",
"    </a>",
"    ). Options for step-up therapy include increasing the dose of inhaled glucocorticoid, adding a long-acting beta agonist (LABA), or adding a leukotriene receptor antagonist (LTRA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/5\">",
"     5",
"    </a>",
"    ]. Potential issues with long-term use of LABAs should be considered and the black box warning on the package insert should be discussed with patients and their families when choosing step-up therapy. These concerns are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/19/16698?source=see_link\">",
"     \"Beta agonists in asthma: Controversy regarding chronic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adherence with the current regimen should be assessed before escalating therapy. Potentially modifiable factors associated with underuse of controller medications include absence of a consistent routine for administration of medications, poor technique administering medications, poor parental understanding and assessment of asthma control, and parental concerns about the medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When asthma control has been achieved for two to six months, attempts should be made to reduce the regimen at one- to two-month intervals as tolerated. Acute exacerbations of asthma demand more intensive management at any time, including the addition of oral glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39670?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Quick-relief agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33034?source=see_link\">",
"     \"Acute asthma exacerbations in children: Outpatient management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INHALED GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are the most potent antiinflammatory agents available for the treatment of asthma. They act by inhibiting most steps in the cascade of the inflammatory response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The benefits of glucocorticoids include reduced bronchial hyperresponsiveness, prevention of the late asthmatic response, and enhanced lung function.",
"   </p>",
"   <p>",
"    Inhaled glucocorticoid treatment is associated with reduction in measures associated with impairment (symptom frequency and severity, functional limitations) and risk (side effects from medications, irreversible decline in lung function, likelihood of asthma exacerbations) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Improvements in these parameters are generally greater than changes seen with leukotriene receptor antagonists (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"     montelukast",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We suggest inhaled glucocorticoids as the first-line controller therapy for children with persistent asthma or those who require Step 2 therapy (",
"    <a class=\"graphic graphic_table graphicRef80908 graphicRef71181 \" href=\"mobipreview.htm?28/58/29614\">",
"     table 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"     figure 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68517 \" href=\"mobipreview.htm?26/18/26925\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/1,13,14\">",
"     1,13,14",
"    </a>",
"    ]. Inhaled glucocorticoids can be delivered directly to the airways at a fraction of the dose used systemically, with minimal side effects. Furthermore, much of the small amount of drug that is absorbed at low doses is deactivated after one pass through the liver.",
"   </p>",
"   <p>",
"    It is essential to provide adequate instruction to the child's caregivers regarding proper use of the medication delivery system(s) that has been prescribed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30376?source=see_link\">",
"     \"Use of medication nebulizers in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36760?source=see_link\">",
"     \"The use of inhaler devices in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If asthma control is not achieved with the use of inhaled glucocorticoids alone, step-up therapy is recommended, either by increasing the dose of inhaled glucocorticoids, or by adding another medication, such as a LABA or LTRA (",
"    <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"     figure 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57761 \" href=\"mobipreview.htm?2/45/2782\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, there are controversial data pertaining to the guideline recommendations. In one meta-analysis, there was little dose-response in children aged 4 to 18 years with mild to severe asthma receiving &lt;200",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/40/35456?source=see_link\">",
"     beclomethasone",
"    </a>",
"    -equivalent compared with doses of 300 to 400",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/15\">",
"     15",
"    </a>",
"    ]. Outcomes measured were beta agonist use, daily symptom score, and spirometry indices of airway obstruction. In another meta-analysis, there was no difference in the frequency of oral glucocorticoid treatment for asthma exacerbations among children aged 4 to 17 years with mild to severe asthma taking a combined inhaled glucocorticoid and long-acting beta agonist treatment (200 to 400",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    beclomethasone-equivalent) and those on twice the daily dose of inhaled glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/5\">",
"     5",
"    </a>",
"    ]. However, this same study showed improved peak expiratory flow rates, lower rescue medication use, and better short-term growth rates in children taking lower dose inhaled glucocorticoids in combination with the long-acting beta agonist agent than those on the higher dose of inhaled glucocorticoids alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Specific preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inhaled glucocorticoid preparations currently available in the United States and approved by the Food and Drug Administration (FDA) for use in children younger than 12 years include (",
"    <a class=\"graphic graphic_table graphicRef68517 \" href=\"mobipreview.htm?26/18/26925\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"       Budesonide",
"      </a>",
"      &mdash; via nebulizer for children &ge;12 months, via dry-powder inhaler (DPI) for children &ge;6 years",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/63/37872?source=see_link\">",
"       Fluticasone",
"      </a>",
"      &mdash; via metered-dose inhaler (MDI) and DPI for children &ge;4 years",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/40/35456?source=see_link\">",
"       Beclomethasone",
"      </a>",
"      &mdash; via hydrofluoroalkane-MDI for children &ge;5 years",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33392?source=see_link\">",
"       Flunisolide",
"      </a>",
"      &mdash; via MDI for children &ge;6 years (has not been available since June 30, 2011 due to phase out of MDIs containing chlorofluorocarbons; HFA version slated to launch in the US market in 2013)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/57/36752?source=see_link\">",
"       Mometasone",
"      </a>",
"      &mdash; via DPI for children 4 to 11 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/43/21169?source=see_link\">",
"     Ciclesonide",
"    </a>",
"    is only approved for children &ge;12 years of age in the United States, but is approved for use in younger children in other countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     For children &lt;4 years",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children younger than four years of age, the only FDA-approved inhaled glucocorticoid is the nebulized form of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    . In addition, off-label use of inhaled",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/40/35456?source=see_link\">",
"     beclomethasone",
"    </a>",
"    or inhaled",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/63/37872?source=see_link\">",
"     fluticasone",
"    </a>",
"    administered by MDI with spacer device (most will need a facemask) are reasonable alternatives for young children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"       Budesonide",
"      </a>",
"      &mdash; Budesonide is an esterified glucocorticoid and has demonstrated efficacy in prophylaxis against recurrent wheezing attacks even in very young infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/19-24\">",
"       19-24",
"      </a>",
"      ]. Of the inhaled glucocorticoids, budesonide is reputed to be more active topically, but less systemically potent than other inhaled glucocorticoids.",
"      <br/>",
"      <br/>",
"      The efficacy of budesonide compared with other antiinflammatory agents in the treatment of asthma was demonstrated in the Childhood Asthma Management Program (CAMP) study, a large, multicenter, prospective, randomized, controlled trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/25\">",
"       25",
"      </a>",
"      ]. Children with mild to moderate asthma received budesonide (200 mcg twice daily),",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/37/23122?source=see_link\">",
"       nedocromil",
"      </a>",
"      , or placebo. Data from the initial six years of the study demonstrated improved asthma symptom control in patients receiving budesonide [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Budesonide is available as a nebulizer solution for children as young as 12 months. The nebulizable formulation of budesonide must be administered through a jet nebulizer and should not be allowed to spray up into the patient's eyes because of concerns about risk of developing cataracts due to topical exposure. The US Food and Drug Administration recommends that budesonide not be mixed with other drugs, a limitation that may necessitate multiple nebulization treatments per day for children also receiving inhaled beta agonists. However, nebulized budesonide and beta agonists are often combined in practice. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30376?source=see_link&amp;anchor=H3#H3\">",
"       \"Use of medication nebulizers in children\", section on 'Basic types of nebulizers'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/63/37872?source=see_link\">",
"       Fluticasone",
"      </a>",
"      &mdash; Fluticasone is another inhaled glucocorticoid that is useful in children with chronic asthma. Fluticasone has an excellent safety profile and demonstrated efficacy in children of all ages. In an open-label controlled trial of children (ages one to three years) with recurrent wheezing, 635 children were randomly assigned to receive fluticasone (100 mcg twice per day) or cromolyn via MDI and spacer device for 52 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/26\">",
"       26",
"      </a>",
"      ]. Compared with those treated with cromolyn, children in the fluticasone group had fewer episodes of severe exacerbation (7 versus 16 percent) and requirements for oral glucocorticoid treatment (6 versus 12 percent), as well as more symptom-free days (OR 0.5, 95% CI 0.3-0.7) and days without use of rescue treatment (OR 0.6, 95% CI 0.3-0.9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Potency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inhaled glucocorticoid preparations currently available in the United States have a range of potencies (",
"    <a class=\"graphic graphic_table graphicRef68517 \" href=\"mobipreview.htm?26/18/26925\">",
"     table 3",
"    </a>",
"    ). It should be noted that potency simply refers to the dose required to achieve the same clinical effect.",
"   </p>",
"   <p>",
"    Information about the bioequivalence of inhaled versus oral glucocorticoids is limited to studies performed with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    . One report found that 2000 mcg per day of budesonide (equivalent to 10 inhalations of the dry-powder inhaler) provided the same control of asthma symptoms as 40 mg per day of prednisone. However, adrenal suppression equivalent to that produced by 15 mg of prednisone was demonstrated with approximately 1800 mcg of budesonide, indicating significant systemic toxicity at this dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/27\">",
"     27",
"    </a>",
"    ]. Rough equivalences among inhaled glucocorticoids at various doses, based on the amount of prednisone spared, have been reviewed elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/28\">",
"     28",
"    </a>",
"    ]. A sizable knowledge gap remains in this area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial dosing of inhaled glucocorticoids depends upon the severity of asthma symptoms at the time treatment is initiated (",
"    <a class=\"graphic graphic_table graphicRef80908 graphicRef71181 \" href=\"mobipreview.htm?28/58/29614\">",
"     table 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"     figure 1A-B",
"    </a>",
"    ). Low, medium, and high doses for each of the available preparations have been defined (",
"    <a class=\"graphic graphic_table graphicRef68517 \" href=\"mobipreview.htm?26/18/26925\">",
"     table 3",
"    </a>",
"    ). The dose is then stepped up or down at one- to six-month intervals, depending upon clinical response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Delivery devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mode of delivery for inhaled glucocorticoids greatly influences drug deposition in the lungs and the frequency of local and systemic side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Delivery systems include metered-dose inhalers (with or without spacers), nebulizers, and dry-powder inhalers. These delivery systems are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31014?source=see_link\">",
"     \"Delivery of inhaled medication in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30376?source=see_link\">",
"     \"Use of medication nebulizers in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36760?source=see_link\">",
"     \"The use of inhaler devices in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of inhaled glucocorticoids appear to be rare and are dose related; they are reviewed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=see_link\">",
"     \"Major side effects of inhaled glucocorticoids\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    To minimize the risk of adverse effects of inhaled glucocorticoids in children, we recommend the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Step down treatment to the lowest possible dose of inhaled glucocorticoids that maintains symptom control (",
"      <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"       figure 1A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef78322 graphicRef64986 \" href=\"mobipreview.htm?29/50/30510\">",
"       table 2A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increase the medication frequency while decreasing the daily dose",
"     </li>",
"     <li>",
"      Optimize adherence",
"     </li>",
"     <li>",
"      Optimize delivery (use spacer device [with facemask for younger children] with MDIs)",
"     </li>",
"     <li>",
"      Evaluate and treat for complicating features of asthma",
"     </li>",
"     <li>",
"      Maximize nonpharmacologic treatment (eg, trigger avoidance)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Impact on disease progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important question in the management of childhood asthma is whether early or sustained use of inhaled glucocorticoids after the development of asthma symptoms can alter the natural progression of the disease. A small number of studies have addressed this question [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/2,25,32-35\">",
"     2,25,32-35",
"    </a>",
"    ]. These studies enrolled young children who were defined as \"at risk\" for asthma development and assessed whether the use of inhaled glucocorticoids altered later clinical outcomes. The three studies described below suggest that the early use of inhaled glucocorticoids does not impact the subsequent development of asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/2,32,33\">",
"     2,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first, 285 children, two to three years old, with a history of &ge;4 wheezing episodes were randomly assigned to inhaled",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/63/37872?source=see_link\">",
"       fluticasone",
"      </a>",
"      (88 mcg twice daily) or placebo for two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/2\">",
"       2",
"      </a>",
"      ]. Children in both groups received reliever medications as needed. They were monitored during the two years of therapy and for one year after, during which they received no study medication. During treatment, the fluticasone group had fewer symptoms and exacerbations. However, there were no significant differences in symptom-free days or asthma exacerbations between the two groups during the third observational year, suggesting that inhaled glucocorticoid use had no long-term disease-modifying effects.",
"     </li>",
"     <li>",
"      In a second study, 411 infants in the first three years of life received either inhaled glucocorticoids or placebo if they wheezed for three consecutive days, which was continued for two weeks after each episode of symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/32\">",
"       32",
"      </a>",
"      ]. This early, intermittent intervention had no effect on the progression from episodic to persistent wheezing by the third year of life.",
"     </li>",
"     <li>",
"      In the third study, 200 children (median age one to two years) received either inhaled",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/63/37872?source=see_link\">",
"       fluticasone",
"      </a>",
"      , 100 mcg twice daily, or placebo after one prolonged (&gt;1 month) or two brief, medically documented episodes of wheezing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/33\">",
"       33",
"      </a>",
"      ]. The dose was reduced every three months to the lowest level that controlled symptoms, and those who remained symptomatic during the study were given open-label inhaled glucocorticoids. There were no differences between the groups at five years of age, including lung function, clinician diagnosis of asthma, current wheeze, or current use of asthma medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar to the study findings in infants, a study of older children showed that the effects of long-term daily treatment with inhaled glucocorticoids on asthma control and lung function do not appear to persist once these medications are discontinued:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the CAMP study, children ages 5 to 12 years with mild to moderate asthma enrolled in the initial randomized trial were treated for four to six years with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"       budesonide",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/37/23122?source=see_link\">",
"       nedocromil",
"      </a>",
"      , or placebo. In an observational extension of the study, these children were followed for an additional five years after the controller study phase was completed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/36\">",
"       36",
"      </a>",
"      ]. Asthma management during this observational period was directed by each child's primary care clinician, and the average percentage of time using no medication for asthma control was less than 50 percent. No differences were seen between either treatment group and placebo with regard to lung function, asthma control, and airway responsiveness during the observational period, suggesting that maintaining the benefit of inhaled glucocorticoids on asthma control requires continued use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these studies suggest that, although inhaled glucocorticoids do play a role in the chronic management of infants with wheezing and children with asthma, consistent use in childhood does not appear to alter the natural history of asthma once medication is discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/13/7383?source=see_link\">",
"     \"Natural history of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Intermittent preventive use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma treatment guidelines recommend the daily use of inhaled glucocorticoids as first-line controller therapy for all children with persistent asthma (",
"    <a class=\"graphic graphic_table graphicRef80908 graphicRef71181 \" href=\"mobipreview.htm?28/58/29614\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/1\">",
"     1",
"    </a>",
"    ]. However, many parents and patients, particularly those with milder baseline disease, are using inhaled glucocorticoids only intermittently, either at the onset of an upper respiratory infection (URI) or at the onset of lower respiratory symptoms. Additionally, many clinicians are recommending symptom-based, intermittent therapy for patients with mild persistent asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. However, this approach remains controversial, based upon available data. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39670?source=see_link&amp;anchor=H13#H13\">",
"     \"Chronic asthma in children younger than 12 years: Quick-relief agents\", section on 'Inhaled glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are limited data from randomized trials on preventive use of intermittent inhaled glucocorticoids in children with asthma and the results are mixed, as is illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intermittent inhaled glucocorticoids (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"       budesonide",
"      </a>",
"      1 mg twice daily for seven days, started early in the course of an upper respiratory tract infection at the onset of a set of symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs individual to each child that typically preceded the onset of wheezing) were as effective as daily inhaled glucocorticoids (budesonide 0.5 mg nightly) with respect to frequency of exacerbations requiring oral glucocorticoid therapy in children aged 12 to 53 months with recurrent wheezing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/41\">",
"       41",
"      </a>",
"      ]. There were also no significant differences between the two groups in bronchodilator use, episode-free days, or severity of symptoms during respiratory tract illnesses.",
"     </li>",
"     <li>",
"      Intermittent inhaled glucocorticoids (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"       budesonide",
"      </a>",
"      400 mcg twice daily for seven days) for exacerbations were less effective than daily inhaled glucocorticoids and no different than daily disodium cromoglycate in children aged 5 to 10 years with newly diagnosed asthma (symptomatic for at least one month, but naive to controller therapy) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Symptom scores were no different than placebo in children aged 3 to 10 years with virus-induced asthma exacerbations who were treated with high dose inhaled glucocorticoids (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"       budesonide",
"      </a>",
"      400 mcg four times daily, then three times daily, then two times daily, for three days at each dosing level) at the first sign of an upper respiratory tract infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/43\">",
"       43",
"      </a>",
"      ]. Morning and evening peak flows were higher in the budesonide than placebo group.",
"     </li>",
"     <li>",
"      In a trial of children aged 5 to 18 years with well controlled, mild persistent asthma, there were significantly fewer treatment failures (defined as &ge;2 courses of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      in a six month period) in children treated with daily or rescue only inhaled glucocorticoids in addition to a rescue beta agonist compared with a rescue beta agonist alone (placebo) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/44\">",
"       44",
"      </a>",
"      ]. However, the rate of asthma exacerbations was significantly lower only in the groups on daily inhaled glucocorticoids. Linear growth was approximately 1 cm lower in the groups on daily inhaled glucocorticoids, but not the rescue glucocorticoid group, compared with placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of randomized trials published through December 2011 that examined intermittent use of inhaled glucocorticoids for persistent asthma in children and adults found that there was no significant difference between intermittent and daily inhaled glucocorticoid therapy with regard to need for rescue oral glucocorticoids or rate of serious adverse health events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/45\">",
"     45",
"    </a>",
"    ]. In addition, daily therapy was associated with slightly poorer growth in children compared with intermittent therapy. However, daily therapy was superior to intermittent therapy in several other measures, including asthma control, lung function, use of rescue beta agonists, and symptom-free days.",
"   </p>",
"   <p>",
"    Based upon these studies and meta-analysis, we cannot recommend the intermittent use of inhaled glucocorticoids as the preferred treatment of persistent asthma in children. Further studies are needed to determine whether intermittent inhaled glucocorticoids are an effective alternative to daily therapy in some patients and to define the optimal threshold at which patients should begin taking daily controller medication. Similar conclusions were reached in adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18154?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of intermittent and mild persistent asthma in adolescents and adults\", section on 'Inhaled glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of intermittent inhaled glucocorticoids in young children with recurrent virus-induced wheezing is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/44/22216?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of recurrent virus-induced wheezing in young children\", section on 'Intermittent inhaled glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LEUKOTRIENE RECEPTOR ANTAGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukotriene receptor antagonists (LTRA) are another class of controller medications. Cysteinyl leukotrienes (LTC4, LTD4, and LTE4) are potent bronchoconstrictors as well as proinflammatory and mucor-rheic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. They have been identified in plasma, nasal secretions, sputum, and bronchoalveolar lavage fluid in asthmatic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30746?source=see_link\">",
"     \"Agents affecting the 5-lipoxygenase pathway in the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three classes of leukotriene modifiers have been formulated to inhibit leukotriene production or action at various points in the cascade:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LTD4 receptor antagonists (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/22/41316?source=see_link\">",
"       zafirlukast",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"       montelukast",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      5-lipoxygenase inhibitors (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/308?source=see_link\">",
"       zileuton",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      5-lipoxygenase activating protein (FLAP) inhibitors (MK-0591)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    LTRA are suggested as adjuncts to inhaled glucocorticoids in the daily treatment of persistent asthma in children older than one year of age (",
"    <a class=\"graphic graphic_table graphicRef80908 graphicRef71181 \" href=\"mobipreview.htm?28/58/29614\">",
"     table 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"     figure 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/1\">",
"     1",
"    </a>",
"    ]. There are not enough data to recommend LTRA as first-line controller agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/50\">",
"     50",
"    </a>",
"    ] or as intermittent therapy for symptom control. However, they may be used in mild persistent asthma as an alternative to or \"step down\" therapy from inhaled glucocorticoids, particularly for patients who have difficulty with adherence or inhaler technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/51\">",
"     51",
"    </a>",
"    ]. Use of LTRAs for exercise-induced bronchoconstriction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1513?source=see_link\">",
"     \"Exercise-induced bronchoconstriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among the LTRA,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"     montelukast",
"    </a>",
"    is FDA approved for control of asthma in children &ge;12 months of age (it is approved for the treatment of rhinitis in children &ge;6 months of age) and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/22/41316?source=see_link\">",
"     zafirlukast",
"    </a>",
"    is approved for children &ge;5 years (",
"    <a class=\"graphic graphic_table graphicRef57761 \" href=\"mobipreview.htm?2/45/2782\">",
"     table 4",
"    </a>",
"    ). These drugs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30746?source=see_link\">",
"     \"Agents affecting the 5-lipoxygenase pathway in the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Compared with placebo",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"     Montelukast",
"    </a>",
"    improves asthma symptoms, decreases bronchial hyperreactivity, and decreases the use of beta agonists and systemic glucocorticoids in children aged two to five years with intermittent or persistent asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One multicenter, randomized, double-blind, parallel-group study examined children (aged two to five years) with intermittent asthma associated with viral infections and minimal asthma symptoms between exacerbations (approximately 270 children per group). Children were given",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"     montelukast",
"    </a>",
"    or placebo and followed for 12 months. Montelukast significantly reduced the rate of asthma exacerbations by 32 percent compared with placebo (from 2.3 episodes per year to 1.6) and decreased the use of inhaled glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Compared with inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies in adults and children have shown that inhaled glucocorticoids are more effective than leukotriene modifiers for most patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/13,55-60\">",
"     13,55-60",
"    </a>",
"    ]. A meta-analysis of randomized trials found that children with mild-to-moderate persistent asthma who were treated with inhaled glucocorticoids had better pulmonary function and asthma control (eg, fewer asthma exacerbations requiring systemic glucocorticoids, less",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    use, and lower symptom scores) than those treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"     montelukast",
"    </a>",
"    . In addition, one randomized trial found that",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/63/37872?source=see_link\">",
"     fluticasone",
"    </a>",
"    was more cost-effective than montelukast for treatment of mild-to-moderate persistent asthma in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two studies in children comparing",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"     montelukast",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/63/37872?source=see_link\">",
"     fluticasone",
"    </a>",
"    are described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first, 342 children (6 to 12 years of age) with persistent asthma were randomly assigned to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/63/37872?source=see_link\">",
"       fluticasone",
"      </a>",
"      (50 mcg twice daily) or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"       montelukast",
"      </a>",
"      (5 mg daily) for 12 weeks. Fluticasone significantly increased pulmonary function measurements (11 percent versus 5 percent increase) and percent of rescue-free days (45 versus 35), and reduced nighttime symptom scores. There were similar adverse events with both agents. Parent satisfaction was higher and asthma-related costs were lower with fluticasone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the second, a 12-month multicenter, non-inferiority trial in 994 children (aged 6 to 14 years) with mild persistent asthma, children treated with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"       montelukast",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/63/37872?source=see_link\">",
"       fluticasone",
"      </a>",
"      had a similar percentage of rescue-free days (84 versus 87 percent, respectively, a difference of less than one day per month) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/61\">",
"       61",
"      </a>",
"      ]. However, patients treated with fluticasone had fewer asthma attacks, defined as unscheduled health care visits for worsening asthma symptoms or treatment with systemic glucocorticoids (25 versus 32 percent), and fewer episodes requiring treatment with systemic glucocorticoids (11 versus 18 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings support the use of inhaled glucocorticoids as the first-line controller agent (",
"    <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"     figure 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Children with asthma may respond differently to inhaled glucocorticoids and LTRA, depending upon their baseline characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/56,62-64\">",
"     56,62-64",
"    </a>",
"    ]. In a double crossover study, children (age 6 to 17 years) with mild to moderate persistent asthma were treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"     montelukast",
"    </a>",
"    followed by",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/63/37872?source=see_link\">",
"     fluticasone",
"    </a>",
"    or fluticasone followed by montelukast for eight weeks each [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/56,62\">",
"     56,62",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seventeen percent of patients responded to both medications (response was defined as &ge;7.5 percent improvement in FEV1), 23 percent responded only to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/63/37872?source=see_link\">",
"       fluticasone",
"      </a>",
"      , 5 percent only to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"       montelukast",
"      </a>",
"      , and 55 percent to neither.",
"     </li>",
"     <li>",
"      Response to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/63/37872?source=see_link\">",
"       fluticasone",
"      </a>",
"      alone was associated with increased markers of allergic inflammation and decreased pulmonary function. Response to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"       montelukast",
"      </a>",
"      alone was associated with younger age and shorter duration of asthma.",
"     </li>",
"     <li>",
"      Nonresponders had higher baseline pulmonary function and decreased markers of allergic inflammation than responders, but a similar number of asthma-free days (1.2 to 1.3 per week).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results also support the recommendation for inhaled glucocorticoids as the first-line controller agent (",
"    <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"     figure 1A-B",
"    </a>",
"    ). Among patients with mild persistent asthma,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"     montelukast",
"    </a>",
"    may be associated with improved adherence compared with inhaled",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/63/37872?source=see_link\">",
"     fluticasone",
"    </a>",
"    , although this has not been the case in all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/55,65\">",
"     55,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Adjunctive therapy to inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;In randomized controlled trials in children between the ages of 6 and 14 years receiving inhaled glucocorticoids for asthma, the addition of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"     montelukast",
"    </a>",
"    improved morning FEV1 and decreased the need for rescue medication, compared with the addition of cromolyn or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/66-68\">",
"     66-68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, increasing the dose of inhaled glucocorticoids may provide better protection from exacerbations compared with the combination of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"     montelukast",
"    </a>",
"    and low-dose inhaled glucocorticoids. This was illustrated in a trial in which 71 children, aged 6 to 14 years, were randomly assigned to combined therapy with montelukast (5 mg daily) plus",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    (100 mcg twice daily) or budesonide (200 mcg twice daily) for 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/69\">",
"     69",
"    </a>",
"    ]. The two therapies resulted in similar lung function parameters and weekly asthma symptom scores, although more children in the group receiving combined therapy had acute exacerbations (33 versus 9 percent) and these exacerbations were more severe.",
"   </p>",
"   <p>",
"    Another randomized trial found that neither",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"     montelukast",
"    </a>",
"    nor",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    was more effective than placebo in allowing reduction of the dose of inhaled glucocorticoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/70\">",
"     70",
"    </a>",
"    ]. Fifty-five children aged 6 to 17 years with moderate-to-severe asthma controlled on inhaled",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/4/34885?source=see_link\">",
"     salmeterol",
"    </a>",
"    were randomly assigned to montelukast, azithromycin, or placebo, followed by sequential dose reduction of budesonide. There was no difference in time to inadequate asthma control between placebo and either treatment group or between groups. In this trial, there was a lower than expected enrollment rate and a high rate of medication nonadherence prior to randomization, so the results should be interpreted with caution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Intermittent use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent use of LTRAs to prevent or treat symptoms has been studied.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"     Montelukast",
"    </a>",
"    was not effective in preventing the seasonal increase in asthma symptoms, rescue medication use (beta agonists and oral glucocorticoids), and unanticipated health care visits when initiated at the start of the school year in a randomized trial of 1162 children aged 6 to 14 years with asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of a short-course of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"     montelukast",
"    </a>",
"    during periods of increased asthma symptoms was evaluated in a multicenter trial in which 220 children with intermittent asthma were randomly assigned to receive montelukast or placebo, initiated by the parent, at the onset of asthma or upper respiratory tract infection symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/72\">",
"     72",
"    </a>",
"    ]. Patients could receive inhaled beta agonists and oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    according to a customized asthma management plan. The study drug was continued for a minimum of seven days or until the symptoms had resolved for 48 hours.",
"   </p>",
"   <p>",
"    Intermittent use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"     montelukast",
"    </a>",
"    was associated with modest reductions in utilization of health care resources, asthma symptoms, night awakenings, school absence, and parental time off from work [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/72\">",
"     72",
"    </a>",
"    ]. However, there was no statistically significant decrease in hospitalizations, use of beta agonists, or use of systemic glucocorticoids.",
"   </p>",
"   <p>",
"    Although promising, confirmatory studies are needed before parent-initiated",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"     montelukast",
"    </a>",
"    at the onset of asthma or upper respiratory tract infection symptoms can be recommended for children with intermittent asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CHROMONES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The drugs",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/58/39840?source=see_link\">",
"     cromolyn sodium",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/37/23122?source=see_link\">",
"     nedocromil",
"    </a>",
"    are commonly grouped together as chromones (also called cromoglycates). These drugs have mast-cell stabilizing properties and appear to diminish the very early stages of an asthmatic response to external triggers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/29/471?source=see_link\">",
"     \"The use of chromones (cromoglycates) in the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chromones can be used as alternative controller medications in children with mild persistent asthma, but inhaled glucocorticoids are preferred (",
"    <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"     figure 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/1\">",
"     1",
"    </a>",
"    ]. Chromones also can be used for short-term prevention of asthma before trigger exposure or exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Four to six weeks of cromolyn therapy usually is required to produce an effect on chronic asthma symptoms. In contrast, virtually immediate protection may be noted when the drug is used prophylactically against exercise or allergen exposures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/73\">",
"     73",
"    </a>",
"    ]. The usual doses for cromolyn and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/37/23122?source=see_link\">",
"     nedocromil",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef57761 \" href=\"mobipreview.htm?2/45/2782\">",
"     table 4",
"    </a>",
"    ) can be doubled in high-exposure situations (eg, during pollen season in asthmatic children with pollen allergy), because of a dose-response effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The availability of cromoglycates varies from one country to another, due in part to the propellants used in cromoglycate inhalers. In the United States, neither cromolyn nor",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/37/23122?source=see_link\">",
"     nedocromil",
"    </a>",
"    is available in an HFA-containing metered dose inhaler. As a result, the only remaining formulations for asthma in the United States are solutions for nebulization. HFA-based and dry powder inhaler formulations for cromolyn and nedocromil are available in many other countries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/29/471?source=see_link&amp;anchor=H2#H2\">",
"     \"The use of chromones (cromoglycates) in the treatment of asthma\", section on 'Limitations on availability'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cromolyn",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cromolyn (sodium cromoglycate) is an asthma controller medication that has been in use for many years. In the United States, most formulations of cromolyn are no longer available.",
"   </p>",
"   <p>",
"    The efficacy of cromolyn as a controller medication in childhood asthma has not been conclusively demonstrated; its use in young children is largely based upon informal clinical experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/75\">",
"     75",
"    </a>",
"    ]. Although there are studies in which cromolyn compared favorably with other established therapies, a systematic review of trials of cromolyn versus placebo found no clear therapeutic effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/76-79\">",
"     76-79",
"    </a>",
"    ]. The reviewers suggested that publication bias may have contributed to the widespread impression that the efficacy of these agents had been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Compared with inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled glucocorticoids are superior to cromolyn as controller therapy for mild persistent asthma in children. A meta-analysis of 17 studies involving 1279 children concluded that treatment with inhaled glucocorticoids resulted in improved pulmonary function, fewer exacerbations (weighted mean difference of -1.2 exacerbations per year, CI -2.2 to -0.2), lower asthma symptom scores, and less bronchodilator use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fewer studies have been performed in young children. One randomized, parallel-group, open-label study compared 12 months of inhaled",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/63/37872?source=see_link\">",
"     fluticasone",
"    </a>",
"    (100 mcg twice daily) to cromolyn (5 mg four times daily) in children aged one to three years with recurrent episodes of wheezing, and also found fluticasone to be superior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nedocromil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/37/23122?source=see_link\">",
"     Nedocromil",
"    </a>",
"    sodium is another chromone with properties similar to cromolyn. It is FDA-approved for children six years and older; its role in childhood asthma management remains to be established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/81\">",
"     81",
"    </a>",
"    ]. Like cromolyn, nedocromil appears to be less effective than inhaled glucocorticoids in controlling asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/25,82-85\">",
"     25,82-85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/29/471?source=see_link&amp;anchor=H2#H2\">",
"     \"The use of chromones (cromoglycates) in the treatment of asthma\", section on 'Limitations on availability'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the Childhood Asthma Management Program (CAMP) study, children with asthma were randomly assigned to receive",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/37/23122?source=see_link\">",
"     nedocromil",
"    </a>",
"    , inhaled",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    , or placebo. Data from the first six years of the study show that inhaled budesonide provided better asthma control in terms of several outcomes, such as hospitalizations, missed school days, and use of rescue medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Chromones in addition to inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no definitive evidence to support the concurrent use of inhaled chromones and glucocorticoids in order to lower the glucocorticoid dose in patients with chronic asthma. The disadvantages of high cost and multiple daily dosing probably outweigh the unproven potential benefit and concurrent use is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     THEOPHYLLINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/49/24344?source=see_link\">",
"     Theophylline",
"    </a>",
"    is a medication with both bronchodilatory and antiinflammatory properties. It may also have steroid-sparing and immunomodulatory effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. However, the role of theophylline in the stepwise management of childhood asthma has been decreasing worldwide.",
"   </p>",
"   <p>",
"    Sustained-release",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/49/24344?source=see_link\">",
"     theophylline",
"    </a>",
"    is an alternative controller therapy for mild persistent asthma and an adjunctive therapy to inhaled glucocorticoids in children aged 5 to 11 years with moderate persistent asthma (",
"    <a class=\"graphic graphic_figure graphicRef67459 \" href=\"mobipreview.htm?1/41/1684\">",
"     figure 1B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/89\">",
"     89",
"    </a>",
"    ]. Theophylline may have particular utility in patients who are not adherent with or have technical difficulties using inhaled medications and who are unable to tolerate, or have failed to respond to, an oral leukotriene receptor antagonist.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/49/24344?source=see_link\">",
"     theophylline",
"    </a>",
"    to treat chronic childhood asthma is problematic due to potentially serious short-term side effects (eg, cardiac arrhythmias, seizures, death) and long-term adverse effects (learning and behavior disorders). A further encumbrance of theophylline is the need for frequent serum monitoring to maintain a serum concentration of 5 to 15",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    as well as vigilance regarding potential interactions with other drugs. The use of theophylline is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11161?source=see_link\">",
"     \"Theophylline use in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     LONG-ACTING BETA AGONISTS AND INHALED GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-acting inhaled beta agonists (LABA,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/4/34885?source=see_link\">",
"     salmeterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/26/11686?source=see_link\">",
"     formoterol",
"    </a>",
"    ), which have a duration of action of at least 12 hours, are used as an adjunct to inhaled glucocorticoids to provide long-term control of asthma symptoms and prevent nocturnal symptoms and exercise-induced bronchoconstriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/90-94\">",
"     90-94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LABA should NOT be used for acute exacerbations. In addition, LABA should always be used in combination with an inhaled glucocorticoid, because of safety concerns regarding the use of LABA alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/95\">",
"     95",
"    </a>",
"    ]. Pediatric patients should use a combined product that contains both an inhaled glucocorticoid and a LABA to treat the multiple mechanisms that produce airway disease. LABA should be discontinued, if possible, once asthma control is attained. Long-term use of LABA should be reserved for patients who cannot maintain control on asthma controller medications (eg, inhaled glucocorticoids, leukotriene receptor antagonists) alone. The potential safety issues surrounding long-term use of LABAs are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/19/16698?source=see_link\">",
"     \"Beta agonists in asthma: Controversy regarding chronic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monotherapy with LABA does not treat the inflammatory component of asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. Studies in adolescents and adults indicate that LABA have the potential of improving overall asthma control when added to inhaled glucocorticoids in patients who are inadequately controlled with inhaled glucocorticoids alone (",
"    <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"     figure 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57761 \" href=\"mobipreview.htm?2/45/2782\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/98-105\">",
"     98-105",
"    </a>",
"    ]. However, a review of randomized trials of combination therapy with LABA and inhaled glucocorticoids in children suggests that while the addition of LABA may improve lung function, it does not affect other measures of asthma control, such as number of exacerbations requiring treatment with oral glucocorticoids, use of short-acting beta agonists, number of symptom-free days, or quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/106\">",
"     106",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Safety'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H27\">",
"     'Efficacy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/19/16698?source=see_link\">",
"     \"Beta agonists in asthma: Controversy regarding chronic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combination of LABA and inhaled glucocorticoids is included in the NAEPP guidelines as a treatment option for children with moderate or severe persistent asthma or those who require Step 3 (age 5 to 11 years) or Step 4 (age 0 to 4 years) therapy (",
"    <a class=\"graphic graphic_table graphicRef80908 graphicRef71181 \" href=\"mobipreview.htm?28/58/29614\">",
"     table 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"     figure 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/1\">",
"     1",
"    </a>",
"    ]. Combination therapy with inhaled glucocorticoids and LABA should be restricted to children who fail to achieve adequate asthma control with medium",
"    <strong>",
"     -",
"    </strong>",
"    dose inhaled glucocorticoids. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Inhaled glucocorticoids'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;LABA include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/4/34885?source=see_link\">",
"     salmeterol",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/26/11686?source=see_link\">",
"     formoterol",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef57761 \" href=\"mobipreview.htm?2/45/2782\">",
"     table 4",
"    </a>",
"    ). Combinations of inhaled glucocorticoids and LABA also are available.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/4/34885?source=see_link\">",
"       Salmeterol",
"      </a>",
"      has a long duration (12 hours), but delayed onset (20 minutes) of action. The safety of salmeterol, when used as directed, has been established in multiple clinical trials in adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/98,107-109\">",
"       98,107-109",
"      </a>",
"      ] and children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/110,111\">",
"       110,111",
"      </a>",
"      ]. Salmeterol by DPI is approved for children &ge;4 years of age.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/26/11686?source=see_link\">",
"       Formoterol",
"      </a>",
"      is approved for the treatment of asthma and the prevention of bronchospasm in adults and children &ge;5 years. In single-dose studies, when compared with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/4/34885?source=see_link\">",
"       salmeterol",
"      </a>",
"      , formoterol had a shorter onset of action, but similar duration of action [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/112,113\">",
"       112,113",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inhalers with a combination of LABA and glucocorticoids permit easy coadministration of these drugs. Combination",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/63/37872?source=see_link\">",
"       fluticasone",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mcg)/",
"       <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/4/34885?source=see_link\">",
"        salmeterol",
"       </a>",
"      </span>",
"      (50 mcg) DPI is approved in the United States for use in children &ge;4 years. Combination fluticasone (250 or 500",
"      <span class=\"nowrap\">",
"       mcg)/salmeterol",
"      </span>",
"      (50 mcg) DPI, fluticasone (45 or 115",
"      <span class=\"nowrap\">",
"       mcg)/salmeterol",
"      </span>",
"      (21 mcg) MDI,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"       budesonide",
"      </a>",
"      (80 or 160",
"      <span class=\"nowrap\">",
"       mcg)/",
"       <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/26/11686?source=see_link\">",
"        formoterol",
"       </a>",
"      </span>",
"      (4.5 mcg) MDI, and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/57/36752?source=see_link\">",
"       mometasone",
"      </a>",
"      (110 or 200",
"      <span class=\"nowrap\">",
"       mcg)/formoterol",
"      </span>",
"      (5 mcg) MDI are approved in the United States for use in children &ge;12 years, although some are approved for use in younger children in other countries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/53/23384?source=see_link\">",
"     fluticasone-salmeterol",
"    </a>",
"    combination therapy in asthma has been demonstrated in randomized controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/57,114-116\">",
"     57,114-116",
"    </a>",
"    ]. Overall, there are greater improvements in lung function with combination therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/106\">",
"     106",
"    </a>",
"    ]. In addition, the use of combined therapy appears to permit similar control with low to moderate doses of inhaled glucocorticoids, and this is associated with better linear growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/5,57,106\">",
"     5,57,106",
"    </a>",
"    ]. However, higher doses of inhaled glucocorticoid monotherapy may be better for controlling inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Inhaled glucocorticoids'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized, four-arm, placebo-controlled trial of 349 patients &ge;12 years of age with asthma previously treated with medium-dose inhaled glucocorticoids, compared the use of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/63/37872?source=see_link\">",
"       fluticasone",
"      </a>",
"      alone (250 mcg twice daily),",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/4/34885?source=see_link\">",
"       salmeterol",
"      </a>",
"      alone (50 mcg twice daily), combination therapy (fluticasone 250 mcg + salmeterol 50 mcg twice daily), and placebo for a 12-week period. Patients receiving the combination therapy had significantly reduced asthma symptom scores, less rescue inhaler use, and fewer nighttime awakenings, compared with all other therapies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/114\">",
"       114",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two studies evaluated the glucocorticoid-sparing effect of LABA. In the first study, 285 children (aged 6 to 14 years) with mild to moderate asthma were treated with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/63/37872?source=see_link\">",
"       fluticasone",
"      </a>",
"      (100 mcg twice daily), combination of fluticasone (100 mcg once daily) and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/4/34885?source=see_link\">",
"       salmeterol",
"      </a>",
"      (50 mcg twice daily), or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"       montelukast",
"      </a>",
"      (5 mg once daily) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/57\">",
"       57",
"      </a>",
"      ]. Both fluticasone alone and combination",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/53/23384?source=see_link\">",
"       fluticasone-salmeterol",
"      </a>",
"      produced similar symptom control and prevention of exacerbations. However, the higher dose of fluticasone was more effective in improving lung function, reducing exhaled nitric oxide, and reducing bronchial hyperactivity. Montelukast alone was inferior to the other two treatments. In the second study, 158 children (aged 6 to 16) with moderate asthma were treated with fluticasone (200 mcg twice daily) or a combination of fluticasone (100 mcg twice daily) and salmeterol (50 mcg twice daily) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/116\">",
"       116",
"      </a>",
"      ]. Both groups had similar symptomatic improvement, lung function, exacerbation rates, and growth.",
"      <br/>",
"      <br/>",
"      These studies provide justification for treating children with mild to moderate persistent asthma with inhaled glucocorticoids alone initially, and reserving the addition of LABA to the same dose of inhaled glucocorticoids for patients with more severe asthma, whose symptoms are not fully controlled on inhaled glucocorticoids monotherapy (",
"      <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"       figure 1A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In another trial, 182 children aged 6 to 17 years with uncontrolled asthma on 100 mcg",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/63/37872?source=see_link\">",
"       fluticasone",
"      </a>",
"      twice daily received each of these step-up therapy options in random order for 16 weeks (250 mcg fluticasone twice daily, 100 mcg fluticasone twice daily plus 50 mcg",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/4/34885?source=see_link\">",
"       salmeterol",
"      </a>",
"      , and 100 mcg fluticasone plus 5 to 10 mg",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/26/1446?source=see_link\">",
"       montelukast",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/115\">",
"       115",
"      </a>",
"      ]. A differential response to step-up therapy was nearly universal. A higher proportion of patients had a best response to LABA step-up than to inhaled glucocorticoid step-up (52 versus 34 percent, respectively) or LTRA step-up (54 versus 32 percent). Responses to LTRA step-up and inhaled glucocorticoid step-up were similar. These step-up strategies can be used serially if the initial approach does not improve asthma control, since certain patients may respond well to one therapy, but not to another.",
"      <br/>",
"      <br/>",
"      This study was not designed to evaluate long-term safety of changes in baseline asthma therapy, since step-up therapy was only of 16 weeks duration for each regimen. Overall, these data support a closely monitored step-up approach to chronic asthma therapy in children with uncontrolled asthma on low dose inhaled glucocorticoids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Versus theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of studies comparing LABA to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/49/24344?source=see_link\">",
"     theophylline",
"    </a>",
"    for long-term control of asthma found that LABA are at least as effective as theophylline in reducing asthma symptoms, including night waking, and improving lung function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/117\">",
"     117",
"    </a>",
"    ]. In addition, compared with theophylline, long-acting beta-2 agonists are associated with fewer adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhalers containing",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/4/34885?source=see_link\">",
"     salmeterol",
"    </a>",
"    , including those using salmeterol in combination with inhaled glucocorticoids, are labeled with a black box warning that advises health care professionals and patients that these agents may increase the chance of severe asthma episodes and asthma-related death when these episodes occur (",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm108111.htm\">",
"     www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm108111.htm",
"    </a>",
"    ). The boxed warning and the rationale behind it are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/19/16698?source=see_link&amp;anchor=H4#H4\">",
"     \"Beta agonists in asthma: Controversy regarding chronic use\", section on 'Long-acting beta agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SYSTEMIC GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids may be necessary for long-term control in children with severe persistent asthma (",
"    <a class=\"graphic graphic_table graphicRef80908 graphicRef71181 \" href=\"mobipreview.htm?28/58/29614\">",
"     table 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"     figure 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57761 \" href=\"mobipreview.htm?2/45/2782\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although oral glucocorticoids improve asthma control, the adverse effects of their long-term use must be appreciated. These include adrenal suppression, weight gain, diabetes, hypertension, cataracts, delayed growth, immune suppression, osteoporosis, and psychological effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/10,118\">",
"     10,118",
"    </a>",
"    ]. Reducing glucocorticoids to the lowest possible dose, every other day administration, and maximizing all other forms of pharmacologic and preventive therapy minimize these effects. A strategy of substituting inhaled glucocorticoids has generally been successful in older children and adults as well as in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/119\">",
"     119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13591964\">",
"    <span class=\"h1\">",
"     ANTI-IgE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal anti-IgE is another treatment option for moderate-to-severe asthma that is not well-controlled with standard therapy with elevated IgE levels.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/57/38805?source=see_link\">",
"     Omalizumab",
"    </a>",
"    is only approved for children &ge;12 years of age in the United States, but is approved for use in children as young as six years in other countries. Anti-IgE therapy is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/46/17130?source=see_link&amp;anchor=H7765588#H7765588\">",
"     \"Anti-IgE therapy\", section on 'Omalizumab therapy in asthma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/52/13122?source=see_link\">",
"       \"Patient information: How to use your child&rsquo;s dry powder inhaler (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/58/17315?source=see_link\">",
"       \"Patient information: Asthma in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/4/33858?source=see_link\">",
"       \"Patient information: How to use your child&rsquo;s metered dose inhaler (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44083?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/60/18374?source=see_link\">",
"       \"Patient information: Asthma treatment in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/0/37892?source=see_link\">",
"       \"Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The National Asthma Education and Prevention Program Expert Panel (NAEPP) guidelines provide recommendations for the management of chronic childhood asthma in children aged 0 to 4 years and 5 to 11 years (",
"      <a class=\"graphic graphic_table graphicRef80908 graphicRef71181 \" href=\"mobipreview.htm?28/58/29614\">",
"       table 1A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"       figure 1A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef78322 graphicRef64986 \" href=\"mobipreview.htm?29/50/30510\">",
"       table 2A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for controller medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In accordance with the NAEPP guidelines, we recommend the use of daily controller medications in infants and children younger than 12 years with persistent asthma of any severity (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We also recommend the initiation of controller therapy for children aged 0 to 4 years who had &ge;4 episodes of wheezing in the past year that lasted more than one day and affected sleep and who are at risk for developing persistent asthma (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the use of daily controller therapies for the following children (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Children with intermittent asthma who experience severe exacerbations, especially during periods when they are likely to be exposed to known triggers.",
"     </li>",
"     <li>",
"      Those aged 0 to 4 years who require reliever medications more than two days per week for a period of more than four weeks.",
"     </li>",
"     <li>",
"      Infants and young children experiencing severe exacerbations less than six weeks apart or those who have two or more exacerbations requiring systemic glucocorticoids within six months. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initiation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asthma control should be monitored regularly (",
"      <a class=\"graphic graphic_table graphicRef78322 graphicRef64986 \" href=\"mobipreview.htm?29/50/30510\">",
"       table 2A-B",
"      </a>",
"      ) and controller therapy adjusted as necessary (",
"      <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"       figure 1A-B",
"      </a>",
"      ). The lowest effective dose for each patient should be determined over time. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Dosing adjustment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest inhaled glucocorticoids as the first-line controller therapy for children who require Step 2 therapy (",
"      <a class=\"graphic graphic_table graphicRef80908 graphicRef71181 \" href=\"mobipreview.htm?28/58/29614\">",
"       table 1A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"       figure 1A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef68517 \" href=\"mobipreview.htm?26/18/26925\">",
"       table 3",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Inhaled glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not suggest the preventive use of intermittent inhaled glucocorticoids for treatment of persistent asthma or recurrent wheezing in children (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Intermittent preventive use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When inhaled glucocorticoids are prescribed, it is essential to provide adequate instruction to the child's caregivers regarding proper use of the medication delivery system that has been prescribed. Potential side effects should also be discussed with the child&rsquo;s caregivers. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30376?source=see_link\">",
"       \"Use of medication nebulizers in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36760?source=see_link\">",
"       \"The use of inhaler devices in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=see_link\">",
"       \"Major side effects of inhaled glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If asthma control is not achieved with inhaled glucocorticoids, additional controller agents should be added to the patient's daily regimen (",
"      <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"       figure 1A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef57761 \" href=\"mobipreview.htm?2/45/2782\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Inhaled glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Dosing adjustment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that leukotriene receptor antagonists (LTRA) be used as adjuncts to inhaled glucocorticoids in the daily treatment of persistent asthma in children older than one year rather than as monotherapy (",
"      <a class=\"graphic graphic_table graphicRef80908 graphicRef71181 \" href=\"mobipreview.htm?28/58/29614\">",
"       table 1A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"       figure 1A-B",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/30/37354/abstract/46\">",
"       46",
"      </a>",
"      ]. However, LTRA may be used as an alternative to inhaled glucocorticoids or as a \"step down\" from inhaled glucocorticoids in patients with mild persistent asthma, particularly those who have difficulty with adherence or inhaler technique. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Leukotriene receptor antagonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combination therapy with long-acting beta agonists and inhaled glucocorticoids should be reserved for children with moderate or severe persistent asthma or for those who are unable to achieve adequate symptom control with medium doses of inhaled glucocorticoids (",
"      <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"mobipreview.htm?22/39/23160\">",
"       figure 1A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef68517 \" href=\"mobipreview.htm?26/18/26925\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Long-acting beta agonists and inhaled glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on January 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/2\">",
"      Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/3\">",
"      Castro-Rodr&iacute;guez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 2000; 162:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/4\">",
"      Johnston NW, Mandhane PJ, Dai J, et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 2007; 120:e702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/5\">",
"      Castro-Rodriguez JA, Rodrigo GJ. A systematic review of long-acting &beta;2-agonists versus higher doses of inhaled corticosteroids in asthma. Pediatrics 2012; 130:e650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/6\">",
"      Smith LA, Bokhour B, Hohman KH, et al. Modifiable risk factors for suboptimal control and controller medication underuse among children with asthma. Pediatrics 2008; 122:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/7\">",
"      Canny GJ, Levison H. Childhood asthma: a rational approach to treatment. Ann Allergy 1990; 64:406.",
"     </a>",
"    </li>",
"    <li>",
"     Kamada AK, Szefler SJ. Pharmacological management of severe asthma, Marcel Dekker, New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/9\">",
"      Larsen GL. Asthma in children. N Engl J Med 1992; 326:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/10\">",
"      Szefler SJ. Glucocorticoid therapy for asthma: clinical pharmacology. J Allergy Clin Immunol 1991; 88:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/11\">",
"      Rachelefsky G. Inhaled corticosteroids and asthma control in children: assessing impairment and risk. Pediatrics 2009; 123:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/12\">",
"      Castro-Rodriguez JA, Rodrigo GJ. Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. Pediatrics 2009; 123:e519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/13\">",
"      Ng D, Salvio F, Hicks G. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2004; :CD002314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/14\">",
"      Jartti T. Inhaled corticosteroids or montelukast as the preferred primary long-term treatment for pediatric asthma? Eur J Pediatr 2008; 167:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/15\">",
"      Zhang L, Axelsson I, Chung M, Lau J. Dose response of inhaled corticosteroids in children with persistent asthma: a systematic review. Pediatrics 2011; 127:129.",
"     </a>",
"    </li>",
"    <li>",
"     Medscape. FDA approvals: Asmanex twisthaler, accretropin, mycamine. www.medscape.com/viewarticle/570204 (Accessed on March 06, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/17\">",
"      Kramer S, Rottier BL, Scholten RJ, Boluyt N. Ciclesonide versus other inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2013; 2:CD010352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/18\">",
"      Qaqundah PY, Sugerman RW, Ceruti E, et al. Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study. J Pediatr 2006; 149:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/19\">",
"      Wilson NM, Silverman M. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home. Arch Dis Child 1990; 65:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/20\">",
"      Noble V, Ruggins NR, Everard ML, Milner AD. Inhaled budesonide for chronic wheezing under 18 months of age. Arch Dis Child 1992; 67:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/21\">",
"      Connett GJ, Warde C, Wooler E, Lenney W. Use of budesonide in severe asthmatics aged 1-3 years. Arch Dis Child 1993; 69:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/22\">",
"      Bisgaard H, Munck SL, Nielsen JP, et al. Inhaled budesonide for treatment of recurrent wheezing in early childhood. Lancet 1990; 336:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/23\">",
"      Gleeson JG, Price JF. Controlled trial of budesonide given by the nebuhaler in preschool children with asthma. BMJ 1988; 297:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/24\">",
"      Ilangovan P, Pedersen S, Godfrey S, et al. Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension. Arch Dis Child 1993; 68:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/25\">",
"      Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 2000; 343:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/26\">",
"      Bisgaard H, Allen D, Milanowski J, et al. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics 2004; 113:e87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/27\">",
"      Toogood JH, Baskerville J, Jennings B, et al. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol 1989; 84:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/28\">",
"      Kamada AK, Szefler SJ, Martin RJ, et al. Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. Am J Respir Crit Care Med 1996; 153:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/29\">",
"      Robinson DS, Geddes DM. Inhaled corticosteroids: benefits and risks. J Asthma 1996; 33:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/30\">",
"      Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis 1993; 148:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/31\">",
"      Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child 1993; 69:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/32\">",
"      Bisgaard H, Hermansen MN, Loland L, et al. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 2006; 354:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/33\">",
"      Murray CS, Woodcock A, Langley SJ, et al. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet 2006; 368:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/34\">",
"      Busse WW, Pedersen S, Pauwels RA, et al. The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2008; 121:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/35\">",
"      L&oslash;drup Carlsen KC, Devulapalli CS, Mowinckel P, et al. Lung function at 10 yrs is not improved by early corticosteroid treatment in asthmatic children. Pediatr Allergy Immunol 2010; 21:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/36\">",
"      Strunk RC, Sternberg AL, Szefler SJ, et al. Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents. J Pediatr 2009; 154:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/37\">",
"      Martinez FD. Managing childhood asthma: challenge of preventing exacerbations. Pediatrics 2009; 123 Suppl 3:S146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/38\">",
"      Kraft M, Israel E, O'Connor GT. Clinical Decisions. Treatment of mild persistent asthma. N Engl J Med 2007; 356:2096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/39\">",
"      Sawicki GS, Smith L, Bokhour B, et al. Periodic use of inhaled steroids in children with mild persistent asthma: what are pediatricians recommending? Clin Pediatr (Phila) 2008; 47:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/40\">",
"      Naspitz CK, Cropp GJ. Recommendations for treatment of intermittent mild persistent asthma in children and adolescents. Pediatr Pulmonol 2009; 44:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/41\">",
"      Zeiger RS, Mauger D, Bacharier LB, et al. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med 2011; 365:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/42\">",
"      Turpeinen M, Nikander K, Pelkonen AS, et al. Daily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood asthma study). Arch Dis Child 2008; 93:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/43\">",
"      Svedmyr J, Nyberg E, Asbrink-Nilsson E, Hedlin G. Intermittent treatment with inhaled steroids for deterioration of asthma due to upper respiratory tract infections. Acta Paediatr 1995; 84:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/44\">",
"      Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/45\">",
"      Chauhan BF, Chartrand C, Ducharme FM. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev 2013; 2:CD009611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/46\">",
"      Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996; 98:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/47\">",
"      Drazen JM. Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma. Pharmacotherapy 1997; 17:22S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/48\">",
"      Rachelefsky G. Childhood asthma and allergic rhinitis: the role of leukotrienes. J Pediatr 1997; 131:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/49\">",
"      Horwitz RJ, McGill KA, Busse WW. The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med 1998; 157:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/50\">",
"      Becker A, Lemi&egrave;re C, B&eacute;rub&eacute; D, et al. Summary of recommendations from the Canadian Asthma Consensus guidelines, 2003. CMAJ 2005; 173:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/51\">",
"      Moeller A, Lehmann A, Knauer N, et al. Effects of montelukast on subjective and objective outcome measures in preschool asthmatic children. Pediatr Pulmonol 2008; 43:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/52\">",
"      Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/53\">",
"      Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108:E48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/54\">",
"      Hakim F, Vilozni D, Adler A, et al. The effect of montelukast on bronchial hyperreactivity in preschool children. Chest 2007; 131:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/55\">",
"      Ostrom NK, Decotiis BA, Lincourt WR, et al. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr 2005; 147:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/56\">",
"      Zeiger RS, Szefler SJ, Phillips BR, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 2006; 117:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/57\">",
"      Sorkness CA, Lemanske RF Jr, Mauger DT, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2007; 119:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/58\">",
"      Szefler SJ, Baker JW, Uryniak T, et al. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol 2007; 120:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/59\">",
"      Castro-Rodriguez JA, Rodrigo GJ. The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis. Arch Dis Child 2010; 95:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/60\">",
"      Wang L, Hollenbeak CS, Mauger DT, et al. Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2011; 127:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/61\">",
"      Garcia Garcia ML, Wahn U, Gilles L, et al. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 2005; 116:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/62\">",
"      Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/63\">",
"      Federico MJ, Covar RA, Brown EE, et al. Racial differences in T-lymphocyte response to glucocorticoids. Chest 2005; 127:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/64\">",
"      Gauvreau GM, Inman MD, Kelly M, et al. Increased levels of airway neutrophils reduce the inhibitory effects of inhaled glucocorticosteroids on allergen-induced airway eosinophils. Can Respir J 2002; 9:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/65\">",
"      Bukstein DA, Luskin AT, Bernstein A. \"Real-world\" effectiveness of daily controller medicine in children with mild persistent asthma. Ann Allergy Asthma Immunol 2003; 90:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/66\">",
"      Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998; 279:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/67\">",
"      Bukstein DA, Bratton DL, Firriolo KM, et al. Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study. J Asthma 2003; 40:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/68\">",
"      Phipatanakul W, Greene C, Downes SJ, et al. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann Allergy Asthma Immunol 2003; 91:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/69\">",
"      Jat GC, Mathew JL, Singh M. Treatment with 400 microg of inhaled budesonide vs 200 microg of inhaled budesonide and oral montelukast in children with moderate persistent asthma: randomized controlled trial. Ann Allergy Asthma Immunol 2006; 97:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/70\">",
"      Strunk RC, Bacharier LB, Phillips BR, et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. J Allergy Clin Immunol 2008; 122:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/71\">",
"      Weiss KB, Gern JE, Johnston NW, et al. The Back to School asthma study: the effect of montelukast on asthma burden when initiated prophylactically at the start of the school year. Ann Allergy Asthma Immunol 2010; 105:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/72\">",
"      Robertson CF, Price D, Henry R, et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am J Respir Crit Care Med 2007; 175:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/73\">",
"      Murphy S. Facts and myths about using cromolyn sodium in asthma. J Respir Dis 1992; 13:S28 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/74\">",
"      Robson RA, Taylor BJ, Taylor B. Sodium cromoglycate: spincaps or metered dose aerosol. Br J Clin Pharmacol 1981; 11:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/75\">",
"      Godfrey S, Balfour-Lynn L, K&ouml;nig P. The place of cromolyn sodium in the long-term management of childhood asthma based on a 3- to 5-year follow-up. J Pediatr 1975; 87:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/76\">",
"      Shapiro GG, Sharpe M, DeRouen TA, et al. Cromolyn versus triamcinolone acetonide for youngsters with moderate asthma. J Allergy Clin Immunol 1991; 88:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/77\">",
"      Newth CJ, Newth CV, Turner JA. Comparison of nebulised sodium cromoglycate and oral theophylline in controlling symptoms of chronic asthma in pre-school children: a double blind study. Aust N Z J Med 1982; 12:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/78\">",
"      Springer C, Goldenberg B, Ben Dov I, Godfrey S. Clinical, physiologic, and psychologic comparison of treatment by cromolyn or theophylline in childhood asthma. J Allergy Clin Immunol 1985; 76:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/79\">",
"      van der Wouden JC, Tasche MJ, Bernsen RM, et al. Inhaled sodium cromoglycate for asthma in children. Cochrane Database Syst Rev 2003; :CD002173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/80\">",
"      Guevara JP, Ducharme FM, Keren R, et al. Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. Cochrane Database Syst Rev 2006; :CD003558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/81\">",
"      Sridhar AV, McKean M. Nedocromil sodium for chronic asthma in children. Cochrane Database Syst Rev 2006; :CD004108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/82\">",
"      Harper GD, Neill P, Vathenen AS, et al. A comparison of inhaled beclomethasone dipropionate and nedocromil sodium as additional therapy in asthma. Respir Med 1990; 84:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/83\">",
"      Svendsen UG, Fr&oslash;lund L, Madsen F, Nielsen NH. A comparison of the effects of nedocromil sodium and beclomethasone dipropionate on pulmonary function, symptoms, and bronchial responsiveness in patients with asthma. J Allergy Clin Immunol 1989; 84:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/84\">",
"      Bel EH, Timmers MC, Hermans J, et al. The long-term effects of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects. Am Rev Respir Dis 1990; 141:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/85\">",
"      Groot CA, Lammers JW, Molema J, et al. Effect of inhaled beclomethasone and nedocromil sodium on bronchial hyperresponsiveness to histamine and distilled water. Eur Respir J 1992; 5:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/86\">",
"      Nassif EG, Weinberger M, Thompson R, Huntley W. The value of maintenance theophylline in steroid-dependent asthma. N Engl J Med 1981; 304:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/87\">",
"      Magnussen H, Reuss G, J&ouml;rres R. Theophylline has a dose-related effect on the airway response to inhaled histamine and methacholine in asthmatics. Am Rev Respir Dis 1987; 136:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/88\">",
"      Brenner M, Berkowitz R, Marshall N, Strunk RC. Need for theophylline in severe steroid-requiring asthmatics. Clin Allergy 1988; 18:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/89\">",
"      Seddon P, Bara A, Ducharme FM, Lasserson TJ. Oral xanthines as maintenance treatment for asthma in children. Cochrane Database Syst Rev 2006; :CD002885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/90\">",
"      Becker AB, Simons FE. Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma. J Allergy Clin Immunol 1989; 84:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/91\">",
"      D'Alonzo GE, Nathan RA, Henochowicz S, et al. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 1994; 271:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/92\">",
"      Bronsky EA, Pearlman DS, Pobiner BF, et al. Prevention of exercise-induced bronchospasm in pediatric asthma patients: A comparison of two salmeterol powder delivery devices. Pediatrics 1999; 104:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/93\">",
"      Blake K, Pearlman DS, Scott C, et al. Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. Ann Allergy Asthma Immunol 1999; 82:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/94\">",
"      Nino G, Grunstein MM. Current concepts on the use of glucocorticosteroids and beta-2-adrenoreceptor agonists to treat childhood asthma. Curr Opin Pediatr 2010; 22:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/95\">",
"      Cates CJ, Oleszczuk M, Stovold E, Wieland LS. Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cochrane Database Syst Rev 2012; 10:CD010005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/96\">",
"      Mcivor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/97\">",
"      Verberne AA, Frost C, Roorda RJ, et al. One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med 1997; 156:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/98\">",
"      Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen &amp; Hanburys Limited UK Study Group. Lancet 1994; 344:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/99\">",
"      Nathan RA, Pinnas JL, Schwartz HJ, et al. A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma. Ann Allergy Asthma Immunol 1999; 82:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/100\">",
"      Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/101\">",
"      van der Molen T, Postma DS, Turner MO, et al. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators. Thorax 1997; 52:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/102\">",
"      Pauwels RA, L&ouml;fdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/103\">",
"      Wilding P, Clark M, Thompson Coon J, et al. Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ 1997; 314:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/104\">",
"      Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001; 285:2583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/105\">",
"      Gappa M, Zachgo W, von Berg A, et al. Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED). Pediatr Pulmonol 2009; 44:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/106\">",
"      Ni Chroinin M, Lasserson TJ, Greenstone I, Ducharme FM. Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2009; :CD007949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/107\">",
"      Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/108\">",
"      Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992; 327:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/109\">",
"      Moore RH, Khan A, Dickey BF. Long-acting inhaled beta2-agonists in asthma therapy. Chest 1998; 113:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/110\">",
"      Weinstein SF, Pearlman DS, Bronsky EA, et al. Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma. Ann Allergy Asthma Immunol 1998; 81:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/111\">",
"      Lenney W, Pedersen S, Boner AL, et al. Efficacy and safety of salmeterol in childhood asthma. Eur J Pediatr 1995; 154:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/112\">",
"      Bartow RA, Brogden RN. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 1998; 55:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/113\">",
"      Pohunek P, Matulka M, Rybn&iacute;cek O, et al. Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. Pediatr Allergy Immunol 2004; 15:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/114\">",
"      Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/115\">",
"      Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/116\">",
"      Vaessen-Verberne AA, van den Berg NJ, van Nierop JC, et al. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. Am J Respir Crit Care Med 2010; 182:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/117\">",
"      Shah L, Wilson AJ, Gibson PG, Coughlan J. Long acting beta-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev 2003; :CD001281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/118\">",
"      Milgrom H, Bender BG. Psychologic side effects of therapy with corticosteroids. Am Rev Respir Dis 1993; 147:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/30/37354/abstract/119\">",
"      Godfrey S, Balfour-Lynn L, Tooley M. A three- to five-year follow-up of the use of the aerosol steroid, beclomethasone dipropionate, in childhood asthma. J Allergy Clin Immunol 1978; 62:335.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5744 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-213.134.24.46-B0B7A2AA67-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_30_37354=[""].join("\n");
var outline_f36_30_37354=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR CONTROLLER MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Initiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dosing adjustment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INHALED GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Specific preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - For children &lt;4 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Potency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Delivery devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Impact on disease progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Intermittent preventive use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LEUKOTRIENE RECEPTOR ANTAGONISTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Compared with placebo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Compared with inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Adjunctive therapy to inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Intermittent use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CHROMONES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cromolyn",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Compared with inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nedocromil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Chromones in addition to inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      THEOPHYLLINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      LONG-ACTING BETA AGONISTS AND INHALED GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Versus theophylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SYSTEMIC GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13591964\">",
"      ANTI-IgE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5744\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5744|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/40/37506\" title=\"figure 1A\">",
"      Stepwise asthma Rx 0 to 4 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/41/1684\" title=\"figure 1B\">",
"      Stepwise asthma Rx 5 to 11 yrs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5744|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/40/9869\" title=\"table 1A\">",
"      Initiating Rx 0 to 4 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/62/27629\" title=\"table 1B\">",
"      Initiating Rx 5 to 11 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/62/12269\" title=\"table 2A\">",
"      Adjusting Rx 0 to 4 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/13/26845\" title=\"table 2B\">",
"      Adjusting Rx 5 to 11 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/18/26925\" title=\"table 3\">",
"      Doses inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/45/2782\" title=\"table 4\">",
"      Doses asthma control meds kids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/23/11642?source=related_link\">",
"      Acute asthma exacerbations in children: Inpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33034?source=related_link\">",
"      Acute asthma exacerbations in children: Outpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30746?source=related_link\">",
"      Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/46/17130?source=related_link\">",
"      Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/19/16698?source=related_link\">",
"      Beta agonists in asthma: Controversy regarding chronic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26010?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39670?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Quick-relief agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31014?source=related_link\">",
"      Delivery of inhaled medication in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1513?source=related_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/13/7383?source=related_link\">",
"      Natural history of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/58/17315?source=related_link\">",
"      Patient information: Asthma in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44083?source=related_link\">",
"      Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/0/37892?source=related_link\">",
"      Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/60/18374?source=related_link\">",
"      Patient information: Asthma treatment in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/52/13122?source=related_link\">",
"      Patient information: How to use your child&rsquo;s dry powder inhaler (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/4/33858?source=related_link\">",
"      Patient information: How to use your child&rsquo;s metered dose inhaler (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/29/471?source=related_link\">",
"      The use of chromones (cromoglycates) in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36760?source=related_link\">",
"      The use of inhaler devices in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11161?source=related_link\">",
"      Theophylline use in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18154?source=related_link\">",
"      Treatment of intermittent and mild persistent asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26745?source=related_link\">",
"      Treatment of moderate persistent asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/44/22216?source=related_link\">",
"      Treatment of recurrent virus-induced wheezing in young children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30376?source=related_link\">",
"      Use of medication nebulizers in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_30_37355="Pleurodesis agents I";
var content_f36_30_37355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complete success rates and adverse effects in patients treated with nonantineoplastic agents for malignant pleural effusions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pleurodesis agent (dose)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Success rate cases (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse effects cases (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Talc (2.5 to 10 g)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        153/165 (93)",
"       </td>",
"       <td>",
"        Pain: 9/131 (7)&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever: 21/131 (16)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minocycline (300 mg)",
"       </td>",
"       <td>",
"        6/7 (86)",
"       </td>",
"       <td>",
"        Pain: 1/7 (14)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Corynebacterium parvum (3.5 to 14 mg)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        129/169 (76)",
"       </td>",
"       <td>",
"        Pain: 73/169 (43)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever: 100/169 (59)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea: 5/169 (3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cough: 10/169 (6)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxycycline (500 mg)",
"       </td>",
"       <td>",
"        43/60 (72)",
"       </td>",
"       <td>",
"        Pain: 24/60 (40)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Tetracycline (500 mg to 20 mg/kg)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        240/359 (67)",
"       </td>",
"       <td>",
"        Pain: 51/359 (14)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever: 36/359 (10)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methylprednisolone acetate (160 to 820 mg)",
"       </td>",
"       <td>",
"        6/10 (60)",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Walker-Renard, PB, Vaughan, LM, Sahn, SA Ann Intern Med 1994; 120:56.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_30_37355=[""].join("\n");
var outline_f36_30_37355=null;
var title_f36_30_37356="Confounding factors";
var content_f36_30_37356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Possible confounding factors in the interpretation of mainly cross-sectional information about risk factors and vascular calcification",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk factor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Association",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confounded by",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High plasma phosphate",
"       </td>",
"       <td>",
"        Phenotypic shift of contractile vascular smooth muscle cells to secretory CVC; mortality data",
"       </td>",
"       <td>",
"        Is high phosphate a marker of severe bone disease, or noncompliance with dialysis, drugs, and diet?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High plasma calcium",
"       </td>",
"       <td>",
"        Hypercalcemic episodes leading to direct precipitation",
"       </td>",
"       <td>",
"        Hyperparathyroidism, vitamin D; lack of relation between calcium balance and blood calcium levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High parathyroid hormone",
"       </td>",
"       <td>",
"        Increases intracellular calcium levels",
"       </td>",
"       <td>",
"        Use of more phosphate binders and vitamin D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low parathyroid hormone",
"       </td>",
"       <td>",
"        Lack of dynamic bone metabolic activity to buffer changes in plasma calcium",
"       </td>",
"       <td>",
"        Previous use of vitamin D and phosphate binders; parathyroidectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin D therapy",
"       </td>",
"       <td>",
"        Increases plasma calcium and phosphate levels; calcifies vessel wall tunica media; vitamin D receptors on vascular smooth muscle cells (especially with hyperphosphatemia, even if calcium normal); accelerates atherosclerosis",
"       </td>",
"       <td>",
"        Hyperparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammation/redox stress",
"       </td>",
"       <td>",
"        Reduces levels of alpha-2-Heremann Schmitt glycoprotein (fetuin) a naturally occurring inhibitor of calcification; accelerated atherosclerosis",
"       </td>",
"       <td>",
"        Vascular disease may be the cause of inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Warfarin",
"       </td>",
"       <td>",
"        Inhibits matrix GLA protein; naturally occurring inhibitor of calcification",
"       </td>",
"       <td>",
"        Often used in patients with poor hemodialysis access, including diabetics, older patients, and women; sharing risk factors for vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dyslipidemia",
"       </td>",
"       <td>",
"        Oxidized low-density lipoprotein causing endothelial/vascular smooth muscle cell damage; high-density lipoprotein protective against calcification",
"       </td>",
"       <td>",
"        Hyperparathyroidism associated dyslipidemia; sevelamer reduces low-density lipoprotein cholesterol and raises high-density lipoprotein cholesterol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoidance of aluminum; high dose of oral calcium-containing phosphate binders",
"       </td>",
"       <td>",
"        Positive calcium balance",
"       </td>",
"       <td>",
"        High plasma phosphate levels; poor compliance with drugs, dialysis, and diet; alkalosis favors calcification (calcium carbonate/acetate); sevelamer leads to mild acidosis; aluminum is a potent inhibitor of calcification/ossification",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CVC: calcifying vascular cells.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goldsmith D, Ritz E, Cvic A. Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int 2004; 66:1315. Copyright &copy; 2004 Blackwell Publishing.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_30_37356=[""].join("\n");
var outline_f36_30_37356=null;
var title_f36_30_37357="Right atrial enlargement";
var content_f36_30_37357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Right atrial enlargement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 209px; background-image: url(data:image/gif;base64,R0lGODlh6gHRAOYAAP///8DAwEBAQICAgAAAAP8AAP8QEP/w8P8wMP/g4P9gYP8gIP+goP9wcP/AwP/Q0DAwMP+wsP+QkKCgoPDw8CBzOeDg4PL387CwsC58RfP38xAQEP9QUCAgINDQ0EF8RTRzOazLtXBwcJCQkP9AQNbl25C5nP+AgM3czmBgYDyFUliWa0qNXlqNXuTu53SohLrUwpq5nICohObu58jczmeWa4KwkJ7CqWafd6fCqXSfd7PLtdrl202FUsDUwlBQUI2wkLK3s7IrFb8gIHNPJ/InI01kMXOLdfEHA3NvRpk5HDRfNr8jEUBrNb9AQLO3s7ObhfIXE+UOB3SHY8xMPi1rNT8AAIBHI8CgoL8AAL+AgI+pjONORz8wMAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADqAdEAAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIJ2EYMABDwm8WRgwYYeGhuwAEMhIYYJGbAI0bKHRcZ8GhBQICRmrDUDEFgQAq101w6TAmNgsDOkCwqU4EhA0TDDEcypCnMg8CNggQSWgCUYYVjW77KPSpAI5SkWHEOsgp0RQps1Yb8GOACAIdGBUVO6yDiAEQ/wgEVRQgLFtpGDpkFOBBLde7v35k3PAXUV3A5NYifnZ4cTjFjpk1juwNMuVkky9vs6zZWObO2DiDHvZ59NjCpoWVTi1NNGtfq18/cy17V+zazGjjxnV7dzLdvmv1Dm4MOHFZw1UlcHDguCXjzl8lR8XAAAIDCaJPgq6d1XRTDgw8AKCARPdI3M+n+l5qgQRBBww4UO8oPX1T7EcxWEDohIL7fgE4S36iLMAAIQkUkJ2AiNjHYCgEgvIAf4UocMKDhziIoScRftJAA4Y4QOGGg2hI4iYderLAeIYYeKIgJr6ISYqciIgIA+a9GKOMltC4iQIgHhLfgiTuyCMlPmoiXv8iQOqI2pGiJIlJBAgo8oABzRX5JJSgSHkJB+8pQsKBWnKJn12rHKDgIgxUWaaZpHhZCY6NLLmhkXA6IiclYzbSwH93bpknimimkmCWiySAZaCDRlkoKhJw8AgJYT6IZ6N0PXoKAhE8EsGIDF6KqWGalqJoJAvMZ6mgo/ZYKil/RuIfhqK2WsieqKr6yKGr2toJro9MOAmYvfpK6CpNSvJpscZmAqwjdkqyQKcC1trss4wsS8kJklbLarOQYLuIApVKoiaR9FlrrLiJDGmJhd6C6+yroLR5iY0Aqusru4gQe8m0r3nA0FyL6LshBV5FlSkqaiJaSaSvaUSACAHKKxT/SAqTSl23l5zL2gQUUKBXxRYTEkBfI2y0CL+GIEAmJsm+1kFaBX8L7gRyrUxvJ7xmEp5sNBkSwNBEp2CzsR5ssFMhHhA99Ag7cyIBoJq4nBoFLhFMiABcd93B0bYGoDRThIjQNdcQRL0Jp5zQOZoFcV01QMYZgj1qyhu8pfUhLA9yZSfugoaRxDApYjCGH2m0c9+CxNpJzNodPirjAADcyd/nSR4KDTS48Brjwn5idXeac+LCDSxUwMIKGahgwgWmMf5hvTlGbjcrIbD+AgyElIBDBiWMxviKoAQeXemXXMCCCjfAfkgIFfDeWd/agqIA1c4hX4nyLzASAvDTq30J/+SeXOkwcdpT8gIOjtyggvOU9Y3dKH0ef/spNGQAPyMr2KAZy1Qihb3sZ4sLqEB6jnAB+OInvkqQqxTRQt/9SmGCFUiigpfhl8dghb3gpA8SF1ggCDNAAwaKYoCkUNT5dvNBRyRgC1NA1yMwGBl++asU9ZNgLA4ggQUgoQpcKAACdOWIEAbPMexq2ClQ6MEJeiICBiBBBEzAPgBUJ0iPsEH3kNhASTCAY6aIIAudyAkFGKBTISyhIBKAgA4uQoH7uwu7OPCyRPAgBzGogR6BEAMUaGASjmtiKw6AAARkKXeFUBS1HLGCEHARFD07hAZy0IMP6CAGPkABCmIAhBaAoP8GOfjjrhYlyDQhgAOIUoEjCwHFFSYiBCx45CcghogYfKAGPkiEBnagAxDIAAWTqiNuWlgIDtQOADRQQb8uVMQMeA4x4hpdIVDQgxoAsxEzsKU1G7EfHaqiAYYkBA5MgAgVPuIFN1gMtiI5CFvmQBIa0CYPGCGfUqLiSuhyQQWeeQhKPQIGyoRmFx8xtULMoAUtmEEl4vkBGYgSEbPyDTEFQT4qKiKAjxAhW7DFtkH44ANAyMQMdPCBXJazAK5MzUQBIMYDLmJ+jniB/wDzrFMNAggl5cRHdfDQYpZLNhOtniCSyYgHOqIEAZXjQBtRUABooAYJ9YQGSHpNVoIKqGT/rMTsCCFTRrjNES5VqoqoBdWedmIHH4jBIVI1xlQQbxAh5Ge7UDrDLW50qYvAnAxaYFZP8KAHDi1ERGtDzNANApaO6Ggj4ChWTsTqo339hAYQ2lN2soaYWx0EDtLpJyw2ggWrFAuwpqWBnJ5irz294WuIyVa4ViCOiXCAmxyByLty4m86kIEqUDsIoV42q5LA3CBuUEVH0LWI+7TtJv6Egg9ElhS8FURrVwtcWXUQtJCQIiReQE7R4jUR02rBO1khgxoMYrC/3dQiAaBP2CoCvYwAqHIzMaEd9MAVk9UtACw7mg/adLjFdYRhwapGqezpQz3YwStKq2AAqNY0H6Tl/yCwGwkxLsIEdjXKnhYAhfvCornz9G1/q/sIabL3tZIwagJRbODvGmJCNWgwLGLQAumud8SlUOJhA/wIJjZis1mRUwOo8AFatECtEWCRSknMTTACAAehhYSOHSHfFmtiAUlQ6yx48AGFYrUUdCTEBVgsiTBDQgUFtomXHiAFEHh5FjLQL3VJsUFBwMCClPhiJDBsZUw0QAlynsUM3PzlUWB0EOisRJ0Xm1yeeGkBRqgqLeJcaFGoWBDOtMSDGcFdDbvYb0zwsC1m4Nw5jyKCSL3EoR2RP0/7+QpavkUNYi0VCgSAbIZjsiLwNdwMU8LCi6AwQDzQF0ZIqQiExkVzn//bkbq8pBHIy6wgTNBdSwSStknthwVwprYkPUAINdbFrLOikcLVbBTTFcQKEFgJc545zfsYwF4akaQGEGG8ueDym3kib3PnWhTCHUSmMZHD9uH5Hyih96cBgGxmwznQNuk335wWAKOJoqmD0KcmRLyINAIk4YZomtOgZolvh3sXpJ6nUSRuiLNx7WuiUKydD44Jy82Q5vwAeSHMdra0Wfvevsijhl0ygmL/u3jHHYQJZpoJCRyzER7nhwUwAoFb68wSC2jCvnVRWkmPRGJR09xXB9HITcSHiI2gYbwJd3VKPCAK+O6FfXFsvZ8CQKOYgC8jom4RGmH8F+IFjeZgmvH/DACO8AYfCY1k7otld0Zyq565J/TOCFU2+7v/Dca4NSO5TVPbE4qSofeyjZAUSTgYg976Yg43ZbKzexOUX8QKOJuQFBU8GEDQAedtdgAH+B7tvj/E6QUuV7MDWxH5c+9AOtT6YHT9MsZxQAGmXwCYMmD6wgQA49lreFCc4Ok/ZvpBOqRnY+Tg5I6JfgEuJIH1C4IDBjCAkwN+WJxz4uyR0OcRx4/XTQsjwZShfuxXAAeSINezJoMgbYNgA9U2S7N1c7WHV4hHDI6XfjYjfdQHKO0XARFQAOUCbOuGbtnXcWFlEBESecWweat3gQVgIQXQLQhQACRAAkLUWw9ICI0W/wrhkVKJAFDK9w8RooDFkHoWyAjSdyE0yAAPIIMn8H0FwCL+l2qkwAGexUjit3xLlW7HkHtFuAhHCADxIX8FQC0dCCLNJwghwGOQdHyJoED7h4WRkHnI8HyIoS7Dt4ANKAoncINpF0sFQSB3eAznt4KcYGKEsALwFnN2xwgskIcAQSBmxgwACBjWQn84+IOeEB6itwglMHACQSATmAwVyBbWcm29Q3qwAn6MYAP25w/5MWDMoIJiYS1auGOpcADuEQnKQ3uP2EV/xwxESIq6xmuGwICqoImRUAIV8Iau2EX+pwxcKIyaQD6HmIil0ACqeGF+2IuQMETRQIdZUSuhOP8IZMYwuRgJLHCFhQACIFAIPMCOcYcO+ZF0zzCIs8hkKDgIndgKyAgJCvR6hMCOhQAE7Ih+8thA+dgMPRCPEcdkzwgAd+YK2CgJMOCJ69iOhPABCAUCKpcO7EGNzjCK/EZii1YIn+cKCMBMkGADLOBeAulRIJADOQACIaUO7MGGzKADNblyJOZjhdBprrCESvYILOBrgvCSgtBLcQYCRWaT4uOT0BCMI4kJDwkAKsCMq9BDPIgIBsSLRwkCmoQCg1ZNNfABICBj5/AdhigNQseTHYOAhyCFsEACbsQInRhlAMCOejmTDbYDIKB7Hqk2xEgN4MgInGMInIOJ7oAnULn/gOrICopEkRoVlprEA34kCBqgSU7ZCC6CDXPnCBVQAYUAA6H5mPGAJ1V5lbMARZu4CN+DlfSQHD0kCL/HHAjiAEOZDEcGmqLJVaGJivKAJ+NoZ8ApkXzYCK+ZD8OBfwBAfdO3SDFIj8ggkokQmmJWATiAA9FzD0aSkIIAlLNASCoJCcl5D8PBAVQzfVYkg2tEfSNoDJTGCNZ5WBUQAtBjlKcJXELoWsUXC1eCdrRFQuZJL9WBKOrZfoDSAARYg8D4AR1Znb0pCKnDAqlTjsEJXG/1PK0YCwU6Cd+Dl/FwG5E5CM4ZTpXDHwsAl8rQlooQmtRmAsq4AtSWOl6Zn+1m/wCKIGy2UB6U0Imm2Q63gQBVOH0KugDN0YFRZAAFUIVz2AMmBaGhWQE2sJ0QqTr2sCPlF5f6kwuExKRHVZSxWSoKwIfqSYOSwgHrdwIKiqPN8FEPmhA7cmk/iZ+0cCU39gjKgwOKmZaaUh2ip56K4oEMqn1j6Aw05nACsSPeiAh4dwtQlJt4SqF7Wg6lIX2Q+g06AJgPsSMF8ErbuAt7uJWL8AItCQ+fcSXv6Q2TRWsHESOylQhl5ws8WgmkOqnikBmKMp7kwGVoaRAxYoqFZ6s7VEgAek6qCaR2QUh1OQ4gBqdkVIuCoEXCUB0kUKyN8AKNyqfw0UbsgFaIyg4R0f8Q0OZEs3kIRjQMB3AC8teai3AD2VoNC0ERxpYSyuoO0TUPFrABSjMxJBMs9fQ8nyoM6RpF1qoI32ON03AWP7EBdCM0AlCv76ADBgkPZwETH4FrdRMJV6KrYtafAquua+maGVCj0kABCYcRFEMXXcCt8JBf9EAVAMByiZAeCXACHngNDLCsioBUJAsNWyEIOmcYVqCz6pBf32oOMCuzgkBxFZcCTMu0WuAEQ5AFQ4AFT3u1WJu1Wru1XNu1Xpu1QRAEXzu2WGt066EyABC0ACByRDMCVUe2cBu3cju3X/sES3AEdJu3FOcLgiESZ2G2AOBygju4hFu4hnu4gzsziLv/uIzbuF3zE44buZL7uAtXCR7Aryb7Azs3uZzbuWijFJ4buoiLEqJbui5HAL6AMymAARtAM8OwUo9AOeFSuZXQARuAAVlDDLI7CahrC73bCyKwAQQAAYALDLCrJ7T7K8k7CR4QF3lTDLsrCb9LC9NbEMercLYQvc6gvZBQvbLgvQNxvfOavcvLDdz7COALC+kbEOLbdrRwvssAv42wvq5Av/8wAXtDCx6QsvrLv/Swv7pQvpsgwCVTwAZ8wAicwAq8wAy8CwjDEDBha0RTbA8sr6fwwCBjCOFaE6qAwRgLABt8wU6RwYZgax+8Cg88ABHsNBTsFBZsCh6swRLBwakQ/8OFEMIwPMInbMLCkDQdIAB6MTRgB8J6oRGoEDfDe8P6Ghf+ewpIvDSDkK/72sSh8MQO+2yv4MNA/BKDM28WUMQZccQokcSEIMVMvApWXMZLzK+lkMYm8xH+5gsXKwgT0DQE4LQnAwBEB8JUHAoYoDLyRsMVG7gEcMKi8MccEchl82xzPAqIHLMEQMNpmxFxvAqNXMcYgcd9sccW0Meg8MiKPAiD3MinAMqRvMgWW8ikYMqSXG7C4BId8APyihFyAxNknAoS97ODkLRYfAq5jLaCwMuV7Am/jBpKywqwLMsVQcsQnLZQjArFvDW9e8ykEM27PM29HArWTAjUzAtYI/+8BLABdqwRHKG2prDNhAwj2VwK6CzM1fxsuszN64zCKQDO4tzFKmPO7AzPwJzOkDzMotDO2AzQnIDO6kzQuRAV+7sR8QwAtssUDRsKKeMQfzwChNC3APC3qTDRAFDRF63KGj0KHO3RhdDNqaDQZ6HC/fzQghDRoDDSBGDRg4DRIX0KMC3TgkDTBFC8nnDTF4PQuCAAq1txXIwSAwMAKfM19XwKJ1F1cTF1KqO6rOu6TD28AfDUPyvVrVsKTX3VBADVWEHURfcKQo0BRC3EchMUST0AS20KXY3VUX3HU60Kb/3VWS3XW00KdQ3WS0t0PK0LbpsREOAQ+BwWORHOKYCBChOgFx0QFLocvMP716Ow2Gjh2GgL2cRrCpTd2ACgy0PsCoE9vIT92Ye9AYl9Cptt2ViB2ZItCqnd2ZctvJldCq/t2YrTwLid27q927zd277928Ad3MI93MRd3MZ93Mid3Mq93Mzd3M793NAd3dI93dRd3dZ93did3dq93dy93IEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left panel shows the normal pattern of atrial activation as it would appear on lead II of the electrocardiogram: activation of the right atrium (RA) occurs first, followed by left atrial (LA) activation. The right panel shows the pattern in a patient with right atrial enlargement: delayed activation of the right atrium, due to dilatation, hypertrophy, scarring, or a conduction abnormality, results in simultaneous activation of the right and left atria. The synchronous electrical activity has an additive effect upon the surface ECG, resulting in a relatively narrow P wave which is of increased amplitude (P pulmonale). The amplitude of the P wave may become significantly increased in the presence of right atrial hypertrophy; it also becomes peaked due to the increase in amount of depolarized tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_30_37357=[""].join("\n");
var outline_f36_30_37357=null;
var title_f36_30_37358="Contents: Adult procedures";
var content_f36_30_37358=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?10/42/10926\">",
"       Adult and Pediatric Emergency Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Adult procedures",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Adult procedures",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Airway",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/14/28906\">",
"           Direct laryngoscopy and tracheal intubation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/50/4905\">",
"           Emergent surgical cricothyrotomy (cricothyroidotomy)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Anesthesia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/57/33689\">",
"           Infiltration of local anesthetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/51/34618\">",
"           Procedural sedation in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiovascular",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/33/15894\">",
"           Arterial blood gases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/51/26424\">",
"           Arterial catheterization techniques for invasive monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/1/29\">",
"           Complications of central venous catheters and their prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/5/44119\">",
"           Emergency pericardiocentesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/32/44553\">",
"           Overview of central venous access",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/13/6361\">",
"           Peripheral venous access in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/14/3306\">",
"           Placement of jugular venous catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/27/1466\">",
"           Placement of subclavian venous catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/47/3833\">",
"           Principles of ultrasound-guided venous access",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/36/25159\">",
"           Technique of pericardiocentesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/61/21465\">",
"           Temporary cardiac pacing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/35/13877\">",
"           Venous blood gases and other alternatives to arterial blood gases",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dermatology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/22/33124\">",
"           Closure of minor skin wounds with staples",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/7/18553\">",
"           Closure of skin wounds with sutures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/51/31543\">",
"           Dermatologic procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/20/40264\">",
"           Skin biopsy techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/32/41478\">",
"           Superficial wound repair with tissue adhesives",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/46/5865\">",
"           Technique of incision and drainage for skin abscess",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ear nose and throat",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/41/1690\">",
"           Approach to the adult with epistaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/47/24309\">",
"           Evaluation and repair of tongue lacerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/8/9351\">",
"           Subungual hematoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Minor emergency procedures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/9/30872\">",
"           Assessment and management of scalp lacerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/22/33124\">",
"           Closure of minor skin wounds with staples",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/7/18553\">",
"           Closure of skin wounds with sutures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/53/16216\">",
"           Digit dislocation reduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/47/24309\">",
"           Evaluation and repair of tongue lacerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/42/38564\">",
"           Fish-hook removal techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/47/13044\">",
"           Hair entrapment removal techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/25/30100\">",
"           Management of zipper injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/51/32567\">",
"           Minor wound preparation and irrigation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/46/26340\">",
"           Reduction of temporomandibular joint (TMJ) dislocation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/49/8981\">",
"           Ring removal techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/8/9351\">",
"           Subungual hematoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/32/41478\">",
"           Superficial wound repair with tissue adhesives",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/46/5865\">",
"           Technique of incision and drainage for skin abscess",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Musculoskeletal",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/9/23703\">",
"           Digital nerve block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/14/30951\">",
"           Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/57/28564\">",
"           Joint aspiration or injection in adults: Complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/52/23368\">",
"           Joint aspiration or injection in adults: Technique and indications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/31/28148\">",
"           Joint aspiration: The dry tap",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/9/38038\">",
"           Knee (tibiofemoral) dislocation and reduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/46/26340\">",
"           Reduction of temporomandibular joint (TMJ) dislocation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/8/10378\">",
"           Shoulder dislocation and reduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/54/15208\">",
"           Splinting of musculoskeletal injuries",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/6/19561\">",
"           Lumbar puncture: Technique; indications; contraindications; and complications in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Obstetrics and gynecology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/11/2232\">",
"           Antepartum fetal heart rate assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/42/13992\">",
"           Approach to episiotomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/54/24420\">",
"           Culdocentesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/7/26742\">",
"           Mechanism of normal labor and delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/61/36824\">",
"           Ultrasound examination in obstetrics and gynecology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/63/28659\">",
"           Word catheter placement for treatment of Bartholin cysts and abscesses",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ophthalmology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/28/44486\">",
"           Slit lamp examination",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/33/15894\">",
"           Arterial blood gases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/23/12663\">",
"           Diagnostic thoracentesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/12/1226\">",
"           Placement and management of thoracostomy tubes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/35/13877\">",
"           Venous blood gases and other alternatives to arterial blood gases",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-4679F2A3A2-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f36_30_37358=[""].join("\n");
var outline_f36_30_37358=null;
var title_f36_30_37359="Skin findings Wiskott-Aldrich syndrome";
var content_f36_30_37359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin findings in Wiskott-Aldrich syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Eczema and petechiae in a child with Wiskott-Aldrich sydrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas J Barrett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_30_37359=[""].join("\n");
var outline_f36_30_37359=null;
